Sentence,class,file
"2091 –2116, http://dx.doi.org/10.1007/978-1-4419-1795-9_126 .",Non-OADS,/arxiv_data1/oa_pdf/c1/07/main.PMC4060980.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/15/fa/amep-5-177.PMC4061139.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpAdvances in Medical Education and Practice 2014:5 177–184Advances in Medical Education and Practice Dove press submit your manuscript | www.dovepress.co m Dove press  177OriginAl rEsEArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/AMEP .S6180 5The Malaysia DrEEM: perceptions of medical   students about the learning environment   in a medical school in Malaysia redhwan A Al-n aggar1 Mahfoudh Abdulghani2,14 Muhamed T Osman3 Waqar Al-Kubaisy1 Aqil Mohammad Daher15 Khairun nain Bin nor Aripin4 Ali Assabri5 Dawood A Al-hidabi6 Mohamed izham B Mohamed ibrahim7 Ahmed Al-rofaai8 hisham s ibrahim9 hassanain Al-Talib10 Alyaa Al-Khateeb11 gamil Qasem Othman6 Qaid Ali Abdulaziz6 Karuthan chinna12 Yuri V Bobryshev13 1Population health and Preventive Medicine  Department, Faculty of Medicine, Universiti Teknologi  MArA, 2Pharmacology Department, international  Medical school, Management and science University,   3Department of Pathology, Faculty of Medicine &  Defence health, national Defence University of  Malaysia, Kuala lumpur, Malaysia, 4Faculty of Medicine  and health sciences, islamic science University  of Malaysia, Kuala lumpur, Malaysia; 5community  Medicine Department, Faculty of Medicine and health  science, sana’a University, 6University of science and  T echnology, sana’a, Yemen; 7college of Pharmacy, Qatar  University, Doha, Qatar; 8school of Biological sciences,   Universiti sains Malaysia, Minden, Penang, Malaysia,   9Physiology Discipline-Faculty Of Medicine and health  sciences-Universiti sultan Zainal Abidin, T erengganu,   Malaysia, 10laboratory Medical science cluster, Drug  Discovery & health community of research, Faculty of  Medicine, Universiti T eknologi MArA, 11Biochemistry  and Molecular Medicine Discipline, Drug Discovery &  health community of research, Faculty of Medicine,   Universiti T eknologi MArA, 12social and Preventive  Medicine, University Malaya, Kuala lumpur, Malaysia;   13Faculty of Medicine, school of Medical sciences,   University of new south Wales, sydney, nsW, Australia;   14Pharmacology Department, Unaizah college of  Pharmacy (U cP), Qassim University, Al Qassim, saudi  Arabia; 15Department of community medicine, Faculty  of Medicine & Defence health, national Defence  University of Malaysia, Kuala lumpur, Malaysia correspondence: Yuri V Bobryshev   Faculty of Medicine, school of Medical sciences,   University of new south Wales, new south   Wales, sydney, nsW  2052, Australia   Tel +612 93 85 1217  Fax +612 93 85 1217  Email y.bobryshev@unsw.edu.a uBackground:  Students’ perceptions of their learning environment, by defining its strengths  and weaknesses, are important for continuous improvement of the educational environments  and curriculum.",Non-OADS,/arxiv_data1/oa_pdf/15/fa/amep-5-177.PMC4061139.pdf
"Advances in Medical Education and Practice Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/advances-in-medical-education-and-practice-journa lAdvances in Medical Education and Practice is an international, peer- reviewed, open access journal that aims to present and publish research  on Medical Education covering medical, dental, nursing and allied  health care professional education.",Non-OADS,/arxiv_data1/oa_pdf/15/fa/amep-5-177.PMC4061139.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real  quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/15/fa/amep-5-177.PMC4061139.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/28/b0/cia-9-901.PMC4061140.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Interventions in Aging 2014:9 901–914Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  901OrIg InAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S6193 4Journal name: Clinical Interventions in Aging Journal Designation: Original Research Y ear: 2014 Volume: 9 Running head verso: Lisowska et al Running head recto: Aging and the medial olivocochlear system DOI: http://dx.doi.org/10.2147/CIA.S61934 Grażyna Lisowska Grzegorz Namyslowski Boguslawa Orecka Maciej Misiolek Department of Otolaryngology,   Medical University of Silesia,    Zabrze, Poland Correspondence: Grażyna Lisowska   Department of Otolaryngology, Medical  University of Silesia, ul Skłodowskiej- Curie 10, 41-800 Zabrze, Poland   T el +48 32 271 7420   Fax +48 32 271 7420   email grazyna.lisowska@onet.p lInfluence of aging on medial olivocochlear   system function Background:  There is still controversy regarding the influence of aging on medial olivocochlear  (MOC) system function.",Non-OADS,/arxiv_data1/oa_pdf/28/b0/cia-9-901.PMC4061140.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lDove pres s Clinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/28/b0/cia-9-901.PMC4061140.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/28/b0/cia-9-901.PMC4061140.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/88/a8/ceg-7-199.PMC4061141.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical and Experimental Gastroenterology 2014:7 199–204Clinical and Experimental Gastroenterology Increased fat in pancreas not associated   with risk of pancreatitis post-endoscopic  retrograde cholangiopancreatography Bhupesh Pokhrel1 Eun Kwang Choi1 Omer Khalid2 Kumar Sandrasegaran3 Evan L Fogel1 Lee McHenry1 Stuart Sherman1 James Watkins1 Gregory A Cote1 Henry A Pitt4 Nicholas J Zyromski4 Beth Juliar1 Glen A Lehman1 1Department of Medicine, Indiana  University School of Medicine,   Indianapolis, IN, 2Department   of Gastroenterology, St Louis  University School of Medicine,   St Louis, MO, 3Department of  Radiology, 4Department of Surgery,   Indiana University School of Medicine,   Indianapolis, IN, USA Correspondence: Glen A Lehman   IU Health Physicians – ERCP, 550 N  University Blvd, UH4100, Indianapolis,   IN 46202, USA   Tel +1 317 944 4824   Fax +1 317 948 0164   Email glehman@iupui.ed uBackground:  A preliminary study has shown increased pancreatic fat in patients with idiopathic  pancreatitis and sphincter of Oddi dysfunction.",Non-OADS,/arxiv_data1/oa_pdf/88/a8/ceg-7-199.PMC4061141.pdf
"Clinical and Experimental Gastroenterology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-and-experimental-gastroenterology-journa lClinical and Experimental Gastroenterology is an international, peer- reviewed, open access journal, publishing all aspects of gastroenterology  in the clinic and laboratory, including: Pathology, pathophysiology  of gastrointestinal disease; Investigation and treatment of gastointes - tinal disease; Pharmacology of drugs used in the alimentary tract; Immunology/genetics/genomics related to gastrointestinal disease.",Non-OADS,/arxiv_data1/oa_pdf/88/a8/ceg-7-199.PMC4061141.pdf
Visit http://www.dovepress.com/testimonials.php to read real  quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/88/a8/ceg-7-199.PMC4061141.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/eb/4c/amep-5-185.PMC4061142.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpAdvances in Medical Education and Practice 2014:5 185–189Advances in Medical Education and Practice Dove press submit your manuscript | www.dovepress.co m Dove press  185MEthodologyopen access to scientific and medical research open Access Full text Article http: //dx.doi.org/10.2147/AMEP .S5885 8Integrating radiology vertically into   an undergraduate medical education   curriculum: a triphasic integration approach Fahd Al Qahtani1 Adel Abdelaziz2,3 1Radiology department, Faculty of  Medicine, Al-Baha University, Al-Baha,  Saudi Arabia;  2Medical Education  development Unit, Faculty of  Medicine, Al-Baha University, Al-Baha,  Saudi Arabia;  3Medical Education  department, Faculty of Medicine,   Suez Canal University, Ismailia, Egypt Correspondence: Adel Abdelaziz   Medical Education development Unit,  Faculty of Medicine, Al-Baha University,  Po Box  1988, Al-Baha, Saudi Arabia   tel +966 55 524 2678  Fax +966 177 247 272  Email doctoradel5@yahoo.co mAbstract:  Fulfilling the goal of integrating radiology into undergraduate medical curricula is a  real challenge due to the enduring faith assuming that traditional medical disciplines are worthy of  consuming the available study time.",Non-OADS,/arxiv_data1/oa_pdf/eb/4c/amep-5-185.PMC4061142.pdf
"Advances in Medical Education and Practice Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/advances-in-medical-education-and-practice-journa lAdvances in Medical Education and Practice is an international, peer- reviewed, open access journal that aims to present and publish research  on Medical Education covering medical, dental, nursing and allied  health care professional education.",Non-OADS,/arxiv_data1/oa_pdf/eb/4c/amep-5-185.PMC4061142.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real  quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/eb/4c/amep-5-185.PMC4061142.pdf
Available from: http://www.bhmed-emanual.org /.,Non-OADS,/arxiv_data1/oa_pdf/eb/4c/amep-5-185.PMC4061142.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/3a/25/ceor-6-297.PMC4061143.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinicoEconomics and Outcomes Research 2014:6 297–302ClinicoEconomics and Outcomes Research Dove press submit your manuscript | www.dovepress.co m Dove press  297ORiginal REsEaRChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/CEOR.S6320 0Economic impact of infections among   patients with primary immunodeficiency   disease receiving iVig therapy Joseph Menzin1 Matthew sussman1 Michael Munsell1 arthur Zbrozek2 1Boston health Economics, inc.,   Waltham, M a, Usa;  2Csl Behring,   llC, King of Prussia, P a, Usa Correspondence: Joseph Menzin   Boston health Economics, inc.,   20 Fox Road, Waltham, Ma  02451, Usa   Tel +1 781 290 0808  Fax +1 781 290 0029  Email jmenzin@bhei.co mPurpose:  There are limited data on the cost of infections among patients with primary   immunodeficiency disease (PIDD) in clinical practice.",Non-OADS,/arxiv_data1/oa_pdf/3a/25/ceor-6-297.PMC4061143.pdf
Available from:  URL: http://www.primaryimmune.org/publications/book_pats/e_ch01.,Non-OADS,/arxiv_data1/oa_pdf/3a/25/ceor-6-297.PMC4061143.pdf
"ClinicoEconomics and Outcomes Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinicoeconomics-and-outcomes-research-journa lClinicoEconomics & Outcomes Research is an international, peer- reviewed open-access journal focusing on Health Technology Assess - ment, Pharmacoeconomics and Outcomes Research in the areas of  diagnosis, medical devices, and clinical, surgical and pharmacological  intervention.",Non-OADS,/arxiv_data1/oa_pdf/3a/25/ceor-6-297.PMC4061143.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/3a/25/ceor-6-297.PMC4061143.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/5e/53/cia-9-915.PMC4061144.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Interventions in Aging 2014:9 915–928Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  915OrIg InAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S6472 3Journal name: Clinical Interventions in Aging Journal Designation: Original Research Y ear: 2014 Volume: 9 Running head verso: Khanassov et al Running head recto: Case management for dementia DOI: http://dx.doi.org/10.2147/CIA.S64723 Vladimir Khanassov Isabelle Vedel Pierre Pluye Department of Family Medicine,   Mcgill University, Montreal,    QC, Canada Correspondence: Isabelle  Vedel   Department of Family Medicine,   Mcgill University, 5858 Côte-des-neiges,  Third Floor, suite 300, Montreal,   Quebec, h3s 1Z1   T el +1 514 340 8222   email isabelle.vedel@mcgill.c aCase management for dementia in primary   health care: a systematic mixed studies review  based on the diffusion of innovation model Background:  The purpose of this study was to examine factors associated with the implemen - tation of case management (CM) interventions in primary health care (PHC) and to develop  strategies to enhance its adoption by PHC practices.",Non-OADS,/arxiv_data1/oa_pdf/5e/53/cia-9-915.PMC4061144.pdf
Available from: http://www.alz.org/downloads/facts_figures_2013.pdf.,OADS,/arxiv_data1/oa_pdf/5e/53/cia-9-915.PMC4061144.pdf
Available from: http://www.alzheimer.ca/~/ media/Files/national/Advocacy/ASC_Rising%20Tide-Executive%20 Summary_Eng.pdf.,Non-OADS,/arxiv_data1/oa_pdf/5e/53/cia-9-915.PMC4061144.pdf
Available from: http://www.cihr.ca/e/43626.html.,Non-OADS,/arxiv_data1/oa_pdf/5e/53/cia-9-915.PMC4061144.pdf
Available from: https://www.gov.uk/government/uploads/system/ uploads/attachment_data/file/265869/2901668_G8_DementiaSum - mitDeclaration_acc.pdf.,OADS,/arxiv_data1/oa_pdf/5e/53/cia-9-915.PMC4061144.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lDove pres s Clinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/5e/53/cia-9-915.PMC4061144.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/5e/53/cia-9-915.PMC4061144.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/04/20/ott-7-915.PMC4061159.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpOncoTargets and Therapy 2014:7 915–923OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  915Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S5840 9stereotactic body radiation therapy using   the cyberKnife® system for patients   with liver metastases Zhi-Y ong Yuan* Mao-Bin Meng* chun-lei liu* huan-huan Wang* chao Jiang Y ong-chun song hong-Qing Zhuang Dong Yang Jing-sheng Wang Wang Wei Feng-T ong li lu-Jun Zhao Ping Wang Department of radiation Oncology,   cyberKnife® center, Key laboratory  of cancer Prevention and Therapy,   Tianjin Medical University cancer  institute and hospital, national  clinical research center of cancer,   Tianjin, People’s republic of china *These authors contributed equally  to this work correspondence: Zhi-Yong Yuan;   Mao-Bin Meng   Department of radiation Oncology,  cyberKnife® center, Key laboratory   of cancer Prevention and Therapy,   Tianjin Medical University cancer  institute and hospital, national  clinical research center of cancer,  Tianjin 300060, People’s republic  of china   Tel +86 22 2334 1405  Fax +86 22 2334 1405  email zhiyong0524@163.co m;  doctormm991@hotmail .comAbstract:  The aim of this study was to evaluate the efficacy and toxicity of stereotactic body  radiation therapy (SBRT) in the treatment of patients with liver metastases.",Non-OADS,/arxiv_data1/oa_pdf/04/20/ott-7-915.PMC4061159.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open access  journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/04/20/ott-7-915.PMC4061159.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/04/20/ott-7-915.PMC4061159.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/a7/2a/ijgm-7-271.PMC4061160.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of General Medicine 2014:7 271–276International Journal of General Medicine Dove press submit your manuscript | www.dovepress.co m Dove press  271REVIEWopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/IJGM.S4021 6Management options for the treatment   of benign prostatic hyperplasia with   or without erectile dysfunction: a focus   on tadalafil and patient considerations Bader Alsaikhan Khalid Alrabeeah Serge Carrier McGill University Health Centre,   Montreal, Quebec, QC, Canada Correspondence: Serge Carrier   Jewish General Hospital, E-939,  3755 Côte Ste-Catherine Road, Montréal,  Québec H3T 1E2, QC, Canada   Email: serge.carrier@mcgill.c aAbstract:  Lower urinary tract symptoms (LUTS) and erectile dysfunction increase with age.",Non-OADS,/arxiv_data1/oa_pdf/a7/2a/ijgm-7-271.PMC4061160.pdf
"International Journal of General Medicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-general-medicine-journa lThe International Journal of General Medicine is an international,  peer-reviewed open-access journal that focuses on general and internal  medicine, pathogenesis, epidemiology, diagnosis, monitoring and treat - ment protocols.",Non-OADS,/arxiv_data1/oa_pdf/a7/2a/ijgm-7-271.PMC4061160.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/a7/2a/ijgm-7-271.PMC4061160.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/ca/5f/ott-7-969.PMC4061161.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpOncoTargets and Therapy 2014:7 969–983OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  969Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OTT .S4024 1The potential roles of hepatocyte growth   factor (HGF)-MeT pathway inhibitors   in cancer treatment Rahul A Parikh1 Peng wang2 Jan H Beumer3 edward Chu1 Leonard J Appleman1 1Division of Hematology-Oncology,   University of Pittsburgh School  of Medicine, Cancer Therapeutics  Program, University of Pittsburgh  Cancer institute, Pittsburgh, PA,   USA; 2Division of Medical Oncology,   University of Kentucky College of  Medicine, Markey Cancer Center,   Lexington, KY, USA; 3University  of Pittsburgh School of Pharmacy,   Cancer Therapeutics Program,   University of Pittsburgh Cancer  institute, Pittsburgh, PA, USA Correspondence: Leonard J Appleman   Division of Hematology-Oncology,  University of Pittsburgh School of  Medicine, Cancer Therapeutics Program,  University of Pittsburgh Cancer institute,  5150 Centre Ave, Pittsburgh, PA,  USA 15215   Tel +1 412 648 6507   Fax +1 617 344 0759   email applemanlj@upmc.ed uAbstract:  MET  is located on chromosome 7q31 and is a proto-oncogene that encodes for hepa - tocyte growth factor (HGF) receptor, a member of the receptor tyrosine kinase (RTK)  family.",Non-OADS,/arxiv_data1/oa_pdf/ca/5f/ott-7-969.PMC4061161.pdf
Available from: http://clinicaltrials.gov/show/NCT0169707 2.,Non-OADS,/arxiv_data1/oa_pdf/ca/5f/ott-7-969.PMC4061161.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open access  journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/ca/5f/ott-7-969.PMC4061161.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/ca/5f/ott-7-969.PMC4061161.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/99/75/ott-7-985.PMC4061162.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpOncoTargets and Therapy 2014:7 985–994OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  985Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S6288 7xcelligence system for real-time label-free   monitoring of growth and viability of cell   lines from hematological malignancies Jordi Martinez-serra1 antonio gutierrez1 saúl Muñoz-capó1 María n avarro-Palou1 T eresa ros1 Juan carlos amat1 Bernardo lopez1 T oni F Marcus1 laura Fueyo2 angela g suquia2 Jordi gines3 Francisco rubio1 rafael ramos4 Joan Besalduch1 1Department of hematology,   2Department of clinical analysis,   3Department of Pharmacy,   4Department of Pathology, University  hospital son espases, Palma de  Mallorca, Balearic islands, spain correspondence: Jordi Martinez-serra   Department of hematology,   University hospital of son espases,   crta Valldemossa n °79, Palma de   Mallorca, Baleares, spain   Tel +34 871 205 000, ext  76267  email jorgej.martinez@ssib.e sAbstract:  The xCELLigence system is a new technological approach that allows the real-time  cell analysis of adherent tumor cells.",Non-OADS,/arxiv_data1/oa_pdf/99/75/ott-7-985.PMC4061162.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open access  journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/99/75/ott-7-985.PMC4061162.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/99/75/ott-7-985.PMC4061162.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/c1/ba/opth-8-1089.PMC4061163.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Ophthalmology 2014:8 1089–1095Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  1089Case seriesopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OPTH.S5708 6Journal name: Clinical Ophthalmology Journal Designation: Case Series Y ear: 2014 Volume: 8 Running head verso: Dinah et al Running head recto: Retinal detachment and type 3 staphylomas DOI: http://dx.doi.org/10.2147/OPTH.S57086 Progressive retinal detachment secondary  to juxtapapillary microholes in association  with type 3 posterior staphylomas Christiana B Dinah1 Daniela Vaideanu-Collins2 David HW steel1,3 1Ophthalmology Department,   sunderland eye infirmary, sunderland,   2Ophthalmology Department,   James Cook University Hospital,   Middlesbrough, UK, 3institute  of Genetic Medicine, Newcastle  University, Newcastle Upon Tyne, UKPurpose:  This study describes a novel subtype of retinal detachment occurring in eyes with  pathological myopia associated with type 3 posterior staphyloma and discusses the manage - ment options.",Non-OADS,/arxiv_data1/oa_pdf/c1/ba/opth-8-1089.PMC4061163.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journalClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/c1/ba/opth-8-1089.PMC4061163.pdf
Visit http://www.dovepress.com/ testimonials.php to read real quotes from published authors.Dove pres s Clinical Ophthalmology 2014:8submit your manuscript | www.dovepress.co m Dove press Dove press 1095retinal detachment and type 3 staphylomas  endo-tamponade with long-acting gas in the majority of our  cases.,Non-OADS,/arxiv_data1/oa_pdf/c1/ba/opth-8-1089.PMC4061163.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/d7/ea/ott-7-1015.PMC4061164.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpOncoTargets and Therapy 2014:7 1015–1023OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1015Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OTT .S6011 4Chemotherapy-enhanced inflammation may   lead to the failure of therapy and metastasis Dinesh vyas Gieric Laput Arpitak K vyas College of Human Medicine, Michigan  State University, east Lansing, M i, USA Correspondence: Dinesh vyas   Department of Surgery, Nanomedical  OncoSepsis Laboratory, institute of  international Health, College of Human  Medicine, Michigan State University,    1200 east Michigan Avenue, Suite  655,  east Lansing, Mi  48824, USA   Tel +1 517 267 2460  email dinesh.vyas@hc.msu.ed uAbstract:  The lack of therapy and the failure of existing therapy has been a challenge for  clinicians in treating various cancers.",Non-OADS,/arxiv_data1/oa_pdf/d7/ea/ott-7-1015.PMC4061164.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open access  journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/d7/ea/ott-7-1015.PMC4061164.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/d7/ea/ott-7-1015.PMC4061164.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/92/96/ott-7-1001.PMC4061165.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpOncoTargets and Therapy 2014:7 1001–1014OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1001Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OTT .S4494 1emerging molecular targets in oncology:   clinical potential of MeT/hepatocyte   growth-factor inhibitors elizabeth C Smyth Francesco Sclafani David Cunningham Department of Gastrointestinal   Oncology, Royal Marsden   Hospital, Sutton, UK Correspondence: elizabeth C Smyth   Department of Gastrointestinal Oncology,   Royal Marsden Hospital, Downs Road,   Sutton, Surrey SM7 5PT, UK   Tel +44 208 642 6011 ext 4153   email elizabeth.smyth@rmh.nhs.u kAbstract:  The MET/hepatocyte growth-factor (HGF) signaling pathway plays a key role in  the processes of embryogenesis, wound healing, and organ regeneration.",Non-OADS,/arxiv_data1/oa_pdf/92/96/ott-7-1001.PMC4061165.pdf
Available from:  http://clinicaltrials.gov/ct2/show/NCT0137737 6.,Non-OADS,/arxiv_data1/oa_pdf/92/96/ott-7-1001.PMC4061165.pdf
Available from: http://clinicaltrials.gov/ct2/show/ NCT0139575 8.,Non-OADS,/arxiv_data1/oa_pdf/92/96/ott-7-1001.PMC4061165.pdf
Available from: http://clinicaltrials.gov/ct2/show/ NCT0141822 2.,Non-OADS,/arxiv_data1/oa_pdf/92/96/ott-7-1001.PMC4061165.pdf
Available  from: http://clinicaltrials.gov/ct2/show/NCT0166286 9.,Non-OADS,/arxiv_data1/oa_pdf/92/96/ott-7-1001.PMC4061165.pdf
Available from: http://clinicaltrials.gov/ct2/show/ NCT0169707 2.,Non-OADS,/arxiv_data1/oa_pdf/92/96/ott-7-1001.PMC4061165.pdf
Available from: http://clinicaltrials.gov/ ct2/show/NCT0175576 7.,Non-OADS,/arxiv_data1/oa_pdf/92/96/ott-7-1001.PMC4061165.pdf
Available from: http://clinicaltrials.gov/ ct2/show/NCT0190842 6.,Non-OADS,/arxiv_data1/oa_pdf/92/96/ott-7-1001.PMC4061165.pdf
Available from: http://clinicaltrials.gov/ct2/ show/NCT0189703 8.,Non-OADS,/arxiv_data1/oa_pdf/92/96/ott-7-1001.PMC4061165.pdf
Available from: http://clinicaltrials.gov/ct2/show/NCT0160522 7.,Non-OADS,/arxiv_data1/oa_pdf/92/96/ott-7-1001.PMC4061165.pdf
Available from: http://clinicaltrials.gov/ ct2/show/NCT0199505 8.,Non-OADS,/arxiv_data1/oa_pdf/92/96/ott-7-1001.PMC4061165.pdf
Available from:  http://clinicaltrials.gov/ct2/show/NCT0186574 7.,Non-OADS,/arxiv_data1/oa_pdf/92/96/ott-7-1001.PMC4061165.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open access  journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/92/96/ott-7-1001.PMC4061165.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/92/96/ott-7-1001.PMC4061165.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/a2/78/ijn-9-2905.PMC4061166.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nanomedicine 2014:9 2905–2917International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  2905OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S5955 6enhanced and selective delivery of enzyme   therapy to 9l-glioma tumor via magnetic   targeting of PEG-modified, β-glucosidase-   conjugated iron oxide nanoparticles Jie Zhou1,* Jian Zhang2,* Wenxi gao1 1Department of Urology, Hubei   hospital of Traditional chinese   Medicine, Hubei University of   Chinese Medicine, Wuhan, People’s   Republic of China; 2Department of   Pharmaceutical Sciences, College   of Pharmacy, University of Michigan,    Ann Arbor, MI, USA *These authors contributed equally   to this work correspondence: Jie Zhou   Department of Urology, Hubei Hospital   of Traditional Chinese Medicine,   Hubei University of Chinese Medicine,   Wuhan, People’s Republic of China   Tel +86 185 7172 7602   email zhoujieuser@163.co mAbstract:  The stability of enzyme-conjugated magnetic iron oxide nanoparticles in plasma is  of great importance for in vivo delivery of the conjugated enzyme.",Non-OADS,/arxiv_data1/oa_pdf/a2/78/ijn-9-2905.PMC4061166.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology  in diagnostics, therapeutics, and drug delivery systems throughout  the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/a2/78/ijn-9-2905.PMC4061166.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/a2/78/ijn-9-2905.PMC4061166.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/c9/6e/dddt-8-759.PMC4061167.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpDrug Design, Development and Therapy 2014:8 759–763Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  759Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S6167 9Thrombolytic treatment (alteplase; rt-P a)   in acute massive pulmonary embolism   and cardiopulmonary arrest adem Dirican1 sevket Ozkaya2 ali ekber atas3 esra Kayahan Ulu4 ilknur Kitapci5 Ferah ece2 1Department of Pulmonary Medicine,   Medical Park samsun hospital,   samsun, T urkey;  2Department of  Pulmonary Medicine, Faculty of  Medicine, Bahçeşehir University,   istanbul, T urkey;  3Department of  cardiology, Medical Park samsun  hospital, samsun, T urkey;  4Department  of radiology, Medical Park samsun  hospital, samsun, T urkey;  5Department  of intensive care Unit, Medical Park  samsun hospital, samsun, T urkey correspondence: sevket Ozkaya   Department of Pulmonary Medicine,  Faculty of Medicine, Bahçeşehir  University, Çıra an Caddesi Osmanpaşa  Mektebi Sokak No: 4-6, 34353 Beşiktaş,  istanbul, Turkey   Mob +90 532 474 13 09  email ozkayasevket@yahoo.co mAbstract:  Patients with pulmonary thromboembolism (PE) often decompensate suddenly, and  once hemodynamic compromise has developed, mortality is extremely high.",Non-OADS,/arxiv_data1/oa_pdf/c9/6e/dddt-8-759.PMC4061167.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/c9/6e/dddt-8-759.PMC4061167.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/c9/6e/dddt-8-759.PMC4061167.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/c6/18/opth-8-1119.PMC4061168.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Ophthalmology 2014:8 1119–1127Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  1119Original researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/ 10.2147/OPTH.S6202 2Journal name: Clinical Ophthalmology Journal Designation: Original Research Y ear: 2014 Volume: 8 Running head verso: Nitta et al Running head recto: Ocular microcirculation after intravitreal bevacizumab DOI: http://dx.doi.org/10.2147/OPTH.S62022 The effect of intravitreal bevacizumab on ocular  blood flow in diabetic retinopathy and branch  retinal vein occlusion as measured by laser  speckle flowgraphy Fumihiko nitta1 hiroshi Kunikata1,2 naoko aizawa1 Kazuko Omodaka1 Yukihiro shiga1 Masayuki Yasuda1 T oru nakazawa1–3 1Department of Ophthalmology,   Tohoku University graduate school of  Medicine, sendai, Japan; 2Department  of retinal Disease Control, Tohoku  University graduate school of  Medicine, sendai, Japan; 3Department  of advanced Ophthalmic Medicine,   T ohoku University graduate school  of Medicine, sendai, Japan Correspondence: hiroshi Kunikata   Department of Ophthalmology,   T ohoku University graduate school   of Medicine, 1-1 seiryo-machi,   aoba-ku, sendai 980-8574, Japan   T el +81 22 717 7294   Fax +81 22 717 7298   email kunikata@oph.med.tohoku.ac.j pBackground:  This study evaluated the effect of intravitreal injection of bevacizumab (IVB)  on macular edema associated with diabetic retinopathy (DME) or branch retinal vein occlusion  (BRVOME) using laser speckle flowgraphy.",Non-OADS,/arxiv_data1/oa_pdf/c6/18/opth-8-1119.PMC4061168.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/c6/18/opth-8-1119.PMC4061168.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.Dove pres s Clinical Ophthalmology 2014:8submit your manuscript | www.dovepress.co m Dove press Dove press 1127Ocular microcirculation after intravitreal bevacizumab  16.,Non-OADS,/arxiv_data1/oa_pdf/c6/18/opth-8-1119.PMC4061168.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/c0/07/ott-7-947.PMC4061169.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpOncoTargets and Therapy 2014:7 947–956OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  947Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S6179 4Antitumor activity of total flavonoids   from Tetrastigma hemsleyanum  Diels   et gilg is associated with the inhibition   of regulatory T cells in mice Zhengquan Feng1,2 Wanrong hao3 Xiaoyang lin3 Daping Fan4 Juhua Zhou5 1Department of Oncology, Tongde  hospital of Zhejiang Province,   hangzhou, Zhejiang,    People’s  republic of china;    2Department of Oncology,    guang an Men hospital,    china academy of chinese   Medical sciences, Beijing,    People’s republic of china;    3Department of chinese Medicine,   Zhejiang chinese Medical   University, hangzhou,    Zhejiang, People’s republic   of china;  4Department of cell   Biology and anatomy, school of   Medicine, University of south   carolina, columbia, sc , Usa;   5institute for T umor immunology,   ludong University college of life  sciences, Yantai, shandong, People’s  republic of china correspondence: Juhua Zhou   institute for Tumor immunology,   ludong University school of life   sciences,  186 hongqi Middle road,   Yantai, shandong  264025,   People’s republic of china   Tel +86 183 0050 1903  Fax +86 0535 664 2910  email j uhua.zhou@gmail.co mObjective:  To determine the antitumor activity of Radix tetrastigmae flavonoids and their  inhibitory effect on regulatory T cells (Tregs) in mice.",Non-OADS,/arxiv_data1/oa_pdf/c0/07/ott-7-947.PMC4061169.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open access  journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/c0/07/ott-7-947.PMC4061169.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/c0/07/ott-7-947.PMC4061169.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/4b/d3/ijn-9-2891.PMC4061170.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nanomedicine 2014:9 2891–2903International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  2891OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S6066 1siO2 nanoparticle-induced impairment   of mitochondrial energy metabolism   in hepatocytes directly and through   a Kupffer cell-mediated pathway in vitro Yang Xue Qingqing chen Tingting Ding Jiao sun shanghai Biomaterials research  and Testing center, shanghai Key  laboratory of stomatology, Ninth  People’s hospital, shanghai Jiaotong  University school of Medicine,   shanghai, People’s republic of china correspondence: Jiao sun   shanghai Biomaterials research and  T esting center, shanghai Key laboratory  of stomatology, Ninth People’s hospital,  shanghai Jiaotong University school of  Medicine, 427 Jumen road, shanghai  200023, People’s republic of china   Tel +86 21 6303 4903   Fax +86 21 6301 1643   email jiaosun59@yahoo.co mAbstract:  The liver has been shown to be a primary target organ for SiO2 nanoparticles in vivo,  and may be highly susceptible to damage by these nanoparticles.",Non-OADS,/arxiv_data1/oa_pdf/4b/d3/ijn-9-2891.PMC4061170.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology  in diagnostics, therapeutics, and drug delivery systems throughout  the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/4b/d3/ijn-9-2891.PMC4061170.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/4b/d3/ijn-9-2891.PMC4061170.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/29/e0/cia-9-939.PMC4061171.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Interventions in Aging 2014:9 939–944Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  939OrIg InAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/ 10.2147/CIA.S6033 0Marta Imamura1 rosa Alves Targino1 Wu T u hsing2,3 satiko Imamura1 raymundo soares Azevedo3 lucy santos Villas Boas4 Tania regina T ozetto- Mendoza5 Fábio Marcon Alfieri1,6 Thais raquel Filippo1 linamara rizzo Battistella1,7 1Clinical research Center,    Institute of Physical Medicine and  rehabilitation, University of são Paulo  Medical school, são Paulo, 2Division  of Physical Medicine, Center for  Acupuncture, Institute of Orthopedics  and Traumatology, University of   são Paulo, são Paulo, 3Department   of Pathology, University of são Paulo,   são Paulo, 4laboratory of Medical  Investigation lIM-52-hCFMUsP ,   Institute of Tropical Medicine,   University of são Paulo, são Paulo,   5Tropical laboratory of hematology/ Medical research laboratory-lIM  52,    Institute of Tropical Medicine,   University of são Paulo, são Paulo,   6Program of Master in health  Promotion, são Paulo Adventist  University Center, são Paulo,   7Department of legal Medicine,   Medical ethics, social and labor  Medicine – Medicine school,   University of são Paulo, são Paulo,   Brazil Correspondence: Fábio Marcon Alfieri Clinical research Center, Institute   of Physical Medicine and rehabilitation,  University of são Paulo Medical school,  rua Jandiatuba 580, 05716-150   são Paulo, Brazil T el +55 11 3905 8616 email fabioalfieri@usp.b rConcentration of cytokines in patients   with osteoarthritis of the knee and fibromyalgia Introduction:  Fibromyalgia and osteoarthritis may present a relationship with the   concentration of cytokines.",Non-OADS,/arxiv_data1/oa_pdf/29/e0/cia-9-939.PMC4061171.pdf
"Cytokines are a large group of small proteins and  polypeptides that are molecules that act on cells involved in immune and inflammatory  responses.10 Some authors claim that serum levels of certain cytokines may be cor - related with such symptoms as pain, depression, and fatigue.11 For FM, for example, it  is known that loss of balance between proinflammatory and anti-inflammatory serum Journal name: Clinical Interventions in Aging Journal Designation: Original Research Y ear: 2014 Volume: 9 Running head verso: Imamura et al Running head recto: Cytokines in osteoarthritis and fibromyalgia DOI: http://dx.doi.org/10.2147/CIA.S60330",Non-OADS,/arxiv_data1/oa_pdf/29/e0/cia-9-939.PMC4061171.pdf
Available from: http://www.cdc.gov/arthritis/basics/fibromyalgia.htm.,Non-OADS,/arxiv_data1/oa_pdf/29/e0/cia-9-939.PMC4061171.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lDove pres s Clinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/29/e0/cia-9-939.PMC4061171.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/29/e0/cia-9-939.PMC4061171.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/8f/7a/dddt-8-745.PMC4061172.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpDrug Design, Development and Therapy 2014:8 745–757Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  745Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S6265 9Mapracorat, a selective glucocorticoid receptor  agonist, causes apoptosis of eosinophils infiltrating  the conjunctiva in late-phase experimental   ocular allergy Monica Baiula1 andrea Bedini1 Jacopo Baldi1 Megan e cavet2 Paolo govoni3 santi spampinato1 1Department of Pharmacy and  Biotechnology, University of Bologna,   Bologna, italy; 2global Pharmaceutical  r&D, Bausch & lomb inc., rochester,   nY, Usa;  3Department of Biomedical,   Biotechnological and Translational  sciences, University of Parma,    Parma, italy correspondence: santi spampinato   Department of Pharmacy and  Biotechnology, University of Bologna,  irnerio  48, 40126 Bologna, italy   Tel +39 051 209 1851  Fax +39 051 209 1840  email santi.spampinato@unibo.i tBackground:  Mapracorat, a novel nonsteroidal selective glucocorticoid receptor agonist, has  been proposed for the topical treatment of inflammatory disorders as it binds with high affinity  and selectivity to the human glucocorticoid receptor and displays a potent anti-inflammatory  activity, but seems to be less effective in transactivation of a number of genes, resulting in a lower  potential for side effects.",Non-OADS,/arxiv_data1/oa_pdf/8f/7a/dddt-8-745.PMC4061172.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/8f/7a/dddt-8-745.PMC4061172.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/8f/7a/dddt-8-745.PMC4061172.pdf
Available from: http://www.clinicaltrials.gov/ct2/show/NCT01163 643?term =nct01163643&rank =1.,Non-OADS,/arxiv_data1/oa_pdf/8f/7a/dddt-8-745.PMC4061172.pdf
Available from: http://www.clinicaltrials.gov/ct2/ show/NCT01591161?term =mapracorat&rank =3.,Non-OADS,/arxiv_data1/oa_pdf/8f/7a/dddt-8-745.PMC4061172.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/a1/ec/ijn-9-2863.PMC4061173.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nanomedicine 2014:9 2863–2877International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  2863RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/IJN.S5750 1Nanoparticles for hyperthermic therapy: synthesis  strategies and applications in glioblastoma Jyoti verma1,2 Sumit Lal1 Cornelis JF van Noorden3 1Department of Medicine, Harvard  Medical School, 2Division of  endocrinology, Diabetes and  Hypertension, Brigham and  women’s Hospital, Boston, MA, USA;   3Department of Cell Biology and  Histology, Academic Medical Centre,   University of Amsterdam, Amsterdam,   The Netherlands Correspondence: Sumit Lal   Department of Medicine, Harvard   Medical School, 221 Longwood Ave,   Boston, MA 02115, USA   email slal@research.bwh.harvard.ed uAbstract:  Glioblastoma multiforme (GBM) is the most common and most aggressive malignant  primary brain tumor in humans.",Non-OADS,/arxiv_data1/oa_pdf/a1/ec/ijn-9-2863.PMC4061173.pdf
"Available from: http://www.britannica.com/ EBchecked/topic/146902/Curie-poin t. Accessed October 14, 2013.",Non-OADS,/arxiv_data1/oa_pdf/a1/ec/ijn-9-2863.PMC4061173.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology  in diagnostics, therapeutics, and drug delivery systems throughout  the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/a1/ec/ijn-9-2863.PMC4061173.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/a1/ec/ijn-9-2863.PMC4061173.pdf
International Journal of Nanomedicine 2014:9submit your manuscript | www.dovepress.co m Dove press Dove press Dove pres s 2877Inorganic nanoparticles in hyperthermic ablation of glioblastoma  87. http://www.nanostart.de/en/news/press-releases/portfolio/ archive/2011/873-nanostart-holding-magforce-reimbursement-of- nanotherm-therapy.,Non-OADS,/arxiv_data1/oa_pdf/a1/ec/ijn-9-2863.PMC4061173.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/02/04/ijn-9-2879.PMC4061174.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nanomedicine 2014:9 2879–2889International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  2879OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S6139 2Journal name: International Journal of Nanomedicine Journal Designation: Original Research Y ear: 2014 Volume: 9 Running head verso: Liu et al Running head recto: Chitosan-based gene carrier for hepatoma cells DOI: http://dx.doi.org/10.2147/IJN.S61392 lanxia liu Xia Dong Dunwan Zhu liping song hailing Zhang Xigang g leng laboratory of Bioengineering,   Institute of Biomedical engineering,   chinese academy of Medical sciences  and Peking Union Medical college,   Tianjin Key laboratory of Biomedical  Materials, Tianjin, People’s republic  of china correspondence: Xigang leng lab of Bioengineering, Institute of  Biomedical engineering, chinese  academy of Medical sciences & Peking  Union Medical college, 236 Baidi road,  Nankai District, Tianjin 300192, People’s  republic of china email lengxgyky@163.co mTaT -lhrh conjugated low molecular   weight chitosan as a gene carrier specific   for hepatocellular carcinoma cells Abstract:  To develop a chitosan-based nonviral gene carrier capable of delivering genes  specifically into hepatoma cells, a bifunctional peptide composed of the TAT (transactivator  of transcription) peptide and luteinizing hormone-releasing hormone (LHRH) was conjugated  with low molecular weight chitosan, resulting in a TAT-LHRH-chitosan conjugate (TLC).",Non-OADS,/arxiv_data1/oa_pdf/02/04/ijn-9-2879.PMC4061174.pdf
"Dove pres sInternational Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/02/04/ijn-9-2879.PMC4061174.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.Dove pres s International Journal of Nanomedicine 2014:9submit your manuscript | www.dovepress.co m Dove press Dove press 2889chitosan-based gene carrier for hepatoma cells  23.,Non-OADS,/arxiv_data1/oa_pdf/02/04/ijn-9-2879.PMC4061174.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/df/c6/opth-8-1097.PMC4061175.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Ophthalmology 2014:8 1097–1104Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  1097Original researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/ 10.2147/OPTH.S6376 0Journal name: Clinical Ophthalmology Journal Designation: Original Research Y ear: 2014 Volume: 8 Running head verso: Schmier et al Running head recto: Patterns of adjunctive therapy use DOI: http://dx.doi.org/10.2147/OPTH.S63760 adjunctive therapy patterns in glaucoma patients  using prostaglandin analogs Jordana K schmier1 Carolyn K hulme-lowe1 David W Covert2 1exponent, alexandria, V a, Usa;    2alcon research ltd., Fort Worth,    TX, UsaPurpose:  To analyze patterns of use of adjunctive therapies among new initiators of topical  prostaglandin analogs (PGAs) in a managed care population.",Non-OADS,/arxiv_data1/oa_pdf/df/c6/opth-8-1097.PMC4061175.pdf
Available from: http://one.aao.org/Assets/56c908e3-a939-45ea- b12b-8fe609f547b0/634965436587800000/primary-open-angle- glaucoma-pdf.,Non-OADS,/arxiv_data1/oa_pdf/df/c6/opth-8-1097.PMC4061175.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journalClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/df/c6/opth-8-1097.PMC4061175.pdf
Visit http://www.dovepress.com/ testimonials.php to read real quotes from published authors.Dove pres s Clinical Ophthalmology 2014:8submit your manuscript | www.dovepress.co m Dove press Dove press 1104schmier et al  34.,Non-OADS,/arxiv_data1/oa_pdf/df/c6/opth-8-1097.PMC4061175.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/14/9b/ott-7-965.PMC4061176.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpOncoTargets and Therapy 2014:7 965–968OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  965Case RepORTopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S6217 4paraganglioma of the vagina: a case report   and review of the literature Tao Cai1 Yucong Li2 Qingming Jiang3 Dong Wang2 Yu Huang2 1Department of Dermatology, The  First affiliated Hospital of Chongqing  Medical University,  2Department of  Gynecologic Oncology,  3Department  of pathology, Chongqing Cancer  Research Institute, Chongqing,   people’s Republic of China Correspondence: Yu Huang   Department of Gynecologic Oncology,  Chongqing Cancer Research Institute,   181 Hanyu Road, shapingba, Chongqing   400030, people’s Republic of China   Tel/Fax +86 23 6507 5621  email amy_huang310@163.co mAbstract:  Vaginal paraganglioma is a rare and unusual tumor occurring in the vaginal wall.",Non-OADS,/arxiv_data1/oa_pdf/14/9b/ott-7-965.PMC4061176.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open access  journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/14/9b/ott-7-965.PMC4061176.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/14/9b/ott-7-965.PMC4061176.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/6a/da/ndt-10-1039.PMC4061177.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpNeuropsychiatric Disease and Treatment 2014:10 1039–1044Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1039OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/ 10.2147/NDT .S6475 1Journal name: Neuropsychiatric Disease and Treatment Journal Designation: Original Research Y ear: 2014 Volume: 10 Running head verso: De Pasquale et al Running head recto: Multiple sclerosis-percutaneous transluminal angioplasty QoL DOI: http://dx.doi.org/10.2147/NDT.S64751 correspondence: Michele Fornaro   Department of education science,  University of catania, via T eatro greco  n.84, 95125, catania, italy   T el +39 95 378 2629   Fax +39 95 378 2948   email dott.fornaro@gmail.co mcognitive functioning and subjective quality of life  in relapsing-remitting multiple sclerosis patients  before and after percutaneous transluminal  angioplasty: a preliminary report concetta De Pasquale1,2 Maria luisa Pistorio1 Massimiliano Veroux2 alessia giaquinta2 Pierfrancesco Veroux2 Michele Fornaro1 1Department of education science,   University of catania, catania,   italy; 2Vascular surgery and Organ  Transplant Unit, Department of  surgery Transplantation and advanced  T echnologies, University hospital   of catania, catania, italyBackground:  Multiple sclerosis (MS) is a disease of the nervous system that has profound  effects on everyday functioning and quality of life of not only the person who is diagnosed, but  also her/his family and acquaintances.",Non-OADS,/arxiv_data1/oa_pdf/6a/da/ndt-10-1039.PMC4061177.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/6a/da/ndt-10-1039.PMC4061177.pdf
"Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.Dove pres s Neuropsychiatric Disease and Treatment 2014:10submit your manuscript | www.dovepress.co m Dove press Dove press 1044De Pasquale et al Also, the inclusion of severe MS cases highlights the chance  of a recall bias in MS patients, potentially characterized by  a more pronounced cognitive decline (though the presence  of caregivers as an anamnestic source should have counter - balanced this).",Non-OADS,/arxiv_data1/oa_pdf/6a/da/ndt-10-1039.PMC4061177.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/04/87/ott-7-995.PMC4061178.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpOncoTargets and Therapy 2014:7 995–999OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  995Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S6268 7single incision versus conventional laparoscopic   resection in gastrointestinal stromal tumors:   a retrospective cohort analysis at a single   tertiary care center Jing Kong shuo-Dong Wu Yang su Ying Fan china Medical University   shengjing hospital, shenyang,    People’s republic of china correspondence: shuo-Dong Wu   china Medical University shengjing   hospital, shenyang, sanhao street,   #36, liaoning  110004,   People’s republic of china   Tel +86 24 966 1513 1211  email wushuodong_1980@163.co mBackground:  Single-incision laparoscopic surgery (SILS), an advanced form of minimally  invasive surgery, has recently been used for surgical management of gastrointestinal stromal  tumors (GIST).",Non-OADS,/arxiv_data1/oa_pdf/04/87/ott-7-995.PMC4061178.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open access  journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/04/87/ott-7-995.PMC4061178.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/04/87/ott-7-995.PMC4061178.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/1d/7f/cia-9-929.PMC4061179.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Interventions in Aging 2014:9 929–937Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  929OrIg InAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/ 10.2147/CIA.S6436 1Flavia Baderca1,2 Dana Vincze3 nicolae Balica4 Caius solovan5,6 1Department of Microscopic  Morphology, Victor Babes University  of Medicine and Pharmacy,   Timisoara, romania; 2service of  Pathology, emergency City hospital,   Timisoara, romania; 3Victor Babes  University of Medicine and Pharmacy,   Timisoara, romania; 4Otolaryngology  Department, 5Department of  Dermatology, Victor Babes  University of Medicine and Pharmacy,   Timisoara, romania; 6Department  of Dermatology, emergency City  hospital, Timisoara, romania Correspondence: Flavia Baderca   52 Cozia street, 300580, Timisoara,  romania   T el +40 7331 06101   Fax +40 2562 04900   email flaviabaderca@yahoo.co mMucosal melanomas in the elderly: challenging  cases and review of the literature Abstract:  Melanomas are malignant tumors that originate from melanocytes.",Non-OADS,/arxiv_data1/oa_pdf/1d/7f/cia-9-929.PMC4061179.pdf
"Nowadays, genetic studies have  demonstrated that melanomas are not a disease but are a family of diseases, with  mucosal melanomas playing a distinct, important, and specific role.5 The aim of the study The purpose of the study was to investigate the epidemiologic and morphologic data  of mucosal melanomas diagnosed at Emergency City Hospital (Timisoara, Romania)  during a period of 12 years.Journal name: Clinical Interventions in Aging Journal Designation: Original Research Y ear: 2014 Volume: 9 Running head verso: Baderca et al Running head recto: Mucosal melanomas in the elderly DOI: http://dx.doi.org/10.2147/CIA.S64361",Non-OADS,/arxiv_data1/oa_pdf/1d/7f/cia-9-929.PMC4061179.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lDove pres s Clinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/1d/7f/cia-9-929.PMC4061179.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/1d/7f/cia-9-929.PMC4061179.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/13/1b/ott-7-957.PMC4061180.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpOncoTargets and Therapy 2014:7 957–964OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  957Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S6492 1Prognosis of patients with hepatocellular  carcinoma and hypersplenism after surgery:  a single-center experience from the People’s  republic of china cong li hong Zhao Jianjun Zhao Zhiyu li Zhen huang Yefan Zhang Xinyu Bi Jianqiang cai Department of abdominal surgery,   cancer institute and hospital, Peking  Union Medical college and chinese  academy of Medical sciences, Beijing,   People’s republic of china correspondence: Jianqiang cai; Xinyu Bi   Department of abdominal surgery,  cancer institute and hospital, Peking  Union Medical college and chinese  academy of Medical sciences, Beijing  100021, People’s republic of china   Tel +86 10 8778 7100   Fax +86 10 6770 9001   email caijianqiang188@163.co m;  beexy1971@hotmail.co mPurpose:  As prognosis of patients with hepatocellular carcinoma (HCC) and hypersplenism  is rarely reported, this study examined prognostic factors for patients who underwent surgery  for this condition.",Non-OADS,/arxiv_data1/oa_pdf/13/1b/ott-7-957.PMC4061180.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open access  journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/13/1b/ott-7-957.PMC4061180.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/13/1b/ott-7-957.PMC4061180.pdf
This  is  an  open  access  article  under  the  CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"Stable  fearfulness  over  time increases one’s  likelihood  of  receiving  an  anxiety  diag- nosis (Chronis-Tuscano  et  al.,  2009)  and  quantiﬁcations of extreme  fearfulness  in  minimally-threatening  contexts http://dx.doi.org/10.1016/j.dcn.2014.03.001 1878-9293/©  2014  The  Authors.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-SA  license (http://creativecommons.org/licenses/by-nc-sa/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"133  (1), 1–24,  http://dx.doi.org/10.1037/0033-2909.133.1.1.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"J.  Psychiatry  158  (10),  1673–1679, http://dx.doi.org/10.1176/appi.ajp.158.10.1673.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"108  (3),  624–652, http://dx.doi.org/10.1037/0033-295X.108.3.624.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"39  (1),  1–8, http://dx.doi.org/10.1080/87565641.2013.826661.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"1  (2),  141–152, http://dx.doi.org/10.1016/j.dcn.2010.12.002.",OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"Psychol.,  1–14, http://dx.doi.org/10.1080/15374416.2013.769170.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"35  (2),  136–143, http://dx.doi.org/10.1177/0165025410375922.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"Psychiatry  48  (9),  928–935, http://dx.doi.org/10.1097/CHI.0b013e3181ae09df.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"Psychiatry  51  (10),  1066–1075, http://dx.doi.org/10.1016/j.jaac.2012.08.002, e1.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"56  (3), 173–189, http://dx.doi.org/10.1016/S0301-0511(01)00076-X.",OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"40  (6), 1123–1132, http://dx.doi.org/10.1037/0012-1649.40.6.1123.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"1  (2),  101–109, http://dx.doi.org/10.1016/j.dcn.2010.12.001.",OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"25  (3), 355–376,  http://dx.doi.org/10.1207/s15326942dn2503  6.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"Psychiatry  Allied  Disciplines  51  (4),  497–517, http://dx.doi.org/10.1111/j.1469-7610.2010.02228.x.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"Psychiatry  51  (4),  497–517, http://dx.doi.org/10.1111/j.1469-7610.2010.02228.x.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"Methods  134  (1),  9–21, http://dx.doi.org/10.1016/j.jneumeth.2003.10.009.",OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"72  (4),  1112–1134, http://dx.doi.org/10.1111/1467-8624.00337.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"34  (3–4),  285–310, http://dx.doi.org/10.1300/J002v34n03 05.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"78  (6),  447–455, http://dx.doi.org/10.1016/0013-4694(91)90062-9.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"51  (2–3),  87–107, http://dx.doi.org/10.1016/S0301-0511(99)00031-9.",OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"117  (1),  32–47, http://dx.doi.org/10.1037/0021-843X.117.1.32.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"64  (1–2),  77–90, http://dx.doi.org/10.1016/S0301-0511(03)00103-0.",OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"17 (4), 795–811,  http://dx.doi.org/10.1111/j.1467-9507.2008.00481.x.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"8  (6),  525–534, http://dx.doi.org/10.1111/j.1467-7687.2005.00444.x.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"109  (4),  679–709, http://dx.doi.org/10.1037/0033-295X.109.4.679.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"77  (2),  355–370, http://dx.doi.org/10.1111/j.1467-8624.2006.00875.x.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"31  (2),  181–191, http://dx.doi.org/10.1080/87565640701190775.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"Psychiatry  47  (10), 1073–1082, http://dx.doi.org/10.1111/j.1469-7610.2006.01654.x.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"10  (6),  874–891, http://dx.doi.org/10.1111/j.1467-7687.2007.00639.x.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"33  (5),  505–520, http://dx.doi.org/10.1007/s10802-005-6734-7.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"41  (3),  723, http://dx.doi.org/10.2307/1127219.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"Psychophysiology  46  (5),  957–961, http://dx.doi.org/10.1111/j.1469-8986.2009.00848.x.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"Psychophysiology  39  (2),  198–206, http://dx.doi.org/10.1111/1469-8986.3920198.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"39  (6),  885–895, http://dx.doi.org/10.1007/s10802-011-9495-5.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"Psychophysiology  49  (2),  239–247, http://dx.doi.org/10.1111/j.1469-8986.2011.01298.x.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"Neuropsychologia  42  (8),  1029–1040, http://dx.doi.org/10.1016/j.neuropsychologia.2003.12.012.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"29  (3), 431–445,  http://dx.doi.org/10.1207/s15326942dn2903  3.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"Psychophysiology 47 (2),  260–270, http://dx.doi.org/10.1111/j.1469-8986.2009.00942.x.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"Psychiatry  Allied  Disciplines  49  (1), 34–42, http://dx.doi.org/10.1111/j.1469-7610.2007.01822.x.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"19  (02),  455–480, http://dx.doi.org/10.1017/S0954579407070228.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"10  (2),  189–201, http://dx.doi.org/10.1111/1467-9507.00158.Tomoda, A.,  Suzuki,  H.,  Rabi,  K.,  Sheu,  Y.-S.,  Polcari,  A.,  Teicher,  M.H., 2009.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"2), T66–T71,  http://dx.doi.org/10.1016/j.neuroimage.2009.03.005.",OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"34  (6),  749–761, http://dx.doi.org/10.1080/87565640903265103.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"15  (5),  237–240, http://dx.doi.org/10.1111/j.1467-8721.2006.00443.x.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"Neuropsychologia  45  (8),  1649–1657, http://dx.doi.org/10.1016/j.neuropsychologia.2007.01.004.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"Psychiatry  47  (6),  560–567, http://dx.doi.org/10.1111/j.1469-7610.2005.01592.x.",Non-OADS,/arxiv_data1/oa_pdf/e0/51/main.PMC4061243.pdf
"During middle  childhood,  children’s  ER  skills  progress from rudimentary  behavioral  strategies  (e.g.,  covering  ears) http://dx.doi.org/10.1016/j.dcn.2014.02.003 1878-9293 ©  2014  The  Authors.",Non-OADS,/arxiv_data1/oa_pdf/fe/21/main.PMC4061244.pdf
"Supplementary  data Supplementary  data  associated  with  this  article  can  be found, in the online version,  at  http://dx.doi.org/10.1016/j.",OADS,/arxiv_data1/oa_pdf/fe/21/main.PMC4061244.pdf
Published  by  Elsevier  Ltd.   http://dx.doi.org/10.1016/j.dcn.2014.01.005Open access under CC BY-NC-SA license.,Non-OADS,/arxiv_data1/oa_pdf/57/5c/main.PMC4061265.pdf
"Supplementary  data Supplementary  data  associated  with  this  article can be  found,  in  the  online  version,  at  http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/57/5c/main.PMC4061265.pdf
"( Imaging Sci Dent 2014; 44: 103-13 ) KEY WORDS : Tooth Calcification; Tooth Eruption; Age Determination by Teeth; Radiography, PanoramicS Received September 6, 2013; Revised October 8, 2013; Accepted January 17, 2014 *Correspondence to : Dr. Beytullah KaradayUniversity of Istanbul, Cerrahpasa Faculty of Medicine, Forensic Medicine Depart-ment, Kocamustafapa  a street, 34098, Fatih, Istanbul, Turkey Tel) 90-212-414-30-00, Fax) 90-212-414-30-28, E-mail) bkaradayi1970@gmail.comImaging Science in Dentistry 2014; 44: 103-13 http://dx.doi.org/10.5624/isd.2014.44.2.103 Copyright ⓒ2014 by Korean Academy of Oral and Maxillofacial Radiology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://cr eativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is prop erly cited.",Non-OADS,/arxiv_data1/oa_pdf/80/22/isd-44-103.PMC4061293.pdf
"( Imaging Sci Dent 2014; 44: 115-9 ) KEY WORDS : Cone-Beam Computed Tomography; Radiography, Dental, Digital; Dental Pulp Cavity Received April 28, 2013; Revised June 10, 2013; Accepted June 20, 2013 *Correspondence to : Dr. Naghi AbbaszadehDepartment of Oral and Maxillofacial Radiology, Dental Faculty, Babol Universityof Medical Sciences, Ganj Afrooz Ave., Babol, Mazandaran Province, Iran Tel) 98-111-2291408 , Fax) 98-111-2291093 , E-mail) dr.abbaszadeh1@gmail.comImaging Science in Dentistry 2014; 44: 115-9 http://dx.doi.org/10.5624/isd.2014.44.2.115 Copyright ⓒ2014 by Korean Academy of Oral and Maxillofacial Radiology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://cr eativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is prop erly cited.",Non-OADS,/arxiv_data1/oa_pdf/a5/f4/isd-44-115.PMC4061294.pdf
"Received January 20, 2014; Revised February 21, 2014; Accepted February 27, 2014*Correspondence to : Prof. Reinhilde JacobsDepartment of Imaging and Pathology, Faculty of Medicine, University of Leuven,Kapucijnenvoer 7, Leuven 3000, Belgium Tel) 32-16-3-32410 , Fax) 32-16-3-32410 , E-mail) reinhilde.jacobs@uzleuven.beImaging Science in Dentistry 2014; 44: 121-8 http://dx.doi.org/10.5624/isd.2014.44.2.121 Copyright ⓒ2014 by Korean Academy of Oral and Maxillofacial Radiology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://cr eativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is prop erly cited.",Non-OADS,/arxiv_data1/oa_pdf/09/7f/isd-44-121.PMC4061295.pdf
"( Imaging Sci Dent 2014; 44: 129-35 ) KEY WORDS : Dental Implants; Bone and Bones; Computer -Assisted Image Analysis Received November 9, 2013; Revised February 13, 2014; Accepted February 22, 2014 *Correspondence to : Dr. Galal Omami Oral Diagnosis and Polyclinics, Faculty of Dentistry, The University of Hong Kong,1B/F, Prince Philip Dental Hospital, 34 Hospital Road, Hong Kong Tel) 852-2859 -0403 , Fax) 852-2559 -4194 , E-mail) jellodent@yahoo.comImaging Science in Dentistry 2014; 44: 129-35 http://dx.doi.org/10.5624/isd.2014.44.2.129 Copyright ⓒ2014 by Korean Academy of Oral and Maxillofacial Radiology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://cr eativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is prop erly cited.",Non-OADS,/arxiv_data1/oa_pdf/da/e7/isd-44-129.PMC4061296.pdf
"( Imaging Sci Dent 2014; 44: 137-41 ) KEY WORDS : Atherosclerosis; Radiography, Panoramic; Diagnosis Received October 24, 2013; Revised December 9, 2013; December 21, 2013 *Correspondence to : Prof. Jae -Seo Lee Department of Oral and Maxillofacial Radiology, School of Dentistry, ChonnamNational University, 77 Yongbong -ro, Buk -gu, Gwangju 500 -757, Korea Tel) 82-62-530-5680 , Fax) 82-62-530-5689 , E-mail) jsyi16@chonnam.ac.krImaging Science in Dentistry 2014; 44: 137-41 http://dx.doi.org/10.5624/isd.2014.44.2.137 Copyright ⓒ2014 by Korean Academy of Oral and Maxillofacial Radiology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://cr eativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is prop erly cited.",Non-OADS,/arxiv_data1/oa_pdf/f0/63/isd-44-137.PMC4061297.pdf
"Received October 12, 2013; Revised October 30, 2013; Accepted November 8, 2013*Correspondence to : Prof. Tae-Il KimDepartment of Periodontology, School of Dentistry, Seoul National University, 101Daehak-ro, Jongno-gu, Seoul 110-749, Korea Tel) 82-2-2072-2642 , Fax) 82-2-744-1349 , E-mail) periopf@snu.ac.krImaging Science in Dentistry 2014; 44: 143-8 http://dx.doi.org/10.5624/isd.2014.44.2.143 Copyright ⓒ2014 by Korean Academy of Oral and Maxillofacial Radiology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://cr eativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is prop erly cited.",Non-OADS,/arxiv_data1/oa_pdf/c4/df/isd-44-143.PMC4061298.pdf
"Received October 12, 2013; Revised November 26, 2013; Accepted December 4, 2013 *Correspondence to : Prof. Allison HunterGeorgia Regents University, College of Dental Medicine, Department of OralHealth and Diagnostic Sciences, GC 2248, 1120 15th Street, Augusta, GA 30912-1241, USA Tel) 1-706-721-4271 , Fax) 1-706-723-0212 , E-mail) ahunter@gru.eduImaging Science in Dentistry 2014; 44: 149-54 http://dx.doi.org/10.5624/isd.2014.44.2.149 Copyright ⓒ2014 by Korean Academy of Oral and Maxillofacial Radiology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://cr eativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is prop erly cited.",Non-OADS,/arxiv_data1/oa_pdf/ee/fe/isd-44-149.PMC4061299.pdf
Available from http://www.sciencedaily.com/releases/2005/04/050419111800.htm.,Non-OADS,/arxiv_data1/oa_pdf/ee/fe/isd-44-149.PMC4061299.pdf
"( Imaging Sci Dent 2014; 44: 155 -60) KEY WORDS : Medical Informatics Computing; User -Computer Interface; Diagnostic Imaging; Surgery, Oral Received November 7, 2013; Revised December 10, 2013; Accepted January 6, 2014 *Correspondence to : Dr. Guillermo M. RosaCORE Dental Clinic, Cordoba 432 (CP 3500), Resistencia, Chaco, Argentina Tel) 54-362-4607748 , Fax) 54-362-4449282 , E-mail) gmrosa@gigared.comImaging Science in Dentistry 2014; 44: 155-60 http://dx.doi.org/10.5624/isd.2014.44.2.155 Copyright ⓒ2014 by Korean Academy of Oral and Maxillofacial Radiology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://cr eativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is prop erly cited.",Non-OADS,/arxiv_data1/oa_pdf/49/e0/isd-44-155.PMC4061300.pdf
Availablefrom: https://www.youtube.com/watch?v=1dc8G5lTVtI.,Non-OADS,/arxiv_data1/oa_pdf/49/e0/isd-44-155.PMC4061300.pdf
"Teja Dental College, Tirupati517501, Andhra Pradesh, India Tel) 91-916-0604522 , Fax) 91-877-2275287 , E-mail) sureshomr@gmail.comImaging Science in Dentistry 2014; 44: 161-4 http://dx.doi.org/10.5624/isd.2014.44.2.161 Copyright ⓒ2014 by Korean Academy of Oral and Maxillofacial Radiology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://cr eativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is prop erly cited.",Non-OADS,/arxiv_data1/oa_pdf/37/8f/isd-44-161.PMC4061301.pdf
"(Imaging Sci Dent 2014; 44: 165-9 ) KEY WORDS : Cranial Fossa, Posterior; Cone-Beam Computed Tomography; Skull Base Neoplasms; Incidental Findings Received July 8, 2013; Revised December 11, 2013; Accepted December 15, 2013 *Correspondence to : Dr. Aniket B. JadhavDepartment of Diagnostic and Biomedical Sciences, University of Texas School ofDentistry at Houston, 7500 Cambridge St, Suite 5371, Houston, TX 77054, USA Tel) 1-713-486-4134 , Fax) 1-713-486-4416 , E-mail) dr.aniket.jadhav@gmail.comImaging Science in Dentistry 2014; 44: 165-9 http://dx.doi.org/10.5624/isd.2014.44.2.165 Copyright ⓒ2014 by Korean Academy of Oral and Maxillofacial Radiology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://cr eativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is prop erly cited.",Non-OADS,/arxiv_data1/oa_pdf/d7/75/isd-44-165.PMC4061302.pdf
"Lineu Prestes, 2227, São Paulo, SP 05508-000, Brazil Tel) 55-11-3091-7831 , Fax) 55-11-3091-7831 , E-mail) arthuro@usp.brImaging Science in Dentistry 2014; 44: 171-5 http://dx.doi.org/10.5624/isd.2014.44.2.171 Copyright ⓒ2014 by Korean Academy of Oral and Maxillofacial Radiology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://cr eativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is prop erly cited.",Non-OADS,/arxiv_data1/oa_pdf/00/f4/isd-44-171.PMC4061303.pdf
"( Imaging Sci Dent 2014; 44: 89-94 ) KEY WORDS : Cone -Beam Computed Tomography; Post Technique; Tooth Fracture Received June 13, 2013; Revised February 17, 2014; Accepted March 7, 2014 *Correspondence to : Prof. Soodeh SarikhaniDepartment of Oral and Maxillofacial Radiology, School of Dentistry, University ofGolestan, Naharkhoran Blvd, Gorgan 49178, Iran Tel) 98-171-5550700 , Fax) 98-171-4422860 , E-mail) e_soodeh@yahoo.comImaging Science in Dentistry 2014; 44: 89-94 http://dx.doi.org/10.5624/isd.2014.44.2.89 Copyright ⓒ2014 by Korean Academy of Oral and Maxillofacial Radiology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://cr eativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is prop erly cited.",Non-OADS,/arxiv_data1/oa_pdf/24/17/isd-44-89.PMC4061304.pdf
"04-2012-0058 from the SNUDH Research Fund.Received September 25, 2013; Revised October 17, 2013; Accepted October 23, 2013*Correspondence to : Prof. Min-Suk HeoDepartment of Oral and Maxillofacial Radiology, School of Dentistry, Seoul Natio-nal University, 101 Daehak-ro, Jongno-gu, Seoul 110-749, Korea Tel) 82-2-2072-3016 , Fax) 82-2-744-3919 , E-mail) hmslsh@snu.ac.krImaging Science in Dentistry 2014; 44: 95-102 http://dx.doi.org/10.5624/isd.2014.44.2.95 Copyright ⓒ2014 by Korean Academy of Oral and Maxillofacial Radiology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://cr eativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is prop erly cited.",Non-OADS,/arxiv_data1/oa_pdf/94/2c/isd-44-95.PMC4061305.pdf
"Keywords:  Knee joint, Root tear, Medial meniscus, Posterior horn, Arthroscopy, Modified pull out sutureOriginal Article Knee Surg Relat Res 2014;26(2):106-113 http://dx.doi.org/10.5792/ksrr.2014.26.2.106 pISSN 2234-0726 · eISSN 2234-2451 Knee Surgery & Related Research Received July 23, 2013; Revised November 6, 2013;  Accepted January 15, 2014 Correspondence to: Jin-Ho Cho, MD Department of Orthopaedic Surgery, Inje University Ilsan Paik Hospital,  170 Juhwa-ro, Ilsanseo-gu, Goyang 411-706, Korea T el: +82-31-910-9733, Fax: +82-31-910-7967 E-mail: osd07@paik.ac.krIntroduction Transection of the posterior horn of the medial meniscus de - stroys the ability of the meniscus to withstand hoop tension.",Non-OADS,/arxiv_data1/oa_pdf/1d/f7/ksrr-26-106.PMC4061404.pdf
"For complete radial tears of the  106This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/1d/f7/ksrr-26-106.PMC4061404.pdf
"Keywords:  Knee joint, Quadriceps,T endon injuries, Epileptic seizuresCase Report Knee Surg Relat Res 2014;26(2):114-116 http://dx.doi.org/10.5792/ksrr.2014.26.2.114 pISSN 2234-0726 · eISSN 2234-2451 Knee Surgery & Related Research Received July 25, 2013; Revised (1st) September 17, 2013;   (2nd) November 14, 2013; Accepted February 27, 2014 Correspondence to: Mehmet Sabri Balik, MD Department of Orthopaedic and Traumatology, Recep Tayyip Erdogan  University School of Medicine, Islampasa Mahallesi, Sehitler Caddesi,  No: 74, 53100, Rize, T urkey T el: +90-464-213-0491, Fax: +90-464-212-3015 E-mail: sabribalik@yahoo.comA quadriceps tendon (QT) rupture can be encountered in all  age groups.",Non-OADS,/arxiv_data1/oa_pdf/e6/c2/ksrr-26-114.PMC4061405.pdf
"114This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/e6/c2/ksrr-26-114.PMC4061405.pdf
"Keywords:  Popliteal artery, Pseudoaneurysm, Arthroplasty Case Report Knee Surg Relat Res 2014;26(2):117-120 http://dx.doi.org/10.5792/ksrr.2014.26.2.117 pISSN 2234-0726 · eISSN 2234-2451 Knee Surgery & Related Research Received July 19, 2013; Revised (1st) September 16, 2013;   (2nd) October 22, 2013; Accepted October 30, 2013 Correspondence to: Seung-Beom Han, MD Department of Orthopedic Surgery, Korea University Anam Hopital,  Korea University College of Medicine, 73 Inchon-ro, Seongbuk-gu,  Seoul 136-705, Korea T el: +82-2-920-5692, Fax: +82-2-924-2471 E-mail: oshan@korea.ac.krComplications involving injury to neurological and vascular  structures are infrequently reported after total knee arthroplasty  (TKA).",Non-OADS,/arxiv_data1/oa_pdf/fc/bb/ksrr-26-117.PMC4061406.pdf
"Thus, in the present report, we describe popliteal artery pseu - 117This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/fc/bb/ksrr-26-117.PMC4061406.pdf
"Keywords:  Knee, Anterior cruciate ligament, Popliteal artery, PsedoaneurysmCase Report Knee Surg Relat Res 2014;26(2):121-124 http://dx.doi.org/10.5792/ksrr.2014.26.2.121 pISSN 2234-0726 · eISSN 2234-2451 Knee Surgery & Related Research Received July 15, 2013; Revised October 4, 2013;   Accepted December 12, 2013 Correspondence to: Gwang Chul Lee, MD Department of Orthopaedic Surgery, Chosun University Hospital,   365 Pilmun-daero, Dong-gu, Gwangju 501-717, Korea T el: +82-62-220-3147, Fax: +82-62-226-3379 E-mail: smileleekci@gmail.comInjury of the popliteal artery from knee arthroscopy is uncom - mon and few cases have been reported after anterior cruciate  ligament (ACL) reconstruction1-5).",Non-OADS,/arxiv_data1/oa_pdf/ad/ba/ksrr-26-121.PMC4061407.pdf
"The patient had a medical history of re-revision of ACL  121This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ad/ba/ksrr-26-121.PMC4061407.pdf
"Keywords:  Knee, Arthroplasty, Instability, Prosthesis failureReview Article Knee Surg Relat Res 2014;26(2):61-67 http://dx.doi.org/10.5792/ksrr.2014.26.2.61 pISSN 2234-0726 · eISSN 2234-2451 Knee Surgery & Related Research Received December 5, 2013; Revised January 2, 2014;   Accepted February 24, 2014 Correspondence to: Y oung-W an Moon, MD Department of Orthopedic Surgery, Samsung Medical Center,  Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam- gu, Seoul 135-710, Korea  T el: +82-2-3410-3533, Fax: +82-2-3410-0061 E-mail: ywmoon@skku.eduIntroduction T otal knee arthropalsty (TKA) has demonstrated superior effi - cacy in terms of pain relief and functional improvement, and the  10-year survival rates of the surgical procedure have been report - ed to be ≥90%1,2).",Non-OADS,/arxiv_data1/oa_pdf/c1/35/ksrr-26-61.PMC4061408.pdf
"Although revision TKA has been considered necessary in only  2%−3.1% of the patients after primary TKA4,5), it seems reason - able to expect that the increasing volume of primary TKA will  61This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c1/35/ksrr-26-61.PMC4061408.pdf
"Keywords:  Knee, Meniscus, RepairReview Article Knee Surg Relat Res 2014;26(2):68-76 http://dx.doi.org/10.5792/ksrr.2014.26.2.68 pISSN 2234-0726 · eISSN 2234-2451 Knee Surgery & Related Research Received November 4, 2013; Revised December 24, 2013;   Accepted January 15, 2014 Correspondence to: Keun Ho Park, MD Department of Orthopaedic Surgery, Kyung Hee University School of  Medicine, 23 Kyungheedae-ro, Dongdaemun-gu, Seoul 130-872, Korea T el: +82-2-958-8348, Fax: +82-2-964-3865 E-mail: khpark79@naver.comIntroduction The meniscus is responsible for load transmission and shock  absorption of the tibiofemoral joint in the human knee1,2).",Non-OADS,/arxiv_data1/oa_pdf/3f/01/ksrr-26-68.PMC4061409.pdf
"In contrast,  68This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/3f/01/ksrr-26-68.PMC4061409.pdf
"Keywords:  Knee, Arthroplasty, Navigation, Hip joint position, Flexion gapOriginal Article Knee Surg Relat Res 2014;26(2):77-81 http://dx.doi.org/10.5792/ksrr.2014.26.2.77 pISSN 2234-0726 · eISSN 2234-2451 Knee Surgery & Related Research Received December 31, 2013; Revised (1st) February 25, 2014;   (2nd) March 11, 2014; Accepted March 14, 2014 Correspondence to: Choong Hyeok Choi, MD Department of Orthopaedic Surgery, Hanyang University College of  Medicine, 222, W angsimni-ro, Seongdong-gu, Seoul 133-791, Korea T el: +82-2-2290-8485, Fax: +82-2-2299-3774 E-mail: chhchoi@hanyang.ac.krIntroduction An essential principle in total knee arthroplasty (TKA) is soft  tissue balance that is obtained by symmetrical medial and lateral  flexion-extension gaps in the coronal plane1-3).",Non-OADS,/arxiv_data1/oa_pdf/25/b8/ksrr-26-77.PMC4061410.pdf
"It has been traditionally perceived that the extension gap of the  knee should be assessed with both the hip and knee in neutral  77This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/25/b8/ksrr-26-77.PMC4061410.pdf
"Keywords:  Knee, Unicompartmental, Arthroplasty, Implant, OverhangOriginal Article Knee Surg Relat Res 2014;26(2):82-87 http://dx.doi.org/10.5792/ksrr.2014.26.2.82 pISSN 2234-0726 · eISSN 2234-2451 Knee Surgery & Related Research Received August 22, 2013; Revised (1st) January 28, 2014;   (2nd) May 11, 2014; Accepted May 15, 2014 Correspondence to: Y ong In, MD Department of Orthopaedic Surgery, Seoul St. Mary’ s Hospital, The  Catholic University of Korea College of Medicine, 222 Banpo-daero,  Seocho-gu, Seoul 137-701, Korea T el: +82-2-2258-2838, Fax: +82-2-535-9834 E-mail: iy1000@catholic.ac.kr Introduction Although unicompartmental knee arthroplasty (UKA) has  been accepted as a reliable procedure for the management of pa - tients with arthritis limited to one compartment of the knee1,2), it  is still considered as a technically demanding procedure3).",Non-OADS,/arxiv_data1/oa_pdf/27/7c/ksrr-26-82.PMC4061411.pdf
"While  a good size match between the component and the resected sur - 82This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/27/7c/ksrr-26-82.PMC4061411.pdf
"Keywords:  Knee, Tibia, V arus, Y oung adult, Corrective osteotomy, Intramedullary nailing Original Article Knee Surg Relat Res 2014;26(2):88-96 http://dx.doi.org/10.5792/ksrr.2014.26.2.88 pISSN 2234-0726 · eISSN 2234-2451 Knee Surgery & Related Research Received January 15, 2014; Revised February 10, 2014;   Accepted March 10, 2014 Correspondence to: Sang Hak Lee, MD Department of Orthopaedic Surgery, Center for Joint Diseases and  Rheumatism, Kyung Hee University Hospital at Gangdong, 892  Dongnam-ro, Gangdong-gu, Seoul 134-727, Korea T el: +82-2-440-6170, Fax: +82-2-440-6296 E-mail: sangdory@hanmail.net Introduction Mechanical axis derangement arising out of either a varus or  valgus deformity in the lower limb will subject the knee to accel - erated degeneration and further deformity1-3).",Non-OADS,/arxiv_data1/oa_pdf/a0/72/ksrr-26-88.PMC4061412.pdf
"In the recent literature,  88This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/a0/72/ksrr-26-88.PMC4061412.pdf
"Keywords:  Knee, Anterior cruciate ligament reconstruction, Arthroscopy, Anteromedial portal, Computed tomographyOriginal Article Knee Surg Relat Res 2014;26(2):97-105 http://dx.doi.org/10.5792/ksrr.2014.26.2.97 pISSN 2234-0726 · eISSN 2234-2451 Knee Surgery & Related Research Received September 6, 2013; Revised February 19, 2014;   Accepted April 10, 2014 Correspondence to: Y oon Sub Hwang, MD Department of Orthopedic Surgery, Eulji University School of Medicine,  77 Gyeryong-ro 771beon-gil, Jung-gu, Daejeon 301-746, Korea T el: +82-42-611-3279, Fax: +82-42-259-1289 E-mail: poxkoreana@gmail.comIntroduction Single-bundle anterior cruciate ligament (ACL) reconstruction  is the most common surgical intervention for ACL injuries ac - companied by pain, functional impairment, and joint instability,  and its efficacy has been demonstrated in a variety of studies1-3).",Non-OADS,/arxiv_data1/oa_pdf/74/0b/ksrr-26-97.PMC4061413.pdf
"97This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/74/0b/ksrr-26-97.PMC4061413.pdf
Contents lists available at ScienceDirect Respiratory Medicine Case Reports journal homepage: www.el sevier.com/locate/rmcr http://dx.doi.org/10.1016/j.rmcr.2013.12.004 2213-0071/C2112014TheAuthors.PublishedbyElsevierLtd.Respiratory Medicine Case Reports 12 (2014) 52 e54 Open access under CC BY-NC-ND license .,Non-OADS,/arxiv_data1/oa_pdf/93/8d/main.PMC4061419.pdf
Contents lists available at ScienceDirect Respiratory Medicine Case Reports journal homepage: www.elsevier.com/locate/rmcr http://dx.doi.org/10.1016/j.rmcr.2013.11.003 2213-0071/C2112014TheAuthors.PublishedbyElsevierLtd.Respiratory Medicine Case Reports 12 (2014) 19 e21 Open access under CC BY-NC-ND license .,Non-OADS,/arxiv_data1/oa_pdf/24/20/main.PMC4061420.pdf
This is an open access article under the CC BY-NC-SA license ( http://creativecommons.org/licenses/by-nc-sa/3.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f5/50/main.PMC4061421.pdf
Contents lists available at ScienceDirect Respiratory Medicine Case Reports journal homepage: www.el sevier.com/locate/rmcr http://dx.doi.org/10.1016/j.rmcr.2014.03.003 2213-0071/ /C2112014 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/f5/50/main.PMC4061421.pdf
This is an open access article under the CC BY-NC-SA license ( http://creativecommons.org/licenses/by-nc-sa/3.0/ ).Respiratory Medicine Case Reports 12 (2014) 50 e51,Non-OADS,/arxiv_data1/oa_pdf/f5/50/main.PMC4061421.pdf
Congenital lobar emphysema in pregnancy thorax 1995;50(8): 909e10.http://dx.doi.org/10.1136/thx.50.8.909 .,Non-OADS,/arxiv_data1/oa_pdf/f5/50/main.PMC4061421.pdf
http://dx.doi.org/10.1136/ thx.29.2.237 .,Non-OADS,/arxiv_data1/oa_pdf/f5/50/main.PMC4061421.pdf
Contents lists available at ScienceDirect Respiratory Medicine Case Reports journal homepage: www.el sevier.com/locate/rmcr http://dx.doi.org/10.1016/j.rmcr.2013.11.002 2213-0071/C2112014TheAuthors.PublishedbyElsevierLtd.Respiratory Medicine Case Reports 12 (2014) 24 e26 Open access under CC BY-NC-ND license .,Non-OADS,/arxiv_data1/oa_pdf/2d/30/main.PMC4061422.pdf
Contents lists available at ScienceDirect Respiratory Medicine Case Reports journal homepage: www.el sevier.com/locate/rmcr http://dx.doi.org/10.1016/j.rmcr.2013.12.009 2213-0071/C2112014TheAuthor.PublishedbyElsevierLtd.Respiratory Medicine Case Reports 12 (2014) 34 e36 Open access under CC BY-NC-SA license.,Non-OADS,/arxiv_data1/oa_pdf/a7/e8/main.PMC4061423.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/3.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f0/8a/main.PMC4061429.pdf
Contents lists available at ScienceDirect Respiratory Medicine Case Reports journal homepage: www.elsevier.com/locate/rmcr http://dx.doi.org/10.1016/j.rmcr.2014.03.001 2213-0071/ /C2112014 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/f0/8a/main.PMC4061429.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/3.0/ ).Respiratory Medicine Case Reports 12 (2014) 37 e38,Non-OADS,/arxiv_data1/oa_pdf/f0/8a/main.PMC4061429.pdf
Contents lists available at ScienceDirect Respiratory Medicine Case Reports journal homepage: www.el sevier.com/locate/rmcr http://dx.doi.org/10.1016/j.rmcr.2014.02.002 2213-0071//C2112014TheAuthors.PublishedbyElsevierLtd.Respiratory Medicine Case Reports 12 (2014) 16 e18 Open access under CC BY-NC-ND license .,Non-OADS,/arxiv_data1/oa_pdf/c1/6f/main.PMC4061430.pdf
Contents lists available at ScienceDirect Respiratory Medicine Case Reports journal homepage: www.elsevier.com/locate/rmcr http://dx.doi.org/10.1016/j.rmcr.2013.12.007 2213-0071//C2112014TheAuthors.PublishedbyElsevierLtd.Respiratory Medicine Case Reports 12 (2014) 13 e15 Open access under CC BY-NC-ND license .,Non-OADS,/arxiv_data1/oa_pdf/dc/f8/main.PMC4061431.pdf
Contents lists available at ScienceDirect Respiratory Medicine Case Reports journal homepage: www.el sevier.com/locate/rmcr http://dx.doi.org/10.1016/j.rmcr.2013.12.011 2213-0071/C2112014TheAuthors.PublishedbyElsevierLtd.Respiratory Medicine Case Reports 12 (2014) 10 e12 Open access under CC BY-NC-SA license.,Non-OADS,/arxiv_data1/oa_pdf/81/55/main.PMC4061432.pdf
Contents lists available at ScienceDirect Respiratory Medicine Case Reports journal homepage: www.el sevier.com/locate/rmcr http://dx.doi.org/10.1016/j.rmcr.2013.11.001 2213-0071/C2112014TheAuthors.PublishedbyElsevierLtd.Respiratory Medicine Case Reports 12 (2014) 22 e23 Open access under CC BY-NC-ND license .,Non-OADS,/arxiv_data1/oa_pdf/fe/bb/main.PMC4061433.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/3.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7d/0d/main.PMC4061434.pdf
Contents lists available at ScienceDirect Respiratory Medicine Case Reports journal homepage: www.elsevier.com/locate/rmcr http://dx.doi.org/10.1016/j.rmcr.2014.04.003 2213-0071/ /C2112014 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/7d/0d/main.PMC4061434.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/3.0/ ).Respiratory Medicine Case Reports 12 (2014) 55 e58,Non-OADS,/arxiv_data1/oa_pdf/7d/0d/main.PMC4061434.pdf
Contents lists available at ScienceDirect Respiratory Medicine Case Reports journal homepage: www.elsevier.com/locate/rmcr http://dx.doi.org/10.1016/j.rmcr.2013.12.005 2213-0071/C2112014TheAuthors.PublishedbyElsevierLtd.Respiratory Medicine Case Reports 12 (2014) 7 e9 Open access under CC BY-NC-ND license .,Non-OADS,/arxiv_data1/oa_pdf/3e/fa/main.PMC4061435.pdf
Contents lists available at ScienceDirect Respiratory Medicine Case Reports journal homepage: www.elsevier.com/locate/rmcr http://dx.doi.org/10.1016/j.rmcr.2013.12.012 2213-0071//C2112014TheAuthors.PublishedbyElsevierLtd.Respiratory Medicine Case Reports 12 (2014) 27 e29 Open access under CC BY-NC-ND license .,Non-OADS,/arxiv_data1/oa_pdf/cb/7d/main.PMC4061436.pdf
Contents lists available at ScienceDirect Respiratory Medicine Case Reports journal homepage: www.elsevier.com/locate/rmcr http://dx.doi.org/10.1016/j.rmcr.2013.10.003 2213-0071//C2112013TheAuthors.PublishedbyElsevierLtd.Respiratory Medicine Case Reports 12 (2014) 41 e43 Open access under CC BY-NC-ND license .,Non-OADS,/arxiv_data1/oa_pdf/22/23/main.PMC4061437.pdf
Contents lists available at ScienceDirect Respiratory Medicine Case Reports journal homepage: www.elsevier.com/locate/rmcr http://dx.doi.org/10.1016/j.rmcr.2014.02.003 2213-0071//C2112014TheAuthors.PublishedbyElsevierLtd.Respiratory Medicine Case Reports 12 (2014) 1 e3 Open access under CC BY-NC-ND license .,Non-OADS,/arxiv_data1/oa_pdf/8c/94/main.PMC4061439.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/3.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/de/22/main.PMC4061440.pdf
Contents lists available at ScienceDirect Respiratory Medicine Case Reports journal homepage: www.el sevier.com/locate/rmcr http://dx.doi.org/10.1016/j.rmcr.2014.04.002 2213-0071/ /C2112014 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/de/22/main.PMC4061440.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/3.0/ ).Respiratory Medicine Case Reports 12 (2014) 44 e46,Non-OADS,/arxiv_data1/oa_pdf/de/22/main.PMC4061440.pdf
[2]http://www.aida-international.org .,Non-OADS,/arxiv_data1/oa_pdf/de/22/main.PMC4061440.pdf
Contents lists available at ScienceDirect Respiratory Medicine Case Reports journal homepage: www.elsevier.com/locate/rmcr http://dx.doi.org/10.1016/j.rmcr.2013.12.010 2213-0071//C2112014TheAuthors.PublishedbyElsevierLtd.Respiratory Medicine Case Reports 12 (2014) 47 e49 Open access under CC BY-NC-ND license .,Non-OADS,/arxiv_data1/oa_pdf/1b/7b/main.PMC4061441.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/3.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7b/b4/main.PMC4061442.pdf
Contents lists available at ScienceDirect Respiratory Medicine Case Reports journal homepage: www.el sevier.com/locate/rmcr http://dx.doi.org/10.1016/j.rmcr.2014.03.002 2213-0071/ /C2112014 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/7b/b4/main.PMC4061442.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/3.0/ ).Respiratory Medicine Case Reports 12 (2014) 30 e33,Non-OADS,/arxiv_data1/oa_pdf/7b/b4/main.PMC4061442.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/3.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/b4/bb/main.PMC4061443.pdf
Contents lists available at ScienceDirect Respiratory Medicine Case Reports journal homepage: www.elsevier.com/locate/rmcr http://dx.doi.org/10.1016/j.rmcr.2014.04.004 2213-0071/ /C2112014 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/b4/bb/main.PMC4061443.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/3.0/ ).Respiratory Medicine Case Reports 12 (2014) 59 e62,Non-OADS,/arxiv_data1/oa_pdf/b4/bb/main.PMC4061443.pdf
Contents lists available at ScienceDirect Respiratory Medicine Case Reports journal homepage: www.elsevier.com/locate/rmcr http://dx.doi.org/10.1016/j.rmcr.2013.10.005 2213-0071/C2112014TheAuthors.PublishedbyElsevierLtd.Respiratory Medicine Case Reports 12 (2014) 39 e40 Open access under CC BY-NC-SA license.,Non-OADS,/arxiv_data1/oa_pdf/0b/e0/main.PMC4061444.pdf
Contents lists available at ScienceDirect Respiratory Medicine Case Reports journal homepage: www.el sevier.com/locate/rmcr http://dx.doi.org/10.1016/j.rmcr.2013.12.008 2213-0071/C2112014TheAuthors.PublishedbyElsevierLtd.Respiratory Medicine Case Reports 12 (2014) 4 e6 Open access under CC BY-NC-SA license.,Non-OADS,/arxiv_data1/oa_pdf/a3/1a/main.PMC4061445.pdf
"Materials and methods Informatics Whole exome somatic variants, gene expression, clinical, and epidemiological data were downloaded from The Can- cer Genome Atlas Breast Invasive Carcinoma data portal(https://tcga-data.nci.nih.gov/tcga/tcgaCancerDetails.jsp?di seaseType=BRCA&diseaseName=Breast%20invasive%20 carcinoma ).",OADS,/arxiv_data1/oa_pdf/b1/86/10549_2014_Article_2991.PMC4061465.pdf
FDA (2010) http://www.fda.gov/ drugs/drugsafety/ucm224370.htm .,Non-OADS,/arxiv_data1/oa_pdf/19/63/134_2014_Article_3323.PMC4061476.pdf
EMA (2012) http://www.ema.europa.,Non-OADS,/arxiv_data1/oa_pdf/19/63/134_2014_Article_3323.PMC4061476.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/fe/d1/srep05341.PMC4061542.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 5341 | DOI: 10.1038/srep05341 6",Non-OADS,/arxiv_data1/oa_pdf/fe/d1/srep05341.PMC4061542.pdf
"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 12, S0925–4439, doi:http://dx.doi.org/10.1016/j.bbadis.2012.11.021 (2012).",OADS,/arxiv_data1/oa_pdf/3b/f8/srep05336.PMC4061543.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 5336 | DOI: 10.1038/srep05336 7",Non-OADS,/arxiv_data1/oa_pdf/3b/f8/srep05336.PMC4061543.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/23/a2/srep05338.PMC4061544.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 5338 | DOI: 10.1038/srep05338 7",Non-OADS,/arxiv_data1/oa_pdf/23/a2/srep05338.PMC4061544.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 5333 | DOI: 10.1038/srep05333 10",Non-OADS,/arxiv_data1/oa_pdf/95/03/srep05333.PMC4061545.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/a3/b9/srep05344.PMC4061546.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/55/44/srep05343.PMC4061549.pdf
"Yokogawa, AQ6370C Optical Spectrum Analyzer, http://tmi.yokogawa.com/files/ uploaded/BUAQ6370SR_10EN_010.pdf (June 2011) Date of access: 29/05/2014.",OADS,/arxiv_data1/oa_pdf/c3/54/srep05351.PMC4061551.pdf
"Nikon, A. F.-S. DX Nikkor 18–300 mm f/3.5–5.6 G, http://imaging.nikon.com/ lineup/lens/zoom/normalzoom/af-s_dx_18-300mmf_35-56g_ed_vr/index.htm (June 2012) Date of access: 29/05/2014.",Non-OADS,/arxiv_data1/oa_pdf/c3/54/srep05351.PMC4061551.pdf
"Mesa Photonics, FROG Scan Users Manual, http://www.mesaphotonics.com/wp- content/themes/Mesaphotonics/images/Frog%20Scan%20Flyer%202011.pdf(April 2011) Date of access: 29/05/2014.",OADS,/arxiv_data1/oa_pdf/c3/54/srep05351.PMC4061551.pdf
"Aragon Photonics, BOSA100 & 200 series – Brillouin High Resolution OSA, http://aragonphotonics.com/?page_id 5149 (March 2014) Date of access: 29/05/ 2014.",Non-OADS,/arxiv_data1/oa_pdf/c3/54/srep05351.PMC4061551.pdf
All authorscontributed to the preparation of the manuscript.Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/c3/54/srep05351.PMC4061551.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 5351 | DOI: 10.1038/srep05351 8",Non-OADS,/arxiv_data1/oa_pdf/c3/54/srep05351.PMC4061551.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests : The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/c4/07/srep05342.PMC4061552.pdf
"URLs .PLINK software v1.07, http://pngu.mgh.harvard.edu/ ,purcell/plink/; EIGENSTRAT software v3.0, http://genetics.med.harvard.edu/reich/Reich_Lab/ Welcome.html; MACH ver.",OADS,/arxiv_data1/oa_pdf/d6/3d/srep05340.PMC4061553.pdf
"1.1.9 softwares, http://www.sph.umich.edu/csg/abecasis/MACH/index.html; Haploview v4.2, http://www.",Non-OADS,/arxiv_data1/oa_pdf/d6/3d/srep05340.PMC4061553.pdf
"R programs, http://www.r-project.org/; SIFT dbSNP DB (build 132), http://sift.jcvi.org/; PolyPhen-2 version 2.2.2 r398, http://genetics.bwh.",Non-OADS,/arxiv_data1/oa_pdf/d6/3d/srep05340.PMC4061553.pdf
"Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: This study has been completed under the Collaborative Research Agreement executed by Kyoto Prefectural University of Medicine and Santen Pharmaceutical Co., Ltd. All materials and information produced throughout this study are parts of co-owned intellectual properties.",OADS,/arxiv_data1/oa_pdf/d6/3d/srep05340.PMC4061553.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/c3/48/srep05346.PMC4061554.pdf
"Results The studies are based on a publicly available dataset (WISE 2012Challenge, http://www.wise2012.cs.ucy.ac.cy/challenge.html) col- lected from Sina Weibo, the largest Chinese micro blogging website, like Twitter.",OADS,/arxiv_data1/oa_pdf/4a/ac/srep05334.PMC4061555.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests : The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/4a/ac/srep05334.PMC4061555.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 5334 | DOI: 10.1038/srep05334 6",Non-OADS,/arxiv_data1/oa_pdf/4a/ac/srep05334.PMC4061555.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/85/bd/srep05294.PMC4061557.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 5294 | DOI: 10.1038/srep05294 9",Non-OADS,/arxiv_data1/oa_pdf/85/bd/srep05294.PMC4061557.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 5337 | DOI: 10.1038/srep05337 7",Non-OADS,/arxiv_data1/oa_pdf/5a/71/srep05337.PMC4061558.pdf
"Surgical Neurology InternationalEditor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.comOriginal Article Visualization of luminal thrombosis and mural Iron accumulation  in giant aneurysms with Ex vivo  4.7T magnetic resonance imaging Petri Honkanen1, Juhana K Frösen1,3, Usama Abo‑Ramadan2, Juha A Hernesniemi1,3,  Mika R Niemelä1,3 1Neurosurgery Research Group, Biomedicum Helsinki, 2Experimental MRI Laboratory, Department of Neurology, 3Department of Neurosurgery,   Helsinki University Central Hospital, Helsinki, Finland E‑mail:  Petri Honkanen; *Juhana Frösen ‑ juhana.frosen@hus.fi; Usama‑Abo‑Ramadan ‑ usama.abo‑ramadan@hus.fi;   Juha Hernesniemi ‑ juha.hernesniemi@hus.fi; Mika Niemelä ‑ mika.niemela@hus.fi   *Corresponding author Received: 15 May 13  Accepted: 14 March 14  Published: 21 May 14 Access this article  online Website: www.surgicalneurologyint.com DOI:   10.4103/2152-7806.132960 Quick Response Code: Abstract Background: Better diagnostic tools to identify rupture‑prone saccular intracranial  aneurysms (sIA)  are needed.",Non-OADS,/arxiv_data1/oa_pdf/cd/f5/SNI-5-74.PMC4061574.pdf
Available FREE in open access from: http://www.surgicalneurologyint.com/text.asp?2014/5/1/74/132960 Copyright: © 2014 Honkanen P .,Non-OADS,/arxiv_data1/oa_pdf/cd/f5/SNI-5-74.PMC4061574.pdf
"Surgical Neurology International 2014, 5:74  http://www.surgicalneurologyint.com/content/5/1/74INTRODUCTION Despite advances in microsurgical and endovascular  therapies, preventive treatment of saccular intracranial  aneurysms (sIA) is not without risk of morbidity and  mortality.",Non-OADS,/arxiv_data1/oa_pdf/cd/f5/SNI-5-74.PMC4061574.pdf
"Analysis of MRI scans MR images were reviewed on a Macintosh workstation  using OsiriX software (OsiriX version 5.5.1, open source,  http://www.osirix‑viewer.com).",OADS,/arxiv_data1/oa_pdf/cd/f5/SNI-5-74.PMC4061574.pdf
"Surgical Neurology International 2014, 5:74  http://www.surgicalneurologyint.com/content/5/1/74inspection of apparent signal intensity (SI), a region of  interest (ROI) analysis was performed.",Non-OADS,/arxiv_data1/oa_pdf/cd/f5/SNI-5-74.PMC4061574.pdf
"Surgical Neurology International 2014, 5:74  http://www.surgicalneurologyint.com/content/5/1/74thrombus did significantly differ from the SI of the aneurysm  wall with or without iron accumulation ( P < 0.001 and  0.027, respectively, Wilcoxon sign test) demonstrating the  capability of MRI to discriminate thrombus in the luminal  surface of the aneurysm from the aneurysm wall itself.",Non-OADS,/arxiv_data1/oa_pdf/cd/f5/SNI-5-74.PMC4061574.pdf
"Surgical Neurology International 2014, 5:74  http://www.surgicalneurologyint.com/content/5/1/74and iron in the sIA wall, but a source of matrix degrading  proteases, as well as an inducer of inflammation in the  aneurysm wall.",Non-OADS,/arxiv_data1/oa_pdf/cd/f5/SNI-5-74.PMC4061574.pdf
"Surgical Neurology InternationalEditor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.comCase Report Intraosseous Angiolipoma of the Cranium: Case report and review  of the literature Lananh Nguyen, Nathan T .",Non-OADS,/arxiv_data1/oa_pdf/b9/ef/SNI-5-79.PMC4061575.pdf
"Available FREE in open access from: http://www.surgicalneurologyint.com/text.asp?2014/5/1/79/133304 Copyright: © 2014 Nguyen L. This is an open‑access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use,  distribution, and reproduction in any medium, provided the original author and source are credited.",Non-OADS,/arxiv_data1/oa_pdf/b9/ef/SNI-5-79.PMC4061575.pdf
"Surgical Neurology International 2014, 5:79  http://www.surgicalneurologyint.com/content/5/1/79discharge.",Non-OADS,/arxiv_data1/oa_pdf/b9/ef/SNI-5-79.PMC4061575.pdf
"Surgical Neurology International 2014, 5:79  http://www.surgicalneurologyint.com/content/5/1/79two‑staged surgical resection after the lesion grew to  being 7 cm in size.",Non-OADS,/arxiv_data1/oa_pdf/b9/ef/SNI-5-79.PMC4061575.pdf
"Surgical Neurology International 2014, 5:79  http://www.surgicalneurologyint.com/content/5/1/797.",Non-OADS,/arxiv_data1/oa_pdf/b9/ef/SNI-5-79.PMC4061575.pdf
"Surgical Neurology International 2014, 5:79  http://www.surgicalneurologyint.com/content/5/1/79The patient should be made aware of the risk‑benefit  ratio of their investigations, interventions, and play a  part in deciding the most suitable management options  available to them.",Non-OADS,/arxiv_data1/oa_pdf/b9/ef/SNI-5-79.PMC4061575.pdf
"Surgical Neurology InternationalEditor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.comCase Report Atypical teratoid/rhabdoid tumor in sellar turcica in an adult:  A case report and review of the literature Satoshi Shitara, Y oshinori Akiyama Department of Neurosurgery, T enri Hospital, T enri, Nara, Japan E‑mail: *Satoshi Shitara ‑ s‑shitara@umin.ac.jp; Yoshinori Akiyama ‑ yakiyama@tenriyorozu.jp   *Correspondence author Received: 19 March 14  Accepted: 04 April 14  Published: 23 May 14 Access this article  online Website: www.surgicalneurologyint.com DOI:   10.4103/2152-7806.133105  Quick Response Code: Abstract Background: Atypical teratoid/rhabdoid tumor (AT/RT) is a rare central nervous  system tumor composed of primitive rhabdoid cells that may differentiate along  neuroectodermal, mesenchymal and epithelial lineages.",Non-OADS,/arxiv_data1/oa_pdf/c7/30/SNI-5-75.PMC4061576.pdf
"Available FREE in open access from: http://www.surgicalneurologyint.com/text.asp?2014/5/1/75/133105 Copyright: © 2014 Shitara S. This is an open‑access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use,   distribution, and reproduction in any medium, provided the original author and source are credited.",Non-OADS,/arxiv_data1/oa_pdf/c7/30/SNI-5-75.PMC4061576.pdf
"Surgical Neurology International 2014, 5:75  http://www.surgicalneurologyint.com/content/5/1/75Table 1: Adult patients with atypical teratoid/rhabdoid tumor in the central nervous system Author (year) Age (years)/sex Tumor location Positive immunostains INI1 analysis Survival (mos) Balaton (1987)[5]59 M Paravertebral CK Vim NE 0.5 Horn (1992)[17]21 M Lt temporal EMA Vim NE 72 Cossu (1993)[13]18 M Lt frontal CK EMA Vim NE 18 Fisher (1996)[15]32 M Lt frontal CK EMA GFAP S100 Vim NE 1 Ashraf (1997)[4]34 M Lt parietal Vim NE 6 Byram (1999)[10]35 M Lt temporal CK EMA Vim NM 60 Kuge (2000)[24]32 F Supracellar CK EMA SMA Vim NE 20+ Arrazola (2000)[3]20 M Lt parietal CK EMA S100 Vim NE 24+ Lutterbach (2001)[26]30 F Cerebellum CK EMA NFP S100 Vim NE 11 Bruch (2001)[9]21 F Spinal cord CK EMA Vim NE 6 34 F Parietal CK EMA GFAP Vim NE 6 Pimentel (2003)[29]31 F Rt parietal NFP S100 Vim NE 6 Kachhara (2003)[21]35 M Thalamus Vim Negative NM Kawaguchi (2004)[23]22 M Lt cerebellum CK EMA NFP NSE SMA Vim NE 24+ Raisanen (2005)[30]20 F Sellar CK EMA SMA Vim Negative 28+ 31 F Sellar CK EMA Vim Negative 9 45 M Rt cerebellum CK EMA SMA S100 Vim Negative 15+ Erickson (2005)[14]20 F Rt occipital EMA GFAP SMA Vim Negative NM Chen (2006)[12]19 M Posterior fossa CK EMA SMA NM 56.5 Ingold (2006)[18]45 F Pineal CK EMA SMA Vim Negative 7 Rezanko (2006)[31]27 M Rt frontal EMA S100 Vim NE 4 Chacko (2007)[11]23 M Rt frontal EMA SMA Vim Negative 1.5 Zarovnaya (2007)[41]43 F Spinal cord EMA Negative 30 Makuria (2008)[27]23 M Lt temporal CK EMA NFP SMA Syn Vim Negative 30+ 25 F Rt frontal SMA Syn Vim Negative 204+ 37 M Rt frontoparietal Vim Negative NM 42 M Rt frontoparietal CK EMA Vim Negative 18+ Arita (2008)[2]56 F Sellar region EMA Vim Negative 23 Samaras (2009)[33]18 M Rt frontotemporal EMA GFAP SMA Vim Negative 4 Las Heras (2010)[25]46 F Sellar CD34 SMA Vim Negative NM Takei (2010)[37]33 F Pineal region CK EMA GFAP NFP Vim Negative 13+ Shonka (2011)[35]33 F Pineal region EMA SMA Negative 18+ Han (2011)[16]24 M Rt temporo‑occipital NM NE 10 25 M Lt parieto‑occipital NM NE 25 32 M Rt frontal NM NE 32+ 35 F Rt frontal NM NE 20 50 F Rt temporal NM NE 13 Umredkar (2010)[39]32 M Lt frontal EMA GFAP Vim NE 6+ Takahashi (2011)[36]27 F Lt parietal EMA MGMT Vim Negative 108+ Schneiderhan (2011)[34]57 F Sellar CK EMA SMA S100 Negative 6+ 61 F Sellar GFAP S100 Negative 3 Our case 44 F Sellar EMA MGMT S100 Negative 17 CK: Cytokeratin, EMA: Epithelial membrane antigen, GFAP: Glial fibrillary acid protein, MGMT: O‑6 methylguanine DNA methyltransferase, NE: Not examined, NFP: Neurofilament  protein, NM: Not mentioned, NSE: Neuron‑specific enolase, SMA: Smooth muscle actin, Syn: Synaptophysin, Vim: Vimentin, mos: months, +: Over (e.g., 24+means over 24 months.)",Non-OADS,/arxiv_data1/oa_pdf/c7/30/SNI-5-75.PMC4061576.pdf
"Surgical Neurology International 2014, 5:75  http://www.surgicalneurologyint.com/content/5/1/75mainly ventral and rostral part of the tumor, via a basal  interhemispheric approach [Figure 3], and malignant cells  were not found from the surgical specimen [Figure 4].",Non-OADS,/arxiv_data1/oa_pdf/c7/30/SNI-5-75.PMC4061576.pdf
"Surgical Neurology International 2014, 5:75  http://www.surgicalneurologyint.com/content/5/1/75tumor cells showed strong immunoreactivity for O-6  methylguanine DNA methyltransferase (MGMT), Nestin  and S100 protein, and focal positivity for epithelial  membrane antigen (EMA) and Glypican-3.",Non-OADS,/arxiv_data1/oa_pdf/c7/30/SNI-5-75.PMC4061576.pdf
"Surgical Neurology International 2014, 5:75  http://www.surgicalneurologyint.com/content/5/1/75but it is natural that the lesions of left cavernous sinus,  left orbital fossa and left forehead were consistently  extended from the sellar turcica.",Non-OADS,/arxiv_data1/oa_pdf/c7/30/SNI-5-75.PMC4061576.pdf
"Surgical Neurology International 2014, 5:75  http://www.surgicalneurologyint.com/content/5/1/7536.",Non-OADS,/arxiv_data1/oa_pdf/c7/30/SNI-5-75.PMC4061576.pdf
"Surgical Neurology InternationalEditor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.comOriginal Article Midkine expression in high grade gliomas: Correlation of this  novel marker with proliferation and survival in human gliomas Yen‑Po Cheng, Chin Lin1, Ping‑ Yi Lin2, Chun‑ Yuan Cheng, Hsin‑I Ma3, Chien‑Min Chen*,  Dueng‑ Yuan Hueng*,3,4 Division of Neurosurgery, Department of Surgery, 2Transplant Medicine and Surgery Research Centre, Changhua Christian Hospital, Changhua, 1Graduate  Institute of Life Science, National Defense Medical Center, 3Department of Neurological Surgery, Tri‑Service General Hospital, National Defense Medical Center,  4Department of Biochemistry, National Defense Medical Center, Taipei, Taiwan, ROC E‑mail:  Yen‑Po Cheng ‑ 134309@cch.org, tw; Chin Lin ‑ xup6fup@hotmail.com; Ping‑Yi Lin ‑ 69221@cch.org.tw; Chun‑Yuan Cheng ‑ 83998@cch.org.tw;   Hsin‑I Ma ‑ uf004693@mail2000.com.tw; *Chien‑Min Chen ‑ 96015@cch.org.tw; *Dueng‑Yuan Hueng ‑ hondy2195@yahoo.com.tw   *Corresponding author Received: 05 January 14  Accepted: 20 March 14  Published: 26 May 14 Access this article  online Website: www.surgicalneurologyint.com DOI:   10.4103/2152-7806.133205  Quick Response Code: Abstract Background: High‑grade primary glioma have poor prognosis and predictive  biomarkers is very important.",Non-OADS,/arxiv_data1/oa_pdf/2c/a4/SNI-5-78.PMC4061577.pdf
Available FREE in open access from: http://www.surgicalneurologyint.com/text.asp?2014/5/1/78/133205 Copyright: © 2014 Cheng YP .,Non-OADS,/arxiv_data1/oa_pdf/2c/a4/SNI-5-78.PMC4061577.pdf
"Surgical Neurology International 2014, 5:78  http://www.surgicalneurologyint.com/content/5/1/78genetic expression in glioma is important for improving  prognostication.",Non-OADS,/arxiv_data1/oa_pdf/2c/a4/SNI-5-78.PMC4061577.pdf
"Surgical Neurology International 2014, 5:78  http://www.surgicalneurologyint.com/content/5/1/78grade III (P = 0.003).",Non-OADS,/arxiv_data1/oa_pdf/2c/a4/SNI-5-78.PMC4061577.pdf
"Surgical Neurology International 2014, 5:78  http://www.surgicalneurologyint.com/content/5/1/78those with low MDK expression in high‑grade human  gliomas ( P = 0.0004).",Non-OADS,/arxiv_data1/oa_pdf/2c/a4/SNI-5-78.PMC4061577.pdf
"Surgical Neurology International 2014, 5:78  http://www.surgicalneurologyint.com/content/5/1/78Acids Res 2009;37:D885‑90.",Non-OADS,/arxiv_data1/oa_pdf/2c/a4/SNI-5-78.PMC4061577.pdf
"Surgical Neurology InternationalEditor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.comCase Report Magnetic resonance spectroscopy imaging characteristics of  cerebral Blastomycosis Jay A. Vachhani, William C. Lee, Jeffrey R. Desanto1, Andrew J. T sung Department of Neurosurgery, Illinois Neurological Institute, 1Department of Radiology, Central Illinois Radiological Associates, University of Illinois,  College of Medicine, Peoria, Illinois, 530 NE Glen Oak Avenue, Peoria, IL 61637, USA E‑mail: *Jay A. Vachhani ‑ jay.vachhani@gmail.com; William C. Lee ‑ lee.william.c@gmail.com; Jeffrey R. Desanto ‑ jeffrey_desanto@yahoo.com;   Andrew J. Tsung ‑ andrew .j.tsung@ini.org   *Corresponding author Received: 10 December 13  Accepted: 14 March 14  Published: 28 May 14 Abstract Background: Blastomycosis is a dimorphic fungus that is endemic to the midwest  and southwestern United States.",Non-OADS,/arxiv_data1/oa_pdf/05/bd/SNI-5-80.PMC4061578.pdf
Available FREE in open access from: http://www.surgicalneurologyint.com/text.asp?2014/5/1/80/133306 Copyright: © 2014  Vachhani JA.,Non-OADS,/arxiv_data1/oa_pdf/05/bd/SNI-5-80.PMC4061578.pdf
"Surgical Neurology International 2014, 5:80  http://www.surgicalneurologyint.com/content/5/1/80and involvement of the CNS is thought to only represent  5-10% of cases of disseminated Blastomycosis.",Non-OADS,/arxiv_data1/oa_pdf/05/bd/SNI-5-80.PMC4061578.pdf
"Surgical Neurology International 2014, 5:80  http://www.surgicalneurologyint.com/content/5/1/80cortical/subcortical mapping.",Non-OADS,/arxiv_data1/oa_pdf/05/bd/SNI-5-80.PMC4061578.pdf
"Surgical Neurology International 2014, 5:80  http://www.surgicalneurologyint.com/content/5/1/80Intraparenchymal and intraventricular lesions are  uncommon and can present as miliary lesions, which  appear dark on T1-weighted imaging and bright on  T2-weighted imaging.",Non-OADS,/arxiv_data1/oa_pdf/05/bd/SNI-5-80.PMC4061578.pdf
"Surgical Neurology International 2014, 5:80  http://www.surgicalneurologyint.com/content/5/1/80of a number of polymorphs in both the crystalline and  amorphous state.",Non-OADS,/arxiv_data1/oa_pdf/05/bd/SNI-5-80.PMC4061578.pdf
"Surgical Neurology InternationalEditor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.comCase Report Spontaneous regression together with increased calcification of  incidental meningioma Kengo Hirota, Toshiyuki Fujita1, Hiroyuki Akagawa1, Hideaki Onda2, Hidetoshi Kasuya Department of Neurosurgery, T okyo Women’s Medical University Medical Center East, 2‑1‑10 Nishiogu, Arakawa‑ku, T okyo, 116‑8567, 1T okyo Women’s Medical  University Institute for Integrated Medical Sciences, 8‑1 Kawada‑cho, Shinjyuku‑ku, T okyo, 162‑8666, 2Kofu Neurosurgery Hospital, 1‑16‑18 Sakaori, Kofu,  Yamanashi, 400‑0805, Japan E‑mail:  Kengo Hirota ‑ k2bumps@gmail.com; T oshiyuki Fujita ‑ fujita.toshiyuki@twmu.ac.jp; Hiroyuki Akagawa ‑ akagawa.hiroyuki@twmu.ac.jp;   Hideaki Onda ‑ onda995@orange.zero.jp; *Hidetoshi Kasuya ‑ kasuyane@dnh.twmu.ac.jp   *Corresponding author Received: 22 February14  Accepted:  20 March 14  Published: 21 May 14 Access this article  online Website: www.surgicalneurologyint.com DOI:   10.4103/2152-7806.132957  Quick Response Code: Abstract Background:  Regression of meningioma has been reported after hemorrhage  or hormonal withdrawal.",Non-OADS,/arxiv_data1/oa_pdf/b4/f1/SNI-5-73.PMC4061579.pdf
"Available FREE in open access from: http://www.surgicalneurologyint.com/text.asp?2014/5/1/73/132957 Copyright: © 2014 Hirota K. This is an open‑access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution,  and reproduction in any medium, provided the original author and source are credited.",Non-OADS,/arxiv_data1/oa_pdf/b4/f1/SNI-5-73.PMC4061579.pdf
"Surgical Neurology International 2014, 5:73  http://www.surgicalneurologyint.com/content/5/1/73gradually reduced with a decrease of edema and increase  of calcification over 7 years.",Non-OADS,/arxiv_data1/oa_pdf/b4/f1/SNI-5-73.PMC4061579.pdf
"Surgical Neurology International 2014, 5:73  http://www.surgicalneurologyint.com/content/5/1/73of time, and it would be beneficial for the mechanisms  and factors related to spontaneous regression to be  clarified.",Non-OADS,/arxiv_data1/oa_pdf/b4/f1/SNI-5-73.PMC4061579.pdf
"Surgical Neurology InternationalEditor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.comEditorial Gross total resection: Do we want survival statistics or quality of  life measurements James I. Ausman Editor‑in‑Chief, Surgical Neurology International, 69844 Highway 111 Suite C, Rancho Mirage, USA  E‑mail: *James I. Ausman ‑ jia@surgicalneurologyint.com   *Corresponding author Received: 15 April 14   Accepted: 15 April 14  Published: 26 May 14 Should a gross total resection (GTR) of malignant  gliomas be made?",Non-OADS,/arxiv_data1/oa_pdf/d1/dc/SNI-5-77.PMC4061580.pdf
Available FREE in open access from: http://www.surgicalneurologyint.com/text.asp?2014/5/1/77/133200 Copyright: © 2014 Ausman JI.,Non-OADS,/arxiv_data1/oa_pdf/d1/dc/SNI-5-77.PMC4061580.pdf
"Surgical Neurology International 2014, 5:77  http://www.surgicalneurologyint.com/content/5/1/77as of this time.",Non-OADS,/arxiv_data1/oa_pdf/d1/dc/SNI-5-77.PMC4061580.pdf
"Surgical Neurology InternationalEditor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.comOriginal Article Do neurosurgeons need Neuroanesthesiologists?",Non-OADS,/arxiv_data1/oa_pdf/e6/7e/SNI-5-76.PMC4061581.pdf
Available FREE in open access from: http://www.surgicalneurologyint.com/text.asp?2014/5/1/76/133106 Copyright: © 2014 Ghaly RF .,Non-OADS,/arxiv_data1/oa_pdf/e6/7e/SNI-5-76.PMC4061581.pdf
"Surgical Neurology International 2014, 5:76  http://www.surgicalneurologyint.com/content/5/1/76not limited to neurosurgery only but to neuroanesthesia,  neurocritical care, pain and neuromonitoring, and  neuroresearch.",Non-OADS,/arxiv_data1/oa_pdf/e6/7e/SNI-5-76.PMC4061581.pdf
"Surgical Neurology International 2014, 5:76  http://www.surgicalneurologyint.com/content/5/1/76VIEWS AMONG NEUROANESTHESIOLOGISTS  WORLDWIDE The majority of neuroanesthesiologists do believe  that general anesthesiologists are as good as  neuroanesthesiologists for neurosurgery cases (9, some  of SNACC members including 9 out 12 personal  communication and from Dr Michael Todd presented  in 2011 “ A neuroanesthesiologist is essential for all  intracranial procedures” debate).",Non-OADS,/arxiv_data1/oa_pdf/e6/7e/SNI-5-76.PMC4061581.pdf
"Surgical Neurology International 2014, 5:76  http://www.surgicalneurologyint.com/content/5/1/76the total cardiac output.",Non-OADS,/arxiv_data1/oa_pdf/e6/7e/SNI-5-76.PMC4061581.pdf
"Surgical Neurology International 2014, 5:76  http://www.surgicalneurologyint.com/content/5/1/76comprehensive fellowship in neuroanesthesia to offer  more than anesthesia training with much brighter  future and potentials in related fields.",Non-OADS,/arxiv_data1/oa_pdf/e6/7e/SNI-5-76.PMC4061581.pdf
"Surgical Neurology International 2014, 5:76  http://www.surgicalneurologyint.com/content/5/1/76are approved and accredited in anesthesiology  and graduate 877 Fellowship yearly.",Non-OADS,/arxiv_data1/oa_pdf/e6/7e/SNI-5-76.PMC4061581.pdf
"Surgical Neurology International 2014, 5:76  http://www.surgicalneurologyint.com/content/5/1/76neuroanesthesiologists?",Non-OADS,/arxiv_data1/oa_pdf/e6/7e/SNI-5-76.PMC4061581.pdf
"Surgical Neurology International 2014, 5:76  http://www.surgicalneurologyint.com/content/5/1/76monitoring, surgical various micro instruments  specific for each surgical procedure.",Non-OADS,/arxiv_data1/oa_pdf/e6/7e/SNI-5-76.PMC4061581.pdf
"Surgical Neurology International 2014, 5:76  http://www.surgicalneurologyint.com/content/5/1/76Some of the positioning and set up is demanding and  complex even for the skilled neuroanesthesiologists.",Non-OADS,/arxiv_data1/oa_pdf/e6/7e/SNI-5-76.PMC4061581.pdf
"Surgical Neurology International 2014, 5:76  http://www.surgicalneurologyint.com/content/5/1/76cerebral vasodilation and should not be used when  hypertension is not permissible.",Non-OADS,/arxiv_data1/oa_pdf/e6/7e/SNI-5-76.PMC4061581.pdf
"Surgical Neurology International 2014, 5:76  http://www.surgicalneurologyint.com/content/5/1/76multidisciplinary team case discussion and grand  rounds.",Non-OADS,/arxiv_data1/oa_pdf/e6/7e/SNI-5-76.PMC4061581.pdf
"Surgical Neurology International 2014, 5:76  http://www.surgicalneurologyint.com/content/5/1/76aneurysms in the United States, 1996‑2000:  The effect of hospital and surgeon  volume.",Non-OADS,/arxiv_data1/oa_pdf/e6/7e/SNI-5-76.PMC4061581.pdf
Available from: http://uu.diva-portal.org/smash/get/diva2:167326/FULLTEXT01.pdf.,Non-OADS,/arxiv_data1/oa_pdf/c7/17/JAIM-5-117.PMC4061586.pdf
Indian medicine.nic.in [homepage on the internet] Available  from: http://indianmedicine.nic.in/show ﬁ le.asp?lid=44 [Last  accessed on 2013 Oct 28].,Non-OADS,/arxiv_data1/oa_pdf/c7/17/JAIM-5-117.PMC4061586.pdf
Availablefrom:http://www.forbes.com/ sites/ larryhusten /2014/01  /15/ medicine-or- mass-murder-guideline-based-on-discredited-   research-may-have-caused-800000-deaths-in-europe-over- the- last-5-years.,Non-OADS,/arxiv_data1/oa_pdf/e8/93/JAIM-5-71.PMC4061591.pdf
Available from: http://apps.who.int/medicinedocs/pdf/s7916e/s7916e.pdf WHO 2005.,OADS,/arxiv_data1/oa_pdf/a4/84/JAIM-5-73.PMC4061592.pdf
Start a QR-code reading software (see list of free applications from http://tinyurl.com/ yzlh2tc) and point the camera to the QR-code printed in the journal.,Non-OADS,/arxiv_data1/oa_pdf/a4/84/JAIM-5-73.PMC4061592.pdf
See http://tinyurl.com/2bw7fn3 or http://tinyurl.com/3y sr3me for the free  applications.,Non-OADS,/arxiv_data1/oa_pdf/a4/84/JAIM-5-73.PMC4061592.pdf
The application can be downloaded from https://market.android.com/details?id=comm.app.medknow.,Non-OADS,/arxiv_data1/oa_pdf/30/d7/JAIM-5-80.PMC4061594.pdf
The application can be downloaded from http://itunes.apple.com/us/app/medknow-journals/id458064375?ls=1&mt=8.,Non-OADS,/arxiv_data1/oa_pdf/3c/6f/JAIM-5-85.PMC4061595.pdf
Available from: http://www.blogs.lse.ac.uk/healthandsocialc are/2013/05/23/global-mental-health-matters [Last accessed on 2013 Oct 05].,Non-OADS,/arxiv_data1/oa_pdf/7f/ea/JAIM-5-89.PMC4061596.pdf
Author Help: Online submission of the manuscripts Articles can be submitted online from http://www.journalonweb.com.,Non-OADS,/arxiv_data1/oa_pdf/7f/ea/JAIM-5-89.PMC4061596.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/3.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/8d/33/nihms-576303.PMC4061617.pdf
Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.scr.2014.02.008 .,OADS,/arxiv_data1/oa_pdf/8d/33/nihms-576303.PMC4061617.pdf
2010; 9:207. http://dx.doi.org/ 10.1186/1476-4598-9-207:207-209 .,Non-OADS,/arxiv_data1/oa_pdf/8d/33/nihms-576303.PMC4061617.pdf
Available from: http://www.nct.org.uk.,Non-OADS,/arxiv_data1/oa_pdf/7b/03/IJNMR-19-233.PMC4061621.pdf
Available from http://tebyan-zn.ir/News-Article/quran/2010/11/9/10505.html.,Non-OADS,/arxiv_data1/oa_pdf/e6/3c/IJNMR-19-238.PMC4061622.pdf
"Available from: http://www.cna-nursesca/CNA/, 2004 .",Non-OADS,/arxiv_data1/oa_pdf/45/85/IJNMR-19-248.PMC4061624.pdf
Available from: http://www.hawazah.net.,Non-OADS,/arxiv_data1/oa_pdf/45/85/IJNMR-19-248.PMC4061624.pdf
Available from: http://hawzah.net [Last accessed on 2010 Mar 5].,Non-OADS,/arxiv_data1/oa_pdf/45/85/IJNMR-19-248.PMC4061624.pdf
Available from: http://www.afmc.ca/img/default_en.htm [Last accessed on 2010 5 Jul] .,OADS,/arxiv_data1/oa_pdf/45/85/IJNMR-19-248.PMC4061624.pdf
Available from: http://www.wolfweb.unr.edu/homepage/crowther/ejse/hudson2.pdf.,Non-OADS,/arxiv_data1/oa_pdf/45/85/IJNMR-19-248.PMC4061624.pdf
"Available from: http://www.iranms.ir, 2012.",Non-OADS,/arxiv_data1/oa_pdf/7f/af/IJNMR-19-255.PMC4061625.pdf
Available  from: https://www.nscisc.uab.edu [Last accessed on 2012  Oct 28].,Non-OADS,/arxiv_data1/oa_pdf/73/54/IJNMR-19-266.PMC4061627.pdf
Available from: http://www.isu.edu/irh/documents/proqol/ProQOL_Manual.pdf.,Non-OADS,/arxiv_data1/oa_pdf/00/f1/IJNMR-19-279.PMC4061629.pdf
Available from: http://www.ahrq.gov/qual/errback.htm [Last accessed on 2008 Nov 17].,OADS,/arxiv_data1/oa_pdf/68/56/IJNMR-19-295.PMC4061632.pdf
Available from: http://www.vtt.fi/publications/index.jsp.,Non-OADS,/arxiv_data1/oa_pdf/68/56/IJNMR-19-295.PMC4061632.pdf
Available from: http://www.creativecommons.org/licenses/by/2.0 [Last accessed on 2011].,Non-OADS,/arxiv_data1/oa_pdf/68/56/IJNMR-19-295.PMC4061632.pdf
"Available from: http://www.ihi.org/lms/home.aspex Institute for Healthcare Improvement 20 University Road, 7 th Floor Cambridge, MA 02138 USA [Last  accessed on 2010].",Non-OADS,/arxiv_data1/oa_pdf/68/56/IJNMR-19-295.PMC4061632.pdf
Available from: http://www.ino.ir [Last updated on 2011 May 16; cited on 2011 May 16].,OADS,/arxiv_data1/oa_pdf/8d/22/IJNMR-19-301.PMC4061633.pdf
"Available from: http://www.astdn.org/partnershipproject-new-1,htm>.2008 [Last accessed on 2013 Jul 4].",Non-OADS,/arxiv_data1/oa_pdf/96/67/IJNMR-19-315.PMC4061635.pdf
Available from: http://www.greenfacts.org/glossary/mno/macro-policy.htm>.2001-2011; [Last accessed on 2013 Jul 22].,Non-OADS,/arxiv_data1/oa_pdf/96/67/IJNMR-19-315.PMC4061635.pdf
Available from: http://www.differencebetween.com/search difference%20between%20macro%20policy>.2010; [Last accessed on 2013 Jul 22].,Non-OADS,/arxiv_data1/oa_pdf/96/67/IJNMR-19-315.PMC4061635.pdf
Available from: http://www.differencebetween.com/search difference%20between%20politics%20policy>.2010; [Last accessed on 2013 Jan 18].,Non-OADS,/arxiv_data1/oa_pdf/96/67/IJNMR-19-315.PMC4061635.pdf
Available from: http://www.rcn.org.uk.,Non-OADS,/arxiv_data1/oa_pdf/96/67/IJNMR-19-315.PMC4061635.pdf
Available from: http://www.nova.edu/ssss/QR/BackIssues/QR2-1/aronson.html.,Non-OADS,/arxiv_data1/oa_pdf/c0/a2/IJNMR-19-323.PMC4061636.pdf
Annu Rev Nutr 1999;19:217- 49. http://www.annualreviews.org/doi/pdf/10.1146/annurev.nutr.19.1.217 [last accessed on 2011 Oct 7].12.,Non-OADS,/arxiv_data1/oa_pdf/bd/e8/IJO-62-291.PMC4061665.pdf
Available from: http://www.orphan.net/data/patho/ GB/uk-nager- pdf.,OADS,/arxiv_data1/oa_pdf/70/22/IJO-62-339.PMC4061675.pdf
Available from: http://www.orphan.net/data/patho/ GB/uk-nager- pdf.,OADS,/arxiv_data1/oa_pdf/09/18/IJO-62-341.PMC4061676.pdf
"NHLBI ESP, NHLBI Exome Sequencing Project (http://evs.gs.washington.edu/)—the absolute frequency of the variant allele followed by the referenc e allele are shown; ND, No variant was detected in this region in this database.NATURE COMMUNICATIONS | DOI: 10.1038/ncomms5039 ARTICLE NATURE COMMUNICATIONS | 5:4039 | DOI: 10.1038/ncomms5039 | www.nature.com/naturecommunications 5 &2014 Macmillan Publishers Limited.",Non-OADS,/arxiv_data1/oa_pdf/e1/78/ncomms5039.PMC4062040.pdf
The resulting sequences were mapped to the reference genome (GRCh37/hg19) obtained from UCSC Genome Browser(http://genome.ucsc.edu) with Bioscope (http://www.lifescopecloud.com/) and NovoalignCS (http://novocraft.com/).,OADS,/arxiv_data1/oa_pdf/e1/78/ncomms5039.PMC4062040.pdf
Sequence variants (SNVs and indels) were identiﬁed with SAMtools (http://samtools.sourceforge.net/) and the mpileup(http://samtools.sourceforge.net/mpileup.shtml) and annotated if present on dbSNP (release #137) or COSMIC v60.,OADS,/arxiv_data1/oa_pdf/e1/78/ncomms5039.PMC4062040.pdf
Clustering was performed with TMEV (http://www.tm4.org/) using Pearson’s correlation and average linkage.,OADS,/arxiv_data1/oa_pdf/e1/78/ncomms5039.PMC4062040.pdf
"For quantiﬁcation of proteins bands, densi-tometry was performed with ImageJ 1.4 (http://imagej.software.informer.com/1.4/).",OADS,/arxiv_data1/oa_pdf/e1/78/ncomms5039.PMC4062040.pdf
Supplementary Information accompanies this paper at http://www.nature.com/ naturecommunications Competing ﬁnancial interests: The authors declare no competing ﬁnancial interests.,Non-OADS,/arxiv_data1/oa_pdf/e1/78/ncomms5039.PMC4062040.pdf
"Reprints and permission information is available online at http://npg.nature.com/ reprintsandpermissions/ How to cite this article: Torrezan, G. T. et al.",Non-OADS,/arxiv_data1/oa_pdf/e1/78/ncomms5039.PMC4062040.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms5039 10 NATURE COMMUNICATIONS | 5:4039 | DOI: 10.1038/ncomms5039 | www.nature.com/naturecommunications &2014 Macmillan Publishers Limited.",Non-OADS,/arxiv_data1/oa_pdf/e1/78/ncomms5039.PMC4062040.pdf
"Haplotype logistic regression, step-wise logistic regression and McKelvey and Zavoina pseudo-R 2analysis, and Mantel–Haenszel test were all performed in R statistical package (http://www.r-project.org/).",OADS,/arxiv_data1/oa_pdf/e4/d1/ncomms4983.PMC4062071.pdf
Supplementary Information accompanies this paper at http://www.nature.com/ naturecommunications Competing ﬁnancial interests: The authors declare no competing ﬁnancial interests.,Non-OADS,/arxiv_data1/oa_pdf/e4/d1/ncomms4983.PMC4062071.pdf
"Reprints and permission information is available online at http://npg.nature.com/ reprintsandpermissions/ How to cite this article: Ko, A. et al.",Non-OADS,/arxiv_data1/oa_pdf/e4/d1/ncomms4983.PMC4062071.pdf
Available from http://imagej.nih.gov/ij/docs/user-guide.pdf.,OADS,/arxiv_data1/oa_pdf/17/79/EUS-1-8.PMC4062202.pdf
"The questionnaire was sent out in English, Spanish and Portuguese  languages and was available through the following site: http://www.cleus-encuesta.com.",Non-OADS,/arxiv_data1/oa_pdf/be/52/EUS-2-208.PMC4062268.pdf
"The questionnaire  was developed together with an IT company (Trajettoria  Information Technology Ltda, São Paulo, SP) and was  available through the site http://www.cleus-encuesta.com  until January 2013.",OADS,/arxiv_data1/oa_pdf/be/52/EUS-2-208.PMC4062268.pdf
The responses were sent directly to a  domain (http://www.cleus-encuesta.com).,OADS,/arxiv_data1/oa_pdf/be/52/EUS-2-208.PMC4062268.pdf
*Source:  http://www.who.int/countries/en/ in 25 June 2013; **Not independent  Latin territory; ***Source: http://www.indexmundi.com/pt/porto_rico/ populacao_perfil.html in 25 June 2013 Table 2.,Non-OADS,/arxiv_data1/oa_pdf/be/52/EUS-2-208.PMC4062268.pdf
Available from:  http://www.hdr.undp.org.,Non-OADS,/arxiv_data1/oa_pdf/be/52/EUS-2-208.PMC4062268.pdf
Available from:  http://www.pnud.org.br/arquivos/rdh-2013.pdf.,Non-OADS,/arxiv_data1/oa_pdf/be/52/EUS-2-208.PMC4062268.pdf
Available from:  http://www2.planalto.gov.br.,Non-OADS,/arxiv_data1/oa_pdf/be/52/EUS-2-208.PMC4062268.pdf
"Available from: http://seer.cancer.gov/ csr/1975_2009_pops09/, based on November 2011 SEER data  submission, posted to the SEER web site, April 2012.",OADS,/arxiv_data1/oa_pdf/78/02/EUS-2-219.PMC4062272.pdf
Available from: http://www.globocan.iarc.fr.,Non-OADS,/arxiv_data1/oa_pdf/24/23/EUS-2-181.PMC4062275.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License(http://creativecommons.org/licenses/by-nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium,provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/be/58/aet338.PMC4062297.pdf
"Available from http://www.ont.es/publicaciones/Paginas/Publicaciones.aspx (accessed 26 November 2013) 5 Locke J, Segev D, Warren D, Dominici F, Simpkins C, Montgomery R. Outcomes of kidneys from donors after cardiac death: implicationsfor allocation and preservation.",Non-OADS,/arxiv_data1/oa_pdf/c9/c9/aet473.PMC4062298.pdf
Available from http://www.nhsbt.nhs.uk/ to2020/resources/OrgansfortransplantsTheOrganDonorTaskForce 1streport.pdf (accessed 26 November 2013) 9 UK Donation Ethics Committee.,Non-OADS,/arxiv_data1/oa_pdf/c9/c9/aet473.PMC4062298.pdf
Available from http://www.bts.org.uk/Documents/Guidelines/Active/DCD for BTSand ICS FINAL.pdf (accessed 26 November 2013) 11 Council of Europe.,Non-OADS,/arxiv_data1/oa_pdf/c9/c9/aet473.PMC4062298.pdf
Availablefrom http://www.ont.es/publicaciones/Documents/Newsletter2008.,Non-OADS,/arxiv_data1/oa_pdf/c9/c9/aet473.PMC4062298.pdf
"Available from http://www.organdonation.nhs.uk/ukt/statistics/centre-speciﬁc_reports/pdf/waiting_time_to_transplant.pdf (accessed 26 November 2013) 26 Mallik M, Callaghan CJ, Hope M, et al.",Non-OADS,/arxiv_data1/oa_pdf/c9/c9/aet473.PMC4062298.pdf
Current Controlled Trials ISRCTN65176374 (http://www.controlled- trials.com/ISRCTN65176374).,Non-OADS,/arxiv_data1/oa_pdf/d9/d7/aeu051.PMC4062299.pdf
"Available from https://www.icnarc.org/documents/Summary%20statistics%20-%202011-12.pdf (accessed 1 August 2013) 2 Desai SV, Law TJ, Needham DM.",Non-OADS,/arxiv_data1/oa_pdf/d9/d7/aeu051.PMC4062299.pdf
Available from http://www-users.york.ac.uk/~mb55/ guide/minim.htm (accessed 1 April 2007) 14 Borg G. Borg’s Perceived Exertion and Pain Scales .,Non-OADS,/arxiv_data1/oa_pdf/d9/d7/aeu051.PMC4062299.pdf
Contents lists available at ScienceDirect Epilepsy & Behavior Case Reports journal homepage: www.elsevier.com/locate/ebcr http://dx.doi.org/10.1016/j.ebcr.2014.03.001 2213-3232/© 2014 Published by Elsevier Inc.,Non-OADS,/arxiv_data1/oa_pdf/f6/b2/main.PMC4062308.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/3.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f6/b2/main.PMC4062308.pdf
22 http://clinicaltrials.gov/ct2/show/NCT01062698.,Non-OADS,/arxiv_data1/oa_pdf/a9/7c/ine-0002-0097.PMC4062314.pdf
37 http://clinicaltrials.gov/show/NCT01492725.,Non-OADS,/arxiv_data1/oa_pdf/a9/7c/ine-0002-0097.PMC4062314.pdf
38 http://clinicaltrials.gov/ct2/show/NCT01657461.,Non-OADS,/arxiv_data1/oa_pdf/a9/7c/ine-0002-0097.PMC4062314.pdf
39 http://clinicaltrials.gov/show/NCT01429350.,Non-OADS,/arxiv_data1/oa_pdf/a9/7c/ine-0002-0097.PMC4062314.pdf
40 http://clinicaltrials.gov/show/NCT01692379.,Non-OADS,/arxiv_data1/oa_pdf/a9/7c/ine-0002-0097.PMC4062314.pdf
41 http://www.mrclean-trial.org/.,Non-OADS,/arxiv_data1/oa_pdf/a9/7c/ine-0002-0097.PMC4062314.pdf
Available at: http://www.ncbi.nlm.nih.gov/pubme -d ISI Web of Science .,OADS,/arxiv_data1/oa_pdf/e2/77/biochem-med-22-1-7-2.PMC4062318.pdf
Available at: https://www.isiknowledge.com -  Scopus SciVerse .,Non-OADS,/arxiv_data1/oa_pdf/e2/77/biochem-med-22-1-7-2.PMC4062318.pdf
Available at: http://www.info.sciverse.com/scopu -s Google Scholar .,Non-OADS,/arxiv_data1/oa_pdf/e2/77/biochem-med-22-1-7-2.PMC4062318.pdf
Available at:  http://scholar.google.it -/ Journal / Author Name Estimator (JANE) .,Non-OADS,/arxiv_data1/oa_pdf/e2/77/biochem-med-22-1-7-2.PMC4062318.pdf
Available at: http://www.biosemantics.org/jane -/ Unbound MEDLINE .,Non-OADS,/arxiv_data1/oa_pdf/e2/77/biochem-med-22-1-7-2.PMC4062318.pdf
Available at: http://www.unboundmedicine.com/medline/eb -m Medscape .,Non-OADS,/arxiv_data1/oa_pdf/e2/77/biochem-med-22-1-7-2.PMC4062318.pdf
Available at: http://www.medscape.co -m .,Non-OADS,/arxiv_data1/oa_pdf/e2/77/biochem-med-22-1-7-2.PMC4062318.pdf
Available at: http://www.biomedcentral.co -m .,Non-OADS,/arxiv_data1/oa_pdf/e2/77/biochem-med-22-1-7-2.PMC4062318.pdf
Available at: http://pubfocus.co -m .,Non-OADS,/arxiv_data1/oa_pdf/e2/77/biochem-med-22-1-7-2.PMC4062318.pdf
Available at: http://pubget.co -m Scientifi  c Electronic Library .,Non-OADS,/arxiv_data1/oa_pdf/e2/77/biochem-med-22-1-7-2.PMC4062318.pdf
Available at: http://www.scielo.org/php/index.ph -p Highwire .,Non-OADS,/arxiv_data1/oa_pdf/e2/77/biochem-med-22-1-7-2.PMC4062318.pdf
Available at: http://highwire.org -/TABLE  1.,Non-OADS,/arxiv_data1/oa_pdf/e2/77/biochem-med-22-1-7-2.PMC4062318.pdf
Available at: http://www.istl.org/10-fall/refereed3.html.,Non-OADS,/arxiv_data1/oa_pdf/e2/77/biochem-med-22-1-7-2.PMC4062318.pdf
Available at: http://www.akreditacija.,Non-OADS,/arxiv_data1/oa_pdf/ac/71/biochem-med-22-1-86-9.PMC4062323.pdf
Available at: http://www.clsi.org/source/orders/free/AU-TO8-A.pdf.,Non-OADS,/arxiv_data1/oa_pdf/ac/71/biochem-med-22-1-86-9.PMC4062323.pdf
Available at: http://www.clsi.org/sour-ce/orders/free/auto12-a.pdf.,Non-OADS,/arxiv_data1/oa_pdf/ac/71/biochem-med-22-1-86-9.PMC4062323.pdf
Available at: http://en.wikipedia.org/wiki/ Health_Level_7.,Non-OADS,/arxiv_data1/oa_pdf/ac/71/biochem-med-22-1-86-9.PMC4062323.pdf
Available at: http://en.wikipedia.org/wiki/Choro- id.,Non-OADS,/arxiv_data1/oa_pdf/af/f3/biochem-med-22-1-39-5.PMC4062327.pdf
Available at: http://en.wikipedia.org/wiki/Retina.,Non-OADS,/arxiv_data1/oa_pdf/af/f3/biochem-med-22-1-39-5.PMC4062327.pdf
Available at: http://en.wikipedia.org/wiki/ Fovea_centralis.,Non-OADS,/arxiv_data1/oa_pdf/af/f3/biochem-med-22-1-39-5.PMC4062327.pdf
Available at: http://en.wikipedia.org/ wiki/Macula_of_retina.,Non-OADS,/arxiv_data1/oa_pdf/af/f3/biochem-med-22-1-39-5.PMC4062327.pdf
Available at: http://en.wikipedia.org/wiki/Sclera.,Non-OADS,/arxiv_data1/oa_pdf/af/f3/biochem-med-22-1-39-5.PMC4062327.pdf
Available at: http://en.wikipedia.org/wiki/Eye.,Non-OADS,/arxiv_data1/oa_pdf/af/f3/biochem-med-22-1-39-5.PMC4062327.pdf
2008; Available at: http://www.wma.net/en/30publications/10policies/b3/index.html.,Non-OADS,/arxiv_data1/oa_pdf/0f/bc/biochem-med-22-1-100-11.PMC4062330.pdf
2010; Available at: http://www.cdc.gov/labstan-dards/crmln_clinical.html.,OADS,/arxiv_data1/oa_pdf/0f/bc/biochem-med-22-1-100-11.PMC4062330.pdf
2010; Available at: http://www.nu- bel.be.,Non-OADS,/arxiv_data1/oa_pdf/0f/bc/biochem-med-22-1-100-11.PMC4062330.pdf
Power analysis was performed using the Quanto  program version 1.2.4 (32) and G*Power 3 software available at http://www.psycho.uni-duesseldorf.de/abteilungen/aap/gpower3.,OADS,/arxiv_data1/oa_pdf/71/25/biochem-med-22-1-76-8.PMC4062331.pdf
"Gauderman W, Morrison J. QUANTO 1.1: A computer pro- gram for power and sample size calculations for genetic-epidemiology studies, http://hydra.usc.edu/gxe.",OADS,/arxiv_data1/oa_pdf/71/25/biochem-med-22-1-76-8.PMC4062331.pdf
"NIB- SC code: 84/500 Instructions for use (Version 3.0, Dated 10/12/2007) Available at: http://www.nibsc.ac.uk/docu-ments/ifu/84-500.pdf.",Non-OADS,/arxiv_data1/oa_pdf/b5/3b/biochem-med-22-2-171-4.PMC4062336.pdf
Available at:  http://www.globalrph.com/map.htm.,Non-OADS,/arxiv_data1/oa_pdf/87/7c/biochem-med-22-2-217-8.PMC4062340.pdf
Available at: http://www.uci.ch/Modules/BUILTIN/getObject.asp?MenuId=MTI1NzE&ObjTypeCode=FILE&type=FILE&id=NDA3MTk&LangId=1.,OADS,/arxiv_data1/oa_pdf/a0/2b/biochem-med-22-2-237-10.PMC4062341.pdf
Available at: http://www.wa-da-ama.org/Documents/Resources/Guidelines/WADA_ABP_OperatingGuidelines_EN_2.1.pdf.,Non-OADS,/arxiv_data1/oa_pdf/a0/2b/biochem-med-22-2-237-10.PMC4062341.pdf
Available at: http://www.westgard.com/biodatabase1.htm#11.,Non-OADS,/arxiv_data1/oa_pdf/7b/04/biochem-med-22-2-202-7.PMC4062343.pdf
2010 [updated January 2012; cited 2010 11/13]; Available from: http://www.westgard.com/biodatabase1.htm.,OADS,/arxiv_data1/oa_pdf/cc/8a/biochem-med-22-2-180-5.PMC4062344.pdf
Available from: http://www.who.int/growthref/en/ 19.,OADS,/arxiv_data1/oa_pdf/03/46/abc-101-04-0288.PMC4062364.pdf
" Annals of Surgical Treatment and Research 283pISSN 2288-6575  • eISSN 2288-6796 http://dx.doi.org/10.4174/astr.2014.86.6.283 Annals of Surgical Treatment and ResearchORIGINAL ARTICLE The risk factors of early recurrence after hepatectomy in  hepatocellular carcinoma Soon-Keun Kwon, Sung-Su Yun, Hong-Jin Kim, Dong-Shik Lee Department of Surgery, Yeungnam University College of Medicine, Daegu, Korea INTRODUCTION Hepatic resection is a curative treatment is performed  preferentially for hepatocellular carcinoma (HCC) patients  with a well-preserved liver function.",Non-OADS,/arxiv_data1/oa_pdf/51/da/astr-86-283.PMC4062445.pdf
"All  articles are distributed under the terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Purpose: Early recurrence after hepatectomy is a well-known poor prognostic factor in patients with hepatocellular  carcinoma.",Non-OADS,/arxiv_data1/oa_pdf/51/da/astr-86-283.PMC4062445.pdf
"314pISSN 2288-6575  • eISSN 2288-6796 http://dx.doi.org/10.4174/astr.2014.86.6.314 Annals of Surgical Treatment and ResearchORIGINAL ARTICLE Long-term results of laparoscopic splenectomy in  pediatric chronic immune thrombocytopenic purpura Dong Jin Kim, Jae Hee Chung Department of Surgery, Yeouido St. Mary’s Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea INTRODUCTION Immune thrombocytopenic purpura (ITP) is a common  autoimmune hematologic disorder that requires splenectomy  in its medically chronic state [1,2].",Non-OADS,/arxiv_data1/oa_pdf/6b/f9/astr-86-314.PMC4062446.pdf
"All  articles are distributed under the terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Purpose:  Laparoscopic splenectomy (LS) for pediatric chronic immune thrombocytopenic purpura (ITP) patients has  recently become widespread.",Non-OADS,/arxiv_data1/oa_pdf/6b/f9/astr-86-314.PMC4062446.pdf
" Annals of Surgical Treatment and Research 289pISSN 2288-6575  • eISSN 2288-6796 http://dx.doi.org/10.4174/astr.2014.86.6.289 Annals of Surgical Treatment and ResearchORIGINAL ARTICLE Higher incidence of gastroesophageal reflux disease after  gastric wedge resections of gastric submucosal tumors  located close to the gastroesophageal junction Seung Yeon Ko, Jeong Sun Lee, Jin-Jo Kim, Seung-Man Park Division of Gastrointestinal Surgery, Department of Surgery, Incheon St. Mary’s Hospital, The Catholic University of Korea College  of Medicine, Incheon, Korea INTRODUCTION It is difficult to make a preoperative pathologically confirmed  diagnosis of a gastrointestinal stromal tumor (GIST) despite  the advancement in endoscopic ultrasonography (EUS) and  EUS-guided biopsy techniques [1-5].",Non-OADS,/arxiv_data1/oa_pdf/78/7e/astr-86-289.PMC4062447.pdf
"All  articles are distributed under the terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Purpose: We hypothesized that gastroesophageal reflux disease (GERD) would be more prevalent after a gastric wedge  resection of a submucosal tumor (SMT) located close to the gastroesophageal junction (GEJ) than after a gastric wedge  resection of an SMT at other locations because of the damage to the lower esophageal sphincter during surgery.",Non-OADS,/arxiv_data1/oa_pdf/78/7e/astr-86-289.PMC4062447.pdf
" Annals of Surgical Treatment and Research 325pISSN 2288-6575  • eISSN 2288-6796 http://dx.doi.org/10.4174/astr.2014.86.6.325 Annals of Surgical Treatment and ResearchCASE REPORT Peutz-Jeghers syndrome with germline mutation of  STK11 Hyun-Dong Chae, Chang-Ho Jeon1 Departments of Surgery and 1Laboratory Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea INTRODUCTION Peutz-Jeghers syndrome (PJS) is a rare autosomal domi  nant  inherited syndrome consisting of gastrointestinal hamar - tomatous polyps and mucocutaneous hyperpigmentation of the  lips, buccal mucosa, and digits.",Non-OADS,/arxiv_data1/oa_pdf/29/5b/astr-86-325.PMC4062448.pdf
"All  articles are distributed under the terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Peutz-Jeghers syndrome (PJS), also known as periorificial lentiginosis, is a rare autosomal dominant inherited disease  with an incidence of 1/200,000 live-borns.",Non-OADS,/arxiv_data1/oa_pdf/29/5b/astr-86-325.PMC4062448.pdf
" Annals of Surgical Treatment and Research 309pISSN 2288-6575  • eISSN 2288-6796 http://dx.doi.org/10.4174/astr.2014.86.6.309 Annals of Surgical Treatment and ResearchORIGINAL ARTICLE Inflammation-based score (Glasgow prognostic score) as  an independent prognostic factor in colorectal cancer  patients Kyeong Woon Choi, Seong Woo Hong, Yeo Goo Chang, Woo Yong Lee, Byungmo Lee, In Wook Paik,  Hyucksang Lee Department of Surgery, Inje University Seoul Paik Hospital, Seoul, Korea INTRODUCTION Malignant disease and inflammation have a close rela - tion ship with each other.",Non-OADS,/arxiv_data1/oa_pdf/4d/07/astr-86-309.PMC4062449.pdf
"All  articles are distributed under the terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Purpose: This study was conducted to evaluate the systemic inflammatory response in colorectal cancer patients, and to  estimate the usefulness of the Glasgow prognostic score (GPS) as a prognostic factor.",Non-OADS,/arxiv_data1/oa_pdf/4d/07/astr-86-309.PMC4062449.pdf
"302pISSN 2288-6575  • eISSN 2288-6796 http://dx.doi.org/10.4174/astr.2014.86.6.302 Annals of Surgical Treatment and ResearchORIGINAL ARTICLE Relationship between 15-hydroxyprostaglandin  dehydrogenase and gastric adenocarcinoma Jae Hyun Kang, Sang Hyun Kang, Sang Hyuk Seo, Jae Ho Shin, Min Sung An, Tae Kwun Ha, Ki Beom Bae,   Tae Hyun Kim, Chang Soo Choi, Sang Hoon Oh, Mi Seon Kang, Kwang Hee Kim Department of Surgery, Inje University College of Medicine, Busan, Korea  INTRODUCTION Prostaglandin is a lipid-protein complex derived from ara - chidonic acid that has various physiologic functions.",Non-OADS,/arxiv_data1/oa_pdf/e1/97/astr-86-302.PMC4062450.pdf
"All  articles are distributed under the terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/e1/97/astr-86-302.PMC4062450.pdf
" Annals of Surgical Treatment and Research 319pISSN 2288-6575  • eISSN 2288-6796 http://dx.doi.org/10.4174/astr.2014.86.6.319 Annals of Surgical Treatment and ResearchORIGINAL ARTICLE Impact of a surgical intensivist on the clinical outcomes of  patients admitted to a surgical intensive care unit Chi-Min Park1,2, Ho-Kyung Chun3, Dae-Sang Lee1, Kyeongman Jeon1,4, Gee Young Suh1,4, Jin Cheol Jeong5  Departments of 1Critical Care Medicine and 2Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine,  Seoul, 3Department of Surgery, Kangbuk Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 4Division  of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of  Medicine, Seoul, 5Department of Surgery, Hallym University Kangdong Sacred Heart Hospital, Hallym University School of  Medicine, Seoul, Korea INTRODUCTION Intensivists are physicians who specialize in the care of  critically ill patients and who direct and provide critical care  in an intensive care unit (ICU) [1].",Non-OADS,/arxiv_data1/oa_pdf/6c/3e/astr-86-319.PMC4062451.pdf
"All  articles are distributed under the terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Purpose: An intensivist is a key factor in the mortality of patients admitted to the intensive care unit (ICU).",Non-OADS,/arxiv_data1/oa_pdf/6c/3e/astr-86-319.PMC4062451.pdf
" Annals of Surgical Treatment and Research 331pISSN 2288-6575  • eISSN 2288-6796 http://dx.doi.org/10.4174/astr.2014.86.6.331 Annals of Surgical Treatment and ResearchCASE REPORT Use of right lobe graft with type IV portal vein  accompanied by type IV biliary tree in living donor liver  transplantation:  report of a case Mahmoud Refaat Shehata, Dong-Sik Kim1, Sung-Won Jung1, Young-Dong Yu1, Sung-Ock Suh1 Department of General Surgery, Assiut University Hospital, Assiut, Egypt, 1Department of HBP Surgery and Liver Transplantation,  Korea University College of Medicine, Seoul, Korea INTRODUCTION Living-donor liver transplantation (LDLT) using a right lobe  graft has become popular because it provides a larger size  of liver graft that is appropriate for adult recipients despite  ethical issues of the safety of a healthy living donor.",Non-OADS,/arxiv_data1/oa_pdf/5a/87/astr-86-331.PMC4062452.pdf
"All  articles are distributed under the terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Anatomic variations of the portal vein (PV) and bile duct (BD) are more common on the right lobe as compared with  left lobe grafts in living donor liver transplantation (LDLT).",Non-OADS,/arxiv_data1/oa_pdf/5a/87/astr-86-331.PMC4062452.pdf
"334pISSN 2288-6575  • eISSN 2288-6796 http://dx.doi.org/10.4174/astr.2014.86.6.334 Annals of Surgical Treatment and ResearchTECHNICAL ADVANCE Mechanical thrombectomy-assisted thrombolysis for  acute symptomatic portal and superior mesenteric  venous thrombosis Kang Woong Jun, Mi Hyeong Kim, Keun Myoung Park, Ho Jong Chun1, Kee Chun Hong2, Yong Sun Jeon3,  Soon Gu Cho3, Jang Yong Kim Departments of Surgery and 1Radiology, The Catholic University of Korea, Seoul St. Mary’s Hospital, Seoul, Departments of  2Surgery and 3Radiology, Inha University Hospital, Inha University, Incheon, Korea  INTRODUCTION Acute portal vein and mesenteric vein thrombosis (PVMVT)  is a rare and insidious disease that is associated with significant  mortality and morbidity.",Non-OADS,/arxiv_data1/oa_pdf/7f/e3/astr-86-334.PMC4062453.pdf
"All  articles are distributed under the terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Acute portal vein and mesenteric vein thrombosis (PVMVT) can cause acute mesenteric ischemia and be fatal with  mortality rate of 37%–76%.",Non-OADS,/arxiv_data1/oa_pdf/7f/e3/astr-86-334.PMC4062453.pdf
" Annals of Surgical Treatment and Research 295pISSN 2288-6575  • eISSN 2288-6796 http://dx.doi.org/10.4174/astr.2014.86.6.295 Annals of Surgical Treatment and ResearchORIGINAL ARTICLE Causes and outcomes of revisional bariatric surgery:  initial experience at a single center Ji Yeon Park, Dan Song, Yong Jin Kim Department of Surgery, Soonchunhyang University Hospital, Soonchunhyang University College of Medicine, Seoul, Korea INTRODUCTION Obesity has become one of the most important public  health problems worldwide.",Non-OADS,/arxiv_data1/oa_pdf/bf/4c/astr-86-295.PMC4062454.pdf
"All  articles are distributed under the terms of the Creative Commons Attribution Non- Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which  permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.Purpose: Bariatric surgery has become more prevalent owing to the worldwide obesity epidemic.",Non-OADS,/arxiv_data1/oa_pdf/bf/4c/astr-86-295.PMC4062454.pdf
Available online at: http://www.cms.hhs.gov/CLIA/.,Non-OADS,/arxiv_data1/oa_pdf/34/c0/ejhg2014108a.PMC4062531.pdf
http://www.c17.ca/ 34 Center for Disease Control.,Non-OADS,/arxiv_data1/oa_pdf/34/c0/ejhg2014108a.PMC4062531.pdf
Available online at: http://www.cdc.gov/ genomics/gtesting/ACCE/.,OADS,/arxiv_data1/oa_pdf/34/c0/ejhg2014108a.PMC4062531.pdf
"To view a copy of thislicense, visit http://creativecommons.org/licenses/by-nc-nd/3.0/To disclose or not to disclose?",Non-OADS,/arxiv_data1/oa_pdf/34/c0/ejhg2014108a.PMC4062531.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/8f/00/ppa-8-853.PMC4062546.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpPatient Preference and Adherence 2014:8 853–864Patient Preference and Adherence Dove press submit your manuscript | www.dovepress.co m Dove press  853Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PPA.S5316 2Combination of brinzolamide and brimonidine  for glaucoma and ocular hypertension: critical  appraisal and patient focus Quang H Nguyen Division of Ophthalmology, Scripps  Clinic, La Jolla, CA, USAAbstract:  Glaucoma is one of the leading causes of blindness and is characterized by optic  nerve damage that results in visual field loss.",Non-OADS,/arxiv_data1/oa_pdf/8f/00/ppa-8-853.PMC4062546.pdf
"Keywords:  adherence, fixed combination, persistence, Simbrinza®, tolerability Introduction In 2010, glaucoma accounted for over 8 million incidences of blindness worldwide  and was one of the leading causes of blindness.1 By 2020, an estimated 79 million  individuals worldwide will have been diagnosed with glaucoma.1 Glaucoma is char - acterized by elevated intraocular pressure (IOP), progressive optic neuropathy, and  corresponding visual field loss.2,3 Lowering IOP to an individualized target level  (typically a 25% reduction from initial IOP) and maintaining that level reduces the  risk of vision loss and improves outcomes,4–6 even among patients with  normal-tension Correspondence: Quang H Nguyen Division of Ophthalmology, Scripps Clinic,  10666 North T orrey Pines Rd, MS 214,   La Jolla, CA 92037, USA T el +1 858 554 9101 Fax +1 858 554 9224 email nguyen.quang@scrippshealth.or gJournal name: Patient Preference and Adherence Journal Designation: Review Y ear: 2014 Volume: 8 Running head verso: Nguyen Running head recto: Brinzolamide/brimonidine for glaucoma DOI: http://dx.doi.org/10.2147/PPA.S53162",Non-OADS,/arxiv_data1/oa_pdf/8f/00/ppa-8-853.PMC4062546.pdf
Available at: http://www.eugs.org/eng/EGS_guidelines.asp.,Non-OADS,/arxiv_data1/oa_pdf/8f/00/ppa-8-853.PMC4062546.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal that focusing on the growing importance of patient   preference  and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/8f/00/ppa-8-853.PMC4062546.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/ed/4a/jpr-7-313.PMC4062547.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpJournal of Pain Research 2014:7 313–326Journal of Pain Research Dove press submit your manuscript | www.dovepress.co m Dove press  313Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JPR.S5914 4Chronic musculoskeletal pain: review   of mechanisms and biochemical biomarkers   as assessed by the microdialysis technique Björn Gerdle1,2 Bijar Ghafouri1,3 Malin ernberg4 Britt Larsson1,2 1Rehabilitation Medicine, Department  of Clinical and experimental Medicine,   Linköping University, Linköping,   Sweden;  2Pain and Rehabilitation  Centre, County Council of  Östergötland, Linköping, Sweden;   3Rehabilitation Medicine, Department  of Medicine and Health Sciences,   Linköping University, Linköping,   Sweden;  4Department of Dental  Medicine, Section of Orofacial  Pain and Jaw Function, Karolinska  institutet, Huddinge, Sweden Correspondence: Björn Gerdle   Rehabilitation Medicine, Department   of Clinical Medicine and experimental   Sciences (iMH), Faculty of Health   Sciences, Linköping University,   Se 581 85 Linköping, Sweden   Tel +46 763 927 191  email bjorn.gerdle@liu.s eAbstract:  Chronic musculoskeletal pain conditions are multifaceted, and approximately  20%  of the adult population lives with severe chronic pain, with a higher prevalence in women and  in lower income groups.",Non-OADS,/arxiv_data1/oa_pdf/ed/4a/jpr-7-313.PMC4062547.pdf
"Available from: http://www.disabilitaincifre.it/documenti/ICF_18.pd f.  Accessed September 10, 2103.",Non-OADS,/arxiv_data1/oa_pdf/ed/4a/jpr-7-313.PMC4062547.pdf
Available  from: http://www.rdc-tmdinternational.org/Portals/18/ protocol_DC - TMD/DC-TMD%20Protocol%20-%202013_06_02.pd f. International  Research Diagnostic Criteria for Temporomandibular Disorders Con - sortium Network;  2014.,OADS,/arxiv_data1/oa_pdf/ed/4a/jpr-7-313.PMC4062547.pdf
A vailable from:  https://www.iasp-pain.org/Education/Content.aspx?ItemNumber =1698.,Non-OADS,/arxiv_data1/oa_pdf/ed/4a/jpr-7-313.PMC4062547.pdf
"Journal of Pain Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-pain-research-journa lThe Journal of Pain Research is an international, peer-reviewed, open  access, online journal that welcomes laboratory and clinical findings  in the fields of pain research and the prevention and management  of pain.",Non-OADS,/arxiv_data1/oa_pdf/ed/4a/jpr-7-313.PMC4062547.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/ed/4a/jpr-7-313.PMC4062547.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/a4/ad/ndt-10-1025.PMC4062548.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpNeuropsychiatric Disease and Treatment 2014:10 1025–1037Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1025OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/ 10.2147/NDT .S6147 5Journal name: Neuropsychiatric Disease and Treatment Journal Designation: Original Research Y ear: 2014 Volume: 10 Running head verso: Petit et al Running head recto: Neurophysiological correlates of response inhibition predict relapse DOI: http://dx.doi.org/10.2147/NDT.S61475 Neurophysiological correlates of response  inhibition predict relapse in detoxified alcoholic  patients: some preliminary evidence from   event-related potentials géraldine Petit agnieszka cimochowska charles Kornreich catherine hanak Paul Verbanck salvatore campanella laboratory of Psychological Medicine  and addictology, UlB Neuroscience  institute (UN i), Université libre de  Bruxelles (UlB), Brussels, BelgiumBackground:  Alcohol dependence is a chronic relapsing disease.",Non-OADS,/arxiv_data1/oa_pdf/a4/ad/ndt-10-1025.PMC4062548.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/a4/ad/ndt-10-1025.PMC4062548.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.Dove pres s Neuropsychiatric Disease and Treatment 2014:10submit your manuscript | www.dovepress.co m Dove press Dove press 1037Neurophysiological correlates of response inhibition predict relapse  75.,Non-OADS,/arxiv_data1/oa_pdf/a4/ad/ndt-10-1025.PMC4062548.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/c0/42/ijwh-6-605.PMC4062549.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Women’s Health 2014:6 605–611International Journal of Women’s Health Dove press submit your manuscript | www.dovepress.co m Dove press  605RevIeWopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/IJWH.S5113 8vertical transmission of hepatitis B virus:  challenges and solutions Ivan Gentile Guglielmo Borgia Department of Clinical Medicine  and Surgery, University of Naples  “Federico II”, Naples, Italy Correspondence: Ivan Gentile   Department of Clinical Medicine   and Surgery (ed  18), University of   Naples “Federico II”, via S Pansini  5,   I-80131 Naples, Italy   Tel +39 081 746 3178  Fax +39 081 746 3190  email ivan.gentile@unina.i tAbstract:  More than  240 million people worldwide are chronically infected with hepatitis B  virus (HBV).",Non-OADS,/arxiv_data1/oa_pdf/c0/42/ijwh-6-605.PMC4062549.pdf
"Available from: http://www.who.int/mediacentre/factsheets/ fs204/en/index.htm l. Accessed May 30, 2014.",Non-OADS,/arxiv_data1/oa_pdf/c0/42/ijwh-6-605.PMC4062549.pdf
"International Journal of Women’s Health Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-womens-health-journa lThe International Journal of Women’ s Health is an international, peer- reviewed open-access journal publishing original research, reports,  editorials, reviews and commentaries on all aspects of women’s  healthcare including gynecology, obstetrics, and breast cancer.",Non-OADS,/arxiv_data1/oa_pdf/c0/42/ijwh-6-605.PMC4062549.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes  from published authors.,Non-OADS,/arxiv_data1/oa_pdf/c0/42/ijwh-6-605.PMC4062549.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/a9/40/clep-6-199.PMC4062550.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pClinical Epidemiology 2014:6 199–211Clinical Epidemiology Dove press submit your manuscript | www.dovepress.co m Dove press  199Original rEsEarChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/CLEP .S6099 1The Copenhagen Primary Care Differential   Count (CopDiff) database Christen lykkegaard  andersen1,2 Volkert Dirk siersma1 Willy Karlslund1 hans Carl hasselbalch2 Peter Felding3 Ole Weis Bjerrum4 niels de Fine Olivarius1 1The research Unit for general  Practice and section of general  Practice, Department of Public  health, University of Copenhagen,   2Department of hematology,   roskilde University hospital,  3The  Elective laboratory of the Capital  region,  4Department of hematology,   Copenhagen University hospital,   Copenhagen, Denmark Correspondence: Christen lykkegaard  andersen   The research Unit for general Practice   and section of general Practice,   Department of Public health, University   of Copenhagen, Denmark, Øster   Farimagsgade  5, 1014 Copenhagen,   Denmark   Tel +45 2612 2840  Fax +45 3532 7131  Email christenla@gmail.co mBackground:  The differential blood cell count provides valuable information about a person’ s  state of health.",Non-OADS,/arxiv_data1/oa_pdf/a9/40/clep-6-199.PMC4062550.pdf
"Further information on the CopDiff database, steering  committee, bylaws, and ways to collaborate can be found by  visiting the CopDiff homepage ( http://almenpraksis.ku.dk/ english/research/copdiff /).",Non-OADS,/arxiv_data1/oa_pdf/a9/40/clep-6-199.PMC4062550.pdf
Available from: http://www.cgps.dk/SteeringCommittee.php.,Non-OADS,/arxiv_data1/oa_pdf/a9/40/clep-6-199.PMC4062550.pdf
Available from: http://www.iupac.org /.,Non-OADS,/arxiv_data1/oa_pdf/a9/40/clep-6-199.PMC4062550.pdf
"Clinical Epidemiology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical­epidemiology­journa lClinical Epidemiology is an international, peer-reviewed, open access  journal focusing on disease and drug epidemiology, identification of  risk factors and screening procedures to develop optimal preventative  initiatives and programs.",Non-OADS,/arxiv_data1/oa_pdf/a9/40/clep-6-199.PMC4062550.pdf
"Available from: http://www.healthcare.siemens.com/services/laboratory- diagnostic s. Accessed May 18, 2014 2.",Non-OADS,/arxiv_data1/oa_pdf/a9/40/clep-6-199.PMC4062550.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/c1/7f/ndt-10-1045.PMC4062551.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpNeuropsychiatric Disease and Treatment 2014:10 1045–1055Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1045Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/NDT .S3882 1Frontotemporal dementia and primary  progressive aphasia, a review Howard S Kirshner Department of Neurology, vanderbilt  University Medical Center, Nashville,   TN, USA Correspondence: Howard S Kirshner   Department of Neurology,   vanderbilt University Medical Center,  A-0118 Medical Center North,   Nashville, TN 37232, USA   email howard.kirshner@vanderbilt.ed uAbstract:  Frontotemporal dementias are neurodegenerative diseases in which symptoms of  frontal and/or temporal lobe disease are the first signs of the illness, and as the diseases progress,  they resemble a focal left hemisphere process such as stroke or traumatic brain injury, even more  than a neurodegenerative disease.",Non-OADS,/arxiv_data1/oa_pdf/c1/7f/ndt-10-1045.PMC4062551.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing  on concise rapid reporting of clinical or pre-clinical studies on a  range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/c1/7f/ndt-10-1045.PMC4062551.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/c1/7f/ndt-10-1045.PMC4062551.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/28/92/jpr-7-301.PMC4062552.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpJournal of Pain Research 2014:7 301–311Journal of Pain Research Dove press submit your manuscript | www.dovepress.co m Dove press  301Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JPR.S3730 6improving opioid prescription practices and  reducing patient risk in the primary care setting Martin D Cheatle Cody Barker Center for Studies of Addiction,   Perelman School of Medicine,   University of Pennsylvania,   Philadelphia, PA, USA Correspondence: Martin D Cheatle   Center for Studies of Addiction,  Perelman School of Medicine,   University of Pennsylvania   3535 Market Street,  4th Floor,  Philadelphia, PA  19104, USA   Tel +1 215 746 7365  Fax +1 610 988 4952  email cheatle@mail.med.upenn.ed uAbstract:  Chronic pain is complex, and the patient suffering from chronic pain frequently  experiences concomitant medical and psychiatric disorders, including mood and anxiety  disorders, and in some cases substance use disorders.",Non-OADS,/arxiv_data1/oa_pdf/28/92/jpr-7-301.PMC4062552.pdf
SBIRT has been designed to be integrated into existing clinics  and utilize community resources ( http://www.samhsa.gov/ prevention/sbirt /).,Non-OADS,/arxiv_data1/oa_pdf/28/92/jpr-7-301.PMC4062552.pdf
Available from:  http://www.hrsa.gov/ruralhealth/about/telehealth /.,Non-OADS,/arxiv_data1/oa_pdf/28/92/jpr-7-301.PMC4062552.pdf
"Journal of Pain Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-pain-research-journa lThe Journal of Pain Research is an international, peer-reviewed, open  access, online journal that welcomes laboratory and clinical findings  in the fields of pain research and the prevention and management  of pain.",Non-OADS,/arxiv_data1/oa_pdf/28/92/jpr-7-301.PMC4062552.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/28/92/jpr-7-301.PMC4062552.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/a3/3c/ppa-8-805.PMC4062553.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpPatient Preference and Adherence 2014:8 805–811Patient Preference and Adherence Dove press submit your manuscript | www.dovepress.co m Dove press  805ORIGINAL RESEARCHopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PPA.S5949 6Enhanced patient support services   improve patient persistence with multiple   sclerosis treatment Jane Roche1 Yvonne McCarry2 Karen Mellors3 1Beaumont Hospital, Dublin,    2Quintiles Ireland Ltd, Fairview,    Dublin, Ireland; 3Merck Serono   Ltd, Feltham, UK Correspondence: Jane Roche   Beaumont Hospital, Beaumont Road,   Dublin 9, Ireland   Tel +353 877 590 537   Fax +353 1797 4780   Email janeoreilly24@hotmail.co mBackground:  Subcutaneous interferon beta-1a (sc IFN β-1a) therapy (44 µg or 22 µg, three  times weekly) improves relapse rates and disability progression in patients with relapsing  multiple sclerosis (MS).",Non-OADS,/arxiv_data1/oa_pdf/a3/3c/ppa-8-805.PMC4062553.pdf
Available from: http://www.nationalmssociety.,Non-OADS,/arxiv_data1/oa_pdf/a3/3c/ppa-8-805.PMC4062553.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal focusing on the growing importance of patient  preference and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/a3/3c/ppa-8-805.PMC4062553.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/a3/3c/ppa-8-805.PMC4062553.pdf
"Available from: http://www.who.int/chp/knowledge/publications/adher - ence_report/en/index.htm l. Accessed December 7, 2013.",OADS,/arxiv_data1/oa_pdf/a3/3c/ppa-8-805.PMC4062553.pdf
"Available from: http://www.pqaalliance.org/ images/uploads/files/PQA%20PDC%20vs%20%20MPR.pd f. Accessed   March 11, 2013.",OADS,/arxiv_data1/oa_pdf/a3/3c/ppa-8-805.PMC4062553.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/25/a4/ndt-10-1079.PMC4062554.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpNeuropsychiatric Disease and Treatment 2014:10 1079–1080Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1079LeTTeropen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/ 10.2147/NDT .S6665 7Journal name: Neuropsychiatric Disease and Treatment Journal Designation: Letter Y ear: 2014 Volume: 10 Running head verso: Lozano et al Running head recto: Running head recto DOI: http://dx.doi.org/10.2147/NDT.S66657 Correspondence: roberto Lozano   Pharmacy Department, Hospital real de  Nuestra Señora de Gracia, ramón y Cajal,  60, 50004 Zaragoza, Spain email rlozano@salud.aragon.e sAnalysis of the cumulative effect of schizophrenia- related single nucleotide polymorphisms roberto Lozano1 reyes Marín2 Isabel Freire2 María-Jesús Santacruz2 Asunción Pascual-García2 1Pharmacy Department, 2Psychiatry  Department, Hospital real de  Nuestra Señora de Gracia,    Zaragoza, SpainDear editor It is currently believed that predisposition for schizophrenia stems from the combined  effect of multiple common polymorphisms.",Non-OADS,/arxiv_data1/oa_pdf/25/a4/ndt-10-1079.PMC4062554.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/25/a4/ndt-10-1079.PMC4062554.pdf
"Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.Dove pres s Neuropsychiatric Disease and Treatment 2014:10submit your manuscript | www.dovepress.co m Dove press Dove press 1080Lozano et al Toll-interleukin-1  receptor domain-containing adaptor  molecule-1  (TICAM-1), which also harbors a proline-rich  region.4 2.",Non-OADS,/arxiv_data1/oa_pdf/25/a4/ndt-10-1079.PMC4062554.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/73/a0/ijnrd-7-219.PMC4062555.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nephrology and Renovascular Disease 2014:7 219–230International Journal of Nephrology and Renovascular Disease Dove press submit your manuscript | www.dovepress.co m Dove press  219RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/IJNRD.S4205 4Hypomagnesemia: a clinical perspective Phuong-Chi T Pham1 Phuong-Anh T Pham2 Son v Pham3 Phuong-Truc T Pham4 Phuong-Mai T Pham5 Phuong-Thu T Pham6 1Olive view–UCLA Medical Center,   Los Angeles, CA, USA;  2veterans  Administration Central California  Health Care System, Fresno, CA, USA ;  3South Texas veterans Health Care  System and University of T exas Health  Science Center, San Antonio, TX, USA;   4Pennsylvania State University wilkes- Barre, Lehman, PA, USA;  5Greater  Los Angeles veterans Administration,   Sepulveda, CA, USA;  6David Geffen  School of Medicine at UCLA, Los  Angeles, CA, USA Correspondence: Phuong-Chi T Pham   Olive view–UCLA Medical Center,   14445 Olive view Drive,  2B-182,   Sylmar, CA  91342, USA   email p ham.pchi@ucla.ed uAbstract:  Although magnesium is involved in a wide spectrum of vital functions in normal  human physiology, the significance of hypomagnesemia and necessity for its treatment are  under-recognized and underappreciated in clinical practice.",Non-OADS,/arxiv_data1/oa_pdf/73/a0/ijnrd-7-219.PMC4062555.pdf
"International Journal of Nephrology and Renovascular Disease Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nephrology-and-renovascular-disease-journa lThe International Journal of Nephrology and Renovascular Disease is  an international, peer-reviewed open-access journal focusing on the  pathophysiology of the kidney and vascular supply.",Non-OADS,/arxiv_data1/oa_pdf/73/a0/ijnrd-7-219.PMC4062555.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/73/a0/ijnrd-7-219.PMC4062555.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/54/fb/ndt-10-1069.PMC4062556.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpNeuropsychiatric Disease and Treatment 2014:10 1069–1077Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1069Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/NDT .S4077 7Tackling nonadherence in psychiatric   disorders: current opinion Saeed Farooq1,2 Farooq Naeem3 1Staffordshire University, Staffordshire,   UK; 2Postgraduate Medical institute,   Lady Reading Hospital, Peshawar,   Pakistan; 3Department of Psychiatry,   Queen’s University, Kingston, Ontario,   Canada Correspondence: Saeed Farooq   Postgraduate Medical institute, Lady   Reading Hospital, Peshawar, Pakistan   email sfarooqlrh@yahoo.co mAbstract:  Nonadherence to treatment is a major challenge in all fields of medicine, and it has  been claimed that increasing the effectiveness of adherence interventions may have far greater  impact on the health of the population than any improvement in specific medical treatments.",Non-OADS,/arxiv_data1/oa_pdf/54/fb/ndt-10-1069.PMC4062556.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing  on concise rapid reporting of clinical or pre-clinical studies on a  range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/54/fb/ndt-10-1069.PMC4062556.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/54/fb/ndt-10-1069.PMC4062556.pdf
Available from  http://www.currentpsychiatry.com/topics/practice-trends/article/ participatory-pharmacotherapy-10-strategies-for-enhancing-adherence.,Non-OADS,/arxiv_data1/oa_pdf/54/fb/ndt-10-1069.PMC4062556.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/0a/e9/mder-7-195.PMC4062557.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pMedical Devices: Evidence and Research 2014:7 195–203Medical Devices: Evidence and Research Dove press submit your manuscript | www.dovepress.co m Dove press  195ORiginal REsEaRchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/MDER.S6391 8Usability of devices for self-injection: results of a  formative study on a new disposable pen injector Jakob lange1 Philipp Richard1 nick Bradley2 1Ypsomed ag, Burgdorf, switzerland;   2Bergo, glasgow, United Kingdom correspondence: Jakob lange   Ypsomed ag, 6 Brunnmattstrasse,   Burgdorf, Bern  3401, switzerland   Tel +41 34 424 3187  Fax +41 34 424 3151  Email jakob.lange@ypsomed.co mAbstract:  This article presents a late-stage formative usability study of a pen-injector platform  device.",Non-OADS,/arxiv_data1/oa_pdf/0a/e9/mder-7-195.PMC4062557.pdf
"Available from:  http://www.fda.gov/medicaldevices/deviceregulationandguidance/ guidancedocuments/ucm259748.ht m. Accessed March  10, 2014.",Non-OADS,/arxiv_data1/oa_pdf/0a/e9/mder-7-195.PMC4062557.pdf
Available from: http://www.pharmaceuticalonline.com/doc/two- key-questions-in-platform-000 1.,Non-OADS,/arxiv_data1/oa_pdf/0a/e9/mder-7-195.PMC4062557.pdf
Submit your manuscript here:  http://www.dovepress.com/medical-devices-evidence-and-research-journa l Medical Devices: Evidence and Research 2014:7submit your manuscript | www.dovepress.co m Dove press Dove press Dove pres s 203Usability of devices for self-injection  11.,Non-OADS,/arxiv_data1/oa_pdf/0a/e9/mder-7-195.PMC4062557.pdf
"Available from: http://www2.dupont.com/ Medical_Device_Material/en_US/news_events/article20111018.htm l.  Accessed March  10, 2014.",Non-OADS,/arxiv_data1/oa_pdf/0a/e9/mder-7-195.PMC4062557.pdf
"Available from:  http://www.ypsomed.com/tl_files/ypsomed/data/documents/yds_down - loads/products/91003_FAS_UP .pd f. Accessed March  10, 2014.",OADS,/arxiv_data1/oa_pdf/0a/e9/mder-7-195.PMC4062557.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/fe/bd/ijnrd-7-231.PMC4062558.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nephrology and Renovascular Disease 2014:7 231–239International Journal of Nephrology and Renovascular Disease Dove press submit your manuscript | www.dovepress.co m Dove press  231RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/IJNRD.S4183 7Management of hemolytic-uremic syndrome   in children Silviu Grisaru University of Calgary, Alberta  Children’s Hospital, Calgary, Alberta,   Canada Correspondence: Silviu Grisaru   University of Calgary, Alberta Children’s  Hospital,  2888 Shaganappi Trail Nw,  Calgary, Alberta, Canada T3B  6A8   email sgrisaru@ucalgary.c aAbstract:  Acute renal failure associated with a fulminant, life-threatening systemic disease is  rare in previously healthy young children; however, when it occurs, the most common cause is  hemolytic-uremic syndrome (HUS).",Non-OADS,/arxiv_data1/oa_pdf/fe/bd/ijnrd-7-231.PMC4062558.pdf
"International Journal of Nephrology and Renovascular Disease Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nephrology-and-renovascular-disease-journa lThe International Journal of Nephrology and Renovascular Disease is  an international, peer-reviewed open-access journal focusing on the  pathophysiology of the kidney and vascular supply.",Non-OADS,/arxiv_data1/oa_pdf/fe/bd/ijnrd-7-231.PMC4062558.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/fe/bd/ijnrd-7-231.PMC4062558.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/1b/70/rru-6-063.PMC4062559.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpResearch and Reports in Urology 2014:6 63–65Research and Reports in Urology Dove press submit your manuscript | www.dovepress.co m Dove press  63CASE REPORTopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/RRU.S6230 2Bilateral spermatocytic seminoma: a case report Hadley Narins1 Kent Chevli1,2 Richard Gilbert2 Michael Duff1,2 Andrew T oenniessen2 Yan Hu3 1Department of Urology, State  University of New Y ork at Buffalo  Medical School, Buffalo, NY, USA;   2Western New York Urology  Associates, Cheektowaga, NY, USA;   3Department of Pathology, State  University of New Y ork at Buffalo  Medical School, Buffalo, NY, USA Correspondence: Michael Duff   Western New York Urology Associates,   3085 Harlem Road, Suite 200,   Cheektowaga, NY 14225, USA   Email mduff@cancercarewny.co mAbstract:  Spermatocytic seminoma (SS) is a rare entity, accounting for  2%–12% of all  seminomas; amongst those, fewer than  10% are bilateral.",Non-OADS,/arxiv_data1/oa_pdf/1b/70/rru-6-063.PMC4062559.pdf
"Research and Reports in Urology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/research-and-reports-in-urology-journa lResearch and Reports in Urology is an international, peer-reviewed,  open access journal publishing original research, reports, editorials,  reviews and commentaries on all aspects of adult and pediatric urology  in the clinic and laboratory including the following topics: Pathology,  pathophysiology of urological disease; Investigation and treatment of urological disease; Pharmacology of drugs used for the treatment of  urological disease.",Non-OADS,/arxiv_data1/oa_pdf/1b/70/rru-6-063.PMC4062559.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/1b/70/rru-6-063.PMC4062559.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/71/02/prbm-7-161.PMC4062560.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpPsychology Research and Behavior Management 2014:7 161–166Psychology Research and Behavior Management Dove press submit your manuscript | www.dovepress.co m Dove press  161ORiginal ReseaRchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/PRBM.S5539 3somatic perception, cultural differences and   immigration: results from administration of the   Modified Somatic Perception Questionnaire   (MSPQ) to a sample of immigrants nicola luigi Bragazzi giovanni Del Puente Werner Maria natta Department of n euroscience,   Rehabilitation, Ophthalmology,   genetics, Maternal and child health,   section of Psychiatry, University   of genoa, genoa, italy correspondence: nicola luigi Bragazzi   school of Public health, Department   of Health Sciences (DISSAL),   University of genoa, Via antonio   Pastore 1, 16132 genoa, italy   Tel +39 01 03 537 664   Fax +39 01 03 537 669   email robertobragazzi@gmail.co mAbstract:  The number of immigrants in Italy has doubled every 10 years from 1972 and Genoa  hosts two large communities of immigrants from South America and Africa.",Non-OADS,/arxiv_data1/oa_pdf/71/02/prbm-7-161.PMC4062560.pdf
"Psychology Research and Behavior Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/psychology-research-and-behavior-management-journa lPsychology Research and Behavior Management is an international, peer- reviewed, open access journal focusing on the science of psychology and  its application in behavior management to develop improved outcomes  in the clinical, educational, sports and business arenas.",Non-OADS,/arxiv_data1/oa_pdf/71/02/prbm-7-161.PMC4062560.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/71/02/prbm-7-161.PMC4062560.pdf
Available from:  http://www.naga.it/tl_files/naga/documenti/CittadiniSenzaDiritti2009.,Non-OADS,/arxiv_data1/oa_pdf/71/02/prbm-7-161.PMC4062560.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/19/f7/jbm-5-069.PMC4062561.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpJournal of Blood Medicine 2014:5 69–86Journal of Blood Medicine Dove press submit your manuscript | www.dovepress.co m Dove press  69REVIEWopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JBM.S4625 5Hemophagocytic lymphohistiocytosis: review   of etiologies and management Melissa R George Department of Pathology, Penn   State Milton S Hershey Medical   Center, Hershey, PA, USA Correspondence: Melissa R George   Penn State Milton S Hershey Medical   Center, Department of Pathology,   500 University Drive, MC H160,   Hershey, PA  17033, USA   Email mgeorge5@hmc.psu.ed uAbstract:  Hemophagocytic lymphohistiocytosis (HLH) covers a wide array of related  life-threatening conditions featuring ineffective immunity characterized by an uncontrolled  hyperinflammatory response.",Non-OADS,/arxiv_data1/oa_pdf/19/f7/jbm-5-069.PMC4062561.pdf
"Table 7  Genetic defects associated with FHL FHL subclass Chromosome Gene Gene function Protein FHL-1 9q21.3-q22 Unknown Unknown Unknown FHL-2 10q21-22 PFR1 Induction of apoptosis Perforin FHL-3 17q25 UNC13D Vesicle priming Munc13-4 FHL-4 6q24 STX11 Vesicle transport Syntaxin11 FHL-5 19p13.2-3 STXBP2  (UNC18B ) Vesicle transport Munc18-2 Other HLH-associated diseases CHS-1 1q42.1-q42.2 LYST Vesicle transport Lyst GS-2 15q21 RAB27A Vesicle transport Rab27a XLP-1 Xq25 SH2D1A Signal transduction and activation of  lymphocytesSAP XLP-2 Xq25 BIRC4 Various signaling pathways XIAP Notes: Modified with permission from the Annual Review of Medicine, Volume 63 © 2012 by Annual Reviews, http://www.annualreviews.org .30 Modified with permission of  American Society of Hematology, from Hematology American Society of Hematology Education Program, Familial and acquired hemophagocytic lymphohistiocytosis.",Non-OADS,/arxiv_data1/oa_pdf/19/f7/jbm-5-069.PMC4062561.pdf
"Journal of Blood Medicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/Journal-of-blood-medicine-journa lThe Journal of Blood Medicine is an international, peer-reviewed, open  access, online journal publishing laboratory, experimental and clinical aspects  of all topics pertaining to blood based medicine including but not limited to:  Transfusion Medicine; Blood collection, Donor issues, Transmittable diseases,  and Blood banking logistics; Immunohematology; Artificial and alternative blood based therapeutics; Hematology; Biotechnology/nanotechnology of  blood related medicine; Legal aspects of blood medicine; Historical perspec - tives.",Non-OADS,/arxiv_data1/oa_pdf/19/f7/jbm-5-069.PMC4062561.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/19/f7/jbm-5-069.PMC4062561.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/03/b8/ppa-8-843.PMC4062562.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpPatient Preference and Adherence 2014:8 843–851Patient Preference and Adherence Dove press submit your manuscript | www.dovepress.co m Dove press  843OriginAl reseArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PPA.S5498 6An observational, retrospective, UK and ireland   audit of patient adherence to subcutaneous   interferon beta-1a injections using   the rebismart® injection device helen Willis1 Julie Webster1 Anne Marie larkin2 laura Parkes3 1Broomfield hospital, chelmsford,   essex, United Kingdom; 2Mysupport  nurse, Quintiles ireland ltd, Dublin,   ireland; 3Medical Affairs, Merck serono  ltd, Feltham, United Kingdom correspondence: helen Willis   Mid essex hospital services national   Health Service Trust, Broomfield   hospital, court road, chelmsford,   essex, cM1 7eT, United Kingdom   Tel +44 01245 516 829   Fax +44 01245 513 9756   email h elen.willis@meht.nhs.u kBackground:  Poor adherence to disease-modifying drugs is associated with an increased risk  of relapse in patients with multiple sclerosis .",Non-OADS,/arxiv_data1/oa_pdf/03/b8/ppa-8-843.PMC4062562.pdf
"Available from: http://www.abn.org.uk/abn/userfiles/file/ABN_MS_ Guidelines_2009_Final(1).pd f. Accessed March 11, 2013.",Non-OADS,/arxiv_data1/oa_pdf/03/b8/ppa-8-843.PMC4062562.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal focusing on the growing importance of patient  preference and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/03/b8/ppa-8-843.PMC4062562.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/03/b8/ppa-8-843.PMC4062562.pdf
Available from: http://clinicaltrials.gov/ct2/show/ NCT0160108 0.,Non-OADS,/arxiv_data1/oa_pdf/03/b8/ppa-8-843.PMC4062562.pdf
Available from: http://eprints.phar - macy.ac.uk/2605/1/Evaluation_of_NHS_Medicines_Waste__web_  publication_version.pdf .,Non-OADS,/arxiv_data1/oa_pdf/03/b8/ppa-8-843.PMC4062562.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/e0/f0/rru-6-059.PMC4062563.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpResearch and Reports in Urology 2014:6 59–62Research and Reports in Urology Dove press submit your manuscript | www.dovepress.co m Dove press  59ORiginal ReseaRchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/RRU.S5860 0adult bipolar diathermy circumcision   and related procedures in adults – a safe   and efficient technique sunny nalavenkata Matthew Winter Rachel Kour nam-Wee Kour Paul Ruljancich Department of Urology, eastern  health, Box hill hospital, Box hill,   Vic, australia correspondence: Matthew Winter   Department of Urology, eastern health,  nelson Road, Box hill hospital,   Box hill, Vic 3128, australia   email matthewwinter01@gmail.co mObjectives:  To present our novel technique and step-by-step approach to bipolar diathermy  circumcision and related procedures in adult males.",Non-OADS,/arxiv_data1/oa_pdf/e0/f0/rru-6-059.PMC4062563.pdf
"Research and Reports in Urology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/research-and-reports-in-urology-journa lResearch and Reports in Urology is an international, peer-reviewed,  open access journal publishing original research, reports, editorials,  reviews and commentaries on all aspects of adult and pediatric urology  in the clinic and laboratory including the following topics: Pathology,  pathophysiology of urological disease; Investigation and treatment of urological disease; Pharmacology of drugs used for the treatment of  urological disease.",Non-OADS,/arxiv_data1/oa_pdf/e0/f0/rru-6-059.PMC4062563.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/e0/f0/rru-6-059.PMC4062563.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/be/f6/ndt-10-1017.PMC4062564.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpNeuropsychiatric Disease and Treatment 2014:10 1017–1023Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1017OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S6385 5Journal name: Neuropsychiatric Disease and Treatment Journal Designation: Original Research Y ear: 2014 Volume: 10 Running head verso: Park et al Running head recto: Factors associated with antenatal depression in Korea DOI: http://dx.doi.org/10.2147/NDT.S63855 correspondence: Young-eun Jung;   Moon-Doo Kim Department of Psychiatry, school   of Medicine, Jeju National University,   15 aran 13-gil, Jeju 690-756, Korea Tel +826 4717 1234 Fax +826 4717 1849 email jyejye77@daum.net;   mdkim66@jejunu.ac.kFactors associated with antenatal depression   in pregnant Korean females: the effect   of bipolarity on depressive symptoms chul Min Park1 hye-Jin seo2 Y oung-eun Jung3 Moon-Doo Kim3 seong-chul hong4 Won-Myong Bahk5 Bo-hyun Y oon6 Min hee hur7 Jae Min song3 1Department of Obstetrics and  gynecology, school of Medicine, Jeju  National University, Jeju, 2Department  of Psychiatry, Yeonkang hospital,   Jeju, 3Department of Psychiatry,   4Department of Preventive Medicine,   school of Medicine, Jeju National  University, Jeju, 5Department of  Psychiatry, Yeouido st Mary’s  hospital, college of Medicine, The  catholic University of Korea, seoul,   6Department of Psychiatry, Naju  National hospital, Naju, 7school of  Medicine, Jeju National University,   Jeju, KoreaBackground:  This cross-sectional study sought to identify factors associated with antenatal  depression in pregnant Korean females, including sociodemographic parameters, social support,  social conflict, and bipolarity.",Non-OADS,/arxiv_data1/oa_pdf/be/f6/ndt-10-1017.PMC4062564.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/be/f6/ndt-10-1017.PMC4062564.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.Dove pres s Neuropsychiatric Disease and Treatment 2014:10submit your manuscript | www.dovepress.co m Dove press Dove press 1023Factors associated with antenatal depression in Korea  12.,Non-OADS,/arxiv_data1/oa_pdf/be/f6/ndt-10-1017.PMC4062564.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org /licenses/by-nc-nd/3.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a4/af/main.PMC4062756.pdf
1 C)t h a tw e r en e g a t i v eContents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/lrrLeukemia Research Reports http://dx.doi.org/10.1016/j.lrr.2014.05.004 2213-0489/ &2014 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/a4/af/main.PMC4062756.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/3.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a4/af/main.PMC4062756.pdf
http://dx.doi.org/10.1016/j.redox.2014.05.004,OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1136/ard.52.9.659  , 8239761  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1038/   ncprheum0920  , 18825134  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"Measurement  and meaning  of markers of reactive species  of oxygen, nitrogen and sulfur in healthy human subjects and patients with in-  ﬂammatory  joint disease,  Biochemical  Society Transactions 39(5)  (2011) 1226– 1232. http://dx.doi.org/10.1042/BST0391226  , 21936794  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1002/   art.21130  , 15986354  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1111/j.1365-3083.2006.01794.x  ,  17032243  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"Barnes, Oxidative  stress in COPD, Chest 144(1) (2013) 266– 273. http://dx.doi.org/10.1378/chest.12-2664  , 23880677  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1038/   nm876 , 12740573  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1074/jbc.M904549199  , 10748075  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1016/j.freeradbiomed.2004.11.001  , 15721982  .",OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
http://dx.doi.org/10.1146/annurev.iy.12.,Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1126/science.1071059  ,  11951032  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1172/JCI63108  , 23281407  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1146/annurev.immunol.26.021607.090248  , 18370922  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
http://dx.doi.org/10.1128/IAI.74.1.,Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
http://dx.doi.org/10.1084/jem.190.,Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/   10.1002/art.27584  , 20872595  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1172/   JCI1316 , 9421490  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
http://dx.doi.org/10.1074/jbc.,Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1038/nm0698-713  , 9623982  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1016/j.coi.2004.09.001  , 15511669  .",OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1172/JCI36800  , 19363291  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
http://dx.doi.org/10.1016/j.freeradbiomed.2012.,OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1007/978-  1- 4939- 0326- 9 12 , 24497361  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1016/   S0968- 0004(02)00003-  8 , 12517450  .",OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1021/jf970818c  , 10554268  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1172/JCI116531  , 8390491  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1016/0003-  9861(92)90431-  U , 1416974  .",OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1021/   tx950133b  , 8839040  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1172/JCI119379  ,  9151778  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1021/bi0474665  , 15882077  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1074/jbc.M106134200  ,  11733505  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"Bruenner,  A.D. Jones, J.B. German, Direct characterization  of protein  adducts of the lipid peroxidation  product 4-hydroxy-2-nonenal  using electro-  spray mass spectrometry,  Chemical  Research  in Toxicology  8(4) (1995) 552– 559. http://dx.doi.org/10.1021/tx00046a009  , 7548735  .",OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
http://dx.doi.org/10.1006/bbrc.1998.,Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1073/   pnas.91.11.4766  , 8197133  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1084/jem.179.4.1317  , 7511686  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/   10.1002/1529-  0131(199807)41:7  < 1241::AID-  ART15 > 3.0.CO;2-  H , 9663482  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1002/art.21783  ,  16645988  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1161/   CIRCRESAHA.110.223875  , 21252151  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.4049/jimmunol.1004134  , 21502377  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1080/10715760802623896  ,  19096973  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1093/rheumatology/kem215  ,  17848401  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1074/   jbc.M110.165175  , 20736172  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1056/NEJMoa021933  , 14561795  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
http://dx.doi.org/10.1111/cei.12094  .,Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1038/ng0598-56  , 9590289  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1136/ard.52.12.851  , 8311534  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1093/ndt/   gﬂ436 , 16877491  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1006/clin.1996.4293  , 9000483  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
http://dx.doi.org/10.1111/j.1365-2249.,Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.4049/   jimmunol.1102859  , 22407922  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1002/1529-0131(200001)43:1  <  155::AID-  ANR20 > 3.0.CO;2-  3 , 10643712  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/   10.1038/nm1637  , 17828273  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1016/j.febslet.2007.03.008  , 17376441  .",OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1016/   S0014- 5793(04)00233-  9 , 15063715  .",OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
http://dx.doi.org/10.3899/jrheum.,Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1093/rheumatology/   37.12.1307  , 9973155  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1016/S0891-5849(98)   00130-0  , 9823543  .",OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
http://dx.doi.org/10.4049/jimmunol.165.11.,Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1002/art.37964  , 23575908  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1007/s00125-  012- 2780- 1 , 23160643  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
http://dx.doi.org/10.1164/rccm.,Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"Oxidative  stress-induced  antibodies  to carbonyl-modiﬁed   protein correlate  with severity of chronic obstructive  pulmonary  disease,  American  Journal of Respiratory  and Critical Care Medicine  184(7) (2011) 796– 802. http://dx.doi.org/10.1164/rccm.201010-1605OC  , 21965015  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"Boosting  antitumor  responses  of T lymphocytes  inﬁltrating  hu-  man prostate cancers, Journal of Experimental  Medicine  201(8) (2005) 1257– 1268. http://dx.doi.org/10.1084/jem.20042028  , 15824085  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1038/nrrheum.2012.14  , 22331061  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1002/art.30283  , 21538320  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
http://dx.doi.org/10.2337/diab.33.3.27110.2337/diabetes.33.,Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1172/JCI4533  , 9884341  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1172/JCI8472  ,  10862788  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1074/   jbc.271.52.33208  , 8969177  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1038/   nm.3459  , 24464187  .",OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1016/j.jacc.2011.07.017  ,  21982317  .",OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1182/blood-  2013- 05- 500074 ,  23813936  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1016/0014-5793(85)   80374-4  , 2411595  .",OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
http://dx.doi.org/10.1016/j.cell.,OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
"http://dx.doi.org/10.1080/   14767050500134217  , 16050144  .",Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/52/42/main.PMC4062766.pdf
Available from: http://www.clinicaltrials.gov.,Non-OADS,/arxiv_data1/oa_pdf/6e/1b/ORT-85-215.PMC4062784.pdf
Available from:  http://www.clinicaltrials.gov.,Non-OADS,/arxiv_data1/oa_pdf/6e/1b/ORT-85-215.PMC4062784.pdf
"These 3 groups were: low (educational level 0–2), middle (educational level 3–4), and high (educational level 5–6) (http://www.unesco.org).",Non-OADS,/arxiv_data1/oa_pdf/76/05/ORT-85-221.PMC4062786.pdf
2008. http://www.shpr.se.,Non-OADS,/arxiv_data1/oa_pdf/76/05/ORT-85-221.PMC4062786.pdf
"Herberts P, Kärrholm J, Garellick G. 2004, Swedish Hip Arthroplasty register,  Annual report 2004. http://www.shpr.se.",OADS,/arxiv_data1/oa_pdf/76/05/ORT-85-221.PMC4062786.pdf
"Quality of life for cities and countries worldwide, report February 2013.  http://numbeo.com Rolfson O, Dahlberg L E, Nilsson J A, Malchau H, Garellick G. Variables  determining outcome in total hip replacement surgery.",OADS,/arxiv_data1/oa_pdf/76/05/ORT-85-221.PMC4062786.pdf
"Swedish  Knee  Arthroplasty  Register:  Annual  report  2012  Lund  Uni- versity Hospital, Lund; 2012 [http://www.knee.se/]. 2012.",Non-OADS,/arxiv_data1/oa_pdf/a3/50/ORT-85-229.PMC4062787.pdf
Available from: http://www.scb.se/sv_/Hitta-statistik/Artiklar/Fort-satt-okning-av-utrikes-fodda-i-Sverige/.,OADS,/arxiv_data1/oa_pdf/02/a6/ORT-85-234.PMC4062788.pdf
Available from: http://www.malmo.se/download/18.24a63bbe13e8ea7a3c692fc/1383644210075/Rapport+Bef+Bokslut+2012.pdf.,Non-OADS,/arxiv_data1/oa_pdf/02/a6/ORT-85-234.PMC4062788.pdf
2013; http://CRAN.R-project.org/package=minpack.lm.,Non-OADS,/arxiv_data1/oa_pdf/07/09/ORT-85-238.PMC4062789.pdf
"R  Foundation for Statistical Computing 2013; Vienna, Austria(http://www.R-project.org/).",Non-OADS,/arxiv_data1/oa_pdf/07/09/ORT-85-238.PMC4062789.pdf
"Available  from: http://CRAN.R-project.org/package=rms Hilsenbeck S G, Clark G M. Practical p-value adjustment for optimally  selected cutpoints.",Non-OADS,/arxiv_data1/oa_pdf/78/bc/ORT-85-244.PMC4062790.pdf
Available from: http://www.R-project.org/ Wickham H. ggplot2: elegant graphics for data analysis (Internet).,Non-OADS,/arxiv_data1/oa_pdf/78/bc/ORT-85-244.PMC4062790.pdf
Available from: http://had.co.nz/ggplot2/book Williams J S. Assessing the suitability of fractional polynomial methods in  health services research: a perspective on the categorization epidemic.,Non-OADS,/arxiv_data1/oa_pdf/78/bc/ORT-85-244.PMC4062790.pdf
"Technology appraisal  Manchester: National Institute for Health and Clinical Excellence Level  1A, City Tower, Piccadilly Plaza, Manchester M1 4BT; 2003 (updated 04-01-201315-08-2013); Available from: http://guidance.nice.org.uk/TA2/Guidance/pdf/English.",Non-OADS,/arxiv_data1/oa_pdf/d1/53/ORT-85-250.PMC4062791.pdf
"National Joint Registry (United Kingdom).http://www.njrcentre.org.uk/njr - centre/default.aspx Pandit H, Glyn-Jones S, McLardy-Smith P, Gundle R, Whitwell D, Gibbons  C L, Ostlere S, Athanasou N, Gill H S, Murray D W. Pseudotumours asso-ciated with metal-on-metal hip resurfacings.",Non-OADS,/arxiv_data1/oa_pdf/dc/d6/ORT-85-259.PMC4062792.pdf
2013;  personal  communication:  http://www.shpr.,Non-OADS,/arxiv_data1/oa_pdf/bd/25/ORT-85-276.PMC4062795.pdf
J Bone  Joint  Surg  (Am)  2002;  84 (1):  17-22. http://www.statistikbanken.dk  - accessed  Nov  13.,OADS,/arxiv_data1/oa_pdf/ac/be/ORT-85-287.PMC4062797.pdf
Available at: http://www.ellipse-tech.com/pages/PRECICE (accessed 25 May 2013).,Non-OADS,/arxiv_data1/oa_pdf/6a/0f/ORT-85-293.PMC4062798.pdf
"ISBN 3-900051-07-0, URL http://www.R-project.org/.",Non-OADS,/arxiv_data1/oa_pdf/2c/13/ORT-85-299.PMC4062799.pdf
available  at: http://Www.ambkir.dk/Faglige%20retningsli- nier/Behandling%20af%20sarkomer.pdf. 2007; 2013.,Non-OADS,/arxiv_data1/oa_pdf/00/ca/ORT-85-323.PMC4062802.pdf
The free Ca2+concentration was ~13 –14 nM based on the calculation using Theo ’s Chelator program ( http://maxchelator.stanford.,OADS,/arxiv_data1/oa_pdf/ee/7d/424_2013_Article_1345.PMC4062818.pdf
"SUPPLEMENTARY MATERIAL  is linked to the online version of the paper at  http://www.nature.com/cpt ACKNOWLEDGMENTS We acknowledge G. Winchell and S. Allerheiligen of Merck & Co., for their   initial assessment of the modeling and drive to incorporate into the  development plan.",Non-OADS,/arxiv_data1/oa_pdf/95/72/clpt201466a.PMC4062834.pdf
"To view a copy of this license,  visit http://creativecommons.org/licenses/by-nc-nd/3.0/ CLInIC aL pharma CoLogy & ThErapEuTICs  | VOLUME 96 NUMBER 1 | JULy 2014  109",Non-OADS,/arxiv_data1/oa_pdf/95/72/clpt201466a.PMC4062834.pdf
http://www.shimoda.,Non-OADS,/arxiv_data1/oa_pdf/d1/9c/srep05356.PMC4062898.pdf
http://portal.cyberjapan.,Non-OADS,/arxiv_data1/oa_pdf/d1/9c/srep05356.PMC4062898.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 5356 | DOI: 10.1038/srep05356 5",Non-OADS,/arxiv_data1/oa_pdf/d1/9c/srep05356.PMC4062898.pdf
Cell culture and transfection .Cell lines were obtained from ATCC (http://www.atcc.,OADS,/arxiv_data1/oa_pdf/41/03/srep05352.PMC4062899.pdf
Wealso thank Life Technologies Corporation (http://www.lifetechnologies.com/) forpermission to use the spectral data of fluorescent Ca 21indicators.,Non-OADS,/arxiv_data1/oa_pdf/41/03/srep05352.PMC4062899.pdf
"Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors are employees of Olympus Corporation, and this work was funded by Olympus Corporation.",Non-OADS,/arxiv_data1/oa_pdf/41/03/srep05352.PMC4062899.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/53/27/srep05357.PMC4062900.pdf
"51, 198–202; DOI: http://dx.doi.org/10.1104/pp.51.1.198 (1973).",Non-OADS,/arxiv_data1/oa_pdf/24/1c/srep05355.PMC4062901.pdf
"47, 6–17; DOI: http://dx.doi.org/ 10.1016/j.jcs.2007.01.005 (2008).",OADS,/arxiv_data1/oa_pdf/24/1c/srep05355.PMC4062901.pdf
"59, 21–30; DOI: http://dx.doi.org/10.1016/S0378- 4290(98)00103-8 (1998).",OADS,/arxiv_data1/oa_pdf/24/1c/srep05355.PMC4062901.pdf
"120, 361–370; DOI: http://dx.doi.org/10.1104/pp.120.2.361 (1999).",Non-OADS,/arxiv_data1/oa_pdf/24/1c/srep05355.PMC4062901.pdf
"99, 501–507; http://dx.doi.org/10.1104/pp.99.2.501 (1992).",Non-OADS,/arxiv_data1/oa_pdf/24/1c/srep05355.PMC4062901.pdf
"135, 1621–1629; DOI: http://dx.doi.org/10.1104/pp.104.041038 (2004).",Non-OADS,/arxiv_data1/oa_pdf/24/1c/srep05355.PMC4062901.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 5355 | DOI: 10.1038/srep05355 8",Non-OADS,/arxiv_data1/oa_pdf/24/1c/srep05355.PMC4062901.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 5353 | DOI: 10.1038/srep05353 5",Non-OADS,/arxiv_data1/oa_pdf/20/dc/srep05353.PMC4062902.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/49/85/srep05358.PMC4062903.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 5358 | DOI: 10.1038/srep05358 7",Non-OADS,/arxiv_data1/oa_pdf/49/85/srep05358.PMC4062903.pdf
"Available from: http://www.ejhs.org/volume16/Transaction.html [5] Montano SM, Hsieh EJ, Calderon M, et al.",OADS,/arxiv_data1/oa_pdf/db/78/TOAIDJ-8-17.PMC4062928.pdf
"Available from: http://data.unaids.org/publications/Fact-Sheets01/peru_en.pdf   Received: December 30, 2013 Revised: May 7, 2014 Accepted: May 9, 2014  © Kinsler et al.",Non-OADS,/arxiv_data1/oa_pdf/db/78/TOAIDJ-8-17.PMC4062928.pdf
"This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/ 3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/db/78/TOAIDJ-8-17.PMC4062928.pdf
"This is an open access article licensed under the terms of the Creative Commons Attribution Non -Commercial License (http://creativecommons.org/ - licenses/by -nc/3.0/) which permits unrestricted, non -commercial use, distribution and reproduction in any medium, provided the work is properly  cited.",Non-OADS,/arxiv_data1/oa_pdf/0c/c7/TOMICROJ-8-32.PMC4062929.pdf
"This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c0/81/TOOPHTJ-8-3.PMC4062930.pdf
Available from:  http://www.cdaadc.ca/en/oral_health/cfyt/dental_care_children/first -visit.asp.,Non-OADS,/arxiv_data1/oa_pdf/98/82/TODENTJ-8-104.PMC4062931.pdf
Available from:  http://www.aap.org/en-us/professional-resources/practice-support/- financing-and-payment/Billing-and-Payment/Docucments/Profile_- Pediatric-Visits [Accessed: January 2014].,Non-OADS,/arxiv_data1/oa_pdf/98/82/TODENTJ-8-104.PMC4062931.pdf
"This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and repr oduction in any medium, provided the  work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/98/82/TODENTJ-8-104.PMC4062931.pdf
http://dx.doi.org/10.1016/j.celrep.2014.04.055 This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/3.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/98/2a/main.PMC4062932.pdf
"Code Availability The latest version of the cloneHD software, including ﬁlterHD, as wellas extensive documentation, can be found at: https://github.com/ andrej-ﬁscher/cloneHD .",OADS,/arxiv_data1/oa_pdf/98/2a/main.PMC4062932.pdf
SUPPLEMENTAL INFORMATION Supplemental Information includes Supplemental Experimental Procedures and two ﬁgures and can be found with this article online at http://dx.doi.org/ 10.1016/j.celrep.2014.04.055 .,Non-OADS,/arxiv_data1/oa_pdf/98/2a/main.PMC4062932.pdf
"Cell Reports Article BRCA2 Coordinates the Activities of Cell-Cycle Kinases to Promote Genome Stability Keiko Yata,1,5,6Jean-Yves Bleuyard,1,5Ryuichiro Nakato,2,3Christine Ralf,1Yuki Katou,2Rebekka A. Schwab,4 Wojciech Niedzwiedz,4Katsuhiko Shirahige,2,3and Fumiko Esashi1,* 1The Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford OX1 3RE, UK 2Research Center for Epigenetic Disease, Graduate School of Frontier Sciences, University of Tokyo, Tokyo 113-0032, Japan 3CREST, Japan Science and Technology Agency (JST), K’s Gobancho, 7, Gobancho, Chiyoda-ku, Tokyo 102-0076, Japan 4The Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK 5Co-ﬁrst author 6Present address: The Gurdon Institute and Department of Zoology, University of Cambridge, Cambridge CB2 1QN, UK *Correspondence: fumiko.esashi@path.ox.ac.uk http://dx.doi.org/10.1016/j.celrep.2014.04.023 This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/3.0/ ).",Non-OADS,/arxiv_data1/oa_pdf/1e/49/main.PMC4062933.pdf
"The data set is available from the NationalCenter for Biotechnology Information, Sequence Read Archive (NCBI-SRA;http://www.ncbi.nlm.nih.gov/Traces/sra/ ).",OADS,/arxiv_data1/oa_pdf/1e/49/main.PMC4062933.pdf
"SUPPLEMENTAL INFORMATION Supplemental Information includes Supplemental Discussion, Supplemental Experimental Procedures, six ﬁgures, and one table and can be found withthis article online at http://dx.doi.org/10.1016/j.celrep.2014.04.023 .",Non-OADS,/arxiv_data1/oa_pdf/1e/49/main.PMC4062933.pdf
"Cell Reports Article Targeting Polycomb to Pericentric Heterochromatin in Embryonic Stem Cells Reveals a Rolefor H2AK119u1 in PRC2 Recruitment Sarah Cooper,1Martin Dienstbier,2Raihann Hassan,1Lothar Schermelleh,3Jafar Sharif,4Neil P. Blackledge,5 Valeria De Marco,6Sarah Elderkin,7Haruhiko Koseki,4Robert Klose,5Andreas Heger,2and Neil Brockdorff1,* 1Developmental Epigenetics, Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK 2CGAT, MRC Functional Genomics Unit, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford OX1 3PT, UK 3Advanced Cellular Imaging, Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK 4Laboratory for Developmental Genetics, RIKEN Center for Integrative Medical Sciences, 1-7-22 Suehiro, Tsurumi-ku, Yokohama 230-0045, Japan 5Chromatin Biology and Transcription, Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK 6MRC National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, UK 7Nuclear Dynamics, Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT, UK *Correspondence: neil.brockdorff@bioch.ox.ac.uk http://dx.doi.org/10.1016/j.celrep.2014.04.012 This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/3.0/ ).",Non-OADS,/arxiv_data1/oa_pdf/c5/9e/main.PMC4062935.pdf
"SUPPLEMENTAL INFORMATION Supplemental Information includes Supplemental Experimental Procedures, seven ﬁgures, and three tables and can be found with this article online athttp://dx.doi.org/10.1016/j.celrep.2014.04.012 .",Non-OADS,/arxiv_data1/oa_pdf/c5/9e/main.PMC4062935.pdf
"This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b0/8f/TOOPHTJ-8-7.PMC4062941.pdf
http://dx.doi.org/10.1016/j.prevetmed.2014.03.028 0167-5877/© 2014  The  Authors.,Non-OADS,/arxiv_data1/oa_pdf/fe/25/main.PMC4062942.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/ licenses/by-nc-nd/3.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/fe/25/main.PMC4062942.pdf
This  is  an  open  access  article  under  the  CC BY-NC-ND license  (http://creativecommons.org/licenses/by-nc-nd/3.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/fe/25/main.PMC4062942.pdf
2012; http://imagej.nih.gov/ij/   [17] Dahl JL.,OADS,/arxiv_data1/oa_pdf/b0/13/TOMICROJ-8-40.PMC4062944.pdf
"This is an open access article licensed under the terms of the Creative Commons Attribution Non -Commercial License (http://creativecommons.org/ - licenses/by -nc/3.0/) which permits unrestricted, non -commercial use, distribution and reproduction in any medium, provided the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b0/13/TOMICROJ-8-40.PMC4062944.pdf
http://dx.doi.org/10.1016/j.prevetmed.2014.03.029 0167-5877/© 2014  The  Authors.,Non-OADS,/arxiv_data1/oa_pdf/ac/e4/main.PMC4062945.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND  license (http://creativecommons.org/licenses/by-nc-nd/3.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ac/e4/main.PMC4062945.pdf
This  is  an  open  access  article  under  the  CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ac/e4/main.PMC4062945.pdf
"The  World  Orga- nization  for  Animal  Health  (OIE,  2008 )  (http://www.oie.int/ eng/normes/mcode/en  chapitre  1.11.8.htm;  last  accessed 14  July  2008)  recommends  the  use  of  complement  ﬁxation test  (CFT)  or  competitive  enzyme-linked  immunosorbent assay  (cELISA)  as  herd-level  test  and  suggests  that  sample size  should  be  adjusted  to  compensate  for  low  sensitiv- ity  of  the  tests.",Non-OADS,/arxiv_data1/oa_pdf/ac/e4/main.PMC4062945.pdf
"The  sample  size  was  calculated  using Win  Episcope  2.0  (http://www.clive.ed.ac.uk )  based  on  95% conﬁdence  level,  5%  absolute  precision  and  an  expected prevalence  of  5%  at  herd  level,  higher  than  the  reported prevalence  of  2.8%  (Wanyoike,  1999 )  given  the  perceived rising  prevalence  (Thomson,  2005 ).",Non-OADS,/arxiv_data1/oa_pdf/ac/e4/main.PMC4062945.pdf
"Economic  and  social  consequences  of  animal  diseases, http://go.worldbank.org/PMRI0CP0R0  (accessed  06.05.13).",Non-OADS,/arxiv_data1/oa_pdf/ac/e4/main.PMC4062945.pdf
This is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/2b/f2/ijbsv10p0576.PMC4062950.pdf
This is an open- access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/40/0a/ijbsv10p0588.PMC4062951.pdf
This is an open- access article distrib uted under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/30/b3/ijbsv10p0596.PMC4062952.pdf
This is an open- access article distributed under the terms o f the Creative Commons License (http://creativecommons.org/   licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/9a/b6/ijbsv10p0602.PMC4062953.pdf
This is an open- access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/6f/b1/ijbsv10p0614.PMC4062954.pdf
This is an open- access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/7a/36/ijbsv10p0620.PMC4062955.pdf
"Roughly 12 -13% of these cases will  result in death (29,720 es timated in 2013), making it  the second leading cause of cancer deaths in U.S. men  (http://seer.cancer.gov/statfacts/html/prost.html).",Non-OADS,/arxiv_data1/oa_pdf/7a/36/ijbsv10p0620.PMC4062955.pdf
"Relative expression level of Fyn in BPH, primary CaP (1º) and metastases  (“Mets”) from Oncomine  (http://www.oncomine.org) from the studies of Dhana- sekaran et al.",OADS,/arxiv_data1/oa_pdf/7a/36/ijbsv10p0620.PMC4062955.pdf
"Relative expression level of Ack1 (TNK2) in normal/BPH, primary CaP and  lymph node metastases (mets) from Oncomine  (http://www.oncomine.org) from the  study of Taylor et al.",OADS,/arxiv_data1/oa_pdf/7a/36/ijbsv10p0620.PMC4062955.pdf
This is an open- access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/63/ad/ijbsv10p0627.PMC4062956.pdf
This is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/2e/c1/ijbsv10p0643.PMC4062957.pdf
"All tissue biospecimens were obtained from  the biospecimen core facilities at the Louisiana Cancer  Research Consortium (LCRC) affiliated with Tulane Medical School and School of Medicine, LSUHSC,  New  Orleans  (http://www.louisianacancercenter.org /collaborative -initiatives/sharedresources/biospeci men -core) ( Additional File 1: supplementary Table  1).",OADS,/arxiv_data1/oa_pdf/2e/c1/ijbsv10p0643.PMC4062957.pdf
"Comparative analysis of AR -E213 G/A SNP in  patients with primar y prostate cancer and in  unrelated normal individuals     The AR -Stu I restriction site, commonly known  as E213 G/A SNP (rs6152) is a synonymous change  (GAG > GAA) for glutamic acid (http://www.ncbi.",Non-OADS,/arxiv_data1/oa_pdf/2e/c1/ijbsv10p0643.PMC4062957.pdf
This is an open- access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/90/49/ijbsv10p0652.PMC4062958.pdf
"This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and repr oduction in any medium, provided the  work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/64/f2/TODENTJ-8-95.PMC4062959.pdf
"OncoImmunology 2014; 3:e28273; http://dx.doi.org/10.4161/onci.28273Lymphocyte-derived interleukin-17A adds another  brick in the wall of inflammation-induced breast  carcinogenesis Jérémy Bastid1, Nathalie Bonnefoy2, Jean-François el iaou2,3, and Armand Bensussan4,5,* 1ore G A Biotech; ec ully, France; 2irC M, in stitut de re cherche en Cancérologie de Montpellier; iNs erM , u8 96; un iversité Montpellier 1; C rL C Val d’Aurelle Paul Lamarque;  Montpellier, France; 3Département d’ im munologie; Centre ho spitalier ré gional un iversitaire de Montpellier et Faculté de Médecine un iversité Montpellier 1; Montpellier,  France; 4in stitut National de la sa nté et de la re cherche Médicale ( iNs erM ) uMr-s  976; Paris, France; 5un iversité Paris Diderot; so rbonne Paris Cité; Laboratoire im munologie  Dermatologie &  on cologie; Paris, France Keywords:  breast cancer, ERK kinases, IL-17A, tumor infiltrating lymphocytes, chemoresistance, monoclonal antibodies we h ave previously reported that a subset of breast tumors are infiltrated with iL -17A-producing tumor-associated  lymphocytes and that  iL -17A cytokine is principally associated with estrogen receptor negative ( e r−) and triple negative,  basal-like tumors.",Non-OADS,/arxiv_data1/oa_pdf/4f/e7/onci-3-e28273.PMC4063083.pdf
Breast Cancer Res 2008; 10:R95; http://dx.doi.org/10.1186/bcr2195 ;  PMID:190146372.,Non-OADS,/arxiv_data1/oa_pdf/4f/e7/onci-3-e28273.PMC4063083.pdf
Histopathology 2013; 63:225-33; http://dx.doi.org/10.1111/his.12156 ;  PMID:23738752 4.,Non-OADS,/arxiv_data1/oa_pdf/4f/e7/onci-3-e28273.PMC4063083.pdf
Breast Cancer Res 2009; 11:R56; http://dx.doi.org/10.1186/bcr2345 ;  PMID:19643025 5.,Non-OADS,/arxiv_data1/oa_pdf/4f/e7/onci-3-e28273.PMC4063083.pdf
BMC Cancer 2011; 11:365; http://dx.doi.org/10.1186/1471-2407-11-365 ; PMID:21859454 6.,Non-OADS,/arxiv_data1/oa_pdf/4f/e7/onci-3-e28273.PMC4063083.pdf
Cancer Res 2008; 68:3915-23; http://dx.doi.org/10.1158/0008-5472.CAN-08-0206 ; PMID:184832777.,Non-OADS,/arxiv_data1/oa_pdf/4f/e7/onci-3-e28273.PMC4063083.pdf
Sci Rep 2013; 3:3456; http://dx.doi.org/10.1038/srep03456 ;  PMID:24316750 8.,OADS,/arxiv_data1/oa_pdf/4f/e7/onci-3-e28273.PMC4063083.pdf
Nat Med 2013; 19:1114-23; http://dx.doi.org/10.1038/nm.3291 ; PMID:23913124 9.,OADS,/arxiv_data1/oa_pdf/4f/e7/onci-3-e28273.PMC4063083.pdf
Oncogene  2013; http://dx.doi.org/10.1038/onc.2013.268   (Forthcoming);  PMID:23851503 10.,OADS,/arxiv_data1/oa_pdf/4f/e7/onci-3-e28273.PMC4063083.pdf
Sci Transl Med 2011; 3:78ra31; http://dx.doi.org/10.1126/scitranslmed.3001374 ;  PMID:21490275 ©2014 Landes Bioscience.,Non-OADS,/arxiv_data1/oa_pdf/4f/e7/onci-3-e28273.PMC4063083.pdf
Statistical tests The statistic analysis were calculated using the free online software from http://www.quantitativeskills.com/sisa/statistics/diagnos.htm.,OADS,/arxiv_data1/oa_pdf/60/a5/ABR-3-116.PMC4063113.pdf
"OncoImmunology 2014; 3:e28328; http://dx.doi.org/10.4161/onci.28328KLRG1+ natural killer cells protect against  pulmonary metastatic disease by  immunosurveillance Philipp re nner1, Jordi ro vira2, Christoph Klein3, han s-Jürgen sc hlitt1, edw ard K Geissler1, and Alexander Kroemer1,* 1Department of su rgery; un iversity ho spital re gensburg; un iversity of re gensburg; re gensburg, Germany; 2Department of Nephrology and re nal tr ansplantation; ho spital  Clinic de Barcelona; Barcelona,  sp ain; 3ex perimental Medicine and th erapy re search; un iversity of re gensburg; re gensburg, Germany Keywords:  Eomes, IL-15, KLRG1, NK cells, T-bet, immunosurveillance, metastasis Natural killer cells (NK cells) play a key role in cancer immunosurveillance.",Non-OADS,/arxiv_data1/oa_pdf/bc/03/onci-3-e28328.PMC4063134.pdf
"In fact, the first clini - cal trials are currently being conducted to evaluate the potency of IL-15 in the clini - cal setting (e.g., http://www.clinicaltri - als.gov: NCT01021059, NCT01369888, NCT01189383, and NCT01337544).",Non-OADS,/arxiv_data1/oa_pdf/bc/03/onci-3-e28328.PMC4063134.pdf
Nat Rev Cancer 2002; 2:850-61; PMID :12415255 ; http://dx.doi.org/10.1038/ nrc928 2.,Non-OADS,/arxiv_data1/oa_pdf/bc/03/onci-3-e28328.PMC4063134.pdf
Cancer Sci 2011; 102:1967-71;  PMID:21781225 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/bc/03/onci-3-e28328.PMC4063134.pdf
Immunity 2012; 36:55-67; PMID:22261438 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/bc/03/onci-3-e28328.PMC4063134.pdf
J Immunol 2014; 192:1954-61; PMID :24415778 ; http://dx.doi.org/10.4049/ jimmunol.1300876 6.,Non-OADS,/arxiv_data1/oa_pdf/bc/03/onci-3-e28328.PMC4063134.pdf
Cancer Res 2004; 64:452-5; PMID:14744755 ; http://dx.doi.org/10.1158/0008- 5472.CAN-03-3401 8.,Non-OADS,/arxiv_data1/oa_pdf/bc/03/onci-3-e28328.PMC4063134.pdf
J Biomed Biotechnol 2011; 2011:861920;  PMID:21716670 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/bc/03/onci-3-e28328.PMC4063134.pdf
Nat Rev Cancer 2009; 9:302-12;   PMID:19308069 ; http://dx.doi.org/10.1038/nrc2627Figure 1.,Non-OADS,/arxiv_data1/oa_pdf/bc/03/onci-3-e28328.PMC4063134.pdf
"OncoImmunology 2014; 3:e28327; http://dx.doi.org/10.4161/onci.28327Engineered chimeric antigen receptor-expressing  T cells for the treatment of pancreatic ductal  adenocarcinoma Gregory L Beatty1,* 1Abramson Cancer Center; Department of Medicine; Division of he matology- on cology; un iversity of Pennsylvania Perelman sc hool of Medicine; Philadelphia, PA usA Keywords:  adoptive cell therapy, chimeric antigen receptor, T cell, cancer, pancreas, epitope spreading, immunosurveillance Abbreviations:  CAR, chimeric antigen receptor; CTLA-4, cytotoxic T-lymphocyte antigen-4; FDG, [18F]-fluorodeoxyglucose;  PDAC, pancreatic ductal adenocarcinoma; PD-1, programmed cell death 1; PD-L1, programmed cell death 1 ligand 1; PET/CT,  positron emission tomography/computed tomography; RECIST, Response Evaluation Criteria in Solid Tumors Adoptive cell therapy with chimeric antigen receptor (CA r) -engineered t  cells is under investigatation as an approach  to restore productive  t  cell immunosurveillance in pancreatic ductal adenocarcinoma patients.",Non-OADS,/arxiv_data1/oa_pdf/91/08/onci-3-e28327.PMC4063135.pdf
N Engl J Med 2012; 366:2443-54; PMID:22658127 ;  http://dx.doi.org/10.1056/NEJMoa1200690 3.,OADS,/arxiv_data1/oa_pdf/91/08/onci-3-e28327.PMC4063135.pdf
N Engl J Med 2010; 363:711-23; PMID:20525992 ; http://dx.doi.org/10.1056/ NEJMoa1003466 4.,OADS,/arxiv_data1/oa_pdf/91/08/onci-3-e28327.PMC4063135.pdf
J Immunother 2010; 33:828-33;  PMID:20842054 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/91/08/onci-3-e28327.PMC4063135.pdf
J Immunother 2013; 36:382-9; PMID:23924790 ;  http://dx.doi.org/10.1097/CJI.0b013e31829fb7a2 6.,Non-OADS,/arxiv_data1/oa_pdf/91/08/onci-3-e28327.PMC4063135.pdf
Immunity 2013; 39:49-60; PMID:23890063 ;  http://dx.doi.org/10.1016/j.immuni.2013.07.002 7.,OADS,/arxiv_data1/oa_pdf/91/08/onci-3-e28327.PMC4063135.pdf
J Exp Med 2004; 200:297-306;  PMID :15289501 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/91/08/onci-3-e28327.PMC4063135.pdf
Cancer Res 2010; 70:9053-61; PMID:20926399 ;  http://dx.doi.org/10.1158/0008-5472.CAN-10-28809.,Non-OADS,/arxiv_data1/oa_pdf/91/08/onci-3-e28327.PMC4063135.pdf
Cancer Immunol Res 2014; 2:112-20; PMID:24579088 ;  http://dx.doi.org/10.1158/2326-6066.CIR-13-0170 10.,Non-OADS,/arxiv_data1/oa_pdf/91/08/onci-3-e28327.PMC4063135.pdf
Cancer Immunol Res 2013; 1:26-31; PMID:24432303 ; http://dx.doi.org/10.1158/2326- 6066.CIR-13-0006 ©2014 Landes Bioscience.,Non-OADS,/arxiv_data1/oa_pdf/91/08/onci-3-e28327.PMC4063135.pdf
OncoImmunology 2014; 3:e28539; http://dx.doi.org/10.4161/onci.28539,Non-OADS,/arxiv_data1/oa_pdf/e3/1e/onci-3-e28539.PMC4063136.pdf
Oncoimmunology 2012; 1:557-9;  PMID:22754786 ;  http://dx.doi.org/10.4161/onci.19367 2.,Non-OADS,/arxiv_data1/oa_pdf/e3/1e/onci-3-e28539.PMC4063136.pdf
J Protein Chem 1990; 9:487-91; PMID:2275758 ;  http://dx.doi.org/10.1007/BF01024625 4.,OADS,/arxiv_data1/oa_pdf/e3/1e/onci-3-e28539.PMC4063136.pdf
2010; 3:69-73; http://dx.doi.org/10.2174/1876822901003010069 7.,Non-OADS,/arxiv_data1/oa_pdf/e3/1e/onci-3-e28539.PMC4063136.pdf
Bioorg Med Chem Lett 1992; 2:919-24; http://dx.doi.org/10.1016/S0960-894X(00)80588-0 8.,OADS,/arxiv_data1/oa_pdf/e3/1e/onci-3-e28539.PMC4063136.pdf
Curr Neurovasc Res 2013; 10:269-74; PMID:23721262 ; http://dx.doi.org/10.2174/156 72026113109990016 11.,Non-OADS,/arxiv_data1/oa_pdf/e3/1e/onci-3-e28539.PMC4063136.pdf
Proc Natl Acad Sci U S A  1998; 95:13363-83;  PMID:9811807 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e3/1e/onci-3-e28539.PMC4063136.pdf
"J Clin Biochem Nutr 2009; 45:355-60; PMID:19902028 ;  http://dx.doi.org/10.3164/jcbn.09-46 14.Ferrucci  L M, Cross AJ, Graubard BI, Brinton LA,  McCarty CA, Ziegler RG, Ma X, Mayne ST, Sinha R. Intake of meat and iron and the risk of breast cancer in the prostate, lung, colorectal and ovarian cancer screening trial.",Non-OADS,/arxiv_data1/oa_pdf/e3/1e/onci-3-e28539.PMC4063136.pdf
Br J Cancer 2009; 101:178-84; PMID:19513076 ; http://dx.doi.org/10.1038/ sj.bjc.6605118 15.,Non-OADS,/arxiv_data1/oa_pdf/e3/1e/onci-3-e28539.PMC4063136.pdf
J Clin Pharmacol 2013; 53:885-91;  PMID:23740857 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e3/1e/onci-3-e28539.PMC4063136.pdf
J Natl Cancer Inst 2008; 100:996-1002;  PMID:18612130 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e3/1e/onci-3-e28539.PMC4063136.pdf
Nutrients 2013; 5:2836-59; PMID:23887041 ;  http://dx.doi.org/10.3390/nu5082836 18.,Non-OADS,/arxiv_data1/oa_pdf/e3/1e/onci-3-e28539.PMC4063136.pdf
Oncoimmunology 2013; 2:e26788; PMID:24498555 ; http://dx.doi.org/10.4161/ onci.26788 22.,Non-OADS,/arxiv_data1/oa_pdf/e3/1e/onci-3-e28539.PMC4063136.pdf
Nat Immunol 2013; 14:1014-22; PMID:24048123 ;  http://dx.doi.org/10.1038/ni.2703 23.,Non-OADS,/arxiv_data1/oa_pdf/e3/1e/onci-3-e28539.PMC4063136.pdf
Br J Cancer 2013; 109:1360-6;  PMID:23928660 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e3/1e/onci-3-e28539.PMC4063136.pdf
Arch Biochem Biophys 2012; 527:81-9;  PMID:22595400 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e3/1e/onci-3-e28539.PMC4063136.pdf
J Carcinog Mutagen 2013; 4:1000142;  PMID:24077764 ;  http://dx.doi.org/10.4172/2157-2518.1000142 26.,Non-OADS,/arxiv_data1/oa_pdf/e3/1e/onci-3-e28539.PMC4063136.pdf
J Clin Biochem Nutr 2007; 40:92-100; PMID:18188410 ; http://dx.doi.org/10.3164/ jcbn.40.92 27.,Non-OADS,/arxiv_data1/oa_pdf/e3/1e/onci-3-e28539.PMC4063136.pdf
Pharmacol Rev 2014; 66:222-307;  PMID:24368738 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e3/1e/onci-3-e28539.PMC4063136.pdf
Med Hypotheses 2005; 64:806-10; PMID :15694701 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/e3/1e/onci-3-e28539.PMC4063136.pdf
"OncoImmunology 2014; 3:e28781; http://dx.doi.org/10.4161/onci.28781IFNα induces prolonged remissions modeling  curative immunologic responses in chronic  myeloid leukemia Mette il ander, Anna Kreutzman, and sa tu Mustjoki* he matology re search un it; Department of he matology; un iversity of he lsinki and he lsinki un iversity Central ho spital Cancer Center; he lsinki, Finland Keywords:  chronic myeloid leukemia, interferon-alpha, immunomodulation, curative treatment, T-cells, NK-cells,  immunosurveillance Abbrevations: CML, chronic myeloid leukemia; TKI, tyrosine kinase inhibitor; Ph, Philadelphia; TNF- α, tumor necrosis factor  alpha; IFN- γ, interferon gamma; IFN- α, interferon alpha ty rosine kinase inhibitor therapy has dramatically changed the outcome of chronic myeloid leukemia (CML) patients.",Non-OADS,/arxiv_data1/oa_pdf/b3/da/onci-3-e28781.PMC4063137.pdf
"10  Furthermore, additional clinical stud - ies combining IFN- α with more potent  2nd generation TKIs are already ongoing (http://clinicaltrial.gov NCT01657604, NCT01725204, NCT01872442).",Non-OADS,/arxiv_data1/oa_pdf/b3/da/onci-3-e28781.PMC4063137.pdf
Lancet  2007; 370:342-50;  PMID:17662883 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b3/da/onci-3-e28781.PMC4063137.pdf
J Clin Oncol 2002; 20:214-20;  PMID:11773172 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b3/da/onci-3-e28781.PMC4063137.pdf
Blood 2010; 116:772-82; PMID:20413659 ; http://dx.doi.org/10.1182/ blood-2009-12-256800 5.,Non-OADS,/arxiv_data1/oa_pdf/b3/da/onci-3-e28781.PMC4063137.pdf
PLoS One 2011; 6:e23022; PMID:21857985 ; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/b3/da/onci-3-e28781.PMC4063137.pdf
PLoS One  2014; 9:e87794;  PMID:24498197 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b3/da/onci-3-e28781.PMC4063137.pdf
Nature 2013; 494:361-5;  PMID:23376950 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b3/da/onci-3-e28781.PMC4063137.pdf
Nature 2009; 457:557-61; PMID:19136945 ; http://dx.doi.org/10.1038/ nature07665 10.,Non-OADS,/arxiv_data1/oa_pdf/b3/da/onci-3-e28781.PMC4063137.pdf
Blood 2011; 118:3228-35; PMID:21685374 ;  http://dx.doi.org/10.1182/blood-2011-02-336685 ©2014 Landes Bioscience.,Non-OADS,/arxiv_data1/oa_pdf/b3/da/onci-3-e28781.PMC4063137.pdf
"OncoImmunology 2014; 3:e28326;   http://dx.doi.org/10.4161/onci.28326Sleep apnea awakens cancer A unifying immunological hypothesis David Gozal*, is aac Almendros, and Fahed ha kim Department of Pediatrics; Comer Children’s ho spital; Pritzker sc hool of Medicine; un iversity of Chicago; Chicago, iL usA Keywords:  sleep fragmentation, macrophage polarity, sleep apnea, angiogenesis, intermittent hypoxia, invasion th e presence of obstructive sleep apnea ( o sA ) in patients with cancer appears to be accompanied by poorer out - comes.",Non-OADS,/arxiv_data1/oa_pdf/eb/98/onci-3-e28326.PMC4063138.pdf
Respir Physiol Neurobiol  2010; 174:307-16;  PMID:20833273 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/eb/98/onci-3-e28326.PMC4063138.pdf
Med Hypotheses 2007; 68:232; PMID:16905275 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/eb/98/onci-3-e28326.PMC4063138.pdf
Am J Respir Crit Care Med 2012; 186:190-4; PMID:22610391 ; http://dx.doi.org/10.1164/ rccm.201201-0130OC 5.,Non-OADS,/arxiv_data1/oa_pdf/eb/98/onci-3-e28326.PMC4063138.pdf
Respir Physiol Neurobiol 2013; 186:303-7; PMID:23499797 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/eb/98/onci-3-e28326.PMC4063138.pdf
Sleep Med Rev 2013; 17:273-84;  PMID:23137527 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/eb/98/onci-3-e28326.PMC4063138.pdf
Arch Gen Psychiatry 2002; 59:131-6; PMID:11825133 ; http://dx.doi.org/10.1001/ archpsyc.59.2.131 8.,Non-OADS,/arxiv_data1/oa_pdf/eb/98/onci-3-e28326.PMC4063138.pdf
J Neuroinflammation  2012; 9:91;  PMID:22578011 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/eb/98/onci-3-e28326.PMC4063138.pdf
Cancer Res 2014; 74:1329-37;  PMID:24448240 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/eb/98/onci-3-e28326.PMC4063138.pdf
Am J Respir Crit Care Med 2014; 189:593-601; PMID:24471484 ; http://dx.doi.org/10.1164/ rccm.201310-1830OC ©2014 Landes Bioscience.,Non-OADS,/arxiv_data1/oa_pdf/eb/98/onci-3-e28326.PMC4063138.pdf
This drug library is freely available to investigators worldwide (source http://dtp.nci.nih.gov/branches/dscb/mechanistic_explanation.html).,OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
"OncoImmunology 2014; 3:e28473; http://dx.doi.org/10.4161/onci.28473Screening of novel immunogenic cell death  inducers within the NCI Mechanistic Diversity Set ab dul Qader suk kurwala1,2,3, sa ndy ad jemian1,2,3, la ura se novilla1,2,3,4, Michael Michaud1,2,3, sab rina sp aggiari1,2,5, er ika  Vacchelli1,2,3, el isa el ena Baracco1,2,3, lo renzo ga lluzzi1,2,3,6, la urence Zitvogel3,4,7, 8, Oliver Kepp1,2,5,*, and gu ido Kroemer1,2,5,6,9,* 1eq uipe 11 labellisée par la li gue na tionale contre le cancer; ce ntre de re cherche des co rdeliers; Paris, France; 2inser M U 1138; Paris, France; 3gu stave ro ussy co mprehensive  ca ncer  ce nter; Villejuif, France; 4inser M , U1015; Villejuif, France; 5Metabolomics and ce ll Biology Platforms; gu stave ro ussy co mprehensive ca ncer ce nter; Villejuif,  France; 6Université Paris Descartes/Paris 5; so rbonne Paris ci té; Paris, France; 7Université de Paris sa clay; Faculté de Médecine; le K remlin Bicêtre, France; 8ce nter of cl inical  in vestigations in Biotherapies of  ca ncer ( c icB T) 507; Villejuif, France; 9Pôle de Biologie; hôpi tal eu ropéen ge orges Pompidou; aP -h P; Paris, France Keywords:  apoptosis, autophagy, C57BL/6 mice, dendritic cells, HTS, mitoxantrone Abbreviations: CRT, calreticulin; ER, endoplasmic reticulum; FDA, Food and Drug Administration; FBS, fetal bovine serum;  GFP, green fluorescent protein; HMGB1, high mobility group box 1; ICD, immunogenic cell death; NCI, National Cancer  Institute; PI, propidium iodide im munogenic cell death ( i cD ) inducers can be defined as agents that exert cytotoxic effects while stimulating an  immune response against dead cell-associated antigens.",Non-OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
"The Mechanistic Diversity Set was indeed constructed starting from preclinical data on growth inhibition, as obtained on 60 distinct human cancer cell lines (source http://dtp.nci.nih.gov/branches/dscb/mechanistic_explanation.html).",OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Nat Rev Immunol 2006; 6:715-27; PMID:16977338 ; http://dx.doi.org/10.1038/ nri1936 2.,Non-OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Nat  Rev Immunol  2008 ; 8:59-73; PMID:18097448 ;  http://dx.doi.org/10.1038/nri2216 3.,Non-OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Nat Rev Drug Discov 2012 ; 11:215-33;  PMID:22301798 ; http://dx.doi.org/10.1038/ nrd3626 5.,Non-OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Oncoimmunology  2013 ; 2: e23714 ;  PMID:23734324 ; http://dx.doi.org/10.4161/ onci.23714 6.,Non-OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Oncoimmunology  2013 ; 2: e23139 ;  PMID:23802066 ; http://dx.doi.org/10.4161/ onci.23139 7.,Non-OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Oncoimmunology  2013 ; 2:e25737 ; PMID:24327935 ;  http://dx.doi.org/10.4161/onci.25737 8.,Non-OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Blood  2012 ; 120:3019 - 29; PMID:22932803 ; http://dx.doi.org/10.1182/ blood-2012-04-426643 9.,Non-OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Immunity 2013 ; 38:729- 41; PMID:23562161 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Cancer Res 2014 ; 74:4 36 -45;  PMID:24302580 ; http://dx.doi.org/10.1158/0008- 5472.CAN-13-1265 11.,Non-OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Oncoimmunology   2013 ; 2:e24786 ; PMID:23894723 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Oncoimmunology   2012 ; 1: 393-5; PMID:22737627 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Eur J Immunol 2013 ; 43:2718 -29;  PMID:23843024 ; http://dx.doi.org/10.1002/ eji.201242505 14.,Non-OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Annu Rev Immunol 2013 ; 31:51-72;  PMID :23157435 ; http://dx.doi.org/10.1146/ annurev-immunol-032712-100008 15.,Non-OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Cell Death Differ 2014 ; 21:26- 38; PMID:23686135 ; http://dx.doi.org/10.1038/ cdd.2013.48 16.,Non-OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Nat Rev Cancer  2012 ; 12:860-75; PMID :23151605 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Oncoimmunology  2012 ; 1:179- 88; PMID:22720239 ; http://dx.doi.org/10.4161/ onci.1.2.19026 18.,Non-OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Oncoimmunology  2013 ; 2:e23510 ;  PMID:23687621 ; http://dx.doi.org/10.4161/ onci.23510 19.,Non-OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
EMBO J 2012 ;  31:1062 -79; PMID:22252128 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
EMBO J 2012 ; 31:1055 -7;  PMID:22252132 ; http://dx.doi.org/10.1038/ emboj.2012.2 21.,Non-OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Cancer Res 2011 ; 71:4821 -33;  PMID:21602432 ; http://dx.doi.org/10.1158/0008- 5472.CAN-11-0950 22.,Non-OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
EMBO J 2009 ; 28:578-90; PMID:19165151 ;  http://dx.doi.org/10.1038/emboj.2009.1 24.,Non-OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Cytokine Growth Factor  Rev 2013 ; 24:311-8; PMID :23787159 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Cell Cycle   2009 ; 8:3723 -8; PMID:19855167 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Science  2011 ; 334:1573 -7; PMID:22174255 ;  http://dx.doi.org/10.1126/science.1208347 28.,Non-OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Nat Med  2007 ;  13:1050 -9; PMID:17704786 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Cell Death Differ  2014 ; 21:69-78; PMID:23811849 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Oncoimmunology   2012 ; 1: 94-6; PMID:22720222 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Oncoimmunology  2013 ; 2: e22197 ;  PMID:23482346 ; http://dx.doi.org/10.4161/ onci.22197 ©2014 Landes Bioscience.,Non-OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Oncoimmunology  2013 ; 2:e24568 ;  PMID:23894718 ; http://dx.doi.org/10.4161/ onci.24568 34.,Non-OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Sci Transl Med  2012 ; 4:143ra99 ; PMID:22814852 ;  http://dx.doi.org/10.1126/scitranslmed.3003807 35.,Non-OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Oncoimmunology   2012 ; 1:1640 -2; PMID:23264921 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Oncoimmunology  2013 ; 2: e23082 ;  PMID:23525565 ; http://dx.doi.org/10.4161/ onci.23082 37.,Non-OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Oncogene   2011 ; 30:1147-58; PMID:21151176 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Cell  Death Differ 2008 ; 15:1499 -509; PMID:18464797 ;  http://dx.doi.org/10.1038/cdd.2008.6739.,Non-OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Nat Rev Mol Cell Biol  2010 ; 11:700-14; PMID:20823910 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Cell Death Differ 2012 ; 19:107- 20; PMID:21760595 ; http://dx.doi.org/10.1038/ cdd.2011.96 42.,Non-OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Cell  Death Differ 2009 ; 16:1093 -107; PMID:19373242 ;  http://dx.doi.org/10.1038/cdd.2009.44 43.,Non-OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Oncogene   2010 ; 29:482-91; PMID :19881547 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Oncogene   2012 ; 31:1869 -83; PMID:21892204 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
J Exp Med 2005 ; 202:1691 -701;  PMID:16365148 ; http://dx.doi.org/10.1084/ jem.20050915 47.,Non-OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Nat Rev Cancer 2006 ; 6:813- 23; PMID:16990858 ; http://dx.doi.org/10.1038/ nrc1951 48.,Non-OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Oncoimmunology  2013 ; 2: e25238 ;  PMID:24083080 ; http://dx.doi.org/10.4161/ onci.25238 51.,Non-OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
Cell Rep  2012 ; 2:257- 69; PMID:22854025 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/d7/d5/onci-3-e28473.PMC4063139.pdf
"OncoImmunology 2014; 3:e28247;   http://dx.doi.org/10.4161/onci.28247Synergistic antitumor effects   of a TGF β inhibitor and cyclophosphamide Xin Chen1,2,*, Lalage M wa kefield3, and Joost J op penheim2,* 1Basic sc ience Program; Leidos Biomedical re search, in c.; Frederick National Laboratory for Cancer re search; Frederick, MD usA ;   2Laboratory of Molecular im munoregulation; Cancer in flammation Program; Center for Cancer re search; National Cancer in stitute; Frederick, MD usA ;   3Laboratory of Cancer Biology and Genetics; Center for Cancer re search; National Cancer in stitute; Frederick, MD usA Keywords:  anti-TGF β antibody, chemoimmunotherapy, cyclophosphamide in a m ouse model of breast carcinoma, the combination of cyclophosphamide and transforming growth factor  β1,2,3 ( tG Fβ1,2,3)-targeting antibody achieved superior antineoplastic effects.",Non-OADS,/arxiv_data1/oa_pdf/43/34/onci-3-e28247.PMC4063140.pdf
FEBS Lett 2014; 588:368- 76; PMID:24161671 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/43/34/onci-3-e28247.PMC4063140.pdf
Curr Opin Immunol  2014 ; 27C:1-7; PMID:24413387 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/43/34/onci-3-e28247.PMC4063140.pdf
PLoS One  2014 ; 9: e85398 ;  PMID:24416401 ; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/43/34/onci-3-e28247.PMC4063140.pdf
Cell Immunol  1993 ; 150:45- 58; PMID:8393732 ; http://dx.doi.org/10.1006/ cimm.1993.11775.,Non-OADS,/arxiv_data1/oa_pdf/43/34/onci-3-e28247.PMC4063140.pdf
Cancer Immunol  Immunother  2009 ; 58:1219 -28; PMID:19052741 ;  http://dx.doi.org/10.1007/s00262-008-0628-9 6.,Non-OADS,/arxiv_data1/oa_pdf/43/34/onci-3-e28247.PMC4063140.pdf
Cytokine  2014 ; 65:56- 64; PMID:24080164 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/43/34/onci-3-e28247.PMC4063140.pdf
Immunity  2011 ; 35:972-85; PMID:22177921 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/43/34/onci-3-e28247.PMC4063140.pdf
Cancer Immunol  Immunother  2013 ; 62:203-16; PMID:23389507 ;  http://dx.doi.org/10.1007/s00262-012-1388-0 10.,Non-OADS,/arxiv_data1/oa_pdf/43/34/onci-3-e28247.PMC4063140.pdf
"OncoImmunology 2014; 3:e28271;  http://dx.doi.org/10.4161/onci.28271The microbiome modulates the tumor  macroenvironment susan e e rdman1,* and t heofilos Poutahidis1,2 1Division of Comparative Medicine; Massachusetts i nstitute of t echnology; Cambridge, MA us A;   2Laboratory of Pathology; Faculty of Veterinary Medicine; Aristotle u niversity of t hessaloniki; t hessaloniki, Greece Keywords:  tumor macroenvironment, carcinogenesis, beneficial microbes, microbiome, regulatory T cells earlier investigations of the tumor microenvironment unveiled systemic networks presenting novel therapeutic  opportunities.",Non-OADS,/arxiv_data1/oa_pdf/69/a0/onci-3-e28271.PMC4063141.pdf
Nat Rev Cancer 2001 ; 1:46-54; PMID:11900251 ;  http://dx.doi.org/10.1038/35094059 3.,Non-OADS,/arxiv_data1/oa_pdf/69/a0/onci-3-e28271.PMC4063141.pdf
Cancer Cell  2012 ; 21:309-22;  PMID:22439926 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/69/a0/onci-3-e28271.PMC4063141.pdf
Nature   2004 ; 427:787; PMID:14985739 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/69/a0/onci-3-e28271.PMC4063141.pdf
Cancer Res 2007 ; 67:847-50;  PMID:17283110 ; http://dx.doi.org/10.1158/0008- 5472.CAN-06-3468 7.,Non-OADS,/arxiv_data1/oa_pdf/69/a0/onci-3-e28271.PMC4063141.pdf
PLoS One  2013 ; 8:e78898 ; PMID:24205344 ;  http://dx.doi.org/10.1371/journal.pone.00788988.,Non-OADS,/arxiv_data1/oa_pdf/69/a0/onci-3-e28271.PMC4063141.pdf
Nat Rev Gastroenterol Hepatol   2012 ; 9:609-14; PMID:22890109 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/69/a0/onci-3-e28271.PMC4063141.pdf
Nature  2012 ; 489:231-41;  PMID:22972296 ; http://dx.doi.org/10.1038/ nature11551,Non-OADS,/arxiv_data1/oa_pdf/69/a0/onci-3-e28271.PMC4063141.pdf
"OncoImmunology 2014; 3:e28398; http://dx.doi.org/10.4161/onci.28398Myeloid-derived cells are key targets   of tumor immunotherapy José Medina- ec heverz, Fernando Aranda, and Pedro Berraondo* Division of Hepatology and Gene Therapy; Center for Applied Medical Research; University of Navarra; Pamplona, Spain Keywords:  myeloid-derived suppressor cells, tumor-associated macrophages, tumor-associated neutrophils,   dendritic cells, immunotherapy Abbreviations:  CSF1, colony stimulating factor 1; DCs, dendritic cells; Gr-MDSCs, granulocytic myeloid-derived suppressor  cells; iDCs, immature dendritic cells; NOS2, inducible nitric oxide synthase 2; IL-10, interleukin 10; mDCs, mature dendritic  cells; Mo-MDSCs, monocytic myeloid-derived suppressor cells; MDSCs, myeloid-derived suppressor cells; NO, nitric oxide; ROS,  reactive oxygen species; TGF- β, transforming growth factor beta; TAMs, tumor-associated macrophages; TANs, tumor-associated  neutrophils; VEGF, vascular endothelial growth factor Tumors are composed of heterogeneous cell populations  recruited by cancer cells to promote growth and metastasis.",Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Genes Dev 1999; 13:1382-97;  PMID :10364156 ;  http://dx.doi.org/10.1101/gad.13.11.1382 2.,OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Front Biosci 2008; 13:6537-53;  PMID:18508679 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Science 2011; 331:1565-70; PMID:21436444 ; http://dx.doi.org/10.1126/ science.1203486 5.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Annu Rev Pathol 2006; 1:119-50; PMID:18039110 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Annu Rev Immunol 2011; 29:235-71; PMID:21219185 ; http://dx.doi.org/10.1146/ annurev-immunol-031210-101324 7.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Trends Immunol 2004; 25:235-41;  PMID:15099563 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Blood 2009; 114:2639-48; PMID:19643985 ; http://dx.doi.org/10.1182/ blood-2009-05-2200049.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Am J Pathol 2010; 177:792-802; PMID:20595635 ;  http://dx.doi.org/10.2353/ajpath.2010.091286 10.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Cancer Cell 2009; 16:183-94; PMID:19732719 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Immunol Rev 2000; 177:195-203;  PMID:11138776 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Clin Cancer Res 2009; 15:4382-90; PMID:19549770 ; http://dx.doi.org/10.1158/1078- 0432.CCR-09-0399 15.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Int J Cancer 2005; 116:275-81;  PMID :15800914 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Nat Rev Immunol 2010; 10:554-67;  PMID:20616810 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Nat Med 2010; 16:880-6; PMID:20622859 ; http://dx.doi.org/10.1038/ nm.2172 23.,OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
J Leukoc Biol 2009; 86:1065-73;  PMID :19741157 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Nat Rev Immunol 2005; 5:953-64; PMID:16322748 ; http://dx.doi.org/10.1038/nri1733 27.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Science 1983; 220:210-2; PMID:6828888 ; http://dx.doi.org/10.1126/ science.6828888 28.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
J Exp Med 2001; 193:727-40;  PMID:11257139 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Nat Rev Cancer 2004; 4:71-8;  PMID:14708027 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Immunobiology 2006; 211:487-501;  PMID:16920488 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Trends Immunol 2002; 23:549-55; PMID:12401408 ; http://dx.doi.org/10.1016/ S1471-4906(02)02302-5 32.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Annu Rev Immunol 2009; 27:451-83; PMID:19105661 ; http://dx.doi.org/10.1146/ annurev.immunol.021908.132532 33.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Cancer Res 2006; 66:605-12;  PMID:16423985 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Eur J Immunol 2010; 40:2969-75; PMID:21061430 ;  http://dx.doi.org/10.1002/eji.201040895 35.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Cancer 2000; 88:563-9; PMID:10649248 ; http://dx.doi.org/10.1002/ (SICI)1097-0142(20000201)88:3<563::AID-CNCR11>3.0.CO;2-D 36.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
J Exp Med 2010; 207:2439-53; PMID:20876310 ; http://dx.doi.org/10.1084/ jem.20100587 38.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Nat Immunol 2013; 14:211-20;  PMID:23354483 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Nat Rev Immunol 2012; 12:253-68; PMID:22437938 ; http://dx.doi.org/10.1038/ nri3175 40.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
J Immunol 2014; 192:1034-43; PMID:24391219 ; http://dx.doi.org/10.4049/ jimmunol.1301309 41.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
J Immunol 2012; 188:5500-10; PMID:22544933 ; http://dx.doi.org/10.4049/ jimmunol.1103505 42.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Immunity 2013; 38:1236-49; PMID:23809164 ;  http://dx.doi.org/10.1016/j.immuni.2013.06.004 43.,OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
J Exp Med 2008; 205:2235-49;  PMID:18809714 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
J Immunol 2010; 184:3106-16;  PMID:20142361 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Cell Rep 2012; 2:628-39; PMID:22959433 ;  http://dx.doi.org/10.1016/j.celrep.2012.08.006 50.,OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Clin Cancer Res 2009; 15:2148-57; PMID:19276286 ; http://dx.doi.org/10.1158/1078- 0432.CCR-08-1332 51.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Cancer Res 2010; 70:3526-36; PMID:20406969 ;  http://dx.doi.org/10.1158/0008-5472.CAN-09-327852.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
"Cancer Res 2009; 69:2514-22; PMID:19276342 ; http://dx.doi.org/10.1158/0008- 5472.CAN-08-4709 53.  v an Cruijsen H, van der Veldt AA, Vroling L,  Oosterhoff D, Broxterman HJ, Scheper RJ, Giaccone G, Haanen JB, van den Eertwegh AJ, Boven E, et   al.",Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Clin Cancer Res 2008; 14:5884-92; PMID:18794101 ;  http://dx.doi.org/10.1158/1078-0432.CCR-08-0656 54.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Cancer Res 2009; 69:2506-13; PMID:19244102 ; http://dx.doi.org/10.1158/0008- 5472.CAN-08-4323 55.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Clin Cancer Res 2005; 11:6713-21; PMID:16166452 ; http://dx.doi.org/10.1158/1078- 0432.CCR-05-0883 57.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Cancer Res 2010; 70:3052-61; PMID:20388795 ; http://dx.doi.org/10.1158/0008- 5472.CAN-09-3690 58.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Cancer Immunol Immunother 2009; 58:49-59; PMID:18446337 ; http://dx.doi.org/10.1007/ s00262-008-0523-4 59.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Cancer Immunol Immunother 2004; 53:422-30;  PMID:14648070 ;  http://dx.doi.org/10.1007/s00262-003-0459-7 60.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Cancer Res 2006; 66:9299-307; PMID:16982775 ;  http://dx.doi.org/10.1158/0008-5472.CAN-06-1690 61.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Cancer Res 2007; 67:11438-46; PMID:18056472 ; http://dx.doi.org/10.1158/0008- 5472.CAN-07-1882 ©2014 Landes Bioscience.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Br J Cancer 2010; 103:629-41; PMID:20664588 ;  http://dx.doi.org/10.1038/sj.bjc.6605814 64.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Blood 2008; 111:219-28; PMID:17885078 ;  http://dx.doi.org/10.1182/blood-2007-04-086835 65.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Nature 2007; 450:825-31;  PMID:18064003 ;  http://dx.doi.org/10.1038/nature06348 66.,OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Blood 2010; 115:1461-71; PMID:20008303 ; http://dx.doi.org/10.1182/ blood-2009-08-237412 67.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Cancer Immunol Immunother 2009; 58:941-53;  PMID:18979098 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Cancer Res 2012; 72:1373-83; PMID:22282665 ; http://dx.doi.org/10.1158/0008- 5472.CAN-11-2772 69.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Clin Cancer Res 2009; 15:4391-400 ;  PMID:19549768 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
N Engl J Med 1998; 339:357-63;  PMID:9691101 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Br J Cancer 1996; 73:875-83; PMID:8611420 ;  http://dx.doi.org/10.1038/bjc.1996.176 72.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Cancer Cell 2013; 23:249-62;  PMID:23410977 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
J Exp Med 2009; 206:1089-102; PMID:19398755 ; http://dx.doi.org/10.1084/ jem.20081605 74.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Cancer Discov 2011; 1:54-67; PMID:22039576 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Cancer Res 2008; 68:4340-6; PMID:18519694 ;  http://dx.doi.org/10.1158/0008-5472.CAN-07-6705 77.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Nature 2011; 475:222-5; PMID:21654748 ; http://dx.doi.org/10.1038/ nature10138 78.,OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
J Natl Cancer Inst 2010; 102:522-8; PMID:20233997 ; http://dx.doi.org/10.1093/jnci/ djq044 79.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Int J Cancer 2011; 129:847-58; PMID:21328342 ; http://dx.doi.org/10.1002/ ijc.25987 80.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Clin Cancer Res 2010; 16:1812-23;  PMID:20215551 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
J Exp Med 2006; 203:2691-702; PMID:17101732 ; http://dx.doi.org/10.1084/ jem.20061104 83.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Proc Natl Acad Sci U S A 2011; 108:17111-6; PMID:21969559 ; http://dx.doi.org/10.1073/ pnas.1108121108 84.,OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
J Exp Med 2011; 208:1949-62;  PMID:21930770 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Eur J Immunol 2011; 41:1843-9; PMID:21480210 ;  http://dx.doi.org/10.1002/eji.201040868 86.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
J Exp Med 2001; 194:1549-59; PMID:11733570 ; http://dx.doi.org/10.1084/ jem.194.11.154987.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Cancer Res 2007; 67:8847-55;  PMID:17875726 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
J Immunol 2011; 186:807-15; PMID:21148040 ; http://dx.doi.org/10.4049/ jimmunol.1001483 89.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
J Immunol 2009; 182:2030-40;  PMID:19201856 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Immunity 2013; 38:729-41; PMID:23562161 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Semin Cancer Biol 2013; 23:139-40; PMID:23454237 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
J Exp Med 1993 ; 178:151-61;  PMID:7686211 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
J Clin Oncol 2003; 21:3343-50; PMID:12947071 ;  http://dx.doi.org/10.1200/JCO.2003.07.005 95.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
J Cell Mol Med 2010; 14:2803-15; PMID:19818098 ;  http://dx.doi.org/10.1111/j.1582-4934.2009.00926.x 96.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
PLoS One 2013; 8:e67906; PMID:23874464 ; http://dx.doi.org/10.1371/jour- nal.pone.0067906 98.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Nat Med 2004; 10:48-54; PMID:14702634 ;  http://dx.doi.org/10.1038/nm976 ©2014 Landes Bioscience.,OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Cancer Cell 2009; 15:114-23; PMID:19185846 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Cancer Res 2005; 65:9525-35;  PMID:16230418 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Science 2011; 331:1612-6; PMID:21436454 ; http://dx.doi.org/10.1126/ science.1198443 102.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
J Exp Med 2010; 207:2455-67; PMID:20921282 ;  http://dx.doi.org/10.1084/jem.20100670103.,Non-OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
Proc Natl Acad Sci U S A 2009; 106:19455-60;  PMID:19892741 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/0b/6c/onci-3-e28398.PMC4063142.pdf
"OncoImmunology 2014; 3:e28441; http://dx.doi.org/10.4161/onci.28441Macrophages in the liver prevent metastasis by  efficiently eliminating circulating tumor cells after  monoclonal antibody immunotherapy Nuray Gül1, Liane Babes2, Paul Kubes2, and Marjolein van e gmond1,3,* 1Department of Molecular Cell Biology and i mmunology; V u university Medical Center; Amsterdam, t he Netherlands; 2immunology r esearch Group; u niversity of Calgary;  Calgary, Canada; 3Department of s urgery; V u university Medical Center; Amsterdam, t he Netherlands Keywords:  Fc receptors, antibody-dependent cellular phagocytosis, Kupffer cells, liver metastasis, mAbs Monoclonal antibodies (mAbs) are increasingly being used to treat cancer.",Non-OADS,/arxiv_data1/oa_pdf/03/86/onci-3-e28441.PMC4063143.pdf
Nat Rev Cancer 2012; 12:278-87;  PMID:22437872 ; http://dx.doi.org/10.1038/ nrc3236 2.,Non-OADS,/arxiv_data1/oa_pdf/03/86/onci-3-e28441.PMC4063143.pdf
Nat Med 2000; 6:443-6;  PMID:10742152 ; http://dx.doi.org/10.1038/747043.,OADS,/arxiv_data1/oa_pdf/03/86/onci-3-e28441.PMC4063143.pdf
Blood 2008; 112:1205-13;  PMID:18495955 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/03/86/onci-3-e28441.PMC4063143.pdf
J Clin Invest 2013; 123:5098- 103; PMID:24177426 ; http://dx.doi.org/10.1172/ JCI70972,Non-OADS,/arxiv_data1/oa_pdf/03/86/onci-3-e28441.PMC4063143.pdf
J Immunol  2012; 189:5457-66;  PMID:23105143 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/03/86/onci-3-e28441.PMC4063143.pdf
Ann Surg Oncol 2013; 20:2156-65; PMID:23456317 ; http://dx.doi.org/10.1245/ s10434-013-2907-810.,Non-OADS,/arxiv_data1/oa_pdf/03/86/onci-3-e28441.PMC4063143.pdf
Gut  2011; 60:1076-86;  PMID:21278144 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/03/86/onci-3-e28441.PMC4063143.pdf
"OncoImmunology 2014; http://dx.doi.org/10.4161/onci.28499Radiation and anti-PD-L1 antibody   combinatorial therapy induces T cell-mediated  depletion of myeloid-derived suppressor cells   and tumor regression Liufu Deng1, hua Liang1, Byron Burnette1, ralph r w eichselbaum1,*, and Yang-Xin Fu2 1Department of r adiation and Cellular o ncology; t he Ludwig Center for Metastasis r esearch; u niversity of Chicago, Chicago, i L us A; 2Department of Pathology;   university of Chicago, Chicago, i L us A Keywords:  antibody therapy, myeloid-derived suppressor cell, negative signal, PD-L1, radiation therapy, T-cell activation, TNF tumor relapse after radiotherapy may be due to the upregulation of programmed cell death ligand 1 (PD-L1).",Non-OADS,/arxiv_data1/oa_pdf/9a/6c/onci-3-e28499.PMC4063144.pdf
Nat Rev Cancer  2011; 11:239-53;  PMID:21430696 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9a/6c/onci-3-e28499.PMC4063144.pdf
Sci Transl Med 2013; 5: 173sr2; PMID:23427246 ;  http://dx.doi.org/10.1126/scitranslmed.3005148 3.,Non-OADS,/arxiv_data1/oa_pdf/9a/6c/onci-3-e28499.PMC4063144.pdf
Blood 2009; 114:589-95; PMID:19349616 ;  http://dx.doi.org/10.1182/blood-2009-02-206870 4.,Non-OADS,/arxiv_data1/oa_pdf/9a/6c/onci-3-e28499.PMC4063144.pdf
J Immunol 2013; 190:5874-81; PMID:23630355 ; http://dx.doi.org/10.4049/ jimmunol.12026125.,Non-OADS,/arxiv_data1/oa_pdf/9a/6c/onci-3-e28499.PMC4063144.pdf
N Engl J Med 2012; 366:2517-9; PMID:22658126 ;  http://dx.doi.org/10.1056/NEJMe1205943 6.,Non-OADS,/arxiv_data1/oa_pdf/9a/6c/onci-3-e28499.PMC4063144.pdf
Nat Rev Cancer 2012; 12:252-64;  PMID:22437870 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9a/6c/onci-3-e28499.PMC4063144.pdf
N Engl J Med 2012; 366:2443-54; PMID:22658127 ;  http://dx.doi.org/10.1056/NEJMoa1200690 8.,OADS,/arxiv_data1/oa_pdf/9a/6c/onci-3-e28499.PMC4063144.pdf
N Engl J Med  2013; 369:134-44;  PMID:23724846 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/9a/6c/onci-3-e28499.PMC4063144.pdf
J Clin Invest 2014; 124:687- 95; PMID:24382348 ; http://dx.doi.org/10.1172/ JCI67313 10.,Non-OADS,/arxiv_data1/oa_pdf/9a/6c/onci-3-e28499.PMC4063144.pdf
Nat Rev Immunol 2012; 12:253-68;  PMID:22437938 ; http://dx.doi.org/10.1038/ nri3175,Non-OADS,/arxiv_data1/oa_pdf/9a/6c/onci-3-e28499.PMC4063144.pdf
"OncoImmunology 2014; 3:e28276; http://dx.doi.org/10.4161/onci.28276Synthetic induction of immunogenic   cell death by genetic stimulation   of endoplasmic reticulum stress Mickaël Michaud1,2,3, abdul Qader  su kkurwala1,2,3, Federica Di  sa no4, la urence Zitvogel5,6,7,   Oliver Kepp1,2,3,*, and  gu ido Kroemer1,2,3,8,* 1eq uipe 11 labellisée par la li gue na tionale contre le cancer; inser M U 1138; ce ntre de re cherche des co rdeliers; Paris, France; 2Metabolomics and Molecular ce ll Biology  Platforms;  gu stave  ro ussy  co mprehensive  ca ncer  ce nter; Villejuif, France; 3Université Paris Descartes/Paris V; so rbonne Paris ci té; Paris, France; 4Department of Biology;  University of  ro me ‘Tor Vergata’;  ro me,  it aly; 5inser M U 1015; Villejuif, France; 6 Université Paris su d-Xi; F aculté de Médecine; le K remlin Bicêtre, France; 7ce nter of cl inical  in vestigations in Biotherapies of  ca ncer ( c icB T) 507; Villejuif, France; 8Pôle de Biologie; hôpi tal eu ropéen ge orges Pompidou; aP -h P; Paris, France Keywords:  cancer, calreticulin, chemotherapy, cisplatin, endoplasmic reticulum stress, reticulon 1C Abbreviations:  APCs, antigen-presenting cells; CDDP/cisplatin, Cis -diamminedichloridoplatinum(II); CRT, calreticulin;   CTL, cytotoxic T lymphocyte; DC, dendritic cell; eIF2 α, eukaryotic initiation factor 2 α; ER, endoplasmic reticulum;   ICD, immunogenic cell death; MDSC, myeloid-derived suppressor cell; MTX, mitoxantrone; Rtn1c, reticulon-1, splice variant c;  TET, tetracycline; Tregs, regulatory T cells Cis-diamminedichloridoplatinum( i i) (cD DP), commonly referred to as cisplatin, is a chemotherapeutic drug used for  the treatment of a wide range of solid cancers.",Non-OADS,/arxiv_data1/oa_pdf/ac/a2/onci-3-e28276.PMC4063145.pdf
J Clin Invest 2008; 118:1991-2001;  PMID:18523649 ;  http://dx.doi.org/10.1172/JCI351802.,Non-OADS,/arxiv_data1/oa_pdf/ac/a2/onci-3-e28276.PMC4063145.pdf
Nat Rev Clin Oncol 2011; 8:151-60;   PMID:21364688 ; http://dx.doi.org/10.1038/ nrclinonc.2010.2234.,Non-OADS,/arxiv_data1/oa_pdf/ac/a2/onci-3-e28276.PMC4063145.pdf
Nat Rev Immunol 2008; 8:59-73; PMID:18097448 ;  http://dx.doi.org/10.1038/nri2216 5.,Non-OADS,/arxiv_data1/oa_pdf/ac/a2/onci-3-e28276.PMC4063145.pdf
Nat Rev Immunol 2006; 6:715-27;   PMID:16977338 ; http://dx.doi.org/10.1038/nri1936 ©2014 Landes Bioscience.,Non-OADS,/arxiv_data1/oa_pdf/ac/a2/onci-3-e28276.PMC4063145.pdf
Annu Rev Immunol 2013; 31:51-72;   PMID :23157435 ; http://dx.doi.org/10.1146/ annurev-immunol-032712-100008 8.,Non-OADS,/arxiv_data1/oa_pdf/ac/a2/onci-3-e28276.PMC4063145.pdf
Cell Cycle 2009; 8:3723-8; PMID:19855167 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ac/a2/onci-3-e28276.PMC4063145.pdf
Science 2011; 334:1573-7; PMID:22174255 ;  http://dx.doi.org/10.1126/science.1208347 11.,Non-OADS,/arxiv_data1/oa_pdf/ac/a2/onci-3-e28276.PMC4063145.pdf
Oncoimmunology 2012; 1:393-5; PMID:22737627 ; http://dx.doi.org/10.4161/ onci.19070 12.,Non-OADS,/arxiv_data1/oa_pdf/ac/a2/onci-3-e28276.PMC4063145.pdf
Autophagy 2013; (Forthcoming);  PMID:23989612 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ac/a2/onci-3-e28276.PMC4063145.pdf
Immunity 2013; 38:729-41; PMID:23562161 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/ac/a2/onci-3-e28276.PMC4063145.pdf
Oncoimmunology 2013; 2:e24568;  PMID:23894718 ;  http://dx.doi.org/10.4161/onci.24568 15.,Non-OADS,/arxiv_data1/oa_pdf/ac/a2/onci-3-e28276.PMC4063145.pdf
EMBO J 2012; 31:1062-79;  PMID:22252128 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ac/a2/onci-3-e28276.PMC4063145.pdf
Cell Cycle 2010; 9:3072-7;  PMID:20699648 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ac/a2/onci-3-e28276.PMC4063145.pdf
Cell Death Differ 2008; 15:1499-509;  PMID:18464797 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ac/a2/onci-3-e28276.PMC4063145.pdf
EMBO J 2009; 28:578-90; PMID:19165151 ;  http://dx.doi.org/10.1038/emboj.2009.1 20.,Non-OADS,/arxiv_data1/oa_pdf/ac/a2/onci-3-e28276.PMC4063145.pdf
Cell 2005; 123:321-34; PMID:16239148 ;  http://dx.doi.org/10.1016/j.cell.2005.08.032 22.,OADS,/arxiv_data1/oa_pdf/ac/a2/onci-3-e28276.PMC4063145.pdf
J Exp Med 2005; 202:1691-701; PMID:16365148 ;  http://dx.doi.org/10.1084/jem.20050915 23.,Non-OADS,/arxiv_data1/oa_pdf/ac/a2/onci-3-e28276.PMC4063145.pdf
Oncogene 2010; 29:482-91; PMID :19881547 ; http://dx.doi.org/10.1038/ onc.2009.356 24.,Non-OADS,/arxiv_data1/oa_pdf/ac/a2/onci-3-e28276.PMC4063145.pdf
Oncoimmunology 2012; 1:377-9; PMID:22737621 ; http://dx.doi.org/10.4161/ onci.18804 25.,Non-OADS,/arxiv_data1/oa_pdf/ac/a2/onci-3-e28276.PMC4063145.pdf
Cancer Res 2013; 73:7265-76;  PMID :24158093 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ac/a2/onci-3-e28276.PMC4063145.pdf
Oncoimmunology 2012; 1:1323-43; PMID:23243596 ; http://dx.doi.org/10.4161/ onci.22009 27.,Non-OADS,/arxiv_data1/oa_pdf/ac/a2/onci-3-e28276.PMC4063145.pdf
Science 2012; 337:1678-84; PMID:23019653 ; http://dx.doi.org/10.1126/ science.1224922 28.,Non-OADS,/arxiv_data1/oa_pdf/ac/a2/onci-3-e28276.PMC4063145.pdf
Oncoimmunology 2013; 2:e26198;   PMID:24228232 ; http://dx.doi.org/10.4161/ onci.26198 29.,Non-OADS,/arxiv_data1/oa_pdf/ac/a2/onci-3-e28276.PMC4063145.pdf
Nat Med 2007; 13:1050-9;   PMID:17704786 ; http://dx.doi.org/10.1038/nm1622 30.,Non-OADS,/arxiv_data1/oa_pdf/ac/a2/onci-3-e28276.PMC4063145.pdf
Oncoimmunology 2013; 2:e26536;  PMID:24404424 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ac/a2/onci-3-e28276.PMC4063145.pdf
Oncoimmunology 2013; 2:e25595;  PMID:24319634 ;  http://dx.doi.org/10.4161/onci.2559532.,Non-OADS,/arxiv_data1/oa_pdf/ac/a2/onci-3-e28276.PMC4063145.pdf
Oncoimmunology 2012; 1:786-8; PMID:22934283 ; http://dx.doi.org/10.4161/ onci.19750 33.,Non-OADS,/arxiv_data1/oa_pdf/ac/a2/onci-3-e28276.PMC4063145.pdf
Oncogene 2012; 31:1869-83;  PMID:21892204 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ac/a2/onci-3-e28276.PMC4063145.pdf
Cell Rep 2012; 2:257-69; PMID:22854025 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/ac/a2/onci-3-e28276.PMC4063145.pdf
Oncogene 2011; 30:1147-58;   PMID:21151176 ; http://dx.doi.org/10.1038/ onc.2010.500 36.,Non-OADS,/arxiv_data1/oa_pdf/ac/a2/onci-3-e28276.PMC4063145.pdf
Oncogene 2008; 27:4221-32;  PMID:18362892 ;  http://dx.doi.org/10.1038/onc.2008.63 37.,Non-OADS,/arxiv_data1/oa_pdf/ac/a2/onci-3-e28276.PMC4063145.pdf
Biochem Biophys Res Commun 2006; 342:881-6; PMID:16500619 ;  http://dx.doi.org/10.1016/j.bbrc.2006.02.036 38.,OADS,/arxiv_data1/oa_pdf/ac/a2/onci-3-e28276.PMC4063145.pdf
Cell Death Differ 2008; 15:274-82; PMID:18034188 ; http://dx.doi.org/10.1038/ sj.cdd.4402275 39.,Non-OADS,/arxiv_data1/oa_pdf/ac/a2/onci-3-e28276.PMC4063145.pdf
Nat Med 2009; 15:1170-8 ;  PMID:19767732 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ac/a2/onci-3-e28276.PMC4063145.pdf
Oncoimmunology 2013; 2:e24786;  PMID:23894723 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ac/a2/onci-3-e28276.PMC4063145.pdf
Oncoimmunology 2013; 2:e25770;   PMID:24327936 ; http://dx.doi.org/10.4161/ onci.25770 43.,Non-OADS,/arxiv_data1/oa_pdf/ac/a2/onci-3-e28276.PMC4063145.pdf
Oncoimmunology 2012; 1:179-88; PMID:22720239 ; http://dx.doi.org/10.4161/ onci.1.2.19026 ©2014 Landes Bioscience.,Non-OADS,/arxiv_data1/oa_pdf/ac/a2/onci-3-e28276.PMC4063145.pdf
"OncoImmunology 2014; 3:e28440; http://dx.doi.org/10.4161/onci.28440A novel combinatorial cancer immunotherapy poly-IC and blockade of the PD-1/PD-L1 pathway to shihiro Nagato1,2 and es teban Celis3,* 1Department of ot olaryngology- he ad and Neck su rgery; Asahikawa Medical un iversity; Asahikawa, Japan; 2im munology Program; Moffitt Cancer Center; ta mpa, FL usA ;  3Cancer im munology, in flammation and to lerance Program; Georgia re gents un iversity Cancer Center; Augusta, GA usA Keywords:  cancer immunotherapy, poly-IC, PD-1, PD-L1, melanoma, lung cancer, colon cancer A non-antigen specific immunotherapy consisting of repeated co-administration of poly- iC a nd blocking antibodies  targeting the programmed cell death-1 (PD-1) pathway dramatically inhibits tumor development in several mouse mod - els of cancer.",Non-OADS,/arxiv_data1/oa_pdf/4b/f2/onci-3-e28440.PMC4063146.pdf
Cancer Res 2009; 69:9012-9; http://dx.doi.org/10.1158/0008-5472.CAN-09-2019 ; PMID:19903852 2.,Non-OADS,/arxiv_data1/oa_pdf/4b/f2/onci-3-e28440.PMC4063146.pdf
Blood 2011; 117:135-44; http://dx.doi.org/10.1182/blood-2010-08-298117 ; PMID:20889921 3.,Non-OADS,/arxiv_data1/oa_pdf/4b/f2/onci-3-e28440.PMC4063146.pdf
Cancer Res 2012; 72:1986-95; http://dx.doi.org/10.1158/0008-5472.CAN-11-3246 ;  PMID:22367213 4.,Non-OADS,/arxiv_data1/oa_pdf/4b/f2/onci-3-e28440.PMC4063146.pdf
Cancer Immunol Immunother 2012; 61:1307-17; http://dx.doi.org/10.1007/s00262-012-1259-8 ;  PMID:22527249 5.,Non-OADS,/arxiv_data1/oa_pdf/4b/f2/onci-3-e28440.PMC4063146.pdf
Cancer Immunol Immunother 2013; 62:787-99; http://dx.doi.org/10.1007/s00262-012-1382-6 ; PMID:23266830 6.,Non-OADS,/arxiv_data1/oa_pdf/4b/f2/onci-3-e28440.PMC4063146.pdf
J Clin Oncol 2011; 29:330-6; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/4b/f2/onci-3-e28440.PMC4063146.pdf
Clin Cancer Res 2012; 18:6497-508; http://dx.doi.org/10.1158/1078-0432.CCR-12-2189 ; PMID:230327459.,Non-OADS,/arxiv_data1/oa_pdf/4b/f2/onci-3-e28440.PMC4063146.pdf
N Engl J Med 2012; 366:2443-54; http://dx.doi.org/10.1056/NEJMoa1200690 ; PMID:2265812710.,OADS,/arxiv_data1/oa_pdf/4b/f2/onci-3-e28440.PMC4063146.pdf
N Engl J Med 2012; 366:2455-65; http://dx.doi.org/10.1056/NEJMoa1200694 ; PMID:22658128 ©2014 Landes Bioscience.,OADS,/arxiv_data1/oa_pdf/4b/f2/onci-3-e28440.PMC4063146.pdf
"OncoImmunology 2014; 3:e28248; http://dx.doi.org/10.4161/onci.28248Dual targeting of CD137 co-stimulatory   and PD-1 co-inhibitory molecules   for ovarian cancer immunotherapy hu afeng we i1,2,3,*, Likun Zhao4, inge gerd he llstrom5, Karl er ik he llstrom5, and Yajun Guo1,2,3,4,* 1in ternational Joint Cancer in stitute; se cond Military Medical un iversity; shan ghai, China; 2sc hool of Pharmacy; Liaocheng un iversity; Liaocheng, China;   3st ate Key Laboratory of Antibody Medicine & ta rgeting th erapy and sh anghai Key Laboratory of Cell en gineering & Antibody; sh anghai, China;   4sc hool of Bioscience and Bioengineering; so uth China un iversity of te chnology; Guangzhou, China; 5Department of Pathology; ha rborview Medical Center;   un iversity of  wa shington;  se attle,  wA  usA ;  Keywords:  CD137, PD-1, co-signaling molecules, ovarian cancer, immunotherapy, monoclonal antibody we r ecently demonstrated that simultaneous targeting of CD137 co-stimulatory and programmed cell death 1 (PD-1)  co-inhibitory molecules synergistically induced an anticancer immune response in the iD 8 syngeneic orthotopic mouse  ovarian carcinoma model.",Non-OADS,/arxiv_data1/oa_pdf/0f/61/onci-3-e28248.PMC4063147.pdf
Hum Vaccin  Immunother 2012; 8:1179-91; PMID:22906947 ;  http://dx.doi.org/10.4161/hv.20738 2.,Non-OADS,/arxiv_data1/oa_pdf/0f/61/onci-3-e28248.PMC4063147.pdf
J Immunother 2013; 36:248-57; PMID:23603859 ; http://dx.doi.org/10.1097/ CJI.0b013e3182943549 3.,Non-OADS,/arxiv_data1/oa_pdf/0f/61/onci-3-e28248.PMC4063147.pdf
PLoS One 2013; 8:e84927; PMID:24367702 ; http://dx.doi.org/10.1371/jour- nal.pone.0084927 4.,Non-OADS,/arxiv_data1/oa_pdf/0f/61/onci-3-e28248.PMC4063147.pdf
Immunity 2013; 39:1-10; PMID:23890059 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/0f/61/onci-3-e28248.PMC4063147.pdf
Immunity 2013; 39:61-73; PMID:23890064 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/0f/61/onci-3-e28248.PMC4063147.pdf
Clin Cancer Res 2013; 19:997-1008; PMID:23460531 ; http://dx.doi.org/10.1158/1078- 0432.CCR-12-2214 7.,Non-OADS,/arxiv_data1/oa_pdf/0f/61/onci-3-e28248.PMC4063147.pdf
Cancer Res 2013; 73:6900-12;  PMID:23975756 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/0f/61/onci-3-e28248.PMC4063147.pdf
Cancer Res 2012; 72:3163-74; PMID:22570253 ;  http://dx.doi.org/10.1158/0008-5472.CAN-12-02109.,Non-OADS,/arxiv_data1/oa_pdf/0f/61/onci-3-e28248.PMC4063147.pdf
Semin Oncol 2010; 37:508-16; PMID:21074066 ; http://dx.doi.org/10.1053/j.,Non-OADS,/arxiv_data1/oa_pdf/0f/61/onci-3-e28248.PMC4063147.pdf
J Am Chem Soc 2010; 132:6906-7; PMID:20433206 ;  http://dx.doi.org/10.1021/ja102414t,OADS,/arxiv_data1/oa_pdf/0f/61/onci-3-e28248.PMC4063147.pdf
"OncoImmunology 2014; 3:e28272; http://dx.doi.org/10.4161/onci.28272Tumor vascularity in ovarian cancer T cells need breathing room David Neilson1,2, sarah MacPherson1,2, Katelin N to wnsend1,2, and Julian J Lum1,2,* 1tr ev and Joyce Deeley re search Centre; BC Cancer Agency; Victoria, BC Canada; 2Department of Biochemistry and Microbiology; un iversity of Victoria; Victoria, BC Canada Keywords:  autophagy, hypoxia, VEGF, CD31, T cell, ovarian cancer tu mor-infiltrating lymphocytes ( t iL s) are crucial for effective antitumor responses.",Non-OADS,/arxiv_data1/oa_pdf/b3/c6/onci-3-e28272.PMC4063148.pdf
PLoS One 2009; 4:e6412; PMID:19641607 ; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/b3/c6/onci-3-e28272.PMC4063148.pdf
J Immunol 2006; 177:4962-5; PMID :17015677 ; http://dx.doi.org/10.4049/ jimmunol.177.8.4962 3.,Non-OADS,/arxiv_data1/oa_pdf/b3/c6/onci-3-e28272.PMC4063148.pdf
Nature 2011; 475:226-30;  PMID:21753853 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b3/c6/onci-3-e28272.PMC4063148.pdf
Eur J Immunol 2008; 38:2412-8; PMID:18792019 ; http://dx.doi.org/10.1002/ eji.200838318 6.,Non-OADS,/arxiv_data1/oa_pdf/b3/c6/onci-3-e28272.PMC4063148.pdf
J Clin Invest 2013; 123:3664-71; http://dx.doi.org/10.1172/JCI67230 ; PMID:23999440 7.,OADS,/arxiv_data1/oa_pdf/b3/c6/onci-3-e28272.PMC4063148.pdf
Oncoimmunology 2013; 2:e26383;  PMID:24404426 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b3/c6/onci-3-e28272.PMC4063148.pdf
PLoS One 2013; 8:e82406; PMID:24376535 ;  http://dx.doi.org/10.1371/journal.pone.0082406 9.,Non-OADS,/arxiv_data1/oa_pdf/b3/c6/onci-3-e28272.PMC4063148.pdf
"OncoImmunology 2014; 3:e28270;  http://dx.doi.org/10.4161/onci.28270The role of CUX1 in antagonizing   NF-κB signaling in TAMs Benjamin Kühnemuth and Patrick Michl* Department of Gastroenterology, en docrinology and Metabolism; Philipps- un iversity Marburg; Marburg, Germany Keywords:  CUX1, NF-kB, pancreatic cancer, stroma, tumor-associated macrophages Macrophages represent a major component of the tumor microenvironment and contribute to neoplasia initiation  and cancer progression.",Non-OADS,/arxiv_data1/oa_pdf/a2/5f/onci-3-e28270.PMC4063149.pdf
Nat Immunol 2010; 11:889-96; PMID:20856220 ; http://dx.doi.org/10.1038/ni.1937 2.,Non-OADS,/arxiv_data1/oa_pdf/a2/5f/onci-3-e28270.PMC4063149.pdf
J Clin Invest 2012; 122:787-95;  PMID:22378047 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/a2/5f/onci-3-e28270.PMC4063149.pdf
J Leukoc Biol 2010; 88:877-84;  PMID:20573802 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/a2/5f/onci-3-e28270.PMC4063149.pdf
Curr Top Microbiol Immunol 2011; 349:159-69; PMID:20845109 ;  http://dx.doi.org/10.1007/82_2010_975.,Non-OADS,/arxiv_data1/oa_pdf/a2/5f/onci-3-e28270.PMC4063149.pdf
Oncogene 2013; (Forthcoming);  PMID:24336331 ; http://dx.doi.org/10.1038/ onc.2013.530 7.,Non-OADS,/arxiv_data1/oa_pdf/a2/5f/onci-3-e28270.PMC4063149.pdf
Immunology 2013; 138:93-104;  PMID:23113570 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/a2/5f/onci-3-e28270.PMC4063149.pdf
Science 2011; 331:1612-6; PMID:21436454 ; http://dx.doi.org/10.1126/ science.1198443 10.,Non-OADS,/arxiv_data1/oa_pdf/a2/5f/onci-3-e28270.PMC4063149.pdf
J Exp Med 2008; 205:1261-8; PMID:18490490 ; http://dx.doi.org/10.1084/ jem.20080108,Non-OADS,/arxiv_data1/oa_pdf/a2/5f/onci-3-e28270.PMC4063149.pdf
"OncoImmunology 2014; 3:e28463; http://dx.doi.org/10.4161/onci.28463Sarcoma response to targeted therapy  dynamically polarizes tumor-associated  macrophages Michael J Cavnar, ro nald P DeMatteo* Memorial sl oan-Kettering Cancer Center; New York, NY usA Keywords:  tumor-associated macrophage, gastrointestinal stromal tumor, macrophage, CSF1R, C/EBPβ in g astrointestinal stromal tumor (G is t) , the most common human sarcoma, tumor-associated macrophages ( tA Ms)  have been found to be abundant and surprisingly M1-like, exhibiting antitumoral activities.",Non-OADS,/arxiv_data1/oa_pdf/6f/22/onci-3-e28463.PMC4063150.pdf
Nat Immunol 2010; 11:889-96; PMID:20856220 ; http://dx.doi.org/10.1038/ni.1937 2.,Non-OADS,/arxiv_data1/oa_pdf/6f/22/onci-3-e28463.PMC4063150.pdf
J Transl Med 2011; 9:216;  PMID:22176642 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/6f/22/onci-3-e28463.PMC4063150.pdf
J Exp Med 2013; 210:2873-86; PMID:24323358 ;  http://dx.doi.org/10.1084/jem.201308754.,OADS,/arxiv_data1/oa_pdf/6f/22/onci-3-e28463.PMC4063150.pdf
Clin Cancer Res 2005; 11:4182-90;  PMID :15930355 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/6f/22/onci-3-e28463.PMC4063150.pdf
Proc Natl Acad Sci U S A 2009; 106:17475-80; PMID:19805133 ; http://dx.doi.org/10.1073/ pnas.0908641106 ©2014 Landes Bioscience.,OADS,/arxiv_data1/oa_pdf/6f/22/onci-3-e28463.PMC4063150.pdf
"OncoImmunology 2014; 3:e28500; http://dx.doi.org/10.4161/onci.28500Discovering cancer immunotherapy targets in vivo Penghui Zhou1 and Kai w wuc herpfennig1,2,* 1Dana-Farber Cancer in stitute; Boston, MA usA ; 2Program in im munology; ha rvard Medical sc hool; Boston, MA usA Keywords:  cancer, T cell, therapeutic targets, RNAi screen, tumor microenvironment A key challenge facing the cancer immunology field is the discovery of the most suitable targets for therapeutic inter - vention.",Non-OADS,/arxiv_data1/oa_pdf/c7/2f/onci-3-e28500.PMC4063151.pdf
N Engl J Med 2010; 363:711-23; PMID:20525992 ; http://dx.doi.org/10.1056/ NEJMoa10034662.,OADS,/arxiv_data1/oa_pdf/c7/2f/onci-3-e28500.PMC4063151.pdf
N Engl J Med 2012; 366:2443-54; PMID:22658127 ;  http://dx.doi.org/10.1056/NEJMoa1200690 3.,OADS,/arxiv_data1/oa_pdf/c7/2f/onci-3-e28500.PMC4063151.pdf
Immunity 2013; 39:49-60; PMID:23890063 ;  http://dx.doi.org/10.1016/j.immuni.2013.07.002 5.,OADS,/arxiv_data1/oa_pdf/c7/2f/onci-3-e28500.PMC4063151.pdf
Adv Immunol 2006; 90:297-339;  PMID:16730267 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/c7/2f/onci-3-e28500.PMC4063151.pdf
Nature 2014; 506:52-7;  PMID:24476824 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/c7/2f/onci-3-e28500.PMC4063151.pdf
Cell 2008; 135:852-64;  PMID:19012953 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/c7/2f/onci-3-e28500.PMC4063151.pdf
Genes Dev 2011; 25:2559-72; PMID:22190457 ; http://dx.doi.org/10.1101/ gad.169029.111 10.,OADS,/arxiv_data1/oa_pdf/c7/2f/onci-3-e28500.PMC4063151.pdf
"OncoImmunology 2014; 3:e28344; http://dx.doi.org/10.4161/onci.28344Trial Watch Adoptive cell transfer for anticancer immunotherapy Fernando Aranda1,2,3,4,†, erika v acchelli1,2,3,4,†, Florine Obrist1,2,3,4, Alexander e ggermont1, Jérôme Galon2,5,6,7,   wolf Hervé Fridman2,5,6,8, isabelle Cremer2,5,6,8, eric Tartour9,10, Laurence Zitvogel1,12, Guido Kroemer2,3,5,9,12,‡,*,   and Lorenzo Galluzzi1,3,5,‡,* 1Gustave Roussy; v illejuif, France; 2iNSeRM, UMRS1138; Paris, France; 3equipe 11 labellisée par la Ligue Nationale contre le Cancer; Centre de Recherche des Cordeliers;   Paris, France; 4Université Paris-Sud/Paris X i; Paris, France; 5Université Paris Descartes/Paris v ; Sorbonne Paris Cité; Paris, France; 6Université Pierre et Marie Curie/Paris vi ;   Paris, France; 7equipe 15, Centre de Recherche des Cordeliers; Paris, France; 8equipe 13, Centre de Recherche des Cordeliers; Paris, France;   9Pôle de Biologie; Hôpital e uropéen Georges Pompidou; AP-HP; Paris, France; 10iNSeRM, U970; Paris, France; 11iNSeRM, U1015; C iCBT507; v illejuif, France;   12Metabolomics and Cell Biology Platforms; Gustave Roussy; v illejuif, France †These authors contributed equally to this work.",Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
"49,52-58 Nonetheless, no protocol for  ACT-based immunotherapy is currently approved by the US Food and Drug Administration (FDA) or other international regulatory agencies for use in cancer patients (source http://www.fda.gov).",Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
"Literature Update Since the submission of our previous Trial Watch dealing  with topic (March 2013),75 the results of no less than 14 clinical  trials testing ACT-based immunotherapy in cancer patients have been published in the peer-reviewed scientific literature (source http://www.ncbi.nlm.nih.gov/pubmed).",Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
"Update on Ongoing Clinical Trials When this Trial Watch was being redacted (February 2014),  official sources listed no less than 33 clinical trials launched after March 1st, 2013 that would evaluate the efficacy and safety of ACT-based immunotherapy in cancer patients (source http://www.clinicaltrials.gov ).",Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
"As for the clinical trials listed in our previous Trial Watches  dealing with this topic,75,76 the following studies have changed  status during the past 12 mo: NCT01236573, now listed as “Suspended”; NCT00871481, now listed as “Completed”; as well as NCT01555892, NCT01567891, NCT01653717, NCT01729091, and NCT01758458, now listed as “Recruiting.” Nor the reasons underlying the suspension of NCT01236573, testing IL-12-expressing TILs combined with ipilimumab in metastatic melanoma patients, nor the results of NCT00871481, investigating the therapeutic profile of NY-ESO-1-redirected TILs combined with IL-2 and ipilimumab in a similar setting, appear to be available (source http://www.clinicaltrials.gov).",Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Cancer Discov 2013; 3:379-81; PMID:23580281 ;  http://dx.doi.org/10.1158/2159-8290.CD-13-0064 2.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Clin Cancer Res  2013 ; 19:4550 -2; PMID:23922301 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Immunol Rev  2014 ; 257:14-38;  PMID:24329787 ; http://dx.doi.org/10.1111/ imr.12136 4.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Immunol Rev  2014 ; 257:250-63;  PMID:24329802 ; http://dx.doi.org/10.1111/ imr.12134 5.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Nat Rev Clin Oncol 2013 ; 10:368;  PMID:23689751 ; http://dx.doi.org/10.1038/ nrclinonc.2013.856.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Nature  2013 ; 504:S13-5; PMID:24352359 ;  http://dx.doi.org/10.1038/504S13a 7.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Nat Rev Immunol 2012 ; 12:269-81;  PMID:22437939 ; http://dx.doi.org/10.1038/ nri3191 9.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Cancer J 2010 ; 16:336- 41; PMID:20693844 ; http://dx.doi.org/10.1097/ PPO.0b013e3181eb3879 10.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Nat Rev Cancer  2008 ; 8:299-308; PMID:18354418 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Oncoimmunology  2012 ; 1:1111-34;  PMID:23170259 ; http://dx.doi.org/10.4161/ onci.21494 12.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Oncoimmunology   2013 ; 2:e25771 ; PMID:24286020 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Semin Immunol  2011 ; 23:21- 7; PMID:21277223 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Nat Biotechnol   2010 ; 28:813-5; PMID:20697407 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Immunity  2010 ; 33:464-78;  PMID:21029958 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Nat Rev Cancer 2010 ; 10:213-21;  PMID:20168320 ; http://dx.doi.org/10.1038/ nrc2804 18.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Biol Res  2012 ; 45:307-16;  PMID:23283440 ; http://dx.doi.org/10.4067/ S0716-97602012000300012 19.,OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
N  Engl J Med 2008 ; 358:2698 -703; PMID:18565862 ;  http://dx.doi.org/10.1056/NEJMoa0800251 20.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Science  2002 ; 295:2097 - 100; PMID:11896281 ; http://dx.doi.org/10.1126/ science.1068440 22.,OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Curr Opin Immunol 2009 ; 21:525-30;  PMID:19717293 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Transplantation  2006 ; 82:1712 -9;  PMID:17198265 ; http://dx.doi.org/10.1097/01.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
PLoS One  2013 ; 8:e57922 ; PMID:23483943 ;  http://dx.doi.org/10.1371/journal.pone.0057922 26.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Eur J Immunol 2013 ; 43:331-4; PMID:23322344 ;  http://dx.doi.org/10.1002/eji.20124326427.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Cancer Immunol Immunother  2010 ; 59:1781 - 9; PMID:20703455 ; http://dx.doi.org/10.1007/ s00262-010-0904-3 30.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
OncoImmunology  2013 ; 2:e27156 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Oncoimmunology  2013 ; 2:e26527 ;  PMID:24404423 ; http://dx.doi.org/10.4161/ onci.26527 32.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Clin Cancer Res 2009 ;  15:4857 -66; PMID:19638467 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Leuk Res  2009 ; 33:1255 -9; PMID:19147228 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
"Clin  Cancer Res 2011 ; 17:4987 -95; PMID:21690573 ;  http://dx.doi.org/10.1158/1078-0432.CCR-11-0207 35. de Visser KE, Korets  LV, Coussens  LM.",Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Cancer Cell  2005 ; 7:411- 23; PMID :15894262 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Proc Natl Acad Sci U S A 2011 ;  108:10662 -7; PMID:21670304 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Oncoimmunology  2012 ; 1:1323 - 43; PMID:23243596 ; http://dx.doi.org/10.4161/ onci.22009 38.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Cancer Immunol  Immunother  2009 ; 58:553-66; PMID:18751701 ;  http://dx.doi.org/10.1007/s00262-008-0578-2 40.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Nat Rev Clin Oncol 2011 ; 8:577-85;  PMID:21808266 ; http://dx.doi.org/10.1038/ nrclinonc.2011.116 41.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Clin Immunol  2010 ;  136:338-47; PMID:20547105 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Nat Rev Cancer 2003 ; 3:35-45; PMID:12509765 ;  http://dx.doi.org/10.1038/nrc971 44.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
J Clin Oncol 2011 ; 29:917- 24; PMID:21282551 ; http://dx.doi.org/10.1200/ JCO.2010.32.2537 45.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Immunol Rev   2014 ; 257:107-26; PMID:24329793 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Immunol Rev  2014 ; 257:127- 44; PMID:24329794 ; http://dx.doi.org/10.1111/ imr.12139 48.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
N Engl J Med 2011 ; 365:725- 33; PMID:21830940 ; http://dx.doi.org/10.1056/ NEJMoa1103849 49.,OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Nat Rev Clin Oncol 2013 ; 10:267- 76; PMID:23546520 ; http://dx.doi.org/10.1038/ nrclinonc.2013.46 50.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Oncoimmunology  2013 ; 2:e23621 ;  PMID:23734316 ; http://dx.doi.org/10.4161/ onci.23621 51.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Oncoimmunology  2013 ; 2:e23564 ;  PMID:23734311 ; http://dx.doi.org/10.4161/ onci.23564,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Blood   2012 ; 119:2709 -20; PMID:22160384 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Blood  2010 ;  116:4099 -102; PMID:20668228 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Blood  2010 ; 116:3875 -86;  PMID:20631379 ; http://dx.doi.org/10.1182/ blood-2010-01-265041 55.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Blood  2011 ; 118:4817 - 28; PMID:21849486 ; http://dx.doi.org/10.1182/ blood-2011-04-348540 56.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Sci Transl Med 2011 ; 3:95ra73 ; PMID:21832238 ;  http://dx.doi.org/10.1126/scitranslmed.3002842 57.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
J Clin Invest 2011 ;  121:1822 -6; PMID:21540550 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Semin Cancer Biol 2012 ; 22:14-22;  PMID:22210183 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
J Immunother  2010 ;  33:672-83; PMID:20664359 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Oncoimmunology  2012 ; 1:986-8; PMID:23162781 ;  http://dx.doi.org/10.4161/onci.20213 65.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Nat Rev Immunol 2005 ; 5:928- 40; PMID:16322746 ; http://dx.doi.org/10.1038/ nri1729 66.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Oncoimmunology  2013 ; 2:e24103 ;  PMID:23526137 ; http://dx.doi.org/10.4161/ onci.24103 67.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Nat Rev Cancer 2012 ; 12:671-84; PMID:22996603 ;  http://dx.doi.org/10.1038/nrc3322 68.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Oncoimmunology  2012 ; 1:1435 -7; PMID:23243620 ;  http://dx.doi.org/10.4161/onci.21206 69.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Blood  2013 ; 121:573-84;  PMID:23160470 ; http://dx.doi.org/10.1182/ blood-2012-05-431718 70.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Nat Med  2011 ; 17:1290 -7;  PMID:21926977 ; http://dx.doi.org/10.1038/ nm.2446 72.,OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Cell Stem Cell  2013 ; 12:114-26; PMID:23290140 ;  http://dx.doi.org/10.1016/j.stem.2012.11.002 73.,OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Oncoimmunology  2012 ; 1:735-8; PMID:22934265 ;  http://dx.doi.org/10.4161/onci.20823 74.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Cell Stem Cell   2013 ; 12:31-6; PMID:23290135 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Oncoimmunology  2013 ; 2:e24238 ;  PMID:23762803 ; http://dx.doi.org/10.4161/ onci.24238 76.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Oncoimmunology  2012 ; 1:306- 15; PMID:22737606 ; http://dx.doi.org/10.4161/ onci.1954977.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
J Immunother   2010 ; 33:1-7; PMID:19952961 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Nat Rev Immunol 2009 ; 9:162-74; PMID:19197294 ;  http://dx.doi.org/10.1038/nri2506 79.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
J  Immunother  2012 ; 35:107-15; PMID:22306898 ;  http://dx.doi.org/10.1097/CJI.0b013e318242169f 80.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Cancer J 2010 ;  16:348-53; PMID:20693846 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Immunol Rev  2011 ;  241:63-76; PMID:21488890 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Immunol Rev  2011 ; 241:260-8; PMID:21488902 ;  http://dx.doi.org/10.1111/j.1600-065X.2011.01018.x 83.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Blood  2012 ; 119:5688 -96;  PMID:22555974 ; http://dx.doi.org/10.1182/ blood-2011-10-386482 84.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
J Immunol   2012 ; 189:5147-54; PMID:23100512 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Oncoimmunology  2012 ; 1:326-33;  PMID:22737608 ; http://dx.doi.org/10.4161/ onci.18852 86.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
J Exp Med 2005 ;  202:907- 12; PMID:16203864 ; http://dx.doi.org/10.1084/ jem.20050732 87.,OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Trends Immunol   2005 ; 26:111-7; PMID :15668127 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Cancer Lett 1994 ; 85:39-46; PMID:7923100 ;  http://dx.doi.org/10.1016/0304-3835(94)90236-4 91.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Cancer Immunol Immunother   2010 ; 59:1325 -34; PMID:20532883 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Clin Cancer Res  2011 ; 17:3134 -45; PMID:21252159 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Cancer Res 2010 ; 70:6171 -80;  PMID:20631075 ; http://dx.doi.org/10.1158/0008- 5472.CAN-10-0153 94.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Oncoimmunology   2012 ; 1:699-716; PMID:22934262 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Clin Cancer Res 2007 ; 13:5280 -9;  PMID:17875756 ; http://dx.doi.org/10.1158/1078- 0432.CCR-07-1378 96.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Oncoimmunology  2012 ; 1:894-907;  PMID:23162757 ; http://dx.doi.org/10.4161/ onci.20931 97.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Nat Rev Drug Discov 2012 ; 11:215-33;  PMID:22301798 ; http://dx.doi.org/10.1038/ nrd3626 99.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
"Ophthalmology  2009 ; 116:981, e1; PMID:19410956 ;  http://dx.doi.org/10.1016/j.ophtha.2008.12.004 101.",Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
J Immunother  2013 ; 36:133- 51; PMID:23377668 ; http://dx.doi.org/10.1097/ CJI.0b013e3182829903102.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Proc Natl Acad Sci U S A  2013 ; 110:6973 -8; PMID:23576742 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Oncoimmunology   2012 ; 1:1643 -4; PMID:23264922 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Oncoimmunology  2013 ; 2:e23803 ;  PMID:23734328 ; http://dx.doi.org/10.4161/ onci.23803 105.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Oncoimmunology  2012 ; 1:1557- 76; PMID:23264902 ; http://dx.doi.org/10.4161/ onci.22428 106.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
N Engl J Med  2013 ; 368:1509 -18; PMID:23527958 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Mol Ther  2013 ; 21:2122 - 9; PMID :23831595 ; http://dx.doi.org/10.1038/ mt.2013.154 108.,OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Blood  2013 ; 122:4129 - 39; PMID:24055823 ; http://dx.doi.org/10.1182/ blood-2013-08-519413 109.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Blood   2013 ; 122:2965 -73; PMID:24030379 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
J Clin Oncol 2013 ;  (Forthcoming ); PMID:24344220 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
J Clin Oncol  2013 ; 31:2152 -9; PMID:23650429 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Cancer Immunol Immunother  2013 ; 62:1053 - 60; PMID:23595207 ; http://dx.doi.org/10.1007/ s00262-013-1414-x 114.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Mol Ther  2014 ; 22:132- 9; PMID:24297049 ; http://dx.doi.org/10.1038/ mt.2013.242 115.,OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Hum Vaccin Immunother 2014 ; 10; (Forthcoming );  PMID:24419174 ; http://dx.doi.org/10.4161/ hv.27678 116.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
J Immunother  2014 ; 37:43- 50; PMID:24316555 ; http://dx.doi.org/10.1097/ CJI.0000000000000005 117.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Mol Ther   2013 ; 21:904-12; PMID:23423337 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Oncoimmunology   2012 ; 1:1577 -83; PMID:23264903 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Oncoimmunology  2013 ; 2:e22059 ;  PMID:23483796 ; http://dx.doi.org/10.4161/ onci.22059 120.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Glycobiology   2001 ; 11:677-83; PMID:11479278 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Nat Rev Immunol 2002 ; 2:85-95;  PMID:11910899 ; http://dx.doi.org/10.1038/nri724 124.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Curr  Opin Immunol  1996 ; 8:831-6; PMID:8994863 ;  http://dx.doi.org/10.1016/S0952-7915(96)80012-4,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Clin Cancer Res  2010 ; 16:2646 -55; PMID:20406835 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Clin Cancer Res  2010 ; 16:6122 -31; PMID:20668005 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Oncoimmunology  2013 ; 2:e22789 ;  PMID:23482847 ; http://dx.doi.org/10.4161/ onci.22789 130.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Oncoimmunology   2013 ; 2:e26098 ; PMID:24353909 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Oncoimmunology   2013 ; 2:e24117 ; PMID:23734336 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Oncogene   2012 ; 31:1869 -83; PMID:21892204 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Oncogene   2011 ; 30:1147-58; PMID:21151176 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
J Clin Oncol 2005 ; 23:5779 - 87; PMID:16110035 ; http://dx.doi.org/10.1200/ JCO.2005.06.478 136.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
J Clin Oncol 2003 ; 21:586- 7; PMID:12586792 ; http://dx.doi.org/10.1200/ JCO.2003.12.065 137.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
J Transl Med  2013 ; 11:83; PMID:23536996 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Immunol Lett  2013 ; 155:27-30;  PMID:24084446 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Cancer Res 2014 ; 74:119-29; PMID:24356422 ;  http://dx.doi.org/10.1158/0008-5472.CAN-13-1559 140.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Int Immunopharmacol   2009 ; 9:900-9; PMID:19336265 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Clin Cancer Res 2005 ; 11:6713 -21;  PMID:16166452 ; http://dx.doi.org/10.1158/1078- 0432.CCR-05-0883 142.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Oncoimmunology  2012 ; 1:179- 88; PMID:22720239 ; http://dx.doi.org/10.4161/ onci.1.2.19026 144.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Oncoimmunology  2013 ; 2:e23510 ;  PMID:23687621 ; http://dx.doi.org/10.4161/ onci.23510 145.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Annu Rev Immunol 2013 ; 31:51-72;  PMID :23157435 ; http://dx.doi.org/10.1146/ annurev-immunol-032712-100008 146.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
PLoS One   2013 ; 8:e82742 ; PMID:24358223 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Clin Dev  Immunol  2013 ; 2013 :932318 ; PMID:24194775 ;  http://dx.doi.org/10.1155/2013/932318 148.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Cancer Discov  2013 ; 3:418-29;  PMID:23519018 ; http://dx.doi.org/10.1158/2159- 8290.CD-12-0383 149.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Nat  Rev Mol Cell Biol 2010 ; 11:621-32; PMID:20683470 ;  http://dx.doi.org/10.1038/nrm2952 151.,OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Mol Cell   2010 ; 37:299-310; PMID:20159550 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Proc Natl Acad Sci U S A 2008 ; 105:20327 - 32; PMID:19074266 ; http://dx.doi.org/10.1073/ pnas.0808036105 153.,OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Blood   2013 ; 122:3138 -48; PMID:24030378 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Nat Med  2013 ; 19:747- 52; PMID:23644516 ; http://dx.doi.org/10.1038/ nm.3161 156.,OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Clin  Cancer Res 2012 ; 18:1426 -34; PMID:22241792 ;  http://dx.doi.org/10.1158/1078-0432.CCR-11-1221 158.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Oncoimmunology  2013 ; 2:e26494 ;  PMID:24482747 ; http://dx.doi.org/10.4161/ onci.26494 159.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
J Hematol Oncol  2009 ; 2:36; PMID:19674465 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Oncoimmunology   2012 ; 1:1409 -10; PMID:23243610 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Oncoimmunology  2012 ; 1:1194 -6; PMID:23170277 ;  http://dx.doi.org/10.4161/onci.20686 162.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Nat Rev Cancer 2005 ; 5:615-25;  PMID:16034368 ; http://dx.doi.org/10.1038/ nrc1669 163.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Am J Clin Pathol  2004 ; 121:254-63; PMID:14983940 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Br J Haematol  2012 ; 156:679-83; PMID:21988294 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Semin Oncol 2012 ; 39:263-75;  PMID:22595049 ; http://dx.doi.org/10.1053/j.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Hum Gene Ther 2008 ; 19:496- 510; PMID:18444786 ; http://dx.doi.org/10.1089/ hum.2007.0171 168.,OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Cell Death Dis 2012 ; 3:e262 ;  PMID:22278289 ; http://dx.doi.org/10.1038/ cddis.2012.1 171.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Nat Rev  Drug Discov  2006 ; 5:835-44; PMID:17016424 ;  http://dx.doi.org/10.1038/nrd2130172.,OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Oncoimmunology   2012 ; 1:1537-45; PMID:23264900 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Oncoimmunology  2012 ; 1:1104 -10;  PMID:23170258 ; http://dx.doi.org/10.4161/ onci.21056 174.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Blood   2008 ; 111:2170 -80; PMID:17925489 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Cancer Res 2007 ; 67:6253 -62; PMID:17616683 ;  http://dx.doi.org/10.1158/0008-5472.CAN-07-0538 176.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Oncoimmunology  2013 ; 2:e26621 ;  PMID:24498550 ; http://dx.doi.org/10.4161/ onci.26621178.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Immunity  2013 ; 39:49-60; PMID:23890063 ;  http://dx.doi.org/10.1016/j.immuni.2013.07.002 179.,OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Hum Gene Ther  2012 ; 23:1054 -64; PMID:22734672 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Front Immunol  2013 ; 4:244;  PMID:23970885 ; http://dx.doi.org/10.3389/ fimmu.2013.00244 182.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Blood  2012 ; 119:3872 -3; PMID:22538493 ;  http://dx.doi.org/10.1182/blood-2012-02-410373 183.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
Nat Rev Cancer  2013 ; 13:525-41; PMID:23880905 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/ce/onci-3-e28344.PMC4063152.pdf
"OncoImmunology 2014; 3:e28498; http://dx.doi.org/10.4161/onci.28498Immune response markers in sentinel nodes may  predict melanoma progression Monica ro dolfo*, Chiara Castelli, and Licia ri voltini un it of im munotherapy; Fondazione irC Cs  is tituto Nazionale tu mori; Milan, it aly Keywords:  sentinel node, melanoma, expression profiles, CD30, lymph node we r ecently reported that variable expression of immune-response genes distinguishes tumor positive sentinel  nodes in melanoma patients with malignant progression from those with non-progressing disease.",Non-OADS,/arxiv_data1/oa_pdf/6c/6c/onci-3-e28498.PMC4063153.pdf
Nat Rev Immunol  2006; 6:659-70;  PMID:16932751 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/6c/6c/onci-3-e28498.PMC4063153.pdf
Cancer Sci 2008; 99:441-50;  PMID:18070155 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/6c/6c/onci-3-e28498.PMC4063153.pdf
Int J Cancer 2013; 132:2537-47; PMID:23136075 ; http://dx.doi.org/10.1002/ ijc.279334.,Non-OADS,/arxiv_data1/oa_pdf/6c/6c/onci-3-e28498.PMC4063153.pdf
J Immunol 2010; 185:2071-9; PMID:20631311 ; http://dx.doi.org/10.4049/ jimmunol.09019017.,Non-OADS,/arxiv_data1/oa_pdf/6c/6c/onci-3-e28498.PMC4063153.pdf
Curr Opin Hematol 2003; 10:267-71;  PMID:12799531 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/6c/6c/onci-3-e28498.PMC4063153.pdf
Immunology 2006; 118:143-52;  PMID:16771849 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/6c/6c/onci-3-e28498.PMC4063153.pdf
Immunol Res 2013; 57:151-8; PMID:24233555 ; http://dx.doi.org/10.1007/ s12026-013-8464-1 ©2014 Landes Bioscience.,Non-OADS,/arxiv_data1/oa_pdf/6c/6c/onci-3-e28498.PMC4063153.pdf
"OncoImmunology 2014; 3:e28497;   http://dx.doi.org/10.4161/onci.28497Secretory pathways generating  immunosuppressive NKG2D ligands New targets for therapeutic intervention Aroa Baragaño Raneros1, Beatriz Suarez-Álvarez2, and Carlos López-Larrea1,3,* 1Department of im munology; Hospital Universitario Central de Asturias; Oviedo, Spain; 2Cellular Biology of Renal Diseases Laboratory; in stituto de in vestigación Sanitaria  Fundación Jiménez Díaz; Universidad Autónoma Madrid; Madrid, Spain; 3Fundación Renal “ iñ igo Álvarez de Toledo”; Madrid, Spain Keywords:  NKs, NKG2D, soluble NKG2D ligands, shedding, exosomes Abreviations:  ADAM, a disintegrin and metalloproteinase; CLL, chronic lymphocytic leukemia; CR, complete remission;   DRMs, detergent-resistant membrane microdomains; ERp5/ PDIA6, protein disulfide isomerase family A, member 6;   GRP78/HSPA5, heat shock 70kDa protein 5; GTN, nitroglycerin; HIF1 α, hypoxia-inducible factor 1 α; IFN γ, interferon- γ;   IL-1β, interleukin-1 β; MICA/B, MHC class I chain-related A/B; MMP, matrix metalloprotease; MP, metalloprotease;   MMPI, MMP inhibitors; NKG2D, natural killer group 2 member D; NKG2DL, NKG2D ligands; sNKG2DL, soluble NKG2DL;  OS, overall survival; STAT3, signal transducer and activator of transcription 3; PDAC, pancreatic ductal adenocarcinoma;   TIMP, tissue inhibitors of metalloproteinase; TFS, treatment-free survival; TGF β, transforming growth factor- β;   ULBP, UL-16 binding protein Natural Killer Group 2 member D (NKG2D) activating  receptor, present on the surface of various immune cells,  plays an important role in activating the anticancer immune response by their interaction with stress-inducible NKG2D ligands (NKG2DL) on transformed cells.",Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Curr Top Microbiol  Immunol 2006; 298:121-38; PMID:16329186 ;  http://dx.doi.org/10.1007/3-540-27743-9_6 2.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Trends Mol Med   2008 ; 14:179-89; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Oncoimmunology  2013 ; 2: e26097 ;  PMID:24353908 ; http://dx.doi.org/10.4161/ onci.26097 5.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Annu Rev Immunol 2013 ;  31:413-41; http://dx.doi.org/10.1146/annurev- immunol-032712-095951 ; PMID:23298206 6.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Cancer Res  2012 ; 72:460-71; http://dx.doi.org/10.1158/0008- 5472.CAN-11-1977 ; PMID:22102694 7.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Proc Natl Acad Sci U  S A 2008 ; 105:1686 -91; http://dx.doi.org/10.1073/ pnas.0701675105 ; PMID :18223157 9.,OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
J Exp Med 2012 ; 209:2409 -22; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
J B iol Chem 2010 ; 285:8543 - 51; http://dx.doi.org/10.1074/jbc.M109.045906 ;  PMID:20080967 11.,OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
J Biol Chem 2006 ; 281:30419 - 30; PMID:16901903 ; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Brain  2006 ; 129:2416 -25;  PMID:16891318 ; http://dx.doi.org/10.1093/brain/ awl205 15.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Int J Cancer 2009 ;  124:1594 -604; http://dx.doi.org/10.1002/ijc.24098 ;  PMID:19089914 16.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Hum Immunol   2011 ; 72:470-8; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Nat Immunol  2010 ;  11:806-13; http://dx.doi.org/10.1038/ni.1916 ;  PMID:20694010 18.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
J Immunol 2009 ; 182:39- 43; PMID:19109132 ; http://dx.doi.org/10.4049/ jimmunol.182.1.39 20.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Cancer Res 2012 ;  72:5463 -72; http://dx.doi.org/10.1158/0008-5472.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
J Immunol 2012 ; 188:1847 -55; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
EMBO J  2007 ; 26:1423 -33; PMID:17318190 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Proc Natl Acad Sci U S A 2006 ; 103:11258 -63;  PMID:16849432 ; http://dx.doi.org/10.1073/ pnas.0600721103 24.,OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
EMBO Rep 2009 ; 10:908-15; http://dx.doi.org/10.1038/ embor.2009.92 ; PMID:19498463 25.,OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
J Immunol 2002 ; 169:4098 - 102; PMID:12370336 ; http://dx.doi.org/10.4049/ jimmunol.169.8.4098 26.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Blood  2003 ;  102:1389 -96; PMID:12714493 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
J Immunol  2012 ; 189:1360 -71; http://dx.doi.org/10.4049/ jimmunol.1200796 ; PMID:22730533 28.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Leukemia  2010 ; 24:1152 -9; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Cancer Immunol Immunother  2012 ; 61:1201 -10;  http://dx.doi.org/10.1007/s00262-011-1195-z ;  PMID:22215138 30.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
BMC Cancer  2008 ; 8:16; http://dx.doi.org/10.1186/1471- 2407-8-16 ; PMID:18208618,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
PLoS One  2012 ; 7:e44743 ;  PMID:23024757 ; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Med Oncol  2011 ; 28:466-74;  http://dx.doi.org/10.1007/s12032-010-9480-9 ;  PMID:20354827 33.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Cancer Sci 2011 ; 102:1673 -9;  http://dx.doi.org/10.1111/j.1349-7006.2011.01989.x ;  PMID:21615621 34.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Neoplasia  2004 ; 6: 558- 68; PMID:15548365 ; http://dx.doi.org/10.1593/ neo.04316 35.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Cancer Cell Int  2011 ; 11:15; http://dx.doi.org/10.1186/1475- 2867-11-15 ; PMID:21631944 37.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Cancer Sci 2012 ; 103:1405 -13; http://dx.doi.org/10.1111/ j.1349-7006.2012.02330.x ; PMID:22587355 38.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Tumour Biol  2013 ; 34:565-9; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Clin Immunol  2007 ;  123:114-20; PMID:17218152 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
PLoS One  2009 ; 4: e4503 ;  http://dx.doi.org/10.1371/journal.pone.0004503 ;  PMID:19223974 44.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Front Pharmacol  2012 ; 3:140;  http://dx.doi.org/10.3389/fphar.2012.00140 ;  PMID:22822400 45.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Clin Proteomics 2011 ; 8:9;  http://dx.doi.org/10.1186/1559-0275-8-9 ;  PMID:21906355 46.,OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Cancer Res 2008 ;  68:6368 -76; http://dx.doi.org/10.1158/0008-5472.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Cell Biol Int 2011 ; 35:569-74; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Oncol Rep 2012 ; 28:1585 - 90; http://dx.doi.org/10.3892/or.2012.1981 ;  PMID:22923031 49.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
J Immunol  2010 ; 184:3346 -50; http://dx.doi.org/10.4049/ jimmunol.0903789 ; PMID:20208009 51.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Int J Cancer 2013 ; 133:1557-66; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Science  2012 ; 335:225-8; http://dx.doi.org/10.1126/ science.1214400 ; PMID:2224677754.,OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Science  2012 ; 335:229- 32; http://dx.doi.org/10.1126/science.1214448 ;  PMID:22246778 55.,OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Blood  2012 ; 119:5769 -71;  http://dx.doi.org/10.1182/blood-2012-03-417949 ;  PMID:22550345 56.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Hepatology  2010 ; 51:1264 -73; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Cancer Immunol Immunother  2012 ; 61:1425 - 32; PMID:22302133 ; http://dx.doi.org/10.1007/ s00262-012-1208-6 58.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Int J Oncol 2012 ;  41:83-91; http://dx.doi.org/10.3892/ijo.2012.1438 ;  PMID:22576685 60.,OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Mol Med Rep  2013 ; 7:991- 7; http://dx.doi.org/10.3892/mmr.2013.1272 ;  PMID:23314034 61.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
J Immunol 2009 ; 182:49-53;  PMID:19109134 ; http://dx.doi.org/10.4049/ jimmunol.182.1.49 62.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Eur J Immunol 2011 ; 41:3667 -76; PMID:21928280 ;  http://dx.doi.org/10.1002/eji.201141645 63.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
PLoS One  2011 ; 6:e16899 ;  http://dx.doi.org/10.1371/journal.pone.0016899 ;  PMID:21364924 65.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
J Cell Sci 2002 ; 115 :3719 - 27; PMID:12235282 ; http://dx.doi.org/10.1242/ jcs.00063,OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Semin Cancer  Biol 2010 ; 20:161-8; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Biochim Biophys  Acta 2010 ; 1803 :55-71; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
J Cell Biochem 2010 ; 110:1299 - 305; http://dx.doi.org/10.1002/jcb.22679 ;  PMID:20506407 69.,OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Nature  2007 ; 447:482- 6; PMID:17495932 ; http://dx.doi.org/10.1038/ nature05768 70.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Blood  2012 ; 119:1479 -89;  http://dx.doi.org/10.1182/blood-2011-07-370841 ;  PMID:22167753 71.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
J Immunol 2008 ;  180:7249 -58; PMID:18490724 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
PLoS One   2009 ; 4:e4942 ; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Cancer Res  2010 ; 70:481-9; http://dx.doi.org/10.1158/0008- 5472.CAN-09-1688 ; PMID:20068167 75.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Biochem J  2013 ; 454:295- 302; http://dx.doi.org/10.1042/BJ20130194 ;  PMID:23772752 76.,OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
BMC Cancer 2011 ;  11:194; http://dx.doi.org/10.1186/1471-2407-11- 194; PMID:2160542277.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Cancer Res 2009 ;  69:8050 -7; http://dx.doi.org/10.1158/0008-5472.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Oncol Rep 2012 ; 28:1585 - 90; http://dx.doi.org/10.3892/or.2012.1981 ;  PMID:22923031 80.,Non-OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
Int J  Oncol  2011 ; 39:1491 -9; http://dx.doi.org/10.3892/ ijo.2011.1144 ; PMID:21805029,OADS,/arxiv_data1/oa_pdf/72/18/onci-3-e28497.PMC4063154.pdf
"OncoImmunology 2014; 3:e28464; http://dx.doi.org/10.4161/onci.28464Rethinking the role of myeloid-derived suppressor  cells in adoptive T-cell therapy for cancer Ainhoa Arina Department of Pathology; th e un iversity of Chicago; Chicago, iL usA Keywords:  cancer, immunosuppression, adoptive T-cell therapy, myeloid derived-suppressor cells, tumor-associated macrophages th e expansion of cancer-induced myeloid cells is thought to be one of the main obstacles to successful immuno - therapy.",Non-OADS,/arxiv_data1/oa_pdf/5d/40/onci-3-e28464.PMC4063155.pdf
J Immunol 2014; 192:1286-93;  PMID:24367029 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5d/40/onci-3-e28464.PMC4063155.pdf
Clin Cancer Res 2012; 18:2526-33; PMID :22415314 ;  http://dx.doi.org/10.1158/1078-0432.CCR-12-0127 3.,Non-OADS,/arxiv_data1/oa_pdf/5d/40/onci-3-e28464.PMC4063155.pdf
Nat Med 2004; 10:294-8; PMID:14981514 ;  http://dx.doi.org/10.1038/nm999 4.,OADS,/arxiv_data1/oa_pdf/5d/40/onci-3-e28464.PMC4063155.pdf
Cancer Res 2008; 68:1563-71;  PMID:18316622 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5d/40/onci-3-e28464.PMC4063155.pdf
Cancer Cell 2013; 23:516-26; PMID:23597565 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/5d/40/onci-3-e28464.PMC4063155.pdf
Oncoimmunology 2013; 2:e26677;  PMID:24482750 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5d/40/onci-3-e28464.PMC4063155.pdf
Clin Cancer Res 2012; 18:5212-23; PMID:22837179 ;  http://dx.doi.org/10.1158/1078-0432.CCR-12-1108 8.,Non-OADS,/arxiv_data1/oa_pdf/5d/40/onci-3-e28464.PMC4063155.pdf
Blood 2013; 121:1740-8; PMID:23305737 ;  http://dx.doi.org/10.1182/blood-2012-06-436568 9.,Non-OADS,/arxiv_data1/oa_pdf/5d/40/onci-3-e28464.PMC4063155.pdf
J Exp Med 2010; 207:2469-77; PMID:20921286 ; http://dx.doi.org/10.1084/ jem.20092450 10.,Non-OADS,/arxiv_data1/oa_pdf/5d/40/onci-3-e28464.PMC4063155.pdf
Nat Genet 2011; 43:442-6; PMID:21499247 ; http://dx.doi.org/10.1038/ng.810 Figure 1.  se quence of events during immune-mediated destruction of 8101 tumors by adoptively  transferred immune  t  cells.,OADS,/arxiv_data1/oa_pdf/5d/40/onci-3-e28464.PMC4063155.pdf
"OncoImmunology 2014; 3:e28541; http://dx.doi.org/10.4161/onci.28541Smac mimetics combined with innate immune  stimuli create the perfect cytokine storm   to kill tumor cells shawn t Beug1, eric C LaCasse1, and r obert G Korneluk1,2,* 1solange Gauthier Karsh Molecular Genetics Laboratory; Apoptosis r esearch Centre; Children’s h ospital of e astern o ntario r esearch i nstitute; o ttawa, Canada;   2Department of Biochemistry, Microbiology and i mmunology; u niversity of o ttawa; o ttawa, Canada Keywords:  cIAP1, cIAP2, XIAP, TNF α, interferon (IFN), Smac mimetic, oncolytic virus, poly(I:C), CpG, bystander effect,  immunotherapy Abbreviations:  cIAP, cellular inhibitor of apoptosis; CTLA-4, cytotoxic T-lymphocyte antigen-4; DAMP, damage-associated  molecular pattern; IFN, interferon; NF- κB, nuclear factor- κB; PD-1, programmed cell death 1; PD-L1, programmed cell death  ligand-1; poly(I:C), polyinosinic-polycytidylic acid; Smac, second mitochondria-derived activator of caspases; TLR, toll-like  receptor; TNF α, tumour necrosis factor α ; TRAIL, TNF-related apoptosis-inducing ligand; VSV, Vesicular stomatitis virus; XIAP,  X-linked inhibitor of apoptosis A dual immunotherapy approach employing small-molecule inhibitors of apoptosis ( iAP) protein antagonists in com - bination with innate immune stimuli has proven to be highly synergistic and effective in animal tumor models.",Non-OADS,/arxiv_data1/oa_pdf/79/b8/onci-3-e28541.PMC4063156.pdf
Nat Rev Drug Discov  2012; 11:109-24;  PMID:22293567 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/79/b8/onci-3-e28541.PMC4063156.pdf
Nat Biotechnol 2014; 32:182-90;  PMID:24463573 ;  http://dx.doi.org/10.1038/nbt.2806Figure 1.,OADS,/arxiv_data1/oa_pdf/79/b8/onci-3-e28541.PMC4063156.pdf
Nat Biotechnol 2012; 30:658-70; PMID:22781695 ;  http://dx.doi.org/10.1038/nbt.2287 5.,Non-OADS,/arxiv_data1/oa_pdf/79/b8/onci-3-e28541.PMC4063156.pdf
Trends Immunol 2012; 33:535-45; PMID:22836014 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/79/b8/onci-3-e28541.PMC4063156.pdf
Elife  2013; 2:e00785;  PMID :23951545 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/79/b8/onci-3-e28541.PMC4063156.pdf
Nat Rev Cancer 2012; 12:237-51; PMID:22437869 ;  http://dx.doi.org/10.1038/nrc3237,Non-OADS,/arxiv_data1/oa_pdf/79/b8/onci-3-e28541.PMC4063156.pdf
"OncoImmunology 2014; 3:e28399; http://dx.doi.org/10.4161/onci.28399The ELR+CXCL chemokines and   their receptors CXCR1/CXCR2 A signaling axis and new target for the treatment   of renal cell carcinoma sa ndy Giuliano1, Mélanie Guyot1, re naud Grépin2,†, and Gilles Pagès1,†,* 1un iversity of Nice so phia Antipolis; uMr  CNr s  7284/ u  iNs erM 1 081; Nice, France; 2Centre sc ientifique de Monaco; Monaco †th ese authors co-directed this work.",Non-OADS,/arxiv_data1/oa_pdf/8d/04/onci-3-e28399.PMC4063157.pdf
J Natl Cancer Inst 2012; 104:93-113;  PMID:22235142 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/8d/04/onci-3-e28399.PMC4063157.pdf
Expert Rev Anticancer Ther 2010; 10:305-17;  PMID:20214511 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/8d/04/onci-3-e28399.PMC4063157.pdf
Cancer Cell 2004; 6:447-58; PMID:15542429 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/8d/04/onci-3-e28399.PMC4063157.pdf
Oncogene 2012; 31:1683-94; PMID:21909141 ; http://dx.doi.org/10.1038/ onc.2011.360 5.,Non-OADS,/arxiv_data1/oa_pdf/8d/04/onci-3-e28399.PMC4063157.pdf
Cancer Res 2014; 74:873-83; PMID:24335961 ; http://dx.doi.org/10.1158/0008- 5472.CAN-13-12676.,Non-OADS,/arxiv_data1/oa_pdf/8d/04/onci-3-e28399.PMC4063157.pdf
J Am Soc Nephrol 2007; 18:2359-70; PMID:17634442 ;  http://dx.doi.org/10.1681/ASN.2006040380 8.,Non-OADS,/arxiv_data1/oa_pdf/8d/04/onci-3-e28399.PMC4063157.pdf
J Clin Invest 2010; 120:485-97; PMID:20051626 ; http://dx.doi.org/10.1172/ JCI39397 9.,Non-OADS,/arxiv_data1/oa_pdf/8d/04/onci-3-e28399.PMC4063157.pdf
Cancer Res 2011; 71:614-24; PMID:21224357 ;  http://dx.doi.org/10.1158/0008-5472.CAN-10-0538 10.,Non-OADS,/arxiv_data1/oa_pdf/8d/04/onci-3-e28399.PMC4063157.pdf
Cancer Res 2009; 69:2167-70; PMID:19276354 ; http://dx.doi.org/10.1158/0008- 5472.CAN-08-3772 ©2014 Landes Bioscience.,Non-OADS,/arxiv_data1/oa_pdf/8d/04/onci-3-e28399.PMC4063157.pdf
"OncoImmunology 2014; 3:e28329; http://dx.doi.org/10.4161/onci.28329Natural killer T cell strategies   to combat Epstein-Barr virus infection John J Priatel1,2,*, Brian K Chung1,3, Kevin tsai1,2, and rusung tan1,2,4,* 1Child and Family res earch ins titute; imm unity in hea lth and Disease; uni versity of British Columbia; Vancouver, BC Canada;   2Department of Pathology and Laboratory Medicine; uni versity of British Columbia; Vancouver, BC Canada; 3Department of Medical Genetics; uni versity of British Columbia;  Vancouver, BC Canada; 4Department of Pathology; sid ra Medical and res earch Center; Doha, Qatar Keywords:  B cell lymphoma, Burkitt’s lymphoma, CD1d, Epstein–Barr virus, NKT cells, X-linked lymphoproliferative disease,  herpesvirus, immunodeficiency, infection, mononucleosis Abbreviations:  DC, dendritic cell; EBV, Epstein-Barr virus; α GalCer, α -galactosylceramide; LCL, lymphoblastoid cell line;   NK cell, natural killer cell; NKT cell, natural killer T cell; RAR α, retinoic acid receptor- α; SAP, SLAM-associated protein;   XLP, X-linked lymphoproliferative disease epstein–Barr virus ( eBV ) infection results in rapid loss of CD1d expression from the surface of infected B cells, thus  enabling the virus to evade immune recognition by natural killer t ( NKt) ce lls.",Non-OADS,/arxiv_data1/oa_pdf/20/95/onci-3-e28329.PMC4063158.pdf
Clin Cancer Res 2011; 17:3056-63; PMID:21372216 ; http://dx.doi.org/10.1158/1078- 0432.CCR-10-2578 2.,Non-OADS,/arxiv_data1/oa_pdf/20/95/onci-3-e28329.PMC4063158.pdf
Crit Rev Oncol Hematol 2000 ; 34:27- 53; PMID:10781747 ; http://dx.doi.org/10.1016/ S1040-8428(00)00046-9 3.,Non-OADS,/arxiv_data1/oa_pdf/20/95/onci-3-e28329.PMC4063158.pdf
Annu Rev Immunol 2011 ; 29:665- 705; PMID:21219180 ; http://dx.doi.org/10.1146/ annurev-immunol-030409-101302 4.,Non-OADS,/arxiv_data1/oa_pdf/20/95/onci-3-e28329.PMC4063158.pdf
J Exp Med  2005 ; 201:833-6; PMID :15781574 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/20/95/onci-3-e28329.PMC4063158.pdf
Annu Rev Immunol 2007 ; 25:297- 336; PMID:17150027 ; http://dx.doi.org/10.1146/ annurev.immunol.25.022106.141711 6.,Non-OADS,/arxiv_data1/oa_pdf/20/95/onci-3-e28329.PMC4063158.pdf
J Clin Invest 2005 ; 115:1369 -78;  PMID:15864354 ; http://dx.doi.org/10.1172/ JCI2005240419.,Non-OADS,/arxiv_data1/oa_pdf/20/95/onci-3-e28329.PMC4063158.pdf
Nat Immunol   2006 ; 7:835-42; PMID:16845396 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/20/95/onci-3-e28329.PMC4063158.pdf
Available from: http://www.baoms.org.uk/file.aspx?id 5752 (accessed 14 February 2014).,Non-OADS,/arxiv_data1/oa_pdf/bb/60/jor-41-02-077.PMC4063315.pdf
Available from: http://www.northhampshir eccg.com/website/X00237/files/ship-&-hiow-policy-recommendations.pdf (accessed 12 February 2014).,Non-OADS,/arxiv_data1/oa_pdf/bb/60/jor-41-02-077.PMC4063315.pdf
Available from http://www.who.int/mediacentre/factsheets/fs313/en/index.html.,Non-OADS,/arxiv_data1/oa_pdf/93/bc/jes201378a.PMC4063324.pdf
"United States Environmental Protection Agency, Toxics Release Inventory (TRI) Program 2013, Available from http://www.epa.gov/tri/.",OADS,/arxiv_data1/oa_pdf/93/bc/jes201378a.PMC4063324.pdf
"Canadian National Pollutant Release Inventory 2013, Available from http://www.ec.gc.ca/inrp-npri/.",OADS,/arxiv_data1/oa_pdf/93/bc/jes201378a.PMC4063324.pdf
"2012, [updated June 15, 2012]Available from http://www.nhlbi.nih.gov/health/health-topics/topics/asthma/diagnosis.html.",Non-OADS,/arxiv_data1/oa_pdf/93/bc/jes201378a.PMC4063324.pdf
"United States Census 2010 2010, Available from http://www.census.",OADS,/arxiv_data1/oa_pdf/93/bc/jes201378a.PMC4063324.pdf
"StrategiCare ’08: Phase 1 Final Report 2008, Available from http://www.eriestclairlhinnews.on.ca/blog-strategicare/gallery/1/StrategiCare%2008%20Phase%201%20Final%20Report%20September%202008.pdf.",Non-OADS,/arxiv_data1/oa_pdf/93/bc/jes201378a.PMC4063324.pdf
"Discharge Abstract Database (DAD) Metadata 2013, Available from http://www.cihi.ca/CIHI-ext-portal/internet/en/document/types þof þcare/hospital þcare/acute þcare/dad_metadata.",OADS,/arxiv_data1/oa_pdf/93/bc/jes201378a.PMC4063324.pdf
"National Ambulatory Care Reporting Sys- tem (NACRS) 2013, Available from http://www.cihi.ca/CIHI-ext-portal/internet/en/document/types þofþcare/hospital þcare/emergency þcare/NACRS_METADATA.",OADS,/arxiv_data1/oa_pdf/93/bc/jes201378a.PMC4063324.pdf
Available from http://www.michigan.gov/documents/mdch/epi-mich-asthma- Detroit_Epicenter_of_Asthma_401493_7.pdf.,Non-OADS,/arxiv_data1/oa_pdf/93/bc/jes201378a.PMC4063324.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/Detroit–Windsor air pollution and asthma Lemke et al 357 &2014 Nature America, Inc. Journal of Exposure Science and Environmental Epidemiology (2014), 346 – 357",Non-OADS,/arxiv_data1/oa_pdf/93/bc/jes201378a.PMC4063324.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ Supplementary Information accompanies the paper on the Journal of Exposure Science and Environmental Epidemiology website (http:// www.nature.com/jes)Source apportionment, uncertainty propagation Kioumourtzoglou et al 371 &2014 Nature America, Inc. Journal of Exposure Science and Environmental Epidemiology (2014), 365 – 371",Non-OADS,/arxiv_data1/oa_pdf/41/41/jes20147a.PMC4063325.pdf
"Sequence analysis was performed using Vector-NTI (Invitrogen, Carlsbad, CA, USA), SeqMatch,available through the Ribosomal Database Project II(RDPII database, http://rdp.cme.msu.edu/index.jsp)(Maidak et al.",OADS,/arxiv_data1/oa_pdf/76/5c/jam0115-1037.PMC4063339.pdf
"1997) (National Center for Biotechnology Information, available through http://www.ncbi.nlm.nih.gov/BLAST/).",OADS,/arxiv_data1/oa_pdf/76/5c/jam0115-1037.PMC4063339.pdf
"1953), and recently sequenced as a reference gen- ome by the NIH Human Microbiome Consortium(http://genome.jgi.doe.gov/HumanMicr/HumanMicr.info.html), was used as a reference strain and positive controlin these assays.",OADS,/arxiv_data1/oa_pdf/76/5c/jam0115-1037.PMC4063339.pdf
The genome ofthe bottlenose dolphin has been sequenced from DNAobtained from a healthy female dolphin from the NavyMarine Mammal Program (http://www.hgsc.bcm.tmc.edu/).,Non-OADS,/arxiv_data1/oa_pdf/76/5c/jam0115-1037.PMC4063339.pdf
"Institutional approval is not required and cannot be Molecular Vision  2014; 20:852-863 <http://www.molvis.org/molvis/v 20/852> Received 9 April 2012 | Accepted 17 June 2014 | Published 19 June 2014© 2014 Molecular Vision 852Reappearance of the tapetal-like reflex after prolonged dark  adaptation in a female carrier of RPGR ORF15 X-linked retinitis  pigmentosa Jesper Bregnhøj,1,2 Sermed Al-Hamdani,1,2 Birgit Sander,1,3 Michael Larsen,1,2,3 Patrik Schatz1,2,4 1Department of Ophthalmology, Glostrup Hospital, University of Copenhagen, Denmark; 2National Eye Clinic for the Visually  Impaired and Kennedy Center, Glostrup, Denmark; 3Faculty of Health Sciences, University of Copenhagen, Denmark;  4Department of Ophthalmology, Clinical Sciences, Scane County University Hospital, Lund, Sweden Purpose:  To report changes in the tapetal-like reflex in a female carrier of RPGR  ORF15 c.3395delA X-linked retinitis  pigmentosa (XLRP) between examinations at 16 and 22 years of age, and to report the observation that the tapetal-like  reflex faded due to exposure to daylight and reappeared with prolonged dark adaptation at 22 years of age.",Non-OADS,/arxiv_data1/oa_pdf/e9/73/mv-v20-852.PMC4063355.pdf
Molecular Vision  2014; 20:852-863 <http://www.molvis.org/molvis/v 20/852> © 2014 Molecular Vision  853obtained for retrospective studies under Danish law.,Non-OADS,/arxiv_data1/oa_pdf/e9/73/mv-v20-852.PMC4063355.pdf
Molecular Vision  2014; 20:852-863 <http://www.molvis.org/molvis/v 20/852> © 2014 Molecular Vision  854Table  1.,Non-OADS,/arxiv_data1/oa_pdf/e9/73/mv-v20-852.PMC4063355.pdf
"Molecular Vision  2014; 20:852-863 <http://www.molvis.org/molvis/v 20/852> © 2014 Molecular Vision  855all fundus autofluorescence measurements, the excitation  wavelength was 488 nm, and the retina field applied was 55  degrees [ 16,17].",Non-OADS,/arxiv_data1/oa_pdf/e9/73/mv-v20-852.PMC4063355.pdf
"Molecular Vision  2014; 20:852-863 <http://www.molvis.org/molvis/v 20/852> © 2014 Molecular Vision  856response, at least two similar waveforms were required, to  demonstrate reproducibility.",Non-OADS,/arxiv_data1/oa_pdf/e9/73/mv-v20-852.PMC4063355.pdf
Molecular Vision  2014; 20:852-863 <http://www.molvis.org/molvis/v 20/852> © 2014 Molecular Vision  857Table  2. full-field  ele CTrore Tino GraPhy eXamina Tion resul Ts (riGhT eye) in a female  Carrier  of rPGr orf 15 X- linked  reTiniTis PiGmen Tosa aT aGe 16 and 22 years .,Non-OADS,/arxiv_data1/oa_pdf/e9/73/mv-v20-852.PMC4063355.pdf
Molecular Vision  2014; 20:852-863 <http://www.molvis.org/molvis/v 20/852> © 2014 Molecular Vision  858temporal of the fovea.,Non-OADS,/arxiv_data1/oa_pdf/e9/73/mv-v20-852.PMC4063355.pdf
Molecular Vision  2014; 20:852-863 <http://www.molvis.org/molvis/v 20/852> © 2014 Molecular Vision  859adaptation showed that the tapetal-like reflex had reappeared  in a discrete pattern resembling that seen 6 years earlier  (Figure 2C).,Non-OADS,/arxiv_data1/oa_pdf/e9/73/mv-v20-852.PMC4063355.pdf
Molecular Vision  2014; 20:852-863 <http://www.molvis.org/molvis/v 20/852> © 2014 Molecular Vision  860 Figure 6.,Non-OADS,/arxiv_data1/oa_pdf/e9/73/mv-v20-852.PMC4063355.pdf
"Molecular Vision  2014; 20:852-863 <http://www.molvis.org/molvis/v 20/852> © 2014 Molecular Vision  861DISCUSSION Our female carrier of RPGR  XLRP presented with a tapetal- like reflex after light exposure when first examined at 16  years of age, but when she was examined at 22 years of age,  the reflex was repeatedly absent in the light-adapted state  during daylight but reappeared after prolonged dark adap - tation.",Non-OADS,/arxiv_data1/oa_pdf/e9/73/mv-v20-852.PMC4063355.pdf
Molecular Vision  2014; 20:852-863 <http://www.molvis.org/molvis/v 20/852> © 2014 Molecular Vision  862This hypothesis should clearly be examined in more detail  before any therapeutic conclusions can be drawn.,Non-OADS,/arxiv_data1/oa_pdf/e9/73/mv-v20-852.PMC4063355.pdf
Molecular Vision  2014; 20:852-863 <http://www.molvis.org/molvis/v 20/852> © 2014 Molecular Vision  86322.,Non-OADS,/arxiv_data1/oa_pdf/e9/73/mv-v20-852.PMC4063355.pdf
"METHODS Animals:  Twenty adult male Brown Norway rats (8–9 weeks- old) were obtained from Charles River Laboratories (Yoko - hama, Japan) and maintained under a 12 h:12 h light-dark Molecular Vision  2014; 20:864-871 <http://www.molvis.org/molvis/v 20/864> Received 8 December 2013 | Accepted 17 July 2014 | Published 19 June 2014© 2014 Molecular Vision 864Mechanism for laser-induced neovascularization in rat choroid:  Accumulation of integrin α chain-positive cells and their ligands Takeshi Nakajima,1 Masayuki Hirata,2,3 Thomas R. Shearer,3 Mitsuyoshi Azuma1,2,3 1Senju Laboratory of Ocular Sciences, Senju Pharmaceutical Co., Ltd., Kobe, Japan; 2Senju Laboratory of Ocular Sciences, Senju  Pharmaceutical Co., Ltd.,Portland, OR; 3Department of Integrative Biosciences, Oregon Health & Science University, Portland,  OR Purpose:  Inhibitors binding to integrins α5 and αv are antiangiogenic in models of choroidal neovascularization (CNV).",Non-OADS,/arxiv_data1/oa_pdf/f5/b4/mv-v20-864.PMC4063356.pdf
Molecular Vision  2014; 20:864-871 <http://www.molvis.org/molvis/v 20/864> © 2014 Molecular Vision  865cycle.,Non-OADS,/arxiv_data1/oa_pdf/f5/b4/mv-v20-864.PMC4063356.pdf
"Molecular Vision  2014; 20:864-871 <http://www.molvis.org/molvis/v 20/864> © 2014 Molecular Vision  866Denmark) for 30 min and incubated overnight at 4 °C with  primary antibody diluted with Can Get Signal Solution B  (NKB-601, TOYOBO, Osaka, Japan) containing 10% goat  serum.",Non-OADS,/arxiv_data1/oa_pdf/f5/b4/mv-v20-864.PMC4063356.pdf
Molecular Vision  2014; 20:864-871 <http://www.molvis.org/molvis/v 20/864> © 2014 Molecular Vision  867cells stained 1 day after laser injury (day 1).,Non-OADS,/arxiv_data1/oa_pdf/f5/b4/mv-v20-864.PMC4063356.pdf
Molecular Vision  2014; 20:864-871 <http://www.molvis.org/molvis/v 20/864> © 2014 Molecular Vision  868 Figure 4.,Non-OADS,/arxiv_data1/oa_pdf/f5/b4/mv-v20-864.PMC4063356.pdf
Molecular Vision  2014; 20:864-871 <http://www.molvis.org/molvis/v 20/864> © 2014 Molecular Vision  869influence the accumulation of integrin α5- and αv-positive  cells during retinal neovascularization.,Non-OADS,/arxiv_data1/oa_pdf/f5/b4/mv-v20-864.PMC4063356.pdf
"Molecular Vision  2014; 20:864-871 <http://www.molvis.org/molvis/v 20/864> © 2014 Molecular Vision  870ACKNOWLEDGMENTS  Authors’ Disclosure Statement: These studies were  completely funded by Senju Pharmaceutical Co., Ltd. Dr.  Shearer is a paid consultant for Senju Pharmaceutical Co.,  Ltd., a company that may have a commercial interest in the  results of this research and technology.",Non-OADS,/arxiv_data1/oa_pdf/f5/b4/mv-v20-864.PMC4063356.pdf
Molecular Vision  2014; 20:864-871 <http://www.molvis.org/molvis/v 20/864> © 2014 Molecular Vision  87125.,Non-OADS,/arxiv_data1/oa_pdf/f5/b4/mv-v20-864.PMC4063356.pdf
"U1 snRNP first  recognizes the 5′ splice site, and U2 binds to the branch point;  then the U4/U6.U5 tri-snRNP complex is recruited, and  finally U1 and U4 are released, leading to catalytic activa - tion [ 5].Molecular Vision  2014; 20:843-851 <http://www.molvis.org/molvis/v 20/843> Received 27 January 2014 | Accepted 16 June 2014 | Published 18 June 2014© 2014 Molecular Vision 843Mutational screening of splicing factor genes in cases with  autosomal dominant retinitis pigmentosa Paola Benaglio,1 Patricia Fernandez San Jose,2,3 Almudena Avila-Fernandez,2,3 Giulia Ascari,1 Shyana Harper,4  Gaël Manes,5 Carmen Ayuso,2,3 Christian Hamel,5 Eliot L. Berson,4 Carlo Rivolta1 1Department of Medical Genetics, University of Lausanne, Lausanne, Switzerland; 2Department of Genetics, Instituto de  Investigación Sanitaria-Fundación Jiménez Díaz University Hospital (IIS-FJD, UAM), Madrid, Spain; 3Centro de Investigación  Biomédica en Red de Enfermedades Raras (CIBERER), ISCIII, Madrid, Spain; 4The Berman-Gund Laboratory for the Study  of Retinal Degenerations, Harvard Medical School, Massachusetts Eye and Ear, Boston, MA; 5INSERM U1051, Institut des  Neurosciences de Montpellier, Hôpital Saint Eloi, Montpellier, France Purpose:  Mutations in genes encoding proteins from the tri-snRNP complex of the spliceosome account for more than  12% of cases of autosomal dominant retinitis pigmentosa (adRP).",Non-OADS,/arxiv_data1/oa_pdf/4b/49/mv-v20-843.PMC4063357.pdf
"Molecular Vision  2014; 20:843-851 <http://www.molvis.org/molvis/v 20/843> © 2014 Molecular Vision  844To date, six splicing factors genes have been found to  be mutated in patients with adRP: PRPF8  (RP13; ID: 10594,  OMIM 607300 ) [6], PRPF31  (RP 1 1 ;  ID :  2 6 1 2 1 ,  O MIM   606419 ) [7], PRPF3  (RP18; ID: 9129, OMIM 607301 ) [8],  PAP-1  (RP9; ID: 6100, OMIM 607331 ) [9], SNRNP200   (RP33; ID: 23020, OMIM 601664 ) [10,11], and PRPF6  (ID:  24148, OMIM 613979 ) [12].",Non-OADS,/arxiv_data1/oa_pdf/4b/49/mv-v20-843.PMC4063357.pdf
"Molecular Vision  2014; 20:843-851 <http://www.molvis.org/molvis/v 20/843> © 2014 Molecular Vision  845(LR-PCR) followed by next-generation sequencing (NGS),  using Illumina instruments (San Diego, CA).",Non-OADS,/arxiv_data1/oa_pdf/4b/49/mv-v20-843.PMC4063357.pdf
Molecular Vision  2014; 20:843-851 <http://www.molvis.org/molvis/v 20/843> © 2014 Molecular Vision  846present at different frequencies in the analyzed cohort.,Non-OADS,/arxiv_data1/oa_pdf/4b/49/mv-v20-843.PMC4063357.pdf
Molecular Vision  2014; 20:843-851 <http://www.molvis.org/molvis/v 20/843> © 2014 Molecular Vision  847Of the three missense changes found in the EFTUD2   gene two were novel and present in single individuals  (p.Arg220Cys and p.Ile80Leu) while one (p.Thr272Ala) was  a rare variant found in two heterozygote control African  samples from Exome Variant Server ( rs150633454 ; Table  2).,Non-OADS,/arxiv_data1/oa_pdf/4b/49/mv-v20-843.PMC4063357.pdf
"Molecular Vision  2014; 20:843-851 <http://www.molvis.org/molvis/v 20/843> © 2014 Molecular Vision  848reading frame (uORF), the effect of which could be to reduce  the rate of translation from the downstream, canonical ATG  [30].",Non-OADS,/arxiv_data1/oa_pdf/4b/49/mv-v20-843.PMC4063357.pdf
Molecular Vision  2014; 20:843-851 <http://www.molvis.org/molvis/v 20/843> © 2014 Molecular Vision  849APPENDIX 1.,Non-OADS,/arxiv_data1/oa_pdf/4b/49/mv-v20-843.PMC4063357.pdf
"Molecular Vision  2014; 20:843-851 <http://www.molvis.org/molvis/v 20/843> © 2014 Molecular Vision  850CT, Smith RJH, Stephens K, editors.",Non-OADS,/arxiv_data1/oa_pdf/4b/49/mv-v20-843.PMC4063357.pdf
Molecular Vision  2014; 20:843-851 <http://www.molvis.org/molvis/v 20/843> © 2014 Molecular Vision  85138.,Non-OADS,/arxiv_data1/oa_pdf/4b/49/mv-v20-843.PMC4063357.pdf
[cited 2003]; Available from: URL:  http://www.eu- seniorunion.info/en/activities/projects/Leipzig- Life2years_disabled-enw.pdf /  2.,Non-OADS,/arxiv_data1/oa_pdf/3a/1b/ARYA-10-065.PMC4063512.pdf
[cited 2007 Nov 29]; Available from: URL:   http://sportsmedicine.about.com/od/glossary/g/Over load_def.htm /  8.,Non-OADS,/arxiv_data1/oa_pdf/3a/1b/ARYA-10-065.PMC4063512.pdf
"Journal of Visualized Experiments www.jove.com Copyright © 2014  Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported LicenseJanuary 2014 |  83  | e3298 | Page 1 of 5Video Article Method for Simultaneous fMRI/EEG Data Collection during a Focused Attention Suggestion for Differential Thermal Sensation Pamela K. Douglas1,2, Maureen Pisani2, Rory Reid1, Austin Head2, Edward Lau2, Ebrahim Mirakhor3, Jennifer Bramen2, Billi Gordon2, Ariana Anderson2, Wesley T. Kerr2, Chajoon Cheong4, Mark S. Cohen1,2 1Neuropsychiatric Institute, University of California, Los Angeles 2Laboratory of Neuroimaging Technology, University of California, Los Angeles 3Yale School of Medicine 4Korean Basic Science Institute Correspondence to: Pamela K. Douglas at PDouglas@mednet.ucla.edu URL: http://www.jove.com/video/3298 DOI: doi:10.3791/3298 Keywords: Behavior, Issue 83, hypnosis, EEG, fMRI, MRI, cold glove, MRI compatible, temperature sensor Date Published: 1/5/2014 Citation: Douglas, P.K., Pisani, M., Reid, R., Head, A., Lau, E., Mirakhor, E., Bramen, J., Gordon, B., Anderson, A., Kerr, W.T., Cheong, C., Cohen, M.S.",Non-OADS,/arxiv_data1/oa_pdf/3f/cc/jove-83-3298.PMC4063545.pdf
"Video Link The video component of this article can be found at http://www.jove.com/video/3298/ Introduction Since its inception, there has been considerable controversy as to what hypnosis is, and how exactly measurable physiologic changes in susceptible individuals are produced.",Non-OADS,/arxiv_data1/oa_pdf/3f/cc/jove-83-3298.PMC4063545.pdf
"B. Wilke3, Mauro T. Marrelli3, Jair F. Virginio4, Luke Alphey1,5, Margareth L. Capurro2,6 1Oxitec Ltd 2Departamento de Parasitologia, Instituto de Ciências Biomédicas, Universidade de São Paulo 3Departamento de Epidemiologia, Universidade de São Paulo 4Moscamed Brasil 5Deptartment of Zoology, University of Oxford 6Instituto Nacional de Ciência e Tecnologia em Entomologia Molecular (INCT-EM) Correspondence to: Margareth L. Capurro at mcapurro@icb.usp.br URL: http://www.jove.com/video/3579 DOI: doi:10.3791/3579 Keywords: Basic Protocol, Issue 83, Aedes aegypti , mass rearing, population suppression, transgenic, insect, mosquito, dengue Date Published: 1/4/2014 Citation: Carvalho, D.O., Nimmo, D., Naish, N., McKemey, A.R., Gray, P., Wilke, A.B.B., Marrelli, M.T., Virginio, J.F., Alphey, L., Capurro, M.L.",Non-OADS,/arxiv_data1/oa_pdf/9e/b7/jove-83-3579.PMC4063546.pdf
Video Link The video component of this article can be found at http://www.jove.com/video/3579/ Introduction Mosquitoes transmit many pathogens that can cause a range of diseases in humans and controlling these mosquitoes has been an ongoing battle for centuries.,Non-OADS,/arxiv_data1/oa_pdf/9e/b7/jove-83-3579.PMC4063546.pdf
"Prince3, Alfred E. Chang1, Max S. Wicha2 1Department of Surgery, University of Michigan 2Department of Internal Medicine, University of Michigan 3Department of Otolaryngology, University of Michigan Correspondence to: Qiao Li at qiaoli@med.umich.edu , Max S. Wicha at mwicha@umich.edu URL: http://www.jove.com/video/50561 DOI: doi:10.3791/50561 Keywords: Cancer Biology, Issue 83, Cancer stem cell (CSC), Dendritic cells (DC), Vaccine, Cancer immunotherapy, antitumor immunity, aldehyde dehydrogenase Date Published: 1/6/2014 Citation: Li, Q., Lu, L., Tao, H., Xue, C., Teitz-Tennenbaum, S., Owen, J.H., Moyer, J.S., Prince, M.E., Chang, A.E., Wicha, M.S.",Non-OADS,/arxiv_data1/oa_pdf/42/3b/jove-83-50561.PMC4063547.pdf
"Video Link The video component of this article can be found at http://www.jove.com/video/50561/ Introduction Cancer stem cells are relatively resistant to conventional chemotherapy and radiotherapy1,2.",Non-OADS,/arxiv_data1/oa_pdf/42/3b/jove-83-50561.PMC4063547.pdf
"A. Vleeshouwers at vivianne.vleeshouwers@wur.nl URL: http://www.jove.com/video/50971 DOI: doi:10.3791/50971 Keywords: Plant Biology, Issue 83, Genetics, Bioengineering, Plants, Genetically Modified, DNA, Plant Immunity, Plant Diseases, Genes, Genome, Plant Pathology, Effectoromics, Agroinfiltration, PVX agroinfection, potato, Nicotiana benthamiana , high-throughput, functional genomics Date Published: 1/3/2014 Citation: Du, J., Rietman, H., Vleeshouwers, V.G.A.A.",Non-OADS,/arxiv_data1/oa_pdf/7d/80/jove-83-50971.PMC4063549.pdf
"Video Link The video component of this article can be found at http://www.jove.com/video/50971/ Introduction Effectoromics, a high-throughput functional genomics approach has recently emerged as a powerful tool to identify resistance (R) genes in crop plants and matching avirulence ( Avr) genes of pathogens1-4.",Non-OADS,/arxiv_data1/oa_pdf/7d/80/jove-83-50971.PMC4063549.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d7/30/dmu008.PMC4063701.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/44/52/mder-7-205.PMC4063798.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpMedical Devices: Evidence and Research 2014:7 205–209Medical Devices: Evidence and Research Dove press submit your manuscript | www.dovepress.co m Dove press  205REviEwopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/MDER.S4336 9Barriers to medical device innovation Jacob Bergsland Ole Jakob Elle Erik Fosse The intervention Centre, Oslo   University Hospital, institute of   Clinical Medicine, University of   Oslo, Oslo, Norway Correspondence: Jacob Bergsland   The intervention Centre, Oslo University  Hospital, Sognsvannsveien 20, 0424 Oslo,  Norway   T el +47 9303 1292   Fax +47 2307 0110   Email jacob.bergsland@ous-hf.n oAbstract:  The US Food and Drug Administration (FDA) has defined a medical device as a  health care product that does not achieve it’ s purpose by chemical action or by being  metabolized.",Non-OADS,/arxiv_data1/oa_pdf/44/52/mder-7-205.PMC4063798.pdf
Submit your manuscript here:  http://www.dovepress.com/medical-devices-evidence-and-research-journa l Medical Devices: Evidence and Research 2014:7submit your manuscript | www.dovepress.co m Dove press Dove press Dove pres s 209Barriers to medical device innovation  19.,Non-OADS,/arxiv_data1/oa_pdf/44/52/mder-7-205.PMC4063798.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/40/6a/tcrm-10-423.PMC4063799.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpTherapeutics and Clinical Risk Management 2014:10 423–436Therapeutics and Clinical Risk Management Dove press submit your manuscript | www.dovepress.co m Dove press  423Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/TCRM.S4906 3New orally active anticoagulant agents   for the prevention and treatment of venous   thromboembolism in cancer patients Grigoris T Gerotziafas1,2 isabelle Mahé3 ismail elalamy1,2 1Service d’Hématologie Biologique,   Hôpital T enon, Hô pitaux  Universitaires est Parisien Assistance  Publique Hôpitaux de Paris, Paris,   France; 2eR2UPMC, Facult é de  Médecine Pierre et Marie Curie,   Université Paris vi, Paris, France;   3Service de M édecine interne, Hôpital  Louis Mourier, Université Paris 7,   Assistance Publique Hôpitaux de  Paris, eA ReM eS, Université Paris  Diderot, Sorbonne Paris Cité, Paris,   France Correspondence: Grigoris T Gerotziafas   Service d’Hématologie Biologique,   Hôpital Tenon, 4, rue de la Chine,   75020, Paris, Cedex 20, France   Tel +33 1 5601 8063   Fax +33 1 5601 6044   email grigoris.gerotziafas@tnn.aphp.f rAbstract:  Patients with cancer have a 6–7-fold higher risk of venous thromboembolism (VTE)  as compared with non-cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/40/6a/tcrm-10-423.PMC4063799.pdf
"Therapeutics and Clinical Risk Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/therapeutics-and-clinical-risk-management-journa lTherapeutics and Clinical Risk Management is an international, peer- reviewed journal of clinical therapeutics and risk management, focusing  on concise rapid reporting of clinical studies in all therapeutic areas,  outcomes, safety, and programs for the effective, safe, and sustained  use of medicines.",Non-OADS,/arxiv_data1/oa_pdf/40/6a/tcrm-10-423.PMC4063799.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/40/6a/tcrm-10-423.PMC4063799.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/1c/45/ott-7-1033.PMC4063800.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpOncoTargets and Therapy 2014:7 1033–1042OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1033Original rESEarCHopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S6314 5gemcitabine resistance in breast cancer cells   regulated by Pi3K/aKT -mediated cellular   proliferation exerts negative feedback   via the MEK/MaPK and mTOr pathways Xiao li Yang Feng Juan lin Ya Jie guo Zhi Min Shao Zhou luo Ou Key laboratory of Breast Cancer   in Shanghai, Breast Cancer institute,    Cancer Hospital, Department of   Oncology, Shanghai Medical College,    Fudan University, Shanghai, People’s   republic of China Correspondence: Zhou luo Ou   Breast Cancer institute, Cancer Hospital,   Fudan University, Shanghai  200032,   People’s republic of China   T el +86 21 64175590  ext 8 3422  Fax +86 21 64174774   Email zlou@shmu.edu.c nAbstract:  Chemoresistance is a major cause of cancer treatment failure and leads to a  reduction in the survival rate of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/1c/45/ott-7-1033.PMC4063800.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open access  journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/1c/45/ott-7-1033.PMC4063800.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/1c/45/ott-7-1033.PMC4063800.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/21/0d/ndt-10-1081.PMC4063801.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpNeuropsychiatric Disease and Treatment 2014:10 1081–1092Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1081OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S6248 7cluster-randomized, controlled 12-month trial to  evaluate the effect of a parental psychoeducation  program on medication persistence in children  with attention-deficit/hyperactivity disorder correspondence: alonso Montoya   Medical Neurosciences, lilly research  laboratories, eli lilly canada inc,  3650 Danforth avenue, T oronto,   ON, canada   T el +1 416 693 3405   Fax +1 416 699 7352   email montoya_alonso@lilly.co malonso Montoya1 amaia hervás2 Joaquín Fuentes3 esther cardo4 Pepa Polavieja5 Javier Quintero6 rosemary Tannock7 1Medical Neurosciences, lilly research  laboratories canada, T oronto, ON,   canada; 2child and adolescent Mental  health Unit, hospital Universitari  Mutua de Terrassa, and Developmental  Disorders Unit, hospital sant Joan de  Déu, Barcelona, 3child and adolescent  Psychiatry Unit, Policlinica gipuzkoa,   san sebastian, 4Neuropediatric Unit,   hospital son llatzer, University  of the Balearic islands, Palma de  Mallorca, 5Department of clinical  research, lilly research laboratories  spain, alcobendas, 6Department of  Psychiatry, hospital Universitario  infanta leonor, Madrid, spain; 7applied  Psychology and human Development,   and Neurosciences and Mental health  research Program, The hospital for  sick children, University of T oronto,   T oronto, ON, canadaBackground:  This multicenter, cluster-randomized, nonblinded study evaluated the effect  of parental psychoeducation on medication persistence among children and adolescents with  newly diagnosed attention-deficit/hyperactivity disorder (ADHD).",Non-OADS,/arxiv_data1/oa_pdf/21/0d/ndt-10-1081.PMC4063801.pdf
"Keywords:  psychoeducation, medication persistence, attention-deficit/hyperactivity disorder,  adjunctive psychoeducation, parents Introduction Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder  characterized by inappropriate inattention, hyperactivity, and impulsivity,1 and  is estimated to occur in about 6.5% of school-aged children and 2.5% of adoles - cents.2 ADHD usually manifests during childhood and is associated with poor  self-esteem, reduced social functioning,3 and an increased risk for long-term mor - bidity, including antisocial, mood, anxiety and/or addictive disorders,4 and mor - tality.5  Sufferers may also present with symptoms such as nocturnal enuresis6 and  altered sleep patterns,7 which are commonly associated with sleep disorders (eg,  sleep-related breathing disorder and obstructive sleep apnea syndrome)8 and bor - derline intellectual functioning.9Journal name: Neuropsychiatric Disease and Treatment Journal Designation: Original Research Y ear: 2014 Volume: 10 Running head verso: Montoya et al Running head recto: Psychoeducation and medication persistence in ADHD DOI: http://dx.doi.org/10.2147/NDT.S62487",Non-OADS,/arxiv_data1/oa_pdf/21/0d/ndt-10-1081.PMC4063801.pdf
Available from: http://www.nice.org.,Non-OADS,/arxiv_data1/oa_pdf/21/0d/ndt-10-1081.PMC4063801.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/21/0d/ndt-10-1081.PMC4063801.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.Dove pres s Neuropsychiatric Disease and Treatment 2014:10submit your manuscript | www.dovepress.co m Dove press Dove press 1092Montoya et al 20.,Non-OADS,/arxiv_data1/oa_pdf/21/0d/ndt-10-1081.PMC4063801.pdf
Available from:  http://www.nice.org.uk/nicemedia/pdf/ta098guidance.pdf.,Non-OADS,/arxiv_data1/oa_pdf/21/0d/ndt-10-1081.PMC4063801.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/35/af/ijwh-6-613.PMC4063802.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Women’s Health 2014:6 613–621International Journal of Women’s Health Dove press submit your manuscript | www.dovepress.co m Dove press  613RevIeWopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/IJWH.S4852 7Optimal management of subfertility   in polycystic ovary syndrome Joshua J Berger G Wright Bates Jr University of Alabama at Birmingham,   Department of Obstetrics and  Gynecology, Division of Reproductive  endocrinology and Infertility,   Birmingham, AL, USA Correspondence: G Wright Bates Jr   Department of Obstetrics and   Gynecology, Division of Reproductive   endocrinology and Infertility, University  of Alabama at Birmingham,   619 19th Street South, Room  10390,   Women and Infants’ Center, Birmingham,  AL 35249-7333, USA   Tel +1 205 934 1030  Fax +1 205 975 5732  email gbates@uabmc.ed uAbstract:  The purpose of this paper is to provide a stepwise approach to treating the infertility/ subfertility associated with polycystic ovary syndrome.",Non-OADS,/arxiv_data1/oa_pdf/35/af/ijwh-6-613.PMC4063802.pdf
"International Journal of Women’s Health Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-womens-health-journa lThe International Journal of Women’ s Health is an international, peer- reviewed open-access journal publishing original research, reports,  editorials, reviews and commentaries on all aspects of women’s  healthcare including gynecology, obstetrics, and breast cancer.",Non-OADS,/arxiv_data1/oa_pdf/35/af/ijwh-6-613.PMC4063802.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes  from published authors.,Non-OADS,/arxiv_data1/oa_pdf/35/af/ijwh-6-613.PMC4063802.pdf
"Correspondence to: Byeonghwa Jeon; Email: bjeon@ualberta.ca Submitted: 03/26/2014; Accepted: 03/27/2014; Published Online: 04/04/2014 http://dx.doi.org/10.4161/viru.28690Comment on: Malde A, Gangaiah D, Chandrashekhar K, Pina-Mimbela R, Torrelles JB, Rajashekara G. Functional characterization of exopolyphosphatase/guano - sine pentaphosphate phosphohydrolase (PPX/GPPA) of Campylobacter jejuni .",Non-OADS,/arxiv_data1/oa_pdf/d0/24/viru-5-449.PMC4063803.pdf
"Virulence 2014; 5:521-33; PMID:24569519; http://dx.doi.org/10.4161/viru.28311A tangle of poly-phosphate in Campylobacter Byeonghwa Jeon School of Public Health; University of a lberta; Edmonton, a B Canada Keywords:  Campylobacter jejuni , ppGpp, PPX, GPPA, poly-P, stress response",Non-OADS,/arxiv_data1/oa_pdf/d0/24/viru-5-449.PMC4063803.pdf
Trends  Biochem Sci 2008; 33:284-90; PMID:18487048 ;  http://dx.doi.org/10.1016/j.tibs.2008.04.005 2.,OADS,/arxiv_data1/oa_pdf/d0/24/viru-5-449.PMC4063803.pdf
Clin Microbiol Infect 2004; 10:868-76;  PMID :15373879 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d0/24/viru-5-449.PMC4063803.pdf
J Bacteriol 2007; 189:8099- 108; PMID:17827292 ; http://dx.doi.org/10.1128/ JB.01037-074.,Non-OADS,/arxiv_data1/oa_pdf/d0/24/viru-5-449.PMC4063803.pdf
PLoS One  2010; 5:e12142;  PMID:20808906 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d0/24/viru-5-449.PMC4063803.pdf
Annu Rev Microbiol 2008; 62:35-51; PMID:18454629 ; http://dx.doi.org/10.1146/ annurev.micro.62.081307.1629036.,Non-OADS,/arxiv_data1/oa_pdf/d0/24/viru-5-449.PMC4063803.pdf
Mol Microbiol 2005;  56:8-27;  PMID:15773975 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d0/24/viru-5-449.PMC4063803.pdf
Virulence 2014; 5:521- 33; PMID:24569519 ; http://dx.doi.org/10.4161/ viru.28311,Non-OADS,/arxiv_data1/oa_pdf/d0/24/viru-5-449.PMC4063803.pdf
"The presence of MprF (aa-PG synthase) in L. monocytogenes   did confer resistance to two aminoglycosides, tobramycin and  *Correspondence to: Howard Goldfine; Email: GOLDFINH@mail.med.upenn.edu Submitted: 03/21/2014; Accepted: 03/25/2014; Published Online: 04/04/2014http://dx.doi.org/10.4161/viru.28662Comment on: Dare K, Shepherd J, Roy H, Seveau S, Ibba M. LysPGS formation in Listeria monocytogenes  has broad roles in maintaining mem - brane integrity beyond antimicrobial peptide resistance.",Non-OADS,/arxiv_data1/oa_pdf/db/00/viru-5-451.PMC4063804.pdf
"Virulence 2014; 5:534-46; PMID:24603093; http://dx.doi.org/10.4161/viru.28359Charge counter charge Bacterial response to antimicrobial cationic peptides   and more Howard Goldfine department of Microbiology; Perelman School of Medicine; University of Pennsylvania; Philadelphia, P a US a Keywords:  Listeria monocytogenes , aminoacyl-phosphatidylglycerol, antimicrobial peptides, defensins, membranes, phospholipids,  antibiotics",Non-OADS,/arxiv_data1/oa_pdf/db/00/viru-5-451.PMC4063804.pdf
Biochim Biophys Acta 1965; 106:564-76;  PMID:4956500 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/db/00/viru-5-451.PMC4063804.pdf
Biochim Biophys Acta  1963; 70:211-3;  PMID:13955094 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/db/00/viru-5-451.PMC4063804.pdf
Nature 1962; 196:136-8; http://dx.doi.org/10.1038/196136a0 5.,Non-OADS,/arxiv_data1/oa_pdf/db/00/viru-5-451.PMC4063804.pdf
Biochemistry  1967; 6:2307-12;  PMID:6049461 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/db/00/viru-5-451.PMC4063804.pdf
J Membr Biol 1970; 2:41- 58; PMID:24174136 ; http://dx.doi.org/10.1007/ BF01869849 8.,Non-OADS,/arxiv_data1/oa_pdf/db/00/viru-5-451.PMC4063804.pdf
Nat  Rev Microbiol 2006; 4:529-36; PMID:16778838 ;  http://dx.doi.org/10.1038/nrmicro144110.,OADS,/arxiv_data1/oa_pdf/db/00/viru-5-451.PMC4063804.pdf
IUBMB Life 2009; 61:940-53; PMID:19787708 ;  http://dx.doi.org/10.1002/iub.240 11.,Non-OADS,/arxiv_data1/oa_pdf/db/00/viru-5-451.PMC4063804.pdf
J Biol Chem 2009; 284:29677-83;  PMID:19734140 ; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/db/00/viru-5-451.PMC4063804.pdf
Mol Microbiol 2006;  62:1325-39;  PMID:17042784 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/db/00/viru-5-451.PMC4063804.pdf
Virulence 2014; 5:534-46; PMID:24603093 ; http://dx.doi.org/10.4161/ viru.2835917.,Non-OADS,/arxiv_data1/oa_pdf/db/00/viru-5-451.PMC4063804.pdf
Infect Immun  2005; 73:894-904;  PMID :15664931 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/db/00/viru-5-451.PMC4063804.pdf
Mol Microbiol  2009; 74:421-35;  PMID:19796338 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/db/00/viru-5-451.PMC4063804.pdf
Mol Microbiol  2005; 57:1367-80;  PMID:16102006 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/db/00/viru-5-451.PMC4063804.pdf
"Amoebas are environmental predators, and for  *Correspondence to: Oscar Zaragoza; Email: ozaragoza@isciii.es Submitted: 03/28/2014; Accepted: 04/03/2014; Published Online: 04/09/2014http://dx.doi.org/10.4161/viru.28775Comment on: Freitak D, Schmidtberg H, Dickel F, Lochnit G, Vogel H, Vilcinskas A.",Non-OADS,/arxiv_data1/oa_pdf/9c/6b/viru-5-454.PMC4063805.pdf
"Virulence 2014; 5:547-54; PMID: 24603099; http://dx.doi.org/10.4161/viru.28367Expanding the use of alternative models   to investigate novel aspects of immunity   to microbial pathogens Nuria t revijano-Contador and o scar Zaragoza* Mycology r eference Laboratory; National Centre for Microbiology; i nstituto de Salud Carlos iii ; Madrid, Spain Keywords:  Galleria mellonella , offspring immunity, microbial virulence, alternative hosts, innate immunity",Non-OADS,/arxiv_data1/oa_pdf/9c/6b/viru-5-454.PMC4063805.pdf
Virulence 2014; 5:547-54; PMID:24603099 ;  http://dx.doi.org/10.4161/viru.28367 2.,Non-OADS,/arxiv_data1/oa_pdf/9c/6b/viru-5-454.PMC4063805.pdf
Virulence  2013; 4:271-2;  PMID:23552811 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9c/6b/viru-5-454.PMC4063805.pdf
Avian Dis 2009; 53:608-12;  PMID:20095164 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9c/6b/viru-5-454.PMC4063805.pdf
Methods Mol Biol 2008; 454:109-17;  PMID:19057881 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/9c/6b/viru-5-454.PMC4063805.pdf
Infect Immun 2010; 78:2995-3006;  PMID:20421382 ; http://dx.doi.org/10.1128/ IAI.00268-10 7.,Non-OADS,/arxiv_data1/oa_pdf/9c/6b/viru-5-454.PMC4063805.pdf
J Med Food 2002; 5:159-69; PMID:12495588 ;  http://dx.doi.org/10.1089/10966200260398198 8.,Non-OADS,/arxiv_data1/oa_pdf/9c/6b/viru-5-454.PMC4063805.pdf
BMC Microbiol 2008; 8:12;  PMID:18215272 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/9c/6b/viru-5-454.PMC4063805.pdf
Avian Dis  2000; 44:318-24;  PMID:10879912 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9c/6b/viru-5-454.PMC4063805.pdf
Cold  Spring Harb Symp Quant Biol 2014; (Forthcoming)  PMID:24643219 ; http://dx.doi.org/10.1101/ sqb.2013.78.02328311.,OADS,/arxiv_data1/oa_pdf/9c/6b/viru-5-454.PMC4063805.pdf
Curr  Drug Targets 2011; 12:1000-17; PMID:21366518 ;  http://dx.doi.org/10.2174/138945011795677809 12.,Non-OADS,/arxiv_data1/oa_pdf/9c/6b/viru-5-454.PMC4063805.pdf
"Fish Shellfish  Immunol 2008; 25:341-50;  PMID:18640057 ;  http://dx.doi.org/10.1016/j.fsi.2008.05.005 13. van der Sar AM, Appelmelk BJ, Vandenbroucke- Grauls CM, Bitter W. A star with stripes: zebrafish as  an infection model.",OADS,/arxiv_data1/oa_pdf/9c/6b/viru-5-454.PMC4063805.pdf
Trends Microbiol 2004; 12:451- 7; PMID :15381194 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/9c/6b/viru-5-454.PMC4063805.pdf
PLoS Pathog  2013; 9:e1003634;  PMID:24098114 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9c/6b/viru-5-454.PMC4063805.pdf
Int J Med Microbiol 2002; 292:267-75; PMID:12398217 ;  http://dx.doi.org/10.1078/1438-4221-00209 16.,OADS,/arxiv_data1/oa_pdf/9c/6b/viru-5-454.PMC4063805.pdf
Adv Exp Med Biol  2012; 710:1-10;  PMID:22127880 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/9c/6b/viru-5-454.PMC4063805.pdf
Clin Microbiol Rev 2004; 17:413- 33; PMID:15084508 ; http://dx.doi.org/10.1128/ CMR.17.2.413-433.2004 19.,Non-OADS,/arxiv_data1/oa_pdf/9c/6b/viru-5-454.PMC4063805.pdf
Appl Environ  Microbiol 2012; 78:2075-81; PMID:22286994 ;  http://dx.doi.org/10.1128/AEM.07486-11 20.,Non-OADS,/arxiv_data1/oa_pdf/9c/6b/viru-5-454.PMC4063805.pdf
Nat Rev Immunol  2010; 10:47-58;  PMID:20029447 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9c/6b/viru-5-454.PMC4063805.pdf
Dis Model Mech  2011; 4:300-4;  PMID:21504910 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/9c/6b/viru-5-454.PMC4063805.pdf
Open Biol 2012; 2:120075;  PMID:22724070 ; http://dx.doi.org/10.1098/ rsob.120075 24.,OADS,/arxiv_data1/oa_pdf/9c/6b/viru-5-454.PMC4063805.pdf
Cell  1996; 86:973-83;  PMID:8808632 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/9c/6b/viru-5-454.PMC4063805.pdf
Adv Genet  2013; 83:71-97;  PMID:23890212 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/9c/6b/viru-5-454.PMC4063805.pdf
FEMS Immunol Med Microbiol 2000; 27:163-9;  PMID:10640612 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/9c/6b/viru-5-454.PMC4063805.pdf
Appl  Environ Microbiol 2010; 76:310-7; PMID:19897755 ;  http://dx.doi.org/10.1128/AEM.01301-09 28.,OADS,/arxiv_data1/oa_pdf/9c/6b/viru-5-454.PMC4063805.pdf
Virulence 2013; 4:419-28; PMID:23652836 ;  http://dx.doi.org/10.4161/viru.24930 29.,Non-OADS,/arxiv_data1/oa_pdf/9c/6b/viru-5-454.PMC4063805.pdf
Virulence 2013; 4:324- 32; PMID:23348912 ; http://dx.doi.org/10.4161/ viru.23629,Non-OADS,/arxiv_data1/oa_pdf/9c/6b/viru-5-454.PMC4063805.pdf
"When challenged with primary human macro - phages, a higher rate of phagosome–lysosome colocalization was  Correspondence to: Oliver Bader; Email: obader@gwdg.de Submitted: 04/18/2014; Accepted: 04/21/2014; Published Online: 04/23/2014http://dx.doi.org/10.4161/viru.28955Comment on: Tóth A, Németh T, Csonka K, Horváth P , Vágvölgyi C, Vizler C, Nosanchuk JD, Gácser A. Secreted Candida parapsilosis  lipase modulates the immune  response of primary human macrophages.",Non-OADS,/arxiv_data1/oa_pdf/25/de/viru-5-457.PMC4063806.pdf
"Virulence 2014; 5:555-62; PMID:24626151; http://dx.doi.org/10.4161/viru.28509Looking into the virulence of Candida parapsilosis A diagnostic perspective oliver Bader institute for Medical Microbiology; University Medical Center Göttingen; Göttingen, Germany Keywords:  Candida parapsilosis , yeast infections, macrophages, lipase",Non-OADS,/arxiv_data1/oa_pdf/25/de/viru-5-457.PMC4063806.pdf
Proteomics 2013; 13:788-99;  PMID:23281257 ;  http://dx.doi.org/10.1002/pmic.201200468 2.,OADS,/arxiv_data1/oa_pdf/25/de/viru-5-457.PMC4063806.pdf
PLoS One 2011; 6:e25712;  PMID:22022438 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/25/de/viru-5-457.PMC4063806.pdf
Diagn Microbiol Infect Dis  2011; 71:304-8;  PMID:21855250 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/25/de/viru-5-457.PMC4063806.pdf
Eur J Clin Microbiol Infect Dis 2012; 31:67- 71; PMID :21547602 ; http://dx.doi.org/10.1007/ s10096-011-1277-z 6.,Non-OADS,/arxiv_data1/oa_pdf/25/de/viru-5-457.PMC4063806.pdf
J Clin Microbiol 2008; 46:3237- 42; PMID:18701668 ; http://dx.doi.org/10.1128/ JCM.01451-087.,Non-OADS,/arxiv_data1/oa_pdf/25/de/viru-5-457.PMC4063806.pdf
J Clin Microbiol 2013; 51:117- 24; PMID:23100350 ; http://dx.doi.org/10.1128/ JCM.01686-12 8.,OADS,/arxiv_data1/oa_pdf/25/de/viru-5-457.PMC4063806.pdf
Mycoses 2005; 48:365-77; PMID:16262871 ;  http://dx.doi.org/10.1111/j.1439-0507.2005.01165.x 10.,OADS,/arxiv_data1/oa_pdf/25/de/viru-5-457.PMC4063806.pdf
Microbiology 2004; 150:3363- 82; PMID :15470115 ; http://dx.doi.org/10.1099/ mic.0.27221-0 11.,Non-OADS,/arxiv_data1/oa_pdf/25/de/viru-5-457.PMC4063806.pdf
Genome Res 2009; 19:2231-44; PMID:19745113 ;  http://dx.doi.org/10.1101/gr.097501.109 12.,OADS,/arxiv_data1/oa_pdf/25/de/viru-5-457.PMC4063806.pdf
Genome Biol Evol 2013; 5:2382-92;  PMID:24259314 ; http://dx.doi.org/10.1093/gbe/ evt18513.,OADS,/arxiv_data1/oa_pdf/25/de/viru-5-457.PMC4063806.pdf
PLoS One  2012; 7:e35750;  PMID:22563396 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/25/de/viru-5-457.PMC4063806.pdf
Infect Immun 2007; 75:4710- 8; PMID:17646357 ; http://dx.doi.org/10.1128/ IAI.00372-07 17.,Non-OADS,/arxiv_data1/oa_pdf/25/de/viru-5-457.PMC4063806.pdf
Virulence  2014; 5:555-62;  PMID :24626151 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/25/de/viru-5-457.PMC4063806.pdf
Eur J Oral Sci 2009; 117:669-75;  PMID:20121929 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/25/de/viru-5-457.PMC4063806.pdf
Expert Rev Anti  Infect Ther 2012; 10:935-46; PMID:23030332 ;  http://dx.doi.org/10.1586/eri.12.74 21.,Non-OADS,/arxiv_data1/oa_pdf/25/de/viru-5-457.PMC4063806.pdf
Arch  Microbiol 2000; 174:362-74;  PMID:11131027 ;  http://dx.doi.org/10.1007/s00203000021822.,Non-OADS,/arxiv_data1/oa_pdf/25/de/viru-5-457.PMC4063806.pdf
BMC Microbiol  2011; 11:122;  PMID:21619700 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/25/de/viru-5-457.PMC4063806.pdf
Clin Microbiol Infect  2009; 15:576-85;  PMID:19604278 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/25/de/viru-5-457.PMC4063806.pdf
Eur J Clin Microbiol Infect Dis 2012; 31:2919- 28; PMID:22644055 ; http://dx.doi.org/10.1007/ s10096-012-1642-6,Non-OADS,/arxiv_data1/oa_pdf/25/de/viru-5-457.PMC4063806.pdf
"The authors also showed that InvA  Correspondence to: Jean-Pierre Gorvel; Email: gorvel@ciml.univ-mrs.fr Submitted: 05/01/2014; Accepted: 05/01/2014; Published Online: 05/01/2014 http://dx.doi.org/10.4161/viru.29092Comment on: Alva-Pérez J, Arellano-Reynoso B, Hernández-Castro R, Suárez-Güemes F. The invA  gene of Brucella melitensis  is involved in intracellular  invasion and is required to establish infection in a mouse model.",OADS,/arxiv_data1/oa_pdf/b3/6b/viru-5-460.PMC4063807.pdf
"Virulence 2014; 5:563-74; PMID:24667775; http://dx.doi.org/10.4161/viru.28589“If you bring an alarm, we will destroy it,”   said Brucella  to the host cell Jean-Pierre Gorvel1,2,3 1Centre d’ immunologie de Marseille-Luminy; a ix-Marseille University; Marseille, France; 2CNrS UM r7280; Marseille, France; 3iNSE rM U1104; Marseille, France Keywords:  Brucella , intracellular trafficking, Brucella -containing vacuole, type IV secretion system, pathogenicity, NUDIX  enzyme",Non-OADS,/arxiv_data1/oa_pdf/b3/6b/viru-5-460.PMC4063807.pdf
Immunol Rev 2011;  240:211-34;  PMID:21349096 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b3/6b/viru-5-460.PMC4063807.pdf
Annu Rev Microbiol 2011; 65:523-41;  PMID:21939378 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b3/6b/viru-5-460.PMC4063807.pdf
Lancet Infect Dis 2006; 6:91-9; PMID:16439329 ;  http://dx.doi.org/10.1016/S1473-3099(06)70382-6 4.,Non-OADS,/arxiv_data1/oa_pdf/b3/6b/viru-5-460.PMC4063807.pdf
Prev Vet Med 2011; 102:118-31; PMID :21571380 ;  http://dx.doi.org/10.1016/j.prevetmed.2011.04.007 5.,Non-OADS,/arxiv_data1/oa_pdf/b3/6b/viru-5-460.PMC4063807.pdf
Infect Immun  2002; 70:1640-4;  PMID:11854258 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b3/6b/viru-5-460.PMC4063807.pdf
Microbes Infect 2008; 10:582-90;  PMID:18457975 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b3/6b/viru-5-460.PMC4063807.pdf
J Biol Chem 2001; 276:44435- 43; PMID :11579087 ; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/b3/6b/viru-5-460.PMC4063807.pdf
Infect Immun 2005; 73:8418- 24; PMID:16299342 ; http://dx.doi.org/10.1128/ IAI.73.12.8418-8424.2005 10.,Non-OADS,/arxiv_data1/oa_pdf/b3/6b/viru-5-460.PMC4063807.pdf
Infect Immun 2003; 71:1481-90; PMID:12595466 ;  http://dx.doi.org/10.1128/IAI.71.3.1481-1490.2003 11.,Non-OADS,/arxiv_data1/oa_pdf/b3/6b/viru-5-460.PMC4063807.pdf
J  Leukoc Biol 2003; 74:1045-55; PMID:12960272 ;  http://dx.doi.org/10.1189/jlb.0103015 12.,Non-OADS,/arxiv_data1/oa_pdf/b3/6b/viru-5-460.PMC4063807.pdf
Infect Immun  2004; 72:440-50;  PMID:14688125 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b3/6b/viru-5-460.PMC4063807.pdf
Proc Natl Acad Sci U S A 2002;  99:12375-80;  PMID:12218183 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b3/6b/viru-5-460.PMC4063807.pdf
J Proteome Res 2007; 6:1519-29; PMID:17343405 ;  http://dx.doi.org/10.1021/pr060636a 15.,Non-OADS,/arxiv_data1/oa_pdf/b3/6b/viru-5-460.PMC4063807.pdf
J Bacteriol 2005; 187:5631-9;  PMID:16077108 ; http://dx.doi.org/10.1128/ JB.187.16.5631-5639.2005 16.,Non-OADS,/arxiv_data1/oa_pdf/b3/6b/viru-5-460.PMC4063807.pdf
Microb Pathog 2004; 37:11- 9; PMID :15194155 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/b3/6b/viru-5-460.PMC4063807.pdf
J Exp Med 2003; 198:5-17; PMID:12847134 ; http://dx.doi.org/10.1084/ jem.20021980 18.,Non-OADS,/arxiv_data1/oa_pdf/b3/6b/viru-5-460.PMC4063807.pdf
Cell Microbiol  2006; 8:1877-87;  PMID:16817909 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b3/6b/viru-5-460.PMC4063807.pdf
Microb Pathog 2008; 44:28-33; PMID:17881185 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/b3/6b/viru-5-460.PMC4063807.pdf
Microb Pathog 2012; 52:31-40; PMID:21983596 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/b3/6b/viru-5-460.PMC4063807.pdf
Microbes Infect 2012; 14:79-85; PMID:21911075 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/b3/6b/viru-5-460.PMC4063807.pdf
PLoS Pathog 2008; 4:e21; PMID:18266466 ; http://dx.doi.org/10.1371/jour - nal.ppat.004002127.,Non-OADS,/arxiv_data1/oa_pdf/b3/6b/viru-5-460.PMC4063807.pdf
PLoS Pathog 2012; 8:e1002983;  PMID:23166489 ; http://dx.doi.org/10.1371/jour - nal.ppat.1002983 28.,Non-OADS,/arxiv_data1/oa_pdf/b3/6b/viru-5-460.PMC4063807.pdf
Nat Med  2008; 14:399-406;  PMID:18327267 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b3/6b/viru-5-460.PMC4063807.pdf
J Immunol 2010; 184:956- 64; PMID:20018612 ; http://dx.doi.org/10.4049/ jimmunol.0902008 30.,Non-OADS,/arxiv_data1/oa_pdf/b3/6b/viru-5-460.PMC4063807.pdf
J Biol Chem 2009; 284:9892-8;  PMID:19196716 ; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/b3/6b/viru-5-460.PMC4063807.pdf
Biochem Biophys Res  Commun 2012; 417:299-304; PMID :22155231 ;  http://dx.doi.org/10.1016/j.bbrc.2011.11.104 32.,OADS,/arxiv_data1/oa_pdf/b3/6b/viru-5-460.PMC4063807.pdf
Proc Natl Acad Sci U S A 2002; 99:1544-9;  PMID:11830669 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b3/6b/viru-5-460.PMC4063807.pdf
PLoS Pathog 2009; 5:e1000487;  PMID:19557163 ; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/b3/6b/viru-5-460.PMC4063807.pdf
"J  Biol Chem 2004; 279:54046-52; PMID :15485821 ;  http://dx.doi.org/10.1074/jbc.M409472200 36. de Barsy M, Jamet A, Filopon D, Nicolas C, Laloux G, Rual JF, Muller A, Twizere JC, Nkengfac B,  Vandenhaute J, et al.",OADS,/arxiv_data1/oa_pdf/b3/6b/viru-5-460.PMC4063807.pdf
Cell Microbiol 2011;  13:1044-58;  PMID :21501366 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b3/6b/viru-5-460.PMC4063807.pdf
"*Correspondence to: Georgios N Belibasakis; Email: george.belibasakis@zzm.uzh.ch Submitted: 04/16/2014; Accepted: 04/16/2014; Published Online: 04/23/2014 http://dx.doi.org/10.4161/viru.28930Comment on: Radwan-Oczko  M, Jaworski  A, Duś I, Plonek  T, Szulc  M, Kustrzycki  W. Porphyromonas gingivalis  in periodontal pockets and heart valves.",Non-OADS,/arxiv_data1/oa_pdf/90/81/viru-5-463.PMC4063808.pdf
Virulence   2014 ; 5:575-80;  PMID:24705065 ; http://dx.doi.org/10.4161/viru.28657Porphyromonas gingivalis A heartful oral pathogen?,Non-OADS,/arxiv_data1/oa_pdf/90/81/viru-5-463.PMC4063808.pdf
J Periodontol 1996; 67(Suppl):1123- 37; PMID:8910831 ; http://dx.doi.org/10.1902/ jop.1996.67.10s.1123 2.,Non-OADS,/arxiv_data1/oa_pdf/90/81/viru-5-463.PMC4063808.pdf
Ann Periodontol  1998 ; 3:127- 41; PMID:9722697 ; http://dx.doi.org/10.1902/ annals.1998.3.1.127 5.,Non-OADS,/arxiv_data1/oa_pdf/90/81/viru-5-463.PMC4063808.pdf
Atherosclerosis  2012 ;  222:196-201; PMID:22440543 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/90/81/viru-5-463.PMC4063808.pdf
Am Heart J 2006 ; 151:47;  PMID:16368290 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/90/81/viru-5-463.PMC4063808.pdf
N Engl J Med 2007 ; 356:911- 20; PMID:17329698 ; http://dx.doi.org/10.1056/ NEJMoa063186 10.,OADS,/arxiv_data1/oa_pdf/90/81/viru-5-463.PMC4063808.pdf
FEMS Microbiol Lett 2012 ;  333:1-9; PMID:22530835 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/90/81/viru-5-463.PMC4063808.pdf
Anaerobe   2010 ; 16:629-32; PMID:20816998 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/90/81/viru-5-463.PMC4063808.pdf
J Med  Microbiol  2009 ; 58:1568 -75; PMID:19679682 ;  http://dx.doi.org/10.1099/jmm.0.013383-013.,Non-OADS,/arxiv_data1/oa_pdf/90/81/viru-5-463.PMC4063808.pdf
Oral Microbiol Immunol 2009 ;  24:64-8; PMID:19121072 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/90/81/viru-5-463.PMC4063808.pdf
Virulence   2014 ; 5:575-80 ; PMID:24705065 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/90/81/viru-5-463.PMC4063808.pdf
"The HCV 9.6-kb *Correspondence to: Urania Georgopoulou; Email: uraniag@pasteur.gr Submitted: 11/27/2013; Revised: 03/11/2014; Accepted: 03/11/2014;Published Online: 03/13/2014http://dx.doi.org/10.4161/viru.28508Hepcidin and the iron enigma in HCV infection Urania Georgopoulou1,*, Alexios Dimitriadis2, Pelagia Foka1,2, eirini Karamichali1, and Avgi Mamalaki2 1Laboratory of Molecular Virology; Hellenic Pasteur i nstitute; Athens, Greece; 2Laboratory of Molecular Biology and i mmunobiotechnology;   Hellenic Pasteur i nstitute; Athens, Greece Keywords:  hepatitis C virus, hepcidin, iron, cell signaling pathways, lipid metabolism An estimated 30–40% of patients with chronic hepatitis C  have elevated serum iron, transferrin saturation, and ferritin  levels.",Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Nutrients 2013; 5:3034-61; PMID:23917168 ;  http://dx.doi.org/10.3390/nu5083034 2.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Blood 2011; 118:4129-39;  PMID:21873546 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Antioxid Redox Signal 2008; 10:997-1030;  PMID:18327971 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Blood 2006; 108:1381- 7; PMID:16621968 ; http://dx.doi.org/10.1182/ blood-2005-10-4043 5.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Blood Cells Mol Dis  2008; 40:132-8;  PMID:17905609 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
J Biol Chem 2001; 276:7806-10; PMID:11113131 ;  http://dx.doi.org/10.1074/jbc.M008922200 7.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Blood 2003; 101:2461-3; PMID:12433676 ;  http://dx.doi.org/10.1182/blood-2002-10-3235 8.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Best Pract Res Clin Haematol 2005; 18:171-82;  PMID:15737883 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Science  2004; 306:2090-3;  PMID :15514116 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
J Clin Invest 2002; 110:1037-44; PMID:12370282 ;  http://dx.doi.org/10.1172/JCI0215686 11.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Nat Med 2013; 19:850-8; PMID:23836235 ; http://dx.doi.org/10.1038/ nm.3184 12.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Liver Int 2011;  31:1449-67;  PMID:21745290 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Nat Med 2013; 19:837-49;  PMID:23836234 ; http://dx.doi.org/10.1038/ nm.3248 14.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Haematologica 2007; 92:1037- 42; PMID:17640859 ; http://dx.doi.org/10.3324/ haematol.11281 15.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Annu  Rev Physiol 2007; 69:69-85; PMID:17014365 ;  http://dx.doi.org/10.1146/annurev.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Int J Hematol 2008; 88:7-15; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
J Biol Chem 2000; 275:19906-12;  PMID:10747949 ; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Nature 2000; 403:776-81;  PMID:10693807 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Mol Cell 2000; 5:299- 309; PMID:10882071 ; http://dx.doi.org/10.1016/ S1097-2765(00)80425-6 20.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Haematologica  2010; 95:1261-8;  PMID:20179090 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Clin Chim Acta 2010; 411:1565-9;  PMID:20620132 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Cell Metab 2009; 9:217-27;  PMID:19254567 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Biol Chem 2013;  394:231-8;  PMID:23314535 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Blood 2002; 99:3505-16; PMID:11986201 ;  http://dx.doi.org/10.1182/blood.V99.10.3505 30.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Expert Rev Mol Med 2007; 9:1- 13; PMID:18053288 ; http://dx.doi.org/10.1017/ S1462399407000531 31.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Biochem J 2011; 434:365-81;  PMID:21348856 ; http://dx.doi.org/10.1042/ BJ20101825 32.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Cell  Metab 2008; 8:1-3;  PMID:18590684 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Semin Liver Dis 1996;  16:13-30;  PMID:8723320 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Biometals 2003;  16:103-11;  PMID:12572670 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
J Hepatol 2008; 48:801- 10; http://dx.doi.org/10.1016/j.jhep.2007.12.021 ;  PMID:18313788 36.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Am J Physiol Cell Physiol 2011; 300:C888-95; PMID:21289291 ; http://dx.doi.org/10.1152/ ajpcell.00121.2010 37.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Liver Int  2007; 27:1394-401;  PMID:17927713 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Hepcidin expression in the liver:  relatively low level in patients with chronic hepatitis  C. Mol Med 2007; 13:97-104; PMID :17515961 ;  http://dx.doi.org/10.2119/2006-00057.Fujita 40.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Nat Rev Microbiol 2008; 6:541- 52; PMID:18552864 ; http://dx.doi.org/10.1038/ nrmicro1930 42.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Hepatology 2011; 53:1764-6; PMID :21520181 ;  http://dx.doi.org/10.1002/hep.2426743.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
J Clin Invest  2007; 117:1755-8;  PMID:17607352 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Haematologica 2010; 95:1832-40;  PMID:20634490 ; http://dx.doi.org/10.3324/ haematol.2010.027003 45.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Hepatology  2000; 31:730-6;  PMID:10706565 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Roles of iron and HFE mutations on  severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology  2006; 131:1440-51;  PMID:17101320 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Blood 2014; 123:168-76; http://dx.doi.org/10.1182/blood-2013-06-427757 ;  PMID:24200681 48.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
J Clin Gastroenterol  1994; 19:222-6;  PMID:7528758 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Viruses 2013; 5:439-69; PMID:23358390 ;  http://dx.doi.org/10.3390/v5020439 50.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Nucleic Acids Res 1998; 26:3179-87;  PMID:9628916 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Virus Genes 2008;  37:154-60 ; http://dx.doi.org/10.1007/s11262-008- 0250-0 ; PMID:18566883 52.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
J Infect Dis 2004; 190:819-25;  PMID:15272411 ; http://dx.doi.org/10.1086/422261 54.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
J Biol Chem 1997; 272:7106-13;  PMID:9054404 ; http://dx.doi.org/10.1074/ jbc.272.11.7106 55.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Med Hypotheses 2012; 78:142-3;  PMID:22047986 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
J Gen Virol 2011; 92:2072- 81; PMID :21593278 ; http://dx.doi.org/10.1099/ vir.0.032706-0 58.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
J Hepatol 2010; 53:995-9; PMID:20813419 ;  http://dx.doi.org/10.1016/j.jhep.2010.04.044 59.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
J Biol Chem 2005; 280:9049-57; PMID :15637067 ; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Gastroenterology  2003; 124:1 509-23;  PMID:12730889 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Gastroenterology 2003; 124:318-26;   PMID:12557137 ; http://dx.doi.org/10.1053/ gast.2003.50046 62.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Gastroenterology  2008; 134:226-38;  PMID:18166355 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
J Med Virol 2010; 82:776-92;  PMID:20336713 ; http://dx.doi.org/10.1002/ jmv.21661 64.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Biochem Biophys Res  Commun 2007; 356:312-7;  PMID:17349976 ;  http://dx.doi.org/10.1016/j.bbrc.2007.02.137 65.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Hepatology 2008;  48:1420-9;  PMID:18671304 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
"Nagashima M, Kudo M, Chung H, Ishikawa E, Hagiwara S, Nakatani T, Dote K. Regulatory failure  of serum prohepcidin levels in patients with hepatitis  C. Hepatol Res 2006; 36:288-93; PMID:16979376 ;  http://dx.doi.org/10.1016/j.hepres.2006.08.006 67.",OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Blood 2007; 109:353- 8; PMID:16946298 ; http://dx.doi.org/10.1182/ blood-2006-07-033969 68.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Blood 2006;  108:3204-9;  PMID:16835372 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Hepatol Res 2011;  41:364-74;  PMID:21348906 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Biology 2013; 2:304-16; http://dx.doi.org/10.3390/biology2010304 72.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Hepatology 2005; 41:1096- 105; PMID :15841445 ; http://dx.doi.org/10.1002/ hep.20668 73.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
J Biol Chem 2011; 286:10847-55;  PMID:21282107 ; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
J Exp Med 2002; 196:641-53;  PMID:12208879 ; http://dx.doi.org/10.1084/ jem.20012127 76.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Biochem J 2009; 421:387-95; PMID:19432557 ;  http://dx.doi.org/10.1042/BJ20090069 77.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Gastroenterology 2005; 128:1034-41;  PMID :15825084 ; http://dx.doi.org/10.1053/j.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
J Med Virol 2004; 72:52- 9; PMID:14635011 ; http://dx.doi.org/10.1002/ jmv.10545 79.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Oncogene 2005;  24:6119-32;  PMID:16007207 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Hepatology 2003; 38:820-8; PMID:14512869 ;  http://dx.doi.org/10.1002/hep.1840380408 82.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Cell Mol Life Sci 2011; 68:505-22; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Hepatology  2000; 32:958-61;  PMID:11050045 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Cell Mol Life Sci 2010; 67:2491- 506; PMID:20358251 ; http://dx.doi.org/10.1007/ s00018-010-0351-5 86.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Exp Cell Res  2005; 305:23-32;  PMID:15777784 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Virology 2005; 333:324- 36; PMID:15721365 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
J Gen Virol  2011; 92:2237-48;  PMID:21653755 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
FASEB J 2013; 27:4027- 40; PMID:23781096 ; http://dx.doi.org/10.1096/ fj.13-229187 92.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Br J Haematol  2007; 138:253-62;  PMID:17593032 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Virology  2004; 322:51-60;  PMID :15063116 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Virology  2011; 412:284-96;  PMID:21296375 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
J Biol Chem 2003; 278:17775-84; PMID:12621033 ;  http://dx.doi.org/10.1074/jbc.M210900200 97.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Arch Virol 2003; 148:237- 51; PMID:12556990 ; http://dx.doi.org/10.1007/ s00705-002-0925-0 98.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Curr Gastroenterol Rep 2012; 14:8-16; PMID:22124850 ;  http://dx.doi.org/10.1007/s11894-011-0234-4 99.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Diabetes Care 2005; 28:2211- 6; PMID:16123492 ; http://dx.doi.org/10.2337/ diacare.28.9.2211 100.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Liver Int 2009; 29(Suppl 2):3-12; PMID:19187068 ;  http://dx.doi.org/10.1111/j.1478-3231.2008.01949.x 101.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Nat Cell Biol 2007; 9:1089-97; PMID:17721513 ;  http://dx.doi.org/10.1038/ncb1631 102.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Proc Natl Acad Sci U S A  2007; 104:1661-6;  PMID:17234812 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Arch Med Res 2007; 38:621-7; PMID:17613353 ;  http://dx.doi.org/10.1016/j.arcmed.2006.09.001 104.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
PLoS One 2011; 6:e23641;  PMID :21853158 ; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
J Viral Hepat  2008 ; 15:157-64 ;  PMID:18086178 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Hepatol Res  2010; 40:69-82;  PMID:20156300 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Gut 2006; 55:1801-8; PMID:16581947 ;  http://dx.doi.org/10.1136/gut.2005.070417 108.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Virology 2004; 328:120-30; PMID :15380363 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Hepatology 2002; 35:937- 46; PMID:11915042 ; http://dx.doi.org/10.1053/ jhep.2002.32470 110.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
J Virol  2007; 81:8122-30;  PMID:17507484 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Lab Invest 2012;  92:1191-202;  PMID:22641099 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Gastroenterology  2005; 128:334-42;  PMID :15685545 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
FEBS  Lett 2009; 583:2720-6; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Biochem Biophys Res Commun  2007; 355:883-8;  PMID:17331464 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
J Hepatol 2011; 55:920- 32; PMID:21718726 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Curr Opin Lipidol 2012; 23:258- 9; PMID:22576585 ; http://dx.doi.org/10.1097/ MOL.0b013e328354752d 118.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
J Clin Endocrinol Metab 2011; 96:E958-61; PMID:21430023 ; http://dx.doi.org/10.1210/ jc.2010-2682 119.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
World J Gastroenterol 2012; 18:4651-8;  PMID:23002334 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
J Nutr Biochem 2013; 24:1634-44;  PMID:23643521 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Genes Nutr 2010;  5:1-8;  PMID:19821111 ; http://dx.doi.org/10.1007/ s12263-009-0153-2 124.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Lipids 1998; 33:889-95; PMID:9778136 ;  http://dx.doi.org/10.1007/s11745-998-0285-8 125.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Lipids 1983; 18:673- 6; PMID:6656532 ; http://dx.doi.org/10.1007/ BF02534575 126.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Hepatology 1989; 9:398-404;  PMID:2920996 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Hepatology  1989; 9:686-92;  PMID:2707735 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
J Hepatol 1997; 26:584- 92; PMID:9075666 ; http://dx.doi.org/10.1016/ S0168-8278(97)80424-2 129.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
J Biochem Mol Toxicol 2012; 26:224-9;  PMID:22570273 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
J Hepatol 1995; 22:449-56; PMID:7545199 ;  http://dx.doi.org/10.1016/0168-8278(95)80108-1 132.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
"Kageyama F, Kobayashi Y, Kawasaki T, Toyokuni S, Uchida K, Nakamura H. Successful interferon  therapy reverses enhanced hepatic iron accumulation  and lipid peroxidation in chronic hepatitis C. Am J  Gastroenterol 2000; 95:1041-50;  PMID:10763957 ;  http://dx.doi.org/10.1111/j.1572-0241.2000.01979.x 133.",OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
J Gastroenterol Hepatol 2006; 21:1821-5;  PMID:17074020 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
J Hepatol 2008; 49:123-33; http://dx.doi.org/10.1016/j.jhep.2008.03.011 ; PMID:18462824135.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Hepatology 2009; 49:1828-37;  PMID:19291787 ;  http://dx.doi.org/10.1002/hep.22865 137.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
J Gastroenterol Hepatol 2013;  28(Suppl 4):93-8;  PMID:24251712 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Aliment Pharmacol Ther 2005;  22(Suppl 2):52-5;  PMID:16225474 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Gastroenterology 2006; 130:2229-34;   PMID:16762645 ; http://dx.doi.org/10.1053/j.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
World J Gastroenterol 2008; 14:1339-45; PMID:18322945 ; http://dx.doi.org/10.3748/ wjg.14.1339 142.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
World J Gastroenterol 2009; 15:538-51;  PMID:19195055 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Serum hepcidin levels are  related to the severity of liver histological lesions  in chronic hepatitis C. J Viral Hepat 2010; 17:800-6;  PMID:20002304 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
J Bioenerg Biomembr  2002; 34:67-79;  PMID:11860182 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Hepatology 2011; 53:448-57;  PMID:21274866 ; http://dx.doi.org/10.1002/ hep.24038,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Hepatology 1999; 30:987-96; PMID:10498651 ;  http://dx.doi.org/10.1002/hep.510300433 148.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
"Jaroszewicz J, Rogalska M, Flisiak I, Flisiak R.  Successful antiviral therapy is associated with a  decrease of serum prohepcidin in chronic hepatitis C. World J Gastroenterol 2010; 16:1747-52;  PMID:20380007 ; http://dx.doi.org/10.3748/wjg.",Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
Gut 2007; 56:1302- 8; PMID:17213339 ; http://dx.doi.org/10.1136/ gut.2006.108647151.,Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
"Ryan JD, Altamura S, Devitt E, Mullins S, Lawless MW, Muckenthaler MU, Crowe J. Pegylated  interferon- α induced hypoferremia is associated with  the immediate response to treatment in hepatitis C. Hepatology 2012; 56:492-500; PMID:22334511 ;  http://dx.doi.org/10.1002/hep.25666",Non-OADS,/arxiv_data1/oa_pdf/16/55/viru-5-465.PMC4063809.pdf
"At the time of formulating this review, 1104 articles were  available in PubMed regarding S. suis (http://www.ncbi.nlm.nih.",Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
"Genomic mining combined with bacterial genetics have eluci - dated that Chinese epidemic strains of highly pathogenic S.  suis 2  carry a specific 89K PAI (pathogenicity island).23,27 Further stud - ies suggested that 89K PAI with a transposon-like essence can *Correspondence to: Youjun Feng, Email: fengyj@zju.edu.cn;   Changjun Wang, Email: science2008@hotmail.comSubmitted: 11/26/2013; Revised: 03/16/2014; Accepted: 03/19/2014;Published Online: 03/25/2014http://dx.doi.org/10.4161/viru.28595Streptococcus suis  infection An emerging/reemerging challenge of bacterial infectious  diseases?",Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
"8,39 At the time of writing this review, no  less than 14 genomes of S.  suis strains have been available in  PubMed (http://www.ncbi.nlm.nih.gov/sites/entrez?db=genome&cmd=DetailsSearch&term=streptococcus+suis&save_search=false), most of which were completed by the research groups in China ( Fig.",Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Vet Res Commun  1997; 21:381-407;  PMID:9266659 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Anim Health Res  Rev 2007 ; 8:29-45; PMID:17692141 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Zoonoses  Public Health  2009 ; 56:506-14; PMID:19538458 ;  http://dx.doi.org/10.1111/j.1863-2378.2008.01225.x 5.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Future Microbiol  2010 ; 5:371- 91; PMID:20210549 ; http://dx.doi.org/10.2217/ fmb.10.2 6.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
PLoS One  2009 ; 4:e5973 ;  PMID:19543404 ; http://dx.doi.org/10.1371/ journal.pone.0005973 8.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Trends Microbiol  2010 ; 18:124- 31; PMID:20071175 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Emerg Infect Dis 2006 ; 12:914- 20; PMID:16707046 ; http://dx.doi.org/10.3201/ eid1206.051194 10.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Rev Infect Dis  1988 ; 10:131-7; PMID:3353625 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Emerg  Infect Dis 2014 ; 20:489-91; PMID:24565084 ;  http://dx.doi.org/10.3201/eid2003.130535 13.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Emerg Infect Dis  2009 ; 15:350-2; PMID:19193296 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
J  Med Microbiol  2009 ; 58:1508 -13; PMID:19661209 ;  http://dx.doi.org/10.1099/jmm.0.013656-0 15.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Emerg Infect Dis 2008 ; 14:155-7; PMID:18258097 ;  http://dx.doi.org/10.3201/eid1401.07053416.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Clin Infect Dis 2008 ; 46:659-67; PMID:19413493 ;  http://dx.doi.org/10.1086/527385 17.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Emerg  Infect Dis 2006 ; 12:1203 -8; PMID:16965698 ;  http://dx.doi.org/10.3201/eid1708.060232 18.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Philos Trans R Soc Lond B Biol Sci 2009 ; 364:2725 - 37; PMID:19687041 ; http://dx.doi.org/10.1098/ rstb.2009.0093 20.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Vet Rec   1996 ; 139:225-8; PMID:8883345 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
PLoS One   2007 ; 2:e315; PMID:17375201 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
PLoS One   2009 ; 4:e6072 ; PMID:19603075 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
J Bacteriol  2011 ; 193:3428 -9; PMID :21572001 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
J Bacteriol  2011 ; 193:2375 -6; PMID:21398551 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
PLoS One  2008 ; 3:e2080 ;  PMID:18461172 ; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Mol  Microbiol  2011 ; 79:1670 -83; PMID:21244532 ;  http://dx.doi.org/10.1111/j.1365-2958.2011.07553.x29.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
J Bacteriol  2008 ; 190:7567 -78; PMID:18723622 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
J Bacteriol  2009 ; 191:2601 -12; PMID:19181815 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Infect Immun   2011 ; 79:1319 -28; PMID:21149588 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Vet Microbiol  2000 ; 76:259- 72; PMID:10973700 ;  http://dx.doi.org/10.1016/ S0378-1135(00)00250-9 33.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Emerg Infect Dis  2008 ; 14:787-91; PMID:18439362 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
FEMS  Microbiol Lett 2007 ; 275:80-8; PMID:17854470 ;  http://dx.doi.org/10.1111/j.1574-6968.2007.00859.x 37.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
PLoS One  2011 ; 6:e17604 ;  PMID:21408132 ; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Microbiology   2011 ; 157:572-82; PMID:20947575 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
BMC Microbiol  2011 ; 11:47; PMID:21362190 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Vet Microbiol  2011 ; 148:99-104; PMID:20832201 ;  http://dx.doi.org/10.1016/j.vetmic.2010.08.005,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Proteomics  2008 ; 8:333-49; PMID:18081191 ;  http://dx.doi.org/10.1002/pmic.200600930 44.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Zoonoses  Public Health  2007 ; 54:253-9; PMID:17803514 ;  http://dx.doi.org/10.1111/j.1863-2378.2007.01056.x 45.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Proteomics  2007 ; 7:4468 - 76; PMID:18022935 ; http://dx.doi.org/10.1002/ pmic.200700294 46.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Microb Pathog  2008 ; 45:159-66; PMID:18554861 ;  http://dx.doi.org/10.1016/j.micpath.2008.04.009 47.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
FEMS Immunol Med Microbiol  2008 ; 53:52-9; PMID:18371070 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Lancet Infect Dis 2007 ; 7:201-9; PMID:17317601 ;  http://dx.doi.org/10.1016/S1473-3099(07)70001-4 49.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
N Engl J Med 2006 ; 354:1325 ; PMID:16554543 ;  http://dx.doi.org/10.1056/NEJMc053089 50.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Emerg Infect Dis 2008 ; 14:183- 5; PMID:18258107 ; http://dx.doi.org/10.3201/ eid1401.070930 51.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Rev Infect Dis 1991 ; 13:1251 - 2; PMID:1775866 ; http://dx.doi.org/10.1093/ clinids/13.6.1251 52.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Enferm Infecc  Microbiol Clin  2005 ; 23:110; PMID :15743586 ;  http://dx.doi.org/10.1157/13071618 54.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Emerg Infect Dis  2014 ; 20:500-2; PMID:24565286 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Rev Chilena Infectol 2013 ; 30:557- 61; PMID:24248173 ; http://dx.doi.org/10.4067/ S0716-10182013000500015 56.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Emerg Infect Dis 2013 ; 19:1545 - 6; PMID:23977863 ; http://dx.doi.org/10.3201/ eid1909.121872 57.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
"An Med Interna 2001 ; 18:317-8;  PMID :11503579 ; http://dx.doi.org/10.4321/ S0212-71992001000600007 58. van de Beek D, Spanjaard  L, de Gans J. Streptococcus  suis meningitis in the Netherlands.",Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
J Infect 2008 ;  57:158-61; PMID:18538852 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Eur J Clin Microbiol Infect Dis  2000 ; 19:943-5; PMID:11205632 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
J Med Microbiol 2013 ; 62:483-5; PMID:23222864   http://dx.doi.org/10.1099/jmm.0.046599-0 62.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
J Neurol  2003 ; 250:869- 70; PMID:12883932 ; http://dx.doi.org/10.1007/ s00415-003-1103-3 63.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Nervenarzt  1999 ; 70:738- 41; PMID:10483574 ; http://dx.doi.org/10.1007/ s001150050503 64.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Scand J Infect Dis 2002 ;  34:683-4; PMID:12374361 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Emerg Infect Dis  2008 ; 14:1946 -8; PMID:19046529 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Clin Infect Dis 1997 ; 24:710- 2; PMID:9145747 ; http://dx.doi.org/10.1093/ clind/24.4.710 70.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
J Laryngol Otol  1980 ; 94:425-7; PMID:7391667 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Korean J Lab Med  2011 ; 31:115-7; PMID:21474987 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Tuberc Respir Dis (Seoul) 2012 ; 73:178- 81; PMID:23166552 ; http://dx.doi.org/10.4046/ trd.2012.73.3.17874.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Epidemiol Infect   2008 ; 136:1691 -7; PMID:18252026 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Diagn Microbiol Infect Dis  2007 ; 57:15-20; PMID:16860513 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Clin Neurol Neurosurg   2005 ; 107:366-70; PMID:16023529 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Trans R Soc Trop Med Hyg 1986 ;  80:848-9; PMID:3603627 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Diagn Microbiol Infect Dis 2012 ; 74: 75- 7; PMID:22705228 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Emerg Infect Dis 2008 ; 14:1925 - 7; PMID:19046523 ; http://dx.doi.org/10.3201/ eid1412.080162 91.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
J Clin Microbiol 2005 ; 43:4898 -901;  PMID:16145171 ; http://dx.doi.org/10.1128/ JCM.43.9.4898-4901.2005 93.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
J Infect Dis 2009 ;  199:97-107; PMID:19016627 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
J Infect Dis 2009 ;  200:1583 -92; PMID:19848587 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Vet Immunol Immunopathol  2010 ; 133:207- 11; PMID:19733402 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
J Vet  Diagn Invest 2007 ; 19:355-61; PMID:17609343 ;  http://dx.doi.org/10.1177/104063870701900403 99.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Vet Microbiol  2007 ; 122:135-45;  PMID:17275218 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Infect Immun   2004 ; 72:5322 -30; PMID:15322029 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Infect Immun  2002 ; 70:1319 - 25; PMID:11854216 ; http://dx.doi.org/10.1128/ IAI.70.3.1319-1325.2002 104.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Microb Pathog  2003 ; 34:27- 37; PMID:12620382 ; http://dx.doi.org/10.1016/ S0882-4010(02)00192-4 106.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Protein Cell  2010 ; 1:96- 105; PMID:21204001 ; http://dx.doi.org/10.1007/ s13238-010-0012-3 107.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
BMC Microbiol 2010 ;  10:42 ; PMID:20146817 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Vet Microbiol   2011 ; 148:333-40; PMID:21030165 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
FEMS Microbiol Lett  2011 ; 314:174-82; PMID:21133988 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
FEMS Microbiol Lett  2010 ; 307:12-8; PMID:20402782 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
J Proteomics 2010 ;  73:2365 -9; PMID:20656083 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Vet Microbiol  2013 ;162:186- 94; http://dx.doi.org/10.1016/j.vetmic.2012.09.004 ;  PMID:23021642 114.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
J Bacteriol  2011 ; 193:2375 -6; PMID:21398551 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
J Biol Chem  2013 ; 288:956-63; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Microbiology  2011 ; 157:1823 - 33; PMID:21349980 ; http://dx.doi.org/10.1099/ mic.0.046417-0 119.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
J  Microbiol  2012 ; 50:994-1002 ; PMID:23274986 ;  http://dx.doi.org/10.1007/s12275-012-2035-3 120.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Infect Immun  2006 ;  74:6154 -62; PMID:17057090 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Infect Immun  2006 ; 74:305-12; PMID:16368985 ;  http://dx.doi.org/10.1128/IAI.74.1.305-312.2006 122.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Clin Vaccine Immunol  2007 ; 14:937-43; PMID:17567767 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Microb Pathog  2014 ;  67-68C :31-35; PMID:24530923 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Curr Microbiol 2010 ; 61:494-9;  PMID:20386910 ; http://dx.doi.org/10.1007/ s00284-010-9643-0 125.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Vaccine  2010 ; 28:3609 - 16; PMID:20079873 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Vet Microbiol  2009 ; 139:80-8;  PMID:19447571 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Vaccine  2009 ; 27:1348 -53;  PMID:19150475 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
FEMS Microbiol Lett  2009 ; 294:82-8; PMID:19493012 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Microb Pathog  2009 ; 47:267- 73; PMID:19744553 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Infect Immun  2008 ; 76:3587 - 94; PMID:18474639 ; http://dx.doi.org/10.1128/ IAI.01568-07 133.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Mol  Microbiol  2008 ; 70:1120 -35; PMID:18990186 ;  http://dx.doi.org/10.1111/j.1365-2958.2008.06463.x 134.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Microbiology  2010 ;  156:2818 -28; PMID:20522493 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Curr Microbiol 2009 ; 59:248-55; PMID:19484301 ;  http://dx.doi.org/10.1007/s00284-009-9425-8 136.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Arch Microbiol   2009 ; 191:23-33; PMID:18716756 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Vet Microbiol   2008 ; 127:417-24; PMID:17954016 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Vet Microbiol  2011 ; 148:436- 9; PMID:21041043 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Vet Microbiol   2011 ; 152:151-60; PMID:21621932 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
J Microbiol 2011 ; 49:1000 -11; PMID:22203565 ;  http://dx.doi.org/10.1007/s12275-011-1523-1 141.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Sci Rep 2012 ; 2:710;  PMID:23050094 ; http://dx.doi.org/10.1038/ srep00710 142.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Microbiology  2008 ;  154:2668 -79; PMID:18757800 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Protein Cell   2012 ; 3:769-80; PMID:23055041 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
J Infect Dis 2014 ; (forthcoming );  PMID:24446521 ; http://dx.doi.org/10.1093/infdis/ jiu050 148.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
ACS Chem Biol  2013 ; 8:2622 -9; PMID:24074367 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Vet Microbiol   2010 ; 144:246-9; PMID:20133089 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
BMC Microbiol  2012 ; 12:85; PMID:22646062 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Appl Environ Microbiol  2014 ; 80:1062 - 71; PMID:24271178 ; http://dx.doi.org/10.1128/ AEM.03213-13 152.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Microbiology  2012 ; 158:1852 -66; PMID:22504441 ;  http://dx.doi.org/10.1099/mic.0.057448-0 153.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
FEMS Microbiol Lett  2012 ; 333:160-8; PMID:22670712 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
FEMS Microbiol Lett 2009 ;  292:170-81; PMID:19210676 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Curr Microbiol 2013 ; 67:118-22; PMID:23463517 ;  http://dx.doi.org/10.1007/s00284-013-0343-4 159.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Microb Pathog  2011 ; 51:69-76;  PMID:21093574 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
J Infect Dis  2011 ; 204:274-81; PMID:21673039 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
FEMS Immunol Med Microbiol  2003 ; 35:49-58; PMID:12589957 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Microbes Infect 2011 ;  13:953-62; PMID:21683799 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
J Neuroimmunol  2011 ; 234:71- 83; PMID:21429596 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
"Int  Immunol  2007 ; 19:375-89; PMID:17307800 ;  http://dx.doi.org/10.1093/intimm/dxm003 166. de Greeff  A, Benga  L, Wichgers Schreur  PJ, Valentin- Weigand  P, Rebel  JM, Smith  HE.",OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Vet Microbiol  2010 ; 141:59-67; PMID:19709818 ;  http://dx.doi.org/10.1016/j.vetmic.2009.07.031 167.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Microb Pathog   2010 ; 49:32-7; PMID:20307645 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Vet Microbiol   2002 ; 84:155-68; PMID:11731168 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Vet Microbiol  2001 ; 81:331-44;  PMID:11390114 ; http://dx.doi.org/10.1016/ S0378-1135(01)00359-5,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Vet Rec  2001 ; 148:473-7; PMID:11334073 ;  http://dx.doi.org/10.1136/vr.148.15.473 172.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Curr Microbiol 2009 ; 58:11- 7; PMID:18839251 ; http://dx.doi.org/10.1007/ s00284-008-9258-x 173.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
FEMS Microbiol Lett 2010 ;  307:12-8; PMID:20402782 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Med Pregl 2005 ; 58:236-9;  PMID:16526227 ; http://dx.doi.org/10.2298/ MPNS0506236D 176.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
PLoS One  2011 ; 6:e17604 ;  PMID:21408132 ; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Lancet  2001 ;  357:38; PMID:11197360 ; http://dx.doi.org/10.1016/ S0140-6736(00)03570-4 181.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
J Infect 1991 ; 22:303- 4; PMID:2071918 ; http://dx.doi.org/10.1016/ S0163-4453(05)80022-2 183.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Lancet  1981 ; 1:1017- 21; PMID:6112412 ; http://dx.doi.org/10.1016/ S0140-6736(81)92186-3 184.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Science  1981 ; 211:842- 4; PMID:7466361 ; http://dx.doi.org/10.1126/ science.7466361185.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
PLoS One   2011 ; 6:e17987 ; PMID:21479213 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
BMC Genomics   2011 ; 12:219; PMID :21554741 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Vet Microbiol  1991 ;  28:335-42; PMID:1949547 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
FEMS Microbiol Lett  2003 ; 218:79-84; PMID:12583901 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Vet Microbiol  2005 ; 109:223-8; PMID:16029935 ;  http://dx.doi.org/10.1016/j.vetmic.2005.04.024 196.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
FEMS  Microbiol Lett 2012 ; 337:25-30; PMID:22946506 ;  http://dx.doi.org/10.1111/1574-6968.12002 198.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
J Clin Microbiol 2013 ; 51:3250 - 6; PMID:23884995 ; http://dx.doi.org/10.1128/ JCM.01183-13199.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Diagn Microbiol Infect  Dis 2011 ; 70:461-7; PMID:21767702 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
J Microbiol Methods 2010 ; 83:326- 9; PMID:20869401 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Vet Microbiol   1999 ; 67:143-57; PMID:10414368 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
J Clin Microbiol 2002 ; 40:2922 -9;  PMID:12149353 ; http://dx.doi.org/10.1128/ JCM.40.8.2922-2929.2002 204.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Vet Res  2000 ; 31:473- 9; PMID:11050742 ; http://dx.doi.org/10.1051/ vetres:2000133 205.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Vet Microbiol  2006 ; 115:117-27; PMID:16431041 ;  http://dx.doi.org/10.1016/j.vetmic.2005.12.013 207.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
J Clin Microbiol 2004 ; 42:3169 - 75; PMID :15243078 ; http://dx.doi.org/10.1128/ JCM.42.7.3169-3175.2004 209.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
J Microbiol Methods 2007 ; 68:648- 50; PMID :17157941 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Vet J   2010 ; 186:396-8; PMID:19800823 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
J Clin Microbiol  2003 ; 41:2498 -502; PMID:12791872 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
J Clin Microbiol  2002 ; 40:615-9; PMID:11825980 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
J Clin Microbiol 2002 ; 40:3671 -80;  PMID:12354864 ; http://dx.doi.org/10.1128/ JCM.40.10.3671-3680.2002222.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
APMIS  2001 ;  109:665-9; PMID:11890569 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
J Vet Diagn Invest 2000 ;  12:224-32; PMID:10826835 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Vet Microbiol   1993 ; 34:71-82; PMID:8447081 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Vet Microbiol   1996 ; 52:113-25; PMID:8914256 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
J Vet Med Sci 1996 ; 58:369-72; PMID:8741273 ;  http://dx.doi.org/10.1292/jvms.58.369 229.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Analyst   2012 ; 137:1259 -64; PMID:22282767 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Vaccine   2013 ; 31:4209 -15; PMID:23856333 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
J Med Microbiol 2008 ; 57:488-94; PMID:18349370 ;  http://dx.doi.org/10.1099/jmm.0.47755-0232.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
FEMS Microbiol Lett  2011 ; 316:115-22; PMID:21204934 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Microbiology   2014 ; 160:385-95; PMID:24222615 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Clin Exp  Immunol  2002 ; 127:243-54; PMID:11876746 ;  http://dx.doi.org/10.1046/j.1365-2249.2002.01768.x 235.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Infect Immun  2014 ;  (forthcoming ); PMID:24549326 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
FEMS  Microbiol Lett 2009 ; 296:78-83; PMID:19459970 ;  http://dx.doi.org/10.1111/j.1574-6968.2009.01617.x 239.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
FEMS Microbiol Lett 2011 ;  316:115-22; PMID:21204934 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
Microbiol Res 2013 ;  (forthcoming ); PMID:24120016 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/05/e3/viru-5-477.PMC4063810.pdf
"25 Increasing Incidence of Campylobacteriosis Campylobacter  related gastroenteritis is a prominent cause  of acute bacterial illness in both developed and developing *Correspondence to: Brigid Lucey; Email: Brigid.Lucey@cit.ie; Roy D Sleator;  Email: Roy.Sleator@cit.ieSubmitted: 03/11/2014; Revised: 04/03/2014; Accepted: 04/03/2014; Published Online: 04/09/2014http://dx.doi.org/10.4161/viru.28776Campylobacter ureolyticus A portrait of the pathogen Dylan O’Donovan1, Gerard D Corcoran2, Brigid Lucey1,*, and Roy D Sleator1,* 1Department of Biological Sciences; Cork i nstitute of Technology; Bishopstown, Cork, i reland; 2Department of Diagnostic Microbiology; Cork University Hospital;   wilton, Cork, i reland Keywords:  Campylobacter , virulence, pathogenesis, source, strain heterogeneity Herein, we provide a brief overview of the emerging bacte - rial pathogen Campylobacter ureolyticus .",Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Emerg Infect Dis 1999; 5:28-35; PMID:10081669 ; http://dx.doi.org/10.3201/ eid0501.990104 4.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
PLoS Genet 2008; 4:e1000203; PMID:18818764 ; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Int J Environ Res Public Health 2013; 10:6292- 304; PMID:24287853 ; http://dx.doi.org/10.3390/ ijerph10126292 6.,OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
BMC Infect Dis  2014; 14:30;  PMID:24422983 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
J Food Prot  2012; 75:123-31;  PMID:22221364 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Pediatr Res  2004; 55:3-12;  PMID:14605259 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Vet Res  2005; 36:351-82;  PMID :15845230 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
J Clin Pathol 2002; 55:749- 53; PMID:12354800 ; http://dx.doi.org/10.1136/ jcp.55.10.749 12.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
FEMS Immunol Med Microbiol 2011; 63:248-53; PMID:22077228 ;  http://dx.doi.org/10.1111/j.1574-695X.2011.00847.x 13.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
FEMS Immunol  Med Microbiol 2011; 61:228-30;  PMID:21320172 ;  http://dx.doi.org/10.1111/j.1574-695X.2010.00760.x14.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
PLoS One  2013 ; 8:e71515;  PMID:24023611 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Gut Pathog 2012; 4:14; PMID:23151337 ;  http://dx.doi.org/10.1186/1757-4749-4-14 16.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Epidemiol Infect  2012; 140:684-8;  PMID:21676357 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
"Emerg Infect Dis 2012; 18:1709-10,  author reply 1710-1;  PMID :23017215 ; http://dx.doi.",OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
J Med Microbiol 1987; 24:133-7; PMID:3656394 ;  http://dx.doi.org/10.1099/00222615-24-2-133 20.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Mol Microbiol 2012;  84:352-69;  PMID:22375824 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Int  J Syst Bacteriol 1972; 22:73-7; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Int J Syst Bacteriol 1978; 28:197-200; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
nov. Int  J Syst Bacteriol 1995; 45:145-52; PMID:7857794 ;  http://dx.doi.org/10.1099/00207713-45-1-145 25.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Int J Syst  Evol Microbiol 2010; 60:2016-22; PMID:19801389 ;  http://dx.doi.org/10.1099/ijs.0.017152-0 26.,OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Emerg Infect Dis 2002; 8:237-44; PMID:11927019 ; http://dx.doi.org/10.3201/ eid0803.01023327.,OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Clin Microbiol Rev 2008; 21:505-18; PMID:18625685 ; http://dx.doi.org/10.1128/ CMR.00055-07 28.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
J  Clin Microbiol 2009; 47:3449-53; PMID:19726596 ;  http://dx.doi.org/10.1128/JCM.01026-09 29.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Int J  Biometeorol 2005; 49:207-14;  PMID :15565278 ;  http://dx.doi.org/10.1007/s00484-004-0241-3 30.,OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
BMC Infect Dis 2005; 5:70; PMID:16162289 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Symp Ser Soc Appl Microbiol 2001;  90:68S-79S;  PMID:11422562 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Appl Environ Microbiol 2001; 67:2636-40;  PMID:11375174 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Emerg Infect Dis 2008; 14:895-901;  PMID:18507899 ; http://dx.doi.org/10.3201/ eid1406.071008 34.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
"Emerg  Infect Dis 2009; 15:850-1, author reply 851-2;  PMID:19402998 ; http://dx.doi.org/10.3201/ eid1505.081553 35.",Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Appl Environ Microbiol 2005; 71:6368- 74; PMID:16204559 ; http://dx.doi.org/10.1128/ AEM.71.10.6368-6374.2005 36.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Clin Microbiol Infect 2004;  10:868-76;  PMID :15373879 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Appl Environ Microbiol  2003; 69:4343-51;  PMID:12902214 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Front Microbiol 2011; 2:200;  PMID:21991264 ; http://dx.doi.org/10.3389/ fmicb.2011.00200,OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Epidemiol Infect  1990; 104:101-10;  PMID:2307180 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Emerg Infect Dis 2005; 11:361-4; PMID:15757548 ;  http://dx.doi.org/10.3201/eid1103.040460 43.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Comprehensive Reviews in Food Science and  Food Safety 2004; 3:105-16; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
J Appl  Microbiol 2004; 97:410-20; PMID:15239709 ;  http://dx.doi.org/10.1111/j.1365-2672.2004.02313.x 46.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Appl Environ  Microbiol 2012; 78:7564-71;  PMID:22904055 ;  http://dx.doi.org/10.1128/AEM.01783-12 47.,OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Am J Med 1979; 66:779-83;  PMID:571676 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Epidemiol Infect 2013; 141:987-96;  PMID:22892294 ; http://dx.doi.org/10.1017/ S0950268812001744 49.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
J Appl Microbiol 1998;  84:733-40;  PMID:9674125 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Genome Res  2005; 15:1603-10 ;  PMID:16339357 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Contrib Microbiol 2005; 12:255-71;  PMID :15496784 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Cell  2006; 124:703-14;  PMID:16497582 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Trends Microbiol 2005; 13:58-63;  PMID :15680764 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Mol Microbiol 2007; 64:881-5;  PMID:17501914 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Gut Pathog 2011; 3:15; PMID:21992484 ;  http://dx.doi.org/10.1186/1757-4749-3-15 59.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
PLoS One  2011; 6:e22170;  PMID:21829448 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Nature  2000; 403:665-8;  PMID:10688204 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Syst  Appl Microbiol 2009; 32:91-100; PMID:19201124 ;  http://dx.doi.org/10.1016/j.syapm.2008.12.004 63.,OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Emerg Infect Dis 2012; 18:510- 2; PMID:22377283 ; http://dx.doi.org/10.3201/ eid1803.110875 64.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Int J Syst Evol Microbiol  2007; 57:81-91;  PMID:17220447 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Talanta 2010; 83:457-63; PMID:21111160 ;  http://dx.doi.org/10.1016/j.talanta.2010.09.039 66.,OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
FEMS Immunol Med Microbiol 2008; 54:224-35;  PMID:18754784 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Infect Immun 2001; 69:5509- 19; PMID:11500424 ; http://dx.doi.org/10.1128/ IAI.69.9.5509-5519.200169.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
J Biol Chem 2005; 280:3251-8;  PMID :15525636 ; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Infect Immun 2012; 80:883-90;  PMID:22124656 ; http://dx.doi.org/10.1128/ IAI.06031-11 73.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
J Bacteriol 2000; 182:859-68;  PMID:10648507 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Cell 2006; 124:715-27;  PMID:16497583 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
PLoS Genet 2008; 4:e1000141;  PMID:18654632 ; http://dx.doi.org/10.1371/journal.,OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Mol Cell Probes 1995; 9:247-50; PMID:7477020 ;  http://dx.doi.org/10.1016/S0890-8508(95)90114-0 77.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Arch Microbiol 2011;  193:235-9;  PMID:21249334 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
PLoS One  2011; 6:e21490;  PMID:21738679 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Inflamm Bowel Dis 2011; 17:1971- 8; PMID:21830275 ; http://dx.doi.org/10.1002/ ibd.21606 81.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Microbiology 2007; 153:2817-22 ;  PMID:17768226 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Mol Microbiol  2006; 60:1262-75;  PMID:16689801 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Gut Pathog  2009; 1:2; PMID:19338680 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
J Infect Dis 2010; 202:1855-65;  PMID:21050118 ; http://dx.doi.org/10.1086/657316 88.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Infect Immun  2004; 72:6757-63;  PMID:15557595 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
FEMS Microbiol Lett  2000; 185:43-9;  PMID:10731605 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Mol Microbiol 2005;  57:1022-35;  PMID:16091041 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
J Clin Invest 1995;  96:710-20;  PMID:7635964 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
PLoS One 2011; 6:e18441;  PMID :21541312 ; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
J Clin Pathol 1982; 35:309-12;  PMID:7068922 ; http://dx.doi.org/10.1136/ jcp.35.3.30997.,Non-OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
J Microbiol Methods 2013; 95:68-75;  PMID:23830848 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
Appl Environ Microbiol 2005; 71:6554-63;  PMID:16269681 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/29/18/viru-5-498.PMC4063811.pdf
"com; Yuan-Ying Jiang; Email: 13761571578@163.comSubmitted: 10/29/2013; Revised: 04/11/2014; Accepted: 04/14/2014; Published Online: 04/23/2014http://dx.doi.org/10.4161/viru.28893Molecular genetic techniques for gene  manipulation in Candida albicans Qiu-Rong Xu1,†, Lan Yan2,†, Quan-Zhen Lv2, Mi Zhou2, Xue Sui3, Yong-Bing Cao2,*, and Yuan-Ying Jiang2,* 1Department of Traditional Chinese Medicine; College of Pharmacy; Fujian University of Traditional Chinese Medicine; Fuzhou, Fujian PR China; 2Center for New Drug Research;  School of Pharmacy; Second Military Medical University; Shanghai, PR China; 3School of Life Science and Bio-pharmaceutics; Shenyang Pharmaceutical University;   Shenyang, Liaoning PR China †These authors contributed equally to this work.",Non-OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Med Mycol 2007; 45:321-46; PMID:17510856 ;  http://dx.doi.org/10.1080/13693780701218689 2.,Non-OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
J  Oral Pathol Med 2011; 40:83-9; PMID:20923440 ;  http://dx.doi.org/10.1111/j.1600-0714.2010.00937.x 3.,Non-OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 96:154- 63; PMID:12931087 ; http://dx.doi.org/10.1016/ S1079-2104(03)00296-8 4.,Non-OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Clin  Microbiol Rev 2007; 20:133-63; PMID:17223626 ;  http://dx.doi.org/10.1128/CMR.00029-06 5.,Non-OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
BMC Infect  Dis 2013; 13:46;  PMID:23356471 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Jpn J Infect Dis 2012; 65:510- 5; PMID:23183203 ; http://dx.doi.org/10.7883/ yoken.65.510 7.,Non-OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Nat Rev Microbiol 2008; 6:187-98; PMID:18246082 ; http://dx.doi.org/10.1038/ nrmicro1835 9.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
J Infect Chemother 2008; 14:77-85; PMID:18622668 ; http://dx.doi.org/10.1007/ s10156-007-0595-710.,Non-OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Microbiology 2007; 153:3211-7;  PMID:17906120 ;  http://dx.doi.org/10.1099/mic.0.2007/010405-0 11.,Non-OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Yeast 2008; 25:385- 417; PMID:18509848 ; http://dx.doi.org/10.1002/ yea.1595 12.,Non-OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Infect Immun 2003; 71:2299- 309; PMID:12704098 ; http://dx.doi.org/10.1128/ IAI.71.5.2299-2309.2003 14.,Non-OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
"Annu  Rev Microbiol 2000; 54:463-98; PMID:11018135 ;  http://dx.doi.org/10.1146/annurev.micro.54.1.463 15. d’Enfert C, Goyard S, Rodriguez-Arnaveilhe S, Frangeul L, Jones L, Tekaia F, Bader O, Albrecht  A, Castillo L, Dominguez A, et al.",OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Nucleic Acids Res 2005; 33:D353-7; PMID :15608215 ; http://dx.doi.org/10.1093/nar/ gki124 16.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Yeast  2011; 28:833-41;  PMID:22072586 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Nat Protoc 2008; 3:1414- 21; PMID:18772868 ; http://dx.doi.org/10.1038/ nprot.2008.137 18.,Non-OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
J Basic Microbiol 2006; 46:416- 29; PMID:17009297 ; http://dx.doi.org/10.1002/ jobm.200510133 19.,Non-OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Yeast 2000; 16:65- 70; PMID:10620776 ; http://dx.doi.org/10.1002/ (SICI)1097-0061(20000115)16:1<65::AID-YEA508>3.0.CO;2-M20.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Mol Microbiol 2003;  50:167-81;  PMID:14507372 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Mycoses 2002; 45(Suppl  1):16-21;  PMID:12073557 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Methods Enzymol 2010; 470:737-58;  PMID:20946834 ; http://dx.doi.org/10.1016/ S0076-6879(10)70031-8 23.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Microbiology  1997; 143:297-302;  PMID:9043106 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Yeast 2001; 18:301-11;  PMID:11223939 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Science  2000; 288:1062-4;  PMID:10807578 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Eukaryot Cell 2004; 3:900-9;  PMID :15302823 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Yeast  2006; 23:399-405;  PMID:16598691 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Microbiology 2005; 151:1061-71; PMID:15817775 ;  http://dx.doi.org/10.1099/mic.0.27487-0 33.,Non-OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Infect Immun 2003; 71:6101-3; PMID:14500538 ;  http://dx.doi.org/10.1128/IAI.71.10.6101-6103.2003 34.,Non-OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Yeast  2000; 16:325-7;  PMID:10669870 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Infect Immun  2002; 70:3281-3;  PMID:12011025 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Eukaryot Cell 2003; 2:718-28; PMID:12912891 ;  http://dx.doi.org/10.1128/EC.2.4.718-728.2003 38.,Non-OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Mol Microbiol 1999;  32:547-56;  PMID:10320577 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Gene 2000; 252:127- 35; PMID:10903444 ; http://dx.doi.org/10.1016/ S0378-1119(00)00217-1 41.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Fungal Genet Biol  2011; 48:858-65;  PMID:21511047 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Methods Mol Biol 2012; 845:19-39;  PMID:22328365 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
J Bacteriol 2000; 182:5730-6;  PMID:11004171 ; http://dx.doi.org/10.1128/ JB.182.20.5730-5736.200044.,Non-OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Methods Mol Biol 2009; 499:175-94;  PMID:19152049 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Eukaryot Cell  2005; 4:298-309;  PMID :15701792 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Fungal  Genet Biol 2005; 42:737-48; PMID:16043373 ;  http://dx.doi.org/10.1016/j.fgb.2005.05.006 47.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Mol Microbiol  2000; 36:856-65;  PMID:10844673 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
J Bacteriol 2000; 182:400-4;  PMID:10629186 ; http://dx.doi.org/10.1128/ JB.182.2.400-404.2000 51.,Non-OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Gene 2004; 341:119-27; PMID :15474295 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Infect Immun 2005; 73:1239- 42; PMID :15664973 ; http://dx.doi.org/10.1128/ IAI.73.2.1239-1242.2005 53.,Non-OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Methods Mol Biol 2012;  845:3-17;  PMID:22328364 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Eukaryot Cell 2005; 4:1328-42; PMID:16087738 ;  http://dx.doi.org/10.1128/EC.4.8.1328-1342.2005 55.,Non-OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Mol Microbiol  2002; 46:269-80;  PMID:12366849 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Anal Biochem 2003; 318:152- 4; PMID:12782044 ; http://dx.doi.org/10.1016/ S0003-2697(03)00166-0 57.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Antimicrob Agents Chemother 2012;  56:3785-96;  PMID:22564841 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Yeast 2000; 16:1121-9;  PMID:10953084 ; http://dx.doi.org/10.1002/1097- 0061(20000915)16:12<1121::AID-YEA614>3.0.CO;2-U 60.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Yeast 2003; 20:1339-47;  PMID:14663826 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
"Identification of GIG1, a GlcNAc-induced gene in Candida albicans needed  for normal sensitivity to the chitin synthase inhibi - tor nikkomycin Z. Eukaryot Cell 2010; 9:1476-83; PMID:20675577 ; http://dx.doi.org/10.1128/ EC.00178-10 62.",Non-OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
FEMS Microbiol Lett 2001; 204:323-8;  PMID:11731143 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Trends Microbiol 2003; 11:69- 73; PMID:12598128 ; http://dx.doi.org/10.1016/ S0966-842X(02)00029-X 64.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Nucleic Acids Res  1997; 25:451-2;  PMID:9016579 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
EMBO J 1997; 16:1982-91;  PMID :9155024 ; http://dx.doi.org/10.1093/ emboj/16.8.1982 68.,Non-OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
J Antimicrob Chemother 2004; 54:999- 1006;  PMID:15486081 ; http://dx.doi.org/10.1093/ jac/dkh456 69.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Yeast  2008; 25:301-11;  PMID:18350525 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Yeast 1998; 14:953- 61; PMID:9717241 ; http://dx.doi.org/10.1002/ (SICI)1097-0061(199807)14:10<953::AID-YEA293>3.0.CO;2-U 71.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Yeast 1999; 15:1419-27;  PMID:10509024 ; http://dx.doi.org/10.1002/ (SICI)1097-0061(19990930)15:13<1419::AID-YEA466>3.0.CO;2-Q,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Yeast 1998; 14:943- 51; PMID:9717240 ; http://dx.doi.org/10.1002/ (SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y 73.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Yeast 2004; 21:429-36; PMID :15116343 ;  http://dx.doi.org/10.1002/yea.1080 75.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Yeast 2009; 26:399- 406;  PMID:19504625 ; http://dx.doi.org/10.1002/ yea.1674 76.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Mol Gen Genet 1998; 257:412- 20; PMID:9529522 ; http://dx.doi.org/10.1007/ s004380050665 77.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Microb Pathog 2006; 40:69- 81; PMID:16427765 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Microb Pathog 2006; 40:82-90; PMID:16426810 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Curr Protein Pept Sci  2000; 1:303-8;  PMID:12369911 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
J Med Microbiol 2009; 58:290- 5; PMID:19208876 ; http://dx.doi.org/10.1099/ jmm.0.004846-0 81.,Non-OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Microbiol Immunol  2005; 49:937-9;  PMID:16237272 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
J Bacteriol 2000; 182:4899- 905; PMID:10940034 ; http://dx.doi.org/10.1128/ JB.182.17.4899-4905.2000 84.,Non-OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Antimicrob Agents Chemother 2004; 48:3425-35; PMID :15328107 ; http://dx.doi.org/10.1128/ AAC.48.9.3425-3435.200485.,Non-OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
FEMS Yeast Res  2009; 9:1070-7;  PMID :19732157 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Mol Microbiol  2005; 55:1553-65;  PMID:15720560 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Yeast 2008; 25:433-48; PMID:18509849 ; http://dx.doi.org/10.1002/ yea.1597 88.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
FEMS Yeast Res 2007;  7:2-11;  PMID :17311580 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Genetics 2006; 172:2139- 56; PMID :16452151 ; http://dx.doi.org/10.1534/ genetics.105.054767 92.,Non-OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Science 2006; 313:367-70;  PMID:16857942 ; http://dx.doi.org/10.1126/ science.1128242 93.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Eukaryot Cell 2009; 8:1554-66; PMID:19700634 ;  http://dx.doi.org/10.1128/EC.00209-09 94.,Non-OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
Mol Cell 2005; 18:395- 8; PMID:15893722 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/c3/cf/viru-5-507.PMC4063812.pdf
